AU2007240202A1 - Novel compositions and methods for cancer - Google Patents

Description

AUSTRALIA

F B RICE CO Patent and Trade Mark Attorneys Patents Act 1990 SAGRES DISCOVERY INC.

COMPLETE SPECIFICATION STANDARD PATENT Invention Title: Novel compositions and methods for cancer The following statement is a full description of this invention including the best method of performing it known to us:- NOVEL COMPOSITIONS AND METHODS FOR CANCER

O

Q This is a divisional of AU 2002367390, the entire contents of which are 0 incorporated herein by reference.

CI SEQUENCE LISTING CI The Sequence Listing submitted on compact disc is hereby incorporated by reference. The two, identical compact discs contain the file named A-71249. ST25. txt, created on May 29,2002, and containing 16,870. 127 bytes.

FIELD OF THE INVENTION The present invention relates to novel sequences for use in diagnosis and treatment of cancer, especially carcinomas, as well as the use of the novel compositions in screening methods.

BACKGROUND OF THE INVENTION Oncogenes are genes that can cause cancer. Carcinogenesis can occur by a wide variety of mechanisms, including infection of cells by viruses containing oncogenes.

activation of protooncogenes in the host genome, and mutations of protooncogenes and tumor suppressor genes.

There are a number of viruses known to be involved in human cancer as well as in animal cancer. Of particular interest here are viruses that do not contain oncogenes themselves; these are slow-transforming retroviruses. They induce tumors by integrating into the host genome and affecting neighbouring protooncogenes in a variety of ways, including promoter insertion, enhancer insertion, and/or truncation of a protooncogene or tumor suppressor gene. The analysis of sequences at or near the insertion sites led to the identification of a number of new protooncogenes.

S[0006] With respect to lymphoma and leukemia, murine leukemia retrovirus (MuLV), such as SL3-3 or Akv, is a potent inducer of tumors when inoculated into susceptible newborn mice, or when carried in the germline. A number of sequences have been identified as relevant in the induction of lymphoma and leukemia by analyzing the insertion sites; see Sorensen et al., J. of Virology 74:2161 (2000); Hansen et al., Genome Res. 10(2):237-43 (2000); Sorensen et al., J. Virology 70:4063 (1996); Sorensen et al., J. Virology 67:7118 (1993); Joosten et al., Virology 268:308 (2000); S and Li et al., Nature Genetics 23:348 (1999); all of which are expressly incorporated by reference herein.

C, [0007] Lymphomas are a collection of cancers involving the lymphatic system and are generally categorized as Hodgkin's disease and Non-Hodgkin lymphoma.

Hodgkin's lymphomas are of B lymphocyte origin. Non-Hodgkin lymphomas are a collection of over 30 different types of cancers including T and B lymphomas.

Leukemia is a disease of the blood forming tissues and includes B and T cell lymphocytic leukemias. It is characterized by an abnormal and persistent increase in the number of leukocytes and the amount of bone marrow, with enlargement of the spleen and lymph nodes.

[0008] Breast cancer is one of the most significant diseases that affects women. At the current rate, American women have a 1 in 8 risk of developing breast cancer by age 95 (American Cancer Society, 1992). Treatment of breast cancer at later stages is often futile and disfiguring, making early detection a high priority in medical management of the disease.

[0009] Accordingly, it is an object of the invention to provide sequences involved in cancer and in particular in oncogenesis.

SUMMARY OF THE INVENTION [0010] In accordance with the objects outlined above, the present invention provides methods for screening for compositions which modulate carcinomas, especially lymphoma and leukemia. Also provided herein are methods of inhibiting proliferation of a cell, preferably a lymphoma cell. Methods of treatment of carcinomas, including diagnosis, are also provided herein.

[0011] In one aspect, a method of screening drug candidates comprises providing a S cell that expresses a carcinoma associated (CA) gene or fragments thereof. Preferred C embodiments of CA genes are genes which are differentially expressed in cancer U cells, preferably lymphatic, breast, prostate or epithelial cells, compared to other cells.

Preferred embodiments of CA genes used in the methods herein include, but are not limited to the nucleic acids selected from Tables 1-112. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on C the expression of the CA gene.

[0012] In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of S expression in the presence of the drug candidate.

[0013] Also provided herein is a method of screening for a bioactive agent capable of binding to a CA protein (CAP), the method comprising combining the CAP and a candidate bioactive agent, and determining the binding of the candidate agent to the

CAP.

[0014] Further provided herein is a method for screening for a bioactive agent capable of modulating the activity of a CAP. In one embodiment, the method comprises combining the CAP and a candidate bioactive agent, and determining the effect of the candidate agent on the bioactivity of the CAP.

[0015] Also provided is a method of evaluating the effect of a candidate carcinoma drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile of the patient to an expression profile of a heathy individual.

[0016] In a further aspect, a method for inhibiting the activity of an CA protein is provided. In one embodiment, the method comprises administering to a patient an inhibitor of a CA protein preferably selected from the group consisting of the sequences outlined in Tables 1-112 or their complements.

[0017] A method of neutralizing the effect of a CA protein, preferably a protein encoded by a nucleic acid selected from the group of sequences outlined in Tables 1- 112, is also provided. Preferably, the method comprises contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization.

[0018] Moreover, provided herein is a biochip comprising a nucleic acid segment which encodes a CA protein, preferably selected from the sequences outlined in S Tables 1-112.

[0019] Also provided herein is a method for diagnosing or determining the propensity to carcinomas, especially lymphoma or leukemia by sequencing at least one carcinoma or lymphoma gene of an individual. In yet another aspect of the invention, a method is provided for determining carcinoma including lymphoma and O leukemia gene copy number in an individual.

0 [0020] Novel sequences are also provided herein. Other aspects of the invention will C become apparent to the skilled artisan by the following description of the invention.

O DETAILED DESCRIPTION OF THE INVENTION [0021] The present invention is directed to a number of sequences associated with carcinomas, especially lymphoma, breast cancer or prostate cancer. The relatively tight linkage between clonally-integrated proviruses and protooncogenes forms "provirus tagging", in which slow-transforming retroviruses that act by an insertion mutation mechanism are used to isolate protooncogenes. In some models, uninfected animals have low cancer rates, and infected animals have high cancer rates. It is known that many of the retroviruses involved do not carry transduced host protooncogenes or pathogenic trans-acting viral genes, and thus the cancer incidence must therefor be a direct consequence of proviral integration effects into host protooncogenes. Since proviral integration is random, rare integrants will "activate" host protooncogenes that provide a selective growth advantage, and these rare events result in new proviruses at clonal stoichiometries in tumors.

[0022] The use of oncogenic retroviruses, whose sequences insert into the genome of the host organism resulting in carcinoma, allows the identification of host sequences involved in carcinoma. These sequences may then be used in a number of different ways, including diagnosis, prognosis, screening for modulators (including both agonists and antagonists), antibody generation (for immunotherapy and imaging), etc.

However, as will be appreciated by those in the art, oncogenes that are identified in .one type of cancer such as lymphoma or leukemia have a strong likelihood of being involved in other types of cancers as well. Thus, while the sequences outlined herein are initially identified as correlated with lymphoma, they can also be found in other types of cancers as well, outlined below.

[0023] Accordingly, the present invention provides nucleic acid and protein 0 sequences that are associated with carcinoma, herein termed "carcinoma associated" or "CA" sequences. In a preferred embodiment, the present invention provides S nucleic acid and protein sequences that are associated with carcinomas which originate in lymphatic tissue, herein termed "lymphoma associated", "leukemia associated" or "LA" sequences.

10024] Suitable cancers which can be diagnosed or screened for using the methods of the present invention include cancers classified by site or by histological type.

C Cancers classified by site include cancer of the oral cavity and pharynx (lip, tongue, salivary gland, floor of mouth, gum and other mouth, nasopharynx, tonsil, C1l oropharynx, hypopharynx, other oral/pharynx); cancers of the digestive system (esophagus; stomach; small intestine; colon and rectum; anus, anal canal, and anorectum; liver; intrahepatic bile duct; gallbladder; other biliary; pancreas; retroperitoneum; peritoneum, omentum, and mesentery; other digestive); cancers of the respiratory system (nasal cavity, middle ear, and sinuses; larynx; lung and bronchus; pleura; trachea, mediastinum, and other respiratory); cancers of the mesothelioma; bones and joints; and soft tissue, including heart; skin cancers, including melanomas and other non-epithelial skin cancers; Kaposi's sarcoma and breast cancer; cancer of the female genital system (cervix uteri; corpus uteri; uterus, nos; ovary; vagina; vulva; and other female genital); cancers of the male genital system (prostate gland; testis; penis; and other male genital); cancers of the urinary system (urinary bladder; kidney and renal pelvis; ureter; and other urinary); cancers of the eye and orbit; cancers of the brain and nervous system (brain; and other nervous system); cancers of the endocrine system (thyroid gland and other endocrine, including thymus); cancers of the lymphomas (hodgkin's disease and non-hodgkin's lymphoma), multiple myeloma, and leukemias (lymphocytic leukemia; myeloid leukemia; monocytic leukemia; and other leukemias).

[0025] Other cancers, classified by histological type, that may be associated with the sequences of the invention include, but are not limited to, Neoplasm, malignant; Carcinoma, NOS; Carcinoma, undifferentiated, NOS; Giant and spindle cell carcinoma; Small cell carcinoma, NOS; Papillary carcinoma, NOS; Squamous cell carcinoma, NOS; Lymphoepithelial carcinoma; Basal cell carcinoma, NOS; S Pilomatrix carcinoma; Transitional cell carcinoma, NOS; Papillary transitional cell O carcinoma; Adenocarcinoma, NOS; Gastrinoma, malignant; Cholangiocarcinoma; S Hepatocellular carcinoma, NOS; Combined hepatocellular carcinoma and cholangiocarcinoma; Trabecular adenocarcinoma; Adenoid cystic carcinoma; Adenocarcinoma in adenomatous polyp; Adenocarcinoma, familial polyposis coli; Solid carcinoma, NOS; Carcinoid tumor, malignant; Branchiolo-alveolar adenocarcinoma; Papillary adenocarcinoma, NOS; Chromophobe carcinoma; S Acidophil carcinoma; Oxyphilic adenocarcinoma; Basophil carcinoma; Clear cell S adenocarcinoma, NOS; Granular cell carcinoma; Follicular adenocarcinoma, NOS; S Papillary and follicular adenocarcinoma; Nonencapsulating sclerosing carcinoma; S Adrenal cortical carcinoma; Endometroid carcinoma; Skin appendage carcinoma; (7 Apocrine adenocarcinoma; Sebaceous adenocarcinoma; Ceruminous adenocarcinoma; Mucoepidermoid carcinoma; Cystadenocarcinoma, NOS; Papillary cystadenocarcinoma, NOS; Papillary serous cystadenocarcinoma; Mucinous cystadenocarcinoma, NOS; Mucinous adenocarcinoma; Signet ring cell carcinoma; Infiltrating duct carcinoma; Medullary carcinoma, NOS; Lobular carcinoma; Inflammatory carcinoma; Paget"s disease, mammary; Acinar cell carcinoma; Adenosquamous carcinoma; Adenocarcinoma w/ squamous metaplasia; Thymoma, malignant; Ovarian stromal tumor, malignant; Thecoma, malignant; Granulosa cell tumor, malignant; Androblastoma, malignant; Sertoli cell carcinoma; Leydig cell tumor, malignant; Lipid cell tumor, malignant; Paraganglioma, malignant; Extramammary paraganglioma, malignant; Pheochromocytoma; Glomangiosarcoma; Malignant melanoma, NOS; Amelanotic melanoma; Superficial spreading melanoma; Malig melanoma in giant pigmented nevus; Epithelioid cell melanoma; Blue nevus, malignant; Sarcoma, NOS; Fibrosarcoma, NOS; Fibrous histiocytoma, malignant; Myxosarcoma; Liposarcoma, NOS; Leiomyosarcoma, NOS; Rhabdomyosarcoma, NOS; Embryonal rhabdomyosarcoma; Alveolar rhabdomyosarcoma; Stromal sarcoma, NOS; Mixed tumor, malignant, NOS; Mullerian mixed tumor; Nephroblastoma; Hepatoblastoma; Carcinosarcoma, NOS; Mesenchymoma, malignant; Brenner tumor, malignant; Phyllodes tumor, malignant; Synovial sarcoma, NOS; Mesothelioma, malignant; Dysgerminoma; Embryonal carcinoma, NOS; Teratoma, malignant, NOS; Struma ovarii, malignant; Choriocarcinoma; Mesonephroma, malignant; Hemangiosarcoma; Hemangioendothelioma, malignant; Kaposi's sarcoma; Hemangiopericytoma, malignant; Lymphangiosarcoma; Osteosarcoma, NOS; Juxtacortical osteosarcoma; Chondrosarcoma, NOS; S Chondroblastoma, malignant; Mesenchymal chondrosarcoma; Giant cell tumor of C bone; Ewing's sarcoma; Odontogenic tumor, malignant; Ameloblastic odontosarcoma; Ameloblastoma, malignant; Ameloblastic fibrosarcoma; Pinealoma, malignant; Chordoma; Glioma, malignant; Ependymoma, NOS; Astrocytoma, NOS; Protoplasmic astrocytoma; Fibrillary astrocytoma; Astroblastoma; Glioblastoma, NOS; Oligodendroglioma, NOS; Oligodendroblastoma; Primitive neuroectodermal; CI Cerebellar sarcoma, NOS; Ganglioneuroblastoma; Neuroblastoma, NOS; C1 Retinoblastoma, NOS; Olfactory neurogenic tumor; Meningioma, malignant; Neurofibrosarcoma; Neurilemmoma, malignant; Granular cell tumor, malignant; Malignant lymphoma, NOS; Hodgkin's disease, NOS; Hodgkin's; paragranuloma, NOS; Malignant lymphoma, small lymphocytic; Malignant lymphoma, large cell, diffuse; Malignant lymphoma, follicular, NOS; Mycosis fungoides; Other specified non-Hodgkin's lymphomas; Malignant histiocytosis; Multiple myeloma; Mast cell sarcoma; Immunoproliferative small intestinal disease; Leukemia, NOS; Lymphoid leukemia, NOS; Plasma cell leukemia; Erythroleukemia; Lymphosarcoma cell leukemia; Myeloid leukemia, NOS; Basophilic leukemia; Eosinophilic leukemia; Monocytic leukemia, NOS; Mast cell leukemia; Megakaryoblastic leukemia; Myeloid sarcoma; and Hairy cell leukemia.

[0026] In addition, the genes may be involved in other diseases, such as but not limited to diseases associated with aging or neurodegenerative diseases.

[0027] Association in this context means that the nucleotide or protein sequences are either differentially expressed, activated, inactivated or altered in carcinomas as compared to normal tissue. As outlined below, CA sequences include those that are up-regulated expressed at a higher level), as well as those that are down-regulated expressed at a lower level), in carcinomas. CA sequences also include sequences which have been altered truncated sequences or sequences with substitutions, deletions or insertions, including point mutations) and show either the same expression profile or an altered profile. In a preferred embodiment, the CA sequences are from humans; however, as will be appreciated by those in the art, CA sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other CA sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc). In some cases, prokaryotic CA sequences may be useful. CA sequences from other organisms may be obtained using the techniques outlined below.

[0028] CA sequences can include both nucleic acid and amino acid sequences. In a preferred embodiment, the CA sequences are recombinant nucleic acids. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid by polymerases and endonucleases, in a form not normally found in nature. Thus an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e. using the in vivo cellular 1 machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated nonrecombinantly, are still considered recombinant for the purposes of the invention.

[0029] Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e. through the expression of a recombinant nucleic acid as depicted above. A recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics. For example, the protein may be isolated or purified away from some or all of the proteins and compounds with which it is normally associated in its wild type host, and thus may be substantially pure. For example, an isolated protein is unaccompanied by at least some of the material with which it is normally associated in its natural state, preferably constituting at least about more preferably at least about 5% by weight of the total protein in a given sample. A substantially pure protein comprises at least about 75% by weight of the total protein, with at least about 80% being preferred, and at least about 90% being particularly preferred. The definition includes the production of an CA protein from one organism in a different organism or host cell. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, through the use of an inducible promoter or high expression promoter, such that the protein is made at increased concentration levels. Altemrnatively, the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and deletions, as discussed below.

[0030] In a preferred embodiment, the CA sequences are nucleic acids. As will be appreciated by those in the art and is more fully outlined below, CA sequences are useful in a variety of applications, including diagnostic applications, which will detect 0 naturally occurring nucleic acids, as well as screening applications; for example, CN biochips comprising nucleic acid probes to the CA sequences can be generated. In the broadest sense, then, by "nucleic acid" or "oligonucleotide" or grammatical equivalents herein means at least two nucleotides covalently linked together. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, as outlined below (for example in antisense applications or CN when a candidate agent is a nucleic acid), nucleic acid analogs may be used that have CN alternate backbones, comprising, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem.

35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl.

Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805 (1984), Letsinger et al., J.

Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S.

Patent No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989), O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., Proc. Natl.

Acad. Sci. USA 92:6097 (1995); non-ionic backbones Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowshi et al., Angew. Chem.

Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside Nucleotide 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed.

Y.S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic Medicinal Chem.

Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett.

37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) ppl69-176). Several nucleic acid analogs are described in Rawls, C E News June S 2, 1997 page 35. All of these references are hereby expressly incorporated by O reference. These modifications of the ribose-phosphate backbone may be done for a 0 variety of reasons, for example to increase the stability and half-life of such molecules in physiological environments for use in anti-sense applications or as probes on a biochip.

[0031) As will be appreciated by those in the art, all of these nucleic acid analogs may find use in the present invention. In addition, mixtures of naturally occurring nucleic 0 acids and analogs can be made; alternatively, mixtures of different nucleic acid 0 analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

1, [0032] The nucleic acids may be single stranded or double stranded, as specified, or 0 contain portions of both double stranded or single stranded sequence. As will be C1 appreciated by those in the art, the depiction of a single strand "Watson" also defines the sequence of the other strand "Crick"; thus the sequences described herein also includes the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid contains any combination of deoxyribo- and ribo-nucleotides, and any combination of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non-naturally occurring analog structures. Thus for example the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

[0033] An CA sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the CA sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

[0034] The CA sequences of the invention were initially identified as described herein; basically, infection of mice with murine leukemia viruses (MLV) resulted in lymphoma, although many of these sequences will also be involved in other cancers as is generally outlined herein.

[0035] The CA sequences outlined herein comprise the insertion sites for the virus.

In general, the retrovirus can cause carcinomas in three basic ways: first of all, by inserting upstream of a normally silent host gene and activating it promoter 1 insertion); secondly, by truncating a host gene that leads to oncogenesis; or by S enhancing the transcription of a neighboring gene. For example, retrovirus enhancers, S including SL3-3, arc known to act on genes up to approximately 200 kilobases of the U insertion site.

[00361 In a preferred embodiment, CA sequences are those that are up-regulated in carcinomas; that is, the expression of these genes is higher in carcinoma tissue as compared to normal tissue of the same differentiation stage. "Up-regulation" as used N, herein means at least about 50%, more preferably at least about 100%, more S preferably at least about 150%, more preferably, at least about 200%, with from 300 to at least 1000% being especially preferred.

[0037] In a preferred embodiment, CA sequences are those that are down-regulated in carcinomas; that is, the expression of these genes is lower in carcinoma tissue as compared to normal 1 tissue of the same differentiation stage. "Down-regulation" as used herein means at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably, at least about 200%, with from 300 to at least 1000% being especially preferred.

[0038] In a preferred embodiment, CA sequences are those that are altered but show either the same [0039] expression profile or an altered profile as compared to normal lymphoid tissue of the same [0040] differentiation stage. "Altered CA sequences" as used herein refers to sequences which are truncated, contain insertions or contain point mutations.

[0041] CA proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins.

[0042] In a preferred embodiment the CA protein is an intracellular protein.

Intracellular proteins may be found in the cytoplasm and/or in the nucleus.

Intracellular proteins are involved in all aspects of cellular function and replication (including, for example, signaling pathways); aberrant expression of such proteins results in unregulated or disregulated cellular processes. For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various S subcellular localizations, and are involved in maintaining the structural integrity of organelles.

S [0043] An increasingly appreciated concept in characterizing intracellular proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB 0 domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated N targets. SH3 domains bind to proline-rich targets. In addition, PH domains, 0 tetratricopeptide repeats and WD domains to name only a few, have been shown to C1 mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate.

[0044] In a preferred embodiment, the CA sequences are transmembrane proteins.

Transmembrane proteins are molecules that span the phospholipid bilayer of a cell.

They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

[0045] Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Important transmembrane protein receptors include, but are not limited to insulin receptor, insulinlike growth factor receptor, 0 human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g. IL_1 receptor, II 2 receptor, etc.

[0046] Characteristics of transmembrane domains include approximately S consecutive hydrophobic amino acids that may be followed by charged amino acids.

Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be Spredicted.

[0047] The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains.

Conserved structure and/or functions have been ascribed to different extracellular motifs. For example, cytokine receptors are characterized by a cluster of cysteines and a WSXWS tryptophan, S= serine, X=any amino acid (SEQ ID NO:1613) motif. Immunoglobulin-like domains are highly conserved. Mucin-like domains may be involved in cell adhesion and leucine-rich repeats participate in protein-protein interactions.

[0048] Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell for example via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

[0049] CA proteins that are transmembrane are particularly preferred in the present invention as they are good targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities.

[0050] It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, for example through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

100511 In a preferred embodiment, the CA proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway, Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. CA proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, for example for blood tests.

[0052] An CA sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology to the CA sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

[00531 As used herein, a nucleic acid is a "CA nucleic acid" if the overall homology of the nucleic acid sequence to one of the nucleic acids of Tables 1-112 is preferably greater than about 75%, more preferably greater than about 80%, even more preferably greater than about 85% and most preferably greater than 90%. In some embodiments the homology will be as high as about 93 to 95 or 98%. In a preferred embodiment, the sequences which are used to determine sequence identity or similarity are selected from those of the nucleic acids of Tables 1-1 12. In another embodiment, the sequences are naturally occurring allelic variants of the sequences of the nucleic acids of Tables 1-112. In another embodiment, the sequences are sequence variants as further described herein.

[00541 Homology in this context means sequence similarity or identity, with identity being preferred. A preferred comparison for homology purposes is to compare the sequence containing sequencing errors to the correct sequence. This homology will be determined using standard techniques known in the art, including, but not limited to, the local homology algorithm of Smith Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman Wunsch, J. Mol. Biol.

48:443 (1970), by the search for similarity method of Pearson Lipman, PNAS USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, WI), the Best Fit sequence program described by Devereux et al., Nucl. Acid Res. 12:387-395 (1984), preferably using the default settings, or by inspection.

[0055] One example of a useful algorithm is PILEUP. PILEUP creates a multiple S sequence alignment from a group of related sequences using progressive, pairwise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng Doolittle, J. Mol. Evol. 35:351-360 (1987); the method is similar to that 6 described by Higgins Sharp CABIOS 5:151-153 (1989). Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps.

[0056] Another example of a useful algorithm is the BLAST algorithm, described in Altschul et al., J. Mol. Biol. 215, 403-410, (1990) and Karlin et al., PNAS USA 90:5873-5787 (1993). A particularly useful BLAST program is the WU-BLAST-2 program which was obtained from Altschul et al., Methods in Enzymology, 266: 460- 480 (1996); http://blast.wustl]. WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap span overlap fraction 0.125, word threshold 11.

The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched; however, the values may be adjusted to increase sensitivity. A amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the "longer" sequence in the aligned region. The "longer" sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored).

[00571 Thus, "percent nucleic acid sequence identity" is defined as the percentage of nucleotide residues in a candidate sequence that are identical with the nucleotide residues of the nucleic acids of Tables 1-112. A preferred method utilizes the BLASTN module of WU-BLAST-2 set to the default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively.

[0058] The alignment may include the introduction of gaps in the sequences to be aligned. In addition, for sequences which contain either more or fewer nucleotides than those of the nucleic acids of Tables 1-112, it is understood that the percentage of homology will be determined based on the number of homologous nucleosides in relation to the total number of nucleosides. Thus, for example, homology of O sequences shorter than those of the sequences identified herein and as discussed O below, will be determined using the number of nucleosides in the shorter sequence.

C1 [0059] In one embodiment, the nucleic acid homology is determined through O hybridization studies. Thus, for example, nucleic acids which hybridize under high stringency to the nucleic acids identified in the figures, or their complements, are considered CA sequences. High stringency conditions are known in the art; see for example Maniatis et al., Molecular Cloning: A Laboratory Manual, 2d Edition, 1989, and Short Protocols in Molecular Biology, ed. Ausubel, et al., both of which are hereby incorporated by reference. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-100C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 300C for short probes 10 to nucleotides) and at least about 600C for long probes greater than nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

[0060] In another embodiment, less stringent hybridization conditions are used; for example, moderate or low stringency conditions may be used, as are known in the art; S see Maniatis and Ausubel, supra, and Tijssen, supra.

0 [00611 In addition, the CA nucleic acid sequences of the invention are fragments of larger genes, i.e. they are nucleic acid segments. Alternatively, the CA nucleic acid sequences can serve as indicators of oncogene position, for example, the CA sequence may be an enhancer that activates a protooncogene. "Genes" in this context includes S coding regions, non-coding regions, and mixtures of coding and non-coding regions.

S Accordingly, as will be appreciated by those in the art, using the sequences provided herein, additional sequences of the CA genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Maniatis et al., and Ausubel, et al., supra, hereby expressly incorporated by reference.

Il n general, this is done using PCR, for example, kinetic PCR.

[0062] Once the CA nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire CA nucleic acid. Once isolated from its natural source, contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant CA nucleic acid can be further used as a probe to identify and isolate other CA nucleic acids, for example additional coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant CA nucleic acids and proteins.

10063] The CA nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the CA nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, for example for gene therapy and/or antisense applications.

Alternatively, the CA nucleic acids that include coding regions of CA proteins can be put into expression vectors for the expression of CA proteins, again either for screening purposes or for administration to a patient.

10064] In a preferred embodiment, nucleic acid probes to CA nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the CA nucleic acids, i.e. the target sequence (either the target sequence of the sample or to other probe sequences, for example in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between O the target sequence and the single stranded nucleic acids of the present invention.

S However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to S hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

[00651 A nucleic acid probe is generally single stranded but can be partially single 1 and partially double stranded. The strandedness of the probe is dictated by the O structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.

[00661 In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used.

That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping have some sequence in common), or separate.

[0067] As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can be covalent or non-covalent. By "non-covalent binding" and grammatical equivalents herein is meant one or more of either electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

N [0068] In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be O directly synthesized on the biochip.

[00691 The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant any material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or C\1 functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonTM, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica_based materials including silicon and modified silicon, carbon, metals, inorganic glasses, etc. In general, the substrates allow optical detection and do not appreciably fluoresce.

[0070] In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two.

Thus, for example, the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, for example using linkers as are known in the art; for example, homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross_linkers, pages 155 200, incorporated herein by reference). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

[0071] In this embodiment, the oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

[0072] In an additional embodiment, the immobilization to the solid support may be O very strong, yet non-covalent. For example, biotinylated oligonucleotides can be S made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

[0073] Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO i 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all O of which are expressly incorporated by reference; these methods of attachment form CI the basis of the Affymetrix GeneChip technology.

[0074] In addition to the solid-phase technology represented by biochip arrays, gene expression can also be quantified using liquid-phase arrays. One such system is kinetic polymerase chain reaction (PCR). Kinetic PCR allows for the simultaneous amplification and quantification of specific nucleic acid sequences. The specificity is derived from synthetic oligonucleotide primers designed to preferentially adhere to single-stranded nucleic acid sequences bracketing the target site. This pair of oligonucleotide primers form specific, non-covalently bound complexes on each strand of the target sequence. These complexes facilitate in vitro transcription of double-stranded DNA in opposite orientations. Temperature cycling of the reaction mixture creates a continuous cycle of primer binding, transcription, and re-melting of the nucleic acid to individual strands. The result is an exponential increase of the target dsDNA product. This product can be quantified in real time either through the use of an intercalating dye or a sequence specific probe. SYBR® Greene I, is an example of an intercalating dye, that preferentially binds to dsDNA resulting in a concomitant increase in the fluorescent signal. Sequence specific probes, such as used with TaqMan® technology, consist of a fluorochrome and a quenching molecule covalently bound to opposite ends of an oligonucleotide. The probe is designed to selectively bind the target DNA sequence between the two primers. When the DNA strands are synthesized during the PCR reaction, the fluorochrome is cleaved from the probe by the exonuclease activity of the polymerase resulting in signal dequenching.

The probe signaling method can be more specific than the intercalating dye method, but in each case, signal strength is proportional to the dsDNA product produced.

Each type of quantification method can be used in multi-well liquid phase arrays with each well representing primers and/or probes specific to nucleic acid sequences of C interest. When used with messenger RNA preparations of tissues or cell lines, and an array of probe/primer reactions can simultaneously quantify the expression of multiple gene products of interest. See Germer, et al., Genome Res. 10:258-266 (2000); Heid, C. et al., Genome Res. 6, 986-994 (1996).

[0075] In a preferred embodiment, CA nucleic acids encoding CA proteins are used to make a variety of expression vectors to express CA proteins which can then be C used in screening assays, as described below. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the CA protein.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

10076] [0077] Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. The transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the CA protein; for example, transcriptional and translational regulatory nucleic acid sequences from Bacillus are preferably used to express the CA protein in Bacillus.

Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

[0078] In general, the transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

[0079] Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid S promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

S [0080] In addition, the expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art.

[00811 In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

[0082] The CA proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding an CA protein, under the appropriate conditions to induce or cause expression of the CA protein. The conditions appropriate for CA protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some 'embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial S for product yield.

S [0083] Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect, plant and animal cells, including mammalian cells. Of particular interest are Drosophila melanogaster cells, Saccharomyces cerevisiae and other yeasts, E. coli, S Bacillus subtilis, Sf9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, HeLa cells, THP 1 cell line (a macrophage cell line) and human cells and cell lines.

C[ (0084] In a preferred embodiment, the CA proteins are expressed in mammalian cells.

C Mammalian expression systems are also known in the art, and include retroviral systems. A preferred expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter. Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenlytion signals include those derived form (0085] The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used.

Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

[0086] In a preferred embodiment, CA proteins are expressed in bacterial systems.

Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; for example, the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the CA protein in bacteria. The protein is either secreted into the growth media (gram- S positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, O kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic O genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways.

Ci These components are assembled into expression vectors. Expression vectors for 0 bacteria are well known in the art, and include vectors for Bacillus subtilis, E. coli, C Streptococcus cremoris, and Streptococcus lividans, among others. The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

[0087] In one embodiment, CA proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

[0088] In a preferred embodiment, CA protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

[0089] The CA protein may also be made as a fusion protein, using techniques well known in the art. Thus, for example, for the creation of monoclonal antibodies. If the desired epitope is small, the CA protein may be fused to a carrier protein to form an immunogen. Alternatively, the CA protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the CA protein is an CA peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

[0090] In one embodiment, the CA nucleic acids, proteins and antibodies of the invention are labeled. By "labeled" herein is meant that a compound has at least one element, isotope or chemical compound attached to enable the detection of the compound. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies or antigens; and c) colored or fluorescent dyes. The labels may be incorporated into the CA 0 nucleic acids, proteins and antibodies at any position. For example, the label should C be capable of producing, either directly or indirectly, a detectable signal. The 0 detectable moiety may be a radioisotope, such as 3 H, 14C, 32 P, 5"S, or 1251, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, S rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, betagalactosidase or horseradish peroxidase. Any method known in the art for C conjugating the antibody to the label may be employed, including those methods C" described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, S13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J.

Histochem. and Cytochem., 30:407 (1982).

[0091] Accordingly, the present invention also provides CA protein sequences. An CA protein of the present invention may be identified in several ways. "Protein" in this sense includes proteins, polypeptides, and peptides. As will be appreciated by those in the art, the nucleic acid sequences of the invention can be used to generate protein sequences. There are a variety of ways to do this, including cloning the entire gene and verifying its frame and amino acid sequence, or by comparing it to known sequences to search for homology to provide a frame, assuming the CA protein has homology to some protein in the database being used. Generally, the nucleic acid sequences are input into a program that will search all three frames for homology.

This is done in a preferred embodiment using the following NCBI Advanced BLAST parameters. The program is blastx or blastn. The database is nr. The input data is as "Sequence in FASTA format". The organism list is "none". The "expect" is 10; the filter is default. The "descriptions" is 500, the "alignments" is 500, and the "alignment view" is pairwise. The "query Genetic Codes" is standard The matrix is BLOSUM62; gap existence cost is 11, per residue gap cost is 1; and the lambda ratio is .85 default. This results in the generation of a putative protein sequence.

[0092] Also included within one embodiment of CA proteins are amino acid variants of the naturally occurring sequences, as determined herein. Preferably, the variants are preferably greater than about 75% homologous to the wild-type sequence, more preferably greater than about 80%, even more preferably greater than about 85% and most preferably greater than 90%. In some embodiments the homology will be as high as about 93 to 95 or 98%. As for nucleic acids, homology in this context means sequence similarity or identity, with identity being preferred. This homology will be determined using standard techniques known in the art as are outlined above for the nucleic acid homologies.

O [0093] CA proteins of the present invention may be shorter or longer than the wild type amino acid sequences. Thus, in a preferred embodiment, included within the definition of CA proteins are portions or fragments of the wild type sequences herein.

In addition, as outlined above, the CA nucleic acids of the invention may be used to obtain additional coding regions, and thus additional protein sequence, using techniques known in the art.

[0094] In a preferred embodiment, the CA proteins are derivative or variant CA ri proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative CA peptide will contain at least one amino acid substitution, C, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the CA peptide.

[0095] Also included in an embodiment of CA proteins of the present invention are amino acid sequence variants. These variants fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the CA protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant CA protein fragments having up to about 100-150 residues may be prepared by in vitro synthesisusing established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the CA protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

[0096] While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed CA variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example, Ml 3 primer mutagenesis and LAR mutagenesis. Screening of the mutants is done using assays of CA protein activities.

[0097] Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

[0098] Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the CA protein are desired, substitutions are generally made in accordance with the following chart: Chart I Original Residue Ala Arg Asn Asp Cys Gin Glu Gly His lie Leu Lys Met Phe Ser Thr Trp Tyr Val Exemplary Substitutions Ser Lys Gin, His Glu Ser Asn Asp Pro Asn, Gin Leu, Val lie, Val Arg, Gin, Glu Leu, Ile Met, Leu, Tyr Thr Ser Tyr Trp, Phe lie, Leu [0099] Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those shown in Chart I. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which a O hydrophilic residue, e.g. seryl or threonyl is substituted for (or by) a hydrophobic O residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; a cysteine or proline is CN substituted for (or by) any other residue; a residue having an electropositive side 0 chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative C residue, e.g. glutamyl or aspartyl; or a residue having a bulky side chain, e.g.

phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.

[0100] The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analogue, although variants also are selected to modify the characteristics of the CA proteins as needed.

Alternatively, the variant may be designed such that the biological activity of the CA protein is altered. .For example, glycosylation sites may be altered or removed, dominant negative mutations created, etc.

10101] Covalent modifications of CA polypeptides are included within the scope of this invention, for example for use in screening. One type of covalent modification includes reacting targeted amino acid residues of an CA polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or Cterminal residues of an CA polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking CA polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-CA antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, 1,1 -bis(diazoacetyl)-2-phenylethane, glutaraldehyde, Nhydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido- 1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate.

[0102] Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, S threonyl or tyrosyl residues, methylation of the a-amino groups of lysine, arginine, and histidine side chains Creighton, Proteins: Structure and Molecular 0 Properties, W.H. Freeman Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

C [0103] Another type of covalent modification of the CA polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence O CA polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence CA polypeptide.

[0104] Addition of glycosylation sites to CA polypeptides may be accomplished by altering the amino acid sequence thereof. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence CA polypeptide (for O-linked glycosylation sites). The CA amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the CA polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

[0105] Another means of increasing the number of carbohydrate moieties on the CA polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide.

Such methods are described in the art, in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, LA Crit. Rev. Biochem., pp. 259-306 (1981).

[0106] Removal of carbohydrate moieties present on the CA polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal.

Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

[0107] Another type of covalent modification of CA comprises linking the CA 0 polypeptide to one of a variety of nonproteinaceous polymers, polyethylene 0 glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S.

Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

O [0108] CA polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising an CA polypeptide fused to another, C heterologous polypeptide or amino acid sequence. In one embodiment, such a C chimeric molecule comprises a fusion of an CA polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the CA polypeptide, although internal fusions may also be tolerated in some instances. The presence of such epitope-tagged forms of an CA polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the CA polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of an CA polypeptide with an immunoglobulin or a particular region of an immunoglobulin.

For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

[0109] Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-hisgly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell.

Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

[0110] Also included with the definition of CA protein in one embodiment are other CA proteins of the CA family, and CA proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related CA proteins from humans or other organisms. As will be appreciated by those in the art, particularly Suseful probe and/or PCR primer sequences include the unique areas of the CA nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art.

[0111] In addition, as is outlined herein, CA proteins can be made that are longer than those encoded by the nucleic acids of the figures, for example, by the elucidation of additional sequences, the addition of epitope or purification tags, the addition of other fusion sequences, etc.

10112] CA proteins may also be identified as being encoded by CA nucleic acids.

Thus, CA proteins are encoded by nucleic acids that will hybridize to the sequences of the sequence listings, or their complements, as outlined herein.

[0113] In a preferred embodiment, the invention provides CA antibodies. In a preferred embodiment, when the CA protein is to be used to generate antibodies, for example for immunotherapy, the CA protein should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller CA protein will be able to bind to the full length protein. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.

[0114] In one embodiment, the term "antibody" includes antibody fragments, as are known in the art, including Fab, Fab 2 single chain antibodies (Fv for example), chimeric antibodies, etc., either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies.

[01151 Methods of preparing polyclonal antibodies are known to the skilled artisan.

Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion S protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL- TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The immunization protocol may be selected by one skilled in the art without undue Sexperimentation.

10116] The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by N Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1-112, or fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin.

Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth ofHGPRT-deficient cells.

[0117] In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for a protein encoded by a nucleic acid of Tables 1-112, or a fragment thereof, the other one is for any other antigen, and preferably for a cellsurface protein or receptor or receptor subunit, preferably one that is tumor specific.

S[0118] In a preferred embodiment, the antibodies to CA are capable of reducing or eliminating the biological function of CA, as is described below. That is, the addition of anti-CA antibodies (either polyclonal or preferably monoclonal) to CA (or cells C containing CA) may reduce or eliminate the CA activity. Generally, at least a C1 decrease in activity is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

[0119] In a preferred embodiment the antibodies to the CA proteins are humanized antibodies. Humanized forms of non human murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen binding subsequences of antibodies) which contain minimal sequence derived from non_human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non_human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non_human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non_human immunoglobulin and all or substantially all of the framework residues (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region typically that of a human immunoglobulin [Jones et al., Nature, 321:522_525 (1986); Riechmann et al., Nature, 332:323329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593_596 (1992)].

[0120] Methods for humanizing nonhuman antibodies are well known in the art.

Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is nonhuman. These non_human amino acid residues are S often referred to as import residues, which are typically taken from an import variable C domain. Humanization can be essentially performed following the method of Winter and co_workers [Jones et al., Nature, 321:522_525 (1986); Riechmann et al., Nature, 332:323_327 (1988); Verhoeyen et al., Science, 239:1534_1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[0121] Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boemer et al. are also available for the preparation of human monoclonal antibodies [Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p.

77 (1985) and Boemer et al., J. Immunol., 147(1):86_95 (1991)]. Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 779_783 (1992); Lonberg et al., Nature 368 856_859 (1994); Morrison, Nature 368, 81213 (1994); Fishwild et al., Nature Biotechnology 14, 845_51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev.

Immunol. 13 65_93 (1995).

[0122] By immunotherapy is meant treatment of a carcinoma with an antibody raised against an CA protein. As used herein, immunotherapy can be passive or active.

Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and O under conditions for expression of the antigen.

[0123] In a preferred embodiment, oncogenes which encode secreted growth factors C1 may be inhibited by raising antibodies against CA proteins that are secreted proteins C as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted CA protein.

[0124] In another preferred embodiment, the CA protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the CA protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules.

The antibody may cause down-regulation of the transmembrane CA protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the CA protein. The antibody is also an antagonist of the CA protein.

Further, the antibody prevents activation of the transmembrane CA protein. In one aspect, when the antibody prevents the binding of other molecules to the CA protein, the antibody prevents growth of the cell. The antibody may also sensitize the cell to cytotoxic agents, including, but not limited to TNF.-, TNF-, IL-1, INF. and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity. Thus, carcinomas may be treated by administering to a patient antibodies directed against the transmembrane CA protein.

[0125] In another preferred embodiment, the antibody is conjugated to a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the CA protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the CA protein. The S therapeutic moiety may inhibit enzymatic activity such as protease or protein kinase activity associated with carcinoma.

O [0126] In a preferred embodiment, the therapeutic moiety may also be a cytotoxic agent. In this method, targeting the cytotoxic agent to tumor tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with carcinomas, including lymphoma. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A 0 chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, 71 enomycin and the like. Cytotoxic agents also include radiochemicals made by 0 conjugating radioisotopes to antibodies raised against CA proteins, or binding of a CN radionuclide to a chelating agent that has been covalently attached to the antibody.

Targeting the therapeutic moiety to transmembrane CA proteins not only serves to increase the local concentration of therapeutic moiety in the carcinoma of interest, i.e., lymphoma, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety.

[0127] In another preferred embodiment, the CA protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the CA protein can be targeted within a cell, the nucleus, an antibody thereto contains a signal for that target localization, a nuclear localization signal.

[0128] The CA antibodies of the invention specifically bind to CA proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a binding constant in the range of at least 10 4 10- 6 with a preferred range being 7 10 9

M

1 [0129] In a preferred embodiment, the CA protein is purified or isolated after expression. CA proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample.

Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the CA protein may be purified using a standard anti-CA antibody column. Ultrafiltration S and diafiltration techniques, in conjunction with protein concentration, are also useful.

0 For general guidance in suitable purification techniques, see Scopes, Protein Purification, Springer-Verlag, NY (1982). The degree of purification necessary will S vary depending on the use of the CA protein. In some instances no purification will be necessary.

[0130] Once expressed and purified if necessary, the CA proteins and nucleic acids S are useful in a number of applications.

[0131] In one aspect, the expression levels of genes are determined for different cellular states in the carcinoma phenotype; that is, the expression levels of genes in normal tissue and in carcinoma tissue (and in some cases, for varying severities of lymphoma that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is unique to the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and downregulation of genes) in each of these states is obtained. Then, diagnosis may be done or confirmed: does tissue from a particular patient have the gene expression profile of normal or carcinoma tissue.

[0132] "Differential expression," or grammatical equivalents as used herein, refers to both qualitative as well as quantitative differences in the genes temporal and/or cellular expression patterns within and among the cells. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, for example, normal versus carcinoma tissue. That is, genes may be turned on or turned off in a particular state, relative to another state. As is apparent to the skilled artisan, any comparison of two or more states can be made. Such a qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques in one such state or cell type, but is not detectable in both. Alternatively, the determination is quantitative in that expression is increased or decreased; that is, the expression of the gene is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip® expression arrays, Lockhart, Nature Biotechnology, 14:1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, Northern analysis and RNase protection. As outlined above, preferably the change in expression upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably, at least about 200%, with from 300 to at least 1000% being especially preferred.

1 [0133] As will be appreciated by those in the art, this may be done by evaluation at either the gene transcript, or the protein level; that is, the amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, for example through the use of antibodies to the CA protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc.

Thus, the proteins corresponding to CA genes, i.e. those identified as being important in a particular carcinoma phenotype, lymphoma, can be evaluated in a diagnostic test specific for that carcinoma.

[0134] In a preferred embodiment, gene expression monitoring is done and a number of genes, i.e. an expression profile, is monitored simultaneously, although multiple protein expression monitoring can be done as well. Similarly, these assays may be done on an individual basis as well.

[0135] In this embodiment, the CA nucleic acid probes may be attached to biochips as outlined herein for the detection and quantification of CA sequences in a particular cell. The assays are done as is known in the art. As will be appreciated by those in the art, any number of different CA sequences may be used as probes, with single sequence assays being used in some cases, and a plurality of the sequences described herein being used in other embodiments. In addition, while solid-phase assays are described, any number of solution based assays may be done as well.

[0136] In a preferred embodiment, both solid and solution based assays may be used S to detect CA sequences that are up-regulated or down-regulated in carcinomas as Scompared to normal tissue. In instances where the CA sequence has been altered but 0 shows the same expression profile or an altered expression profile, the protein will be detected as outlined herein.

[0137] In a preferred embodiment nucleic acids encoding the CA protein are detected.

Although DNA or RNA encoding the CA protein may be detected, of particular interest are methods wherein the mRNA encoding a CA protein is detected. The presence of mRNA in a sample is an indication that the CA gene has been transcribed to form the mRNA, and suggests that the protein is expressed. Probes to detect the S mRNA can be any nucleotide/deoxynucleotide probe that is complementary to and base pairs with the mRNA and includes but is not limited to oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample.

Following washing to remove the non-specifically bound probe, the label is detected.

In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA.

Following washing to remove the non-specifically bound probe, the label is detected.

For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a CA protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5_bromo_4_chloro_3_indoyl phosphate.

(0138] In a preferred embodiment, any of the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The CA proteins, antibodies, nucleic acids, modified proteins and cells containing CA sequences are used in diagnostic assays. This can be done on an individual gene or corresponding polypeptide level, or as sets of assays.

[0139] As described and defined herein, CA proteins find use as markers of carcinomas, including lymphomas such as, but not limited to, Hodgkin's and non- Hodgkin lymphoma. Detection of these proteins in putative carcinoma tissue or patients allows for a determination or diagnosis of the type of carcinoma. Numerous S methods known to those of ordinary skill in the art find use in detecting carcinomas.

In one embodiment, antibodies are used to detect CA proteins. A preferred method separates proteins from a sample or patient by electrophoresis on a gel (typically a d denaturing and reducing protein gel, but may be any other type of gel including

C

isoelectric focusing gels and the like). Following separation of proteins, the CA protein is detected by immunoblotting with antibodies raised against the CA protein.

Methods of immunoblottingare well known to those of ordinary skill in the art.

[0140] In another preferred method, antibodies to the CA protein find use in in situ imaging techniques. In this method cells are contacted with from one to many antibodies to the CA protein(s). Following washing to remove non-specific antibody S binding, the presence of the antibody or antibodies is detected. In one embodiment C~ the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the CA protein(s) contains a detectable label. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of CA proteins. As will be appreciated by one of ordinary skill in the art, numerous other histological imaging techniques are useful in the invention.

[0141] In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

[01421 In another preferred embodiment, antibodies find use in diagnosing carcinomas from blood samples. As previously described, certain CA proteins are secreted/circulating molecules. Blood samples, therefore, are useful as samples to be probed or tested for the presence of secreted CA proteins. Antibodies can be used to detect the CA proteins by any of the previously described immunoassay techniques including ELISA, immunoblotting (Western blotting), immunoprecipitation, BIACORE technology and the like, as will be appreciated by one of ordinary skill in the art.

[0143] In a preferred embodiment, in situ hybridization of labeled CA nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including CA tissue and/or normal tissue, are made. In situ hybridization as is known in the art can S then be done.

S [01441 It is understood that when comparing the expression fingerprints between an

U

individual and a standard, the skilled artisan can make a diagnosis as well as a prognosis. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis.

[0145] In a preferred embodiment, the CA proteins, antibodies, nucleic acids, modified proteins and cells containing CA sequences are used in prognosis assays.

As above, gene expression profiles can be generated that correlate to carcinoma, S especially lymphoma, severity, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As S above, the CA probes are attached to biochips for the detection and quantification of CA sequences in a tissue or patient. The assays proceed as outlined for diagnosis.

[0146] In a preferred embodiment, any of the CA sequences as described herein are used in drug screening assays. The CA proteins, antibodies, nucleic acids, modified proteins and cells containing CA sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile ofpolypeptides. In one embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, Zlokamrnik, et al., Science 279, 84-8 (1998), Heid, et al., Genome Res., 6:986-994 (1996).

10147] In a preferred embodiment, the CA proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified CA proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the carcinoma phenotype. As above, this can be done by screening for modulators of gene expression or for modulators of protein activity. Similarly, this may be done on an individual gene or protein level or by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, supra.

S [0148] Having identified the CA genes herein, a variety of assays to evaluate the effects of agents on gene expression may be executed. In a preferred embodiment, N assays may be run on an individual gene or protein level. That is, having identified a particular gene as aberrantly regulated in carcinoma, candidate bioactive agents may

C

be screened to modulate the genes response. "Modulation" thus includes both an increase and a decrease in gene expression or activity. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tumor tissue, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits S a 4 fold increase in tumor compared to normal tissue, a decrease of about four fold is desired; a 10 fold decrease in tumor compared to normal tissue gives a 10 fold increase in expression for a candidate agent is desired, etc. Alternatively, where the CA sequence has been altered but shows the same expression profile or an altered expression profile, the protein will be detected as outlined herein.

[0149] As will be appreciated by those in the art, this may be done by evaluation at either the gene or the protein level; that is, the amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the level of the gene product itself can be monitored, for example through the use of antibodies to the CA protein and standard immunoassays.

Alternatively, binding and bioactivity assays with the protein may be done as outlined below.

[0150] In a preferred embodiment, gene expression monitoring is done and a number of genes, i.e. an expression profile, is monitored simultaneously, although multiple protein expression monitoring can be done as well.

[0151] In this embodiment, the CA nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of CA sequences in a particular cell. The assays are further described below.

[0152] Generally, in a preferred embodiment, a candidate bioactive agent is added to the cells prior to analysis. Moreover, screens are provided to identify a candidate bioactive agent which modulates a particular type of carcinoma, modulates CA proteins, binds to a CA protein, or interferes between the binding of a CA protein and an antibody.

[0153] The term "candidate bioactive agent" or "drug candidate" or grammatical equivalents as used herein describes any molecule, protein, oligopeptide, small organic or inorganic molecule, polysaccharide, polynuclcotide, etc., to be tested for S bioactive agents.that are capable of directly or indirectly altering either the carcinoma phenotype, binding to and/or modulating the bioactivity of an CA protein, or the expression of a CA sequence, including both nucleic acid sequences and protein sequences. In a particularly preferred embodiment, the candidate agent suppresses a CA phenotype, for example to a normal tissue fingerprint. Similarly, the candidate S agent preferably suppresses a severe CA phenotype. Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, at zero concentration or below the level of detection.

[0154] In one aspect, a candidate agent will neutralize the effect of an CA protein.

By "neutralize" is meant that activity of a protein is either inhibited or counter acted against so as to have substantially no effect on a cell.

[0155] Candidate agents encompass numerous chemical classes, though typically they are organic or inorganic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D.

Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.

[0156] Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonuclcotides.

Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through S conventional chemical, physical and biochemical means. Known pharmacological

C

agents may be subjected to directed or random chemical modifications, such as S acylation, alkylation, esterification, amidification to produce structural analogs.

[0157] In a preferred embodiment, the candidate bioactive agents are proteins. By "protein" herein is meant at least two covalently attached amino acids, which includes N proteins, polypeptides, oligopeptides and peptides. The protein may be made up of 0 naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures. Thus "amino acid", or "peptide residue", as used herein means both i naturally occurring and synthetic amino acids. For example, homo-phenylalanine, 0 citrulline and noreleucine are considered amino acids for the purposes of the C1 invention. "Amino acid" also includes imino acid residues such as proline and hydroxyproline. The side chains may be in either the or the configuration. In the preferred embodiment, the amino acids are in the or L-configuration. If nonnaturally occurring side chains are used, non-amino acid substituents may be used, for example to prevent or retard in vivo degradations.

[0158] In a preferred embodiment, the candidate bioactive agents are naturally occurring proteins or fragments of naturally occurring proteins. Thus, for example, cellular extracts containing proteins, or random or directed digests ofproteinaceous cellular extracts, may be used. In this way libraries of procaryotic and eucaryotic proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred.

[0159] In a preferred embodiment, the candidate bioactive agents are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of S the possible combinations over the length of the sequence, thus forming a library of Cr randomized candidate bioactive proteinaceous agents.

U [01601 In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, for example, of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

10161] In a preferred embodiment, the candidate bioactive agents are nucleic acids, as defined above.

[0162] As described above generally for proteins, nucleic acid candidate bioactive agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests ofprocaryotic or eucaryotic genomes may be used as is outlined above for proteins.

[01631 In a preferred embodiment, the candidate bioactive agents are organic chemical moieties, a wide variety of which are available in the literature.

[0164] In assays for altering the expression profile of one or more CA genes, after the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing the target sequences to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR occurring as needed, as will be appreciated by those in the art. For example, an in vitro transcription with labels covalently attached to the nucleosides is done. Generally, the nucleic acids are labeled with a label as defined herein, with biotin-FITC or PE, cy3 and cy5 being particularly preferred.

10165] In a preferred embodiment, the target sequence is labeled with, for example, a fluorescent, chemiluminescent, chemical, or radioactive signal, to provide a means of S detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected.

d Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence.

As known in the art, unbound labeled streptavidin is removed prior to analysis.

S [0166] As will be appreciated by those in the art, these assays can be direct F hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

[0167] A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.

[0168] These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

[0169] The reactions outlined herein may be accomplished in a variety of ways, as will be appreciated by those in the art. Components of the reaction may be added simultaneously, or sequentially, in any order, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents may be included in the assays. These include reagents like salts, buffers, neutral proteins, e.g.

albumin, detergents, etc which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inkibitors, nuclease inhibitors, anti-microbial agents, etc., may be used, depending on the sample preparation methods and purity of the target. In addition, either solid phase or solution based kinetic PCR) assays may be used.

[0170] Once the assay is run, the data is analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

[0171] In a preferred embodiment, as for the diagnosis and prognosis applications, having identified the differentially expressed gene(s) or mutated gene(s) important in any one state, screens can be run to alter the expression of the genes individually.

That is, screening for modulation of regulation of expression of a single gene can be done. Thus, for example, particularly in the case of target genes whose presence or absence is unique between two states, screening is done for modulators of the target gene expression.

[0172] In addition, screens can be done for novel genes that are induced in response to a candidate agent. After identifying a candidate agent based upon its ability to suppress a CA expression pattern leading to a normal expression pattern, or modulate a single CA gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated CA tissue reveals genes that are not expressed in normal tissue or CA tissue, but are expressed in agent treated tissue.

These agent specific sequences can be identified and used by any of the methods described herein for CA genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated CA tissue sample.

[0173] Thus, in one embodiment, a candidate agent is administered to a population of CA cells, that thus has an associated CA expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular O action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent a peptide) ma' be put into a viral construct such as a retroviral construct and added to the cell, such that expression of the peptide agent is accomplished; see PCT US97/01019, hereby expressly incorporated by reference.

C [0174] Once the candidate agent has been administered to the cells, the cells can be C washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

O [01751 Thus, for example, CA tissue may be screened for agents that reduce or suppress the CA phenotype. A change in at least one gene of the expression profile indicates that the agent has an effect on CA activity. By defining such a signature for the CA phenotype, screens for new drugs that alter the phenotype can be devised.

With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

[0176] In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself can be done.

The gene products of differentially expressed genes are sometimes referred to herein as "CA proteins" or an "CAP". The CAP may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of Tables 1-112.

Preferably, the CAP is a fragment. In another embodiment, the sequences are sequence variants as further described herein.

[0177] Preferably, the CAP is a fragment of approximately 14 to 24 amino acids long.

More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an Nterminal Cys to aid in solubility. In one embodiment, the c-terminus of the fragment is kept as a free acid and the n-terminus is a free amine to aid in coupling, to cysteine.

[0178] In one embodiment the CA proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the CA protein is conjugated to BSA.

'[0179] In a preferred embodiment, screening is done to alter the biological function of U the expression product of the CA gene. Again, having identified the importance of a Sgene in a particular state, screening for agents that bind and/or modulate the biological activity of the gene product can be run as is more fully outlined below.

[0180] In a preferred embodiment, screens are designed to first find candidate agents that can bind to CA proteins, and then these agents may be used in assays that evaluate the ability of the candidate agent to modulate the CAP activity and the Scarcinoma phenotype. Thus, as will be appreciated by those in the art, there are a number of different assays which may be run; binding assays and activity assays.

10181] In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more CA nucleic acids are made. In general, this is done as is known in the art. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the CA proteins can be used in the assays.

[0182] Thus, in a preferred embodiment, the methods comprise combining a CA protein and a candidate bioactive agent, and determining the binding of the candidate agent to the CA protein. Preferred embodiments utilize the human or mouse CA protein, although other mammalian proteins may also be used, for example for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative CA proteins may be used.

[0183] Generally, in a preferred embodiment of the methods herein, the CA protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas i microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic polystyrene), polysaccharides, nylon or nitrocellulose, TeflonM, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound C material is removed by washing. The sample receiving areas may then be blocked 0 through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

[0184] In a preferred embodiment, the CA protein is bound to the support, and a candidate bioactive agent is added to the assay. Alternatively, the candidate agent is bound to the support and the CA protein is added. Novel binding agents include specific antibodies, non_natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein_protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

[0185] The determination of the binding of the candidate bioactive agent to the CA protein may be done in a number of ways. In a preferred embodiment, the candidate bioactive agent is labeled, and binding determined directly. For example, this may be done by attaching all or a portion of the CA protein to a solid support, adding a labeled candidate agent (for example a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as is known in the art.

[0186] By "labeled" herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, e.g. radioisotope, fluorescers, enzyme, antibodies, particles such as magnetic particles, chemiluminescers, or specific binding molecules, etc. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal.

S [0187] In some embodiments, only one of the components is labeled. For example, Sthe proteins (or proteinaceous candidate agents) may be labeled at tyrosine positions S using 1251, or with fluorophores. Alternatively, more than one component may be labeled with different labels; using 1251 for the proteins, for example, and a fluorophor Sfor the candidate agents.

[0188] In a preferred embodiment, the binding of the candidate bioactive agent is determined through the use of competitive binding assays. In this embodiment, the competitor is a binding moiety known to bind to the target molecule CA protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding as between the bioactive agent and the binding moiety, with the binding moiety displacing the bioactive agent.

[0189] In one embodiment, the candidate bioactive agent is labeled. Either the candidate bioactive agent, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at any temperature which facilitates optimal activity, typically between 4 and 40 CC.

Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high through put screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

[0190] In a preferred embodiment, the competitor is added first, followed by the candidate bioactive agent. Displacement of the competitor is an indication that the candidate bioactive agent is binding to the CA protein and thus is capable of binding to, and potentially modulating, the activity of the CA protein. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent.

Alternatively, if the candidate bioactive agent is labeled, the presence of the label on the support indicates displacement.

[0191] In an alternative embodiment, the candidate bioactive agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the bioactive agent is bound to the CA protein with a higher affinity. Thus, if the candidate bioactive agent is labeled, the presence of the C label on the support, coupled with a lack of competitor binding, may indicate that the candidate agent is capable of binding to the CA protein.

S [0192] In a preferred embodiment, the methods comprise differential screening to identity bioactive agents that are capable of modulating the activity of the CA proteins. In this embodiment, the methods comprise combining a CA protein and a competitor in a first sample. A second sample comprises a candidate bioactive agent, a CA protein and a competitor. The binding of the competitor is determined for both N"1 samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the CA protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the CA protein.

[0193J Alternatively, a preferred embodiment utilizes differential screening to identify drug candidates that bind to the native CA protein, but cannot bind to modified CA proteins. The structure of the CA protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect CA bioactivity are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

[0194] Positive controls and negative controls may be used in the assays. Preferably all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, all samples are washed free of nonspecifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

[0195] A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc which may be used to facilitate optimal proteinprotein binding and/or reduce non_specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti_microbial agents, etc., may be used. The mixture of components may be added in any order that provides for the requisite binding.

U

[0196] Screening for agents that modulate the activity of CA proteins may also be done. In a preferred embodiment, methods for screening for a bioactive agent capable of modulating the activity of CA proteins comprise the steps of adding a candidate bioactive agent to a sample of CA proteins, as above, and determining an alteration in r the biological activity of CA proteins. "Modulating the activity of an CA protein" includes an increase in activity, a decrease in activity, or a change in the type or kind of activity present. Thus, in this embodiment, the candidate agent should both bind to CA proteins (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both in vitro screening methods, as are generally outlined above, and in vivo screening of cells for alterations in the presence, distribution, activity or amount of CA proteins.

[0197] Thus, in this embodiment, the methods comprise combining a CA sample and a candidate bioactive agent, and evaluating the effect on CA activity. By "CA activity" or grammatical equivalents herein is meant one of the CA protein's biological activities, including, but not limited to, its role in tumorigenesis, including cell division, preferably in lymphatic tissue, cell proliferation, tumor growth and transformation of cells. In one embodiment, CA activity includes activation of or by a protein encoded by a nucleic acid of Tables 1-112. An inhibitor of CA activity is the inhibition of any one or more CA activities.

[0198] In a preferred embodiment, the activity of the CA protein is increased; in another preferred embodiment, the activity of the CA protein is decreased. Thus, bioactive agents that are antagonists are preferred in some embodiments, and bioactive agents that are agonists may be preferred in other embodiments.

[0199] In a preferred embodiment, the invention provides methods for screening fbr bioactive agents capable of modulating the activity of a CA protein. The methods comprise adding a candidate bioactive agent, as defined above, to a cell comprising CA proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a CA protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

S [0200] In one aspect, the assays are evaluated in the presence or absence or previous S or subsequent exposure of physiological signals, for example hormones, antibodies, Speptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells cellcell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

1 0201] In this way, bioactive agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the CA protein.

S [0202] In one embodiment, a method of inhibiting carcinoma cancer cell division, is S provided. The method comprises administration of a carcinoma cancer inhibitor.

S [0203] In a preferred embodiment, a method of inhibiting lymphoma carcinoma cell division is provided comprising administration of a lymphoma carcinoma inhibitor.

[0204] In another embodiment, a method of inhibiting tumor growth is provided. The method comprises administration of a carcinoma cancer inhibitor. In a particularly preferred embodiment, a method of inhibiting tumor growth in lymphatic tissue is provided comprising administration of a lymphoma inhibitor.

[02051 In a further embodiment, methods of treating cells or individuals with cancer are provided. The method comprises administration of a carcinoma cancer inhibitor.

Preferably, the carcinoma is a lymphoma carcinoma.

[0206] In one embodiment, a carcinoma cancer inhibitor is an antibody as discussed above. In another embodiment, the carcinoma cancer inhibitor is an antisense molecule. Antisense molecules as used herein include antisense or sense oligonucleotides comprising a singe-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for carcinoma cancer molecules. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen, Cancer Res. 48:2659, (1988) and van der Krol et al., BioTechniques 6:958, (1988).

[0207] Antisense molecules may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule Sdoes not substantially interfere with the ability of the ligand binding molecule to bind Sto its corresponding molecule or receptor, or block entry of the sense or antisense Soligonucleotide or its conjugated version into the cell. Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to C methods of treatment.

[0208] The compounds having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a host, as previously described.

The agents may be administered in a variety of ways, orally, parenterally e.g., subcutaneously, intraperitoneally, intravascularly, etc. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways. The concentration of therapeutically active compound in the formulation may vary from about 0.1_100% wgt/vol. The agents may be administered alone or in combination with other treatments, radiation.

[0209] The pharmaceutical compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the like. Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically_active compounds. Diluents known to the art include aqueous media, vegetable and animal oils and fats. Stabilizing agents, wetting and emulsifying agents, salts for varying the osmotic pressure or buffers for securing an adequate pH value, and skin penetration enhancers can be used as auxiliary agents.

[0210] Without being bound by theory, it appears that the various CA sequences are important in carcinomas. Accordingly, disorders based on mutant or variant CA genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant CA genes comprising determining all or part of the sequence of at least one endogenous CA genes in a cell. As will be appreciated by those in the art, this may be done using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the CA genotype of an individual comprising determining all or part of the sequence of at least one CA gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different

C

samples of the same tissue. The method may include comparing the sequence of the S sequenced CA gene to a known CA gene, a wild-type gene. As will be appreciated by those in the art, alterations in the sequence of some oncogenes can be an indication of either the presence of the disease, or propensity to develop the disease, or prognosis evaluations.

1 [0211] The sequence of all or part of the CA gene can then be compared to the sequence of a known CA gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the CA gene of the patient and the known CA gene is indicative of a disease state or a propensity for a disease state, as outlined herein.

[0212] In a preferred embodiment, the CA genes are used as probes to determine the number of copies of the CA gene in the genome. For example, some cancers exhibit chromosomal deletions or insertions, resulting in an alteration in the copy number of a gene.

[0213] In another preferred embodiment CA genes are used as probes to determine the chromosomal location of the CA genes. Information such as chromosomal location finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in CA gene loci.

[0214] Thus, in one embodiment, methods of modulating CA in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-CA antibody that reduces or eliminates the biological activity of an endogenous CA protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a CA protein. As will be appreciated by those in the art, this may be accomplished in any number of ways. In a preferred embodiment, for example when the CA sequence is down-regulated in carcinoma, the activity of the CA gene is increased by increasing the amount of CA in the cell, for example by overexpressing the endogenous CA or by administering a gene encoding the CA sequence, using known gene-therapy techniques, for example. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous O gene using enhanced homologous recombination (EHR), for example as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Alternatively, for example when the CA sequence is up-regulated in carcinoma, the activity of the endogenous CA gene is decreased, for example by the administration of a CA antisense nucleic acid.

[0215] In one embodiment, the CA proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to CA proteins, which are useful as described herein. Similarly, the CA proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify CA antibodies. In a preferred embodiment, the antibodies are generated to epitopes unique to a CA protein; that is, the antibodies show little or no crossreactivity to other proteins. These antibodies find use in a number of applications.

For example, the CA antibodies may be coupled to standard affinity chromatography columns and used to purify CA proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the CA protein.

[0216] In one embodiment, a therapeutically effective dose of a CA or modulator thereof is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces the effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art, adjustments for CA degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.

10217] A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals, and organisms. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, and in the most preferred embodiment the patient is human.

[0218] The administration of the CA proteins and modulators of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, Sintramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, for example, in the treatment of wounds and inflammation, the CA proteins and modulators may be directly applied as a solution or spray.

S [0219J The pharmaceutical compositions of the present invention comprise a CA protein in a form suitable for administration to a patient. In the preferred 0 embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both g acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p_toluenesulfonic acid, salicylic acid and the like.

"Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

[0220] The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

Additives are well known in the art, and are used in a variety of formulations.

[0221] In a preferred embodiment, CA proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, CA genes (including both the full-length sequence, partial sequences, or regulatory sequences of the CA coding regions) can be administered in gene therapy applications, as is known in the art. These CA genes can include antisense applications, either as gene therapy for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.

[0222] In a preferred embodiment, CA genes are administered as DNA vaccines, either single genes or combinations of CA genes. Naked DNA vaccines are generally known in the art. Brower, Nature Biotechnology, 16:1304-1305 (1998).

[0223] In one embodiment, CA genes of the present invention are used as DNA vaccines. Methods for the use of genes as DNA vaccines are well known to one of ordinary skill in the art, and include placing a CA gene or portion of a CA gene under the control of a promoter for expression in a patient with carcinoma. The CA gene used for DNA vaccines can encode full-length CA proteins, but more preferably encodes portions of the CA proteins including peptides derived from the CA protein.

In a preferred embodiment a patient is immunized with a DNA vaccine comprising a plurality ofnucleotide sequences derived from a CA gene. Similarly, it is possible to immunize a patient with a plurality of CA genes or portions thereof as defined herein.

Without being bound by theory, expression of the polypeptide encoded by the DNA vaccine, cytotoxic T-cells, helper T-cells and antibodies are induced which recognize and destroy or eliminate cells expressing CA proteins.

[02241 In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the CA polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are known to those of ordinary skill in the art and find use in the invention.

[0225] In another preferred embodiment CA genes find use in generating animal models of carcinomas, particularly lymphoma carcinomas. As is appreciated by one of ordinary skill in the art, when the CA gene identified is repressed or diminished in CA tissue, gene therapy technology wherein antisense RNA directed to the CA gene will also diminish or repress expression of the gene. An animal generated as such serves as an animal model of CA that finds use in screening bioactive drug candidates. Similarly, gene knockout technology, for example as a result of S homologous recombination with an appropriate gene targeting vector, will result in the absence of the CA protein. When desired, tissue-specific expression or knockout of the CA protein may be necessary.

[0226] It is also possible that the CA protein is overexpressed in carcinoma. As such, S transgenic animals can be generated that overexpress the CA protein. Depending on the desired expression level, promoters of various strengths can be employed to 0 express the transgene. Also, the number of copies of the integrated transgene can be N determined and compared for a determination of the expression level of the transgene.

S Animals generated by such methods find use as animal models of CA and are CN additionally useful in screening for bioactive molecules to treat carcinoma.

102271 The CA nucleic acid sequences of the invention are depicted in Tables 1-112.

The sequences in Tables 1 (SEQ ID NOS:1-460) and 2 (SEQ ID NOS:461-952) depict mouse tags, i.e. the genomic insertion sites. SEQ ID NOS:953-1612 include genomic sequence, mRNA and coding sequences for both mouse and human. N/A indicates a gene that has been identified, but for which there has not been a name ascribed. The different sequences of Tables 3-112 are assigned the following SEQ ID Nos: Table 3 (mouse gene: Fscnl; human gene SNL) Mouse genomic sequence (SEQ ID NO:953) Mouse mRNA sequence (SEQ ID NO:954) Mouse coding sequence (SEQ ID NO:955) Human genomic sequence (SEQ ID NO:956) Human mRNA sequence (SEQ ID NO:957) Human coding sequence (SEQ ID NO:958) Table 4 (mouse gene Map3k6; human gene MAP3K6) Mouse genomic sequence (SEQ ID NO:959) Mouse mRNA sequence (SEQ ID NO:960) Mouse coding sequence (SEQ ID NO:961) Human genomic sequence (SEQ ID NO:962) Human mRNA sequence (SEQ ID NO:963) O Human coding sequence (SEQ ID NO:964) Table 5 (mouse gene Fosb; human gene FOSB) Mouse genomic sequence (SEQ ID NO:965) S Mouse mRNA sequence (SEQ ID NO:966) Mouse coding sequence (SEQ ID NO:967) Human genomic sequence (SEQ ID NO:968) Human mRNA sequence (SEQ ID NO:969) Human coding sequence (SEQ ID NO:970) STable 6 (mouse gene cmkbr7; human gene: CCR7) Mouse genomic sequence (SEQ ID NO:971) Mouse mRNA sequence (SEQ ID NO:972) Mouse coding sequence (SEQ ID NO:973) Human genomic sequence (SEQ ID NO:974) Human mRNA sequence (SEQ ID NO:975) Human coding sequence (SEQ ID NO:976) Table 7 (mouse gene: Ccndl; human gene: CCND1) Mouse genomic sequence (SEQ ID NO:977) Mouse mRNA sequence (SEQ ID NO:978) Mouse coding sequence (SEQ ID NO:979) Human genomic sequence (SEQ ID NO:980) Human mRNA sequence (SEQ ID NO:981) Human coding sequence (SEQ ID NO:982) Table 8 (mouse gene: Ccnd3; human gene: CCND3) Mouse genomic sequence (SEQ ID NO:983) Mouse mRNA sequence (SEQ ID NO:984) Mouse coding sequence (SEQ ID NO:985) Human genomic sequence (SEQ ID NO:986) Human mRNA sequence (SEQ ID NO:987) Human coding sequence (SEQ ID NO:988) S Table 9 (mouse gene: Wnt3; human gene: WNT3) S Mouse genomic sequence (SEQ ID NO:989) Mouse mRNA sequence (SEQ ID NO:990) Mouse coding sequence (SEQ ID NO:991) Human genomic sequence (SEQ ID NO:992) Human mRNA sequence (SEQ ID NO:993) Human coding sequence (SEQ ID NO:994) S Table 10 (mouse gene: Batf; human gene: BATF) S Mouse genomic sequence (SEQ ID NO:995) S Mouse mRNA sequence (SEQ ID NO:996) Mouse coding sequence (SEQ ID NO:997) Human genomic sequence (SEQ ID NO:998) Human mRNA sequence (SEQ ID NO:999) Human coding sequence (SEQ ID NO:1000) Table 11 (mouse gene: Irf4; human gene: IRF4) Mouse genomic sequence (SEQ ID NO:1001) Mouse mRNA sequence (SEQ ID NO:1002) Mouse coding sequence (SEQ ID NO:1003) Human genomic sequence (SEQ ID NO:1004) Human mRNA sequence (SEQ ID NO:1005) Human coding sequence (SEQ ID NO:1006) Table 12 (mouse gene: Notchl; human gene: NOTCH1) Mouse genomic sequence (SEQ ID NO:1007) Mouse mRNA sequence (SEQ ID NO:1008) Mouse coding sequence (SEQ ID NO:1009) Human genomic sequence (SEQ ID NO:1010) Human mRNA sequence (SEQ ID NO:1011) Human coding sequence (SEQ ID NO:1012) Table 13 (mouse gene: Myc; human gene MYC) Mouse genomic sequence (SEQ ID NO:1013) S Mouse mRNA sequence (SEQ ID NO: 1014) Mouse coding sequence (SEQ ID NO: 1015) 0 Human genomic sequence (SEQ ID NO:1016) Human mRNA sequence (SEQ ID NO:1017) Human coding sequence (SEQ ID NO:1018) C, Table 14 (mouse gene Bach2; human gene BACH2) N Mouse genomic sequence (SEQ ID NO:1019) Mouse mRNA sequence (SEQ ID NO:1020) Mouse coding sequence (SEQ ID NO:1021) OHuman genomic sequence (SEQ ID NO:1022) Human mRNA sequence (SEQ ID NO:1023) Human coding sequence (SEQ ID NO:1024) Table 15 (mouse gene Wnt human gene WNT 1) Mouse genomic sequence (SEQ ID NO:1025) Mouse mRNA sequence (SEQ ID NO:1026) Mouse coding sequence (SEQ ID NO:1027) Human genomic sequence (SEQ ID NO:1028) Human mRNA sequence (SEQ ID NO:1029) Human coding sequence (SEQ ID NO:1030) Table 16 (mouse gene Rasgrpl; human gene: RASGRP1) Mouse genomic sequence (SEQ ID NO:1031) Mouse mRNA sequence (SEQ ID NO:1032) Mouse coding sequence (SEQ ID NO:1033) Human genomic sequence (SEQ ID NO:1034) Human mRNA sequence (SEQ ID NO:1035) Human coding sequence (SEQ ID NO:1036) Table 17 (mouse gene: Nmycl; human gene: MYCN) Mouse genomic sequence (SEQ ID NO:1037) Mouse mRNA sequence (SEQ ID NO:1038) Mouse coding sequence (SEQ ID NO:1039) Human genomic sequence (SEQ ID NO: 1040) S Human mRNA sequence (SEQ ID NO: 1041) D Human coding sequence (SEQ ID NO:1042) Table 18 (mouse gene: Myb; human gene: MYB) Mouse genomic sequence (SEQ ID NO:1,043) SMouse mRNA sequence (SEQ ID NO:1044) Mouse coding sequence (SEQ ID NO:1045) Human genomic sequence (SEQ ID NO: 1046) Human mRNA sequence (SEQ ID NO:1047) Human coding sequence (SEQ ID NO:1048) Table 19 (mouse gene: Sox4; human gene: SOX4) Mouse genomic sequence (SEQ ID NO:1049) Mouse mRNA sequence (SEQ ID NO:1050) Mouse coding sequence (SEQ ID NO:1051) Human genomic sequence (SEQ ID NO:1052) Human mRNA sequence (SEQ ID NO:1053) Human coding sequence (SEQ ID NO: 1054) Table 20 (mouse gene: Tcofl; human gene: TCOF1) Mouse genomic sequence (SEQ ID NO: 1055) Mouse mRNA sequence (SEQ ID NO:1056) Mouse coding sequence (SEQ ID NO:1057) Human genomic sequence (SEQ ID NO:1058) Human mRNA sequence (SEQ ID NO: 1059) Human coding sequence (SEQ ID NO:1060) Table 21 (mouse gene: Pimi; human gene: PIM1) Mouse genomic sequence (SEQ ID NO:1061) Mouse mRNA sequence (SEQ ID NO:1062) Mouse coding sequence (SEQ ID NO:1063) Human genomic sequence (SEQ ID NO:1064) Human mRNA sequence (SEQ ID NO:1065) S Human coding sequence (SEQ ID NO:1066) Table 22 (mouse gene: Wnt3a; human gene: WNT3A) Mouse genomic sequence (SEQ ID NO:1067) Mouse mRNA sequence (SEQ ID NO:1068) Mouse coding sequence (SEQ ID NO:1069) C Human genomic sequence (SEQ ID NO:1070) C Human mRNA sequence (SEQ IDNO:1071) Human coding sequence (SEQ ID NO:1072) Table 23 (mouse gene: Ly6e; human gene LY6E) Mouse genomic sequence (SEQ ID NO:1073) Mouse mRNA sequence (SEQ ID NO:1074) Mouse coding sequence (SEQ ID NO:1075) Human genomic sequence (SEQ ID NO:1076) Human mRNA sequence (SEQ ID NO:1077) Human coding sequence (SEQ ID NO:1078) Table 24 (mouse gene: Rasa2; human gene RASA2) Mouse genomic sequence (SEQ ID NO: 1079) Mouse mRNA sequence (SEQ ID NO:1080) Mouse coding sequence (SEQ ID NO:1081) Human genomic sequence (SEQ ID NO:1082) Human mRNA sequence (SEQ ID NO:1083) Human coding sequence (SEQ ID NO:1084) Table 25 (mouse gene: Gatal; human gene GATA1) Mouse genomic sequence (SEQ ID NO:1085) Mouse mRNA sequence (SEQ ID NO:1086) Mouse coding sequence (SEQ ID NO:1087) Human genomic sequence (SEQ ID NO:1088) Human mRNA sequence (SEQ ID NO:1089) Human coding sequence (SEQ ID NO:1090) Table 26 (mouse gene: Fkbp5; human gene Mouse genomic sequence (SEQ ID NO: 1091) SMouse mRNA sequence (SEQ ID NO:1092) Mouse coding sequence (SEQ ID NO:1093) Human genomic sequence (SEQ ID NO: 1094) Human mRNA sequence (SEQ ID NO:1095) Human coding sequence (SEQ ID NO:1096) N Table 27 (mouse gene: Rel; human gene REL) Mouse genomic sequence (SEQ ID NO: 1097) S Mouse mRNA sequence (SEQ ID NO: 1098) Mouse coding sequence (SEQ ID NO:1099) Human genomic sequence (SEQ ID NO:1100) Human mRNA sequence (SEQ ID NO: 1101) Human coding sequence (SEQ ID NO: 1102) Table 28 (mouse gene: Icsbp; human gene ICSBP1) Mouse genomic sequence (SEQ ID NO:1103) Mouse mRNA sequence (SEQ ID NO:1104) Mouse coding sequence (SEQ ID NO:1105) Human genomic sequence (SEQ ID NO:1106) Human mRNA sequence (SEQ ID NO:1107) Human coding sequence (SEQ ID NO:1108) Table 29 (mouse gene: Bmil; human gene BMI1) Mouse genomic sequence (SEQ ID NO:1109) Mouse mRNA sequence (SEQ ID NO:1110) Mouse coding sequence (SEQ ID NO: 1111) Human genomic sequence (SEQ ID NO:1112) Human mRNA sequence (SEQ ID NO: 1113) Human coding sequence (SEQ ID NO: 1114) Table 30 (mouse gene: Runxl; human gene RUNX1) Mouse genomic sequence (SEQ ID NO: 1115) Mouse mRNA sequence (SEQ ID NO:1116) Mouse coding sequence (SEQ ID NO:1117) Human genomic sequence (SEQ ID NO:1 118) Human mRNA sequence (SEQ ID NO: 1119) Human coding sequence (SEQ ID NO: 1120) Table 31 (mouse gene: I12ra; human gene IL2RA) Mouse genomic sequence (SEQ ID NO:1121) Mouse mRNA sequence (SEQ ID NO:1122) Mouse coding sequence (SEQ ID NO:1123) Human genomic sequence (SEQ ID NO:1124) Human mRNA sequence (SEQ ID NO:1125) Human coding sequence (SEQ ID NO:1126) Table 32 (mouse gene: Nfkbl; human gene NFKB 1) Mouse genomic sequence (SEQ ID NO:1127) Mouse mRNA sequence (SEQ ID NO:1128) Mouse coding sequence (SEQ ID NO:1129) Human genomic sequence (SEQ ID NO: 1130) Human mRNA sequence (SEQ ID NO:1131) Human coding sequence (SEQ ID NO:1132) Table 33 (mouse gene: Fyn; human gene FYN) Mouse genomic sequence (SEQ ID NO: 1133) Mouse mRNA sequence (SEQ ID NO:1134) Mouse coding sequence (SEQ ID NO: 1135) Human genomic sequence (SEQ ID NO:1136) Human mRNA sequence (SEQ ID NO:1137) Human coding sequence (SEQ ID NO:1138) Table 34 (mouse gene: Nfkbill; human gene NFKBIL1) Mouse genomic sequence (SEQ ID NO:1139) Mouse mRNA sequence (SEQ ID NO:1140) Mouse coding sequence (SEQ ID NO:1141)

O

Human genomic sequence (SEQ ID NO: 1142) Human mRNA sequence (SEQ ID NO:1143) Human coding sequence (SEQ ID NO:1144) Table 35 (mouse gene: Flt3; human gene FLT3) Mouse genomic sequence (SEQ ID NO:1145) S Mouse mRNA sequence (SEQ ID NO: 1146) Mouse coding sequence (SEQ ID NO: 1147) C- Human genomic sequence (SEQ ID NO: 1148) 0 Human mRNA sequence (SEQ ID NO: 1149) C Human coding sequence (SEQ ID NO: 1150) Table 36 (mouse gene: Dntt; human gene DNTT) Mouse genomic sequence (SEQ ID NO:1151) Mouse mRNA sequence (SEQ ID NO:1152) Mouse coding sequence (SEQ ID NO:1153) Human genomic sequence (SEQ ID NO: 1154) Human mRNA sequence (SEQ ID NO: 1155) Human coding sequence (SEQ ID NO:1156) Table 37 (mouse gene: Znfnlal; human gene ZNFN1A1) Mouse genomic sequence (SEQ ID NO:1157) Mouse mRNA sequence (SEQ ID NO:1158) Mouse coding sequence (SEQ ID NO:1159) Human genomic sequence (SEQ ID NO:1160) Human mRNA sequence (SEQ ID NO:1161) Human coding sequence (SEQ ID NO:1162) Table 38 (mouse gene: Tbx21; human gene TBX21) Mouse genomic sequence (SEQ ID NO:1163) Mouse mRNA sequence (SEQ ID NO:1164) Mouse coding sequence (SEQ ID NO:1165) Human genomic sequence (SEQ ID NO:1166) Human mRNA sequence (SEQ ID NO:1167) S Human coding sequence (SEQ ID NO: 1168) Table 39 (mouse gene: Stat5b; human gene Mouse genomic sequence (SEQ ID NO: 1169) S Mouse mRNA sequence (SEQ ID NO: 1170) Mouse coding sequence (SEQ ID NO:1171) C1 Human genomic sequence (SEQ ID NO: 1172) S Human mRNA sequence (SEQ ID NO:1173) Human coding sequence (SEQ ID NO: 1174) S Table 40 (mouse gene: Sema4d; human gene SEMA4D) Mouse genomic sequence (SEQ ID NO: 1175) Mouse mRNA sequence (SEQ ID NO:1176) Mouse coding sequence (SEQ ID NO 1177) Human genomic sequence (SEQ ID NO 1178) Human mRNA sequence (SEQ ID NO:1179) Human coding sequence (SEQ ID NO:1180) Table 41 (mouse gene: Mdm2; human gene MDM2) Mouse genomic sequence (SEQ ID NO:1181) Mouse mRNA sequence (SEQ ID NO:1182) Mouse coding sequence (SEQ ID NO:1183) Human genomic sequence (SEQ ID NO:1184) Human mRNA sequence (SEQ ID NO:1185) Human coding sequence (SEQ ID NO:1186) Table 42 (mouse gene: Prlr; human gene PRLR) Mouse genomic sequence (SEQ ID NO:1187) Mouse mRNA sequence (SEQ ID NO:1188) Mouse coding sequence (SEQ ID NO:1189) Human genomic sequence (SEQ ID NO: 1190) Human mRNA sequence (SEQ ID NO:1191) Human coding sequence (SEQ ID NO: 1192) S Table 43 (mouse gene: Topl; human gene TOP1) Mouse genomic sequence (SEQ ID NO:1193) J Mouse mRNA sequence (SEQ ID NO:1194) Mouse coding sequence (SEQ ID NO: 1195) Human genomic sequence (SEQ ID NO: 1196) Human mRNA sequence (SEQ ID NO:1197) O Human coding sequence (SEQ ID NO: 1198) Table 44 (mouse gene: DusplO; human gene DUSPI0) Mouse genomic sequence (SEQ ID NO: 1199) Mouse mRNA sequence (SEQ ID NO: 1200) Mouse coding sequence (SEQ ID NO:1201) Human genomic sequence (SEQ ID NO:1202) Human mRNA sequence (SEQ ID NO:1203) Human coding sequence (SEQ ID NO:1204) Table 45 (mouse gene: Fil; human gene FLII) ,Mouse genomic sequence (SEQ ID NO:1205) Mouse mRNA sequence (SEQ ID NO:1206) Mouse coding sequence (SEQ ID NO:1207) Human genomic sequence (SEQ ID NO:1208) Human mRNA sequence (SEQ ID NO: 1209) Human coding sequence (SEQ ID NO:1210) Table 46 (mouse gene: Tk2; human gene TK2) Mouse genomic sequence (SEQ ID NO:1211) Mouse mRNA sequence (SEQ ID NO:1212) Mouse coding sequence (SEQ ID NO:1213) Human genomic sequence (SEQ ID NO:1214) Human mRNA sequence (SEQ ID NO:1215) Human coding sequence (SEQ ID NO:1216) Table 47 (mouse gene: Nuprl) Mouse genomic sequence (SEQ ID NO:1217) Mouse mRNA sequence (SEQ ID NO:1218) S Mouse coding sequence (SEQ ID NO:1219) O Human genomic sequence (SEQ ID NO:1220) Human mRNA sequence (SEQ ID NO:1221) Human coding sequence (SEQ ID NO: 1222) C Table 48 (mouse gene: Zfhxlb; human gene ZFHX1B) Mouse genomic sequence (SEQ ID NO: 1223) Mouse mRNA sequence (SEQ ID NO: 1224) S Mouse coding sequence (SEQ ID NO:1225) Human genomic sequence (SEQ ID NO:1226) Human mRNA sequence (SEQ ID NO:1227) Human coding sequence (SEQ ID NO:1228) Table 49 (mouse gene: Vdacl; human gene VDAC1) Mouse genomic sequence (SEQ ID NO: 1229) Mouse mRNA sequence (SEQ ID NO:1230) Mouse coding sequence (SEQ ID NO:1231) Human genomic sequence (SEQ ID NO:1232) Human mlRA sequence (SEQ ID NO:1233) Human coding sequence (SEQ ID NO:1234) Table 50 (mouse gene: Nfatcl; human gene NFATCI) Mouse genomic sequence (SEQ ID NO: 1235) Mouse mRNA sequence (SEQ ID NO:1236) Mouse coding sequence (SEQ ID NO:1237) Human genomic sequence (SEQ ID NO:1238) Human mRNA sequence (SEQ ID NO: 1239) Human coding sequence (SEQ ID NO:1240) Table 51 (mouse gene: Syk; human gene SYK) Mouse genomic sequence (SEQ ID NO:1241) Mouse mRNA sequence (SEQ ID NO:1242) Mouse coding sequence (SEQ ID NO:1243) Human genomic sequence (SEQ ID NO:1244) Human mRNA sequence (SEQ ID NO:1245) Human coding sequence (SEQ ID NO:1246) S Table 52 (mouse gene: Gnbl; human gene GNB1) Mouse genomic sequence (SEQ ID NO:1247) Mouse mRNA sequence (SEQ D NO:1248) Mouse codimRNA sequence (SEQ ID NO:1248) 0 Mouse coding sequence (SEQ ID NO: 1249) N, Human genomic sequence (SEQ ID NO:1250) O Human mRNA sequence (SEQ ID NO:1251) Human coding sequence (SEQ ID NO: 1252).

Table 53 (mouse gene: Ccnd2; human gene CCND2) Mouse genomic sequence (SEQ ID NO:1253) Mouse mRNA sequence (SEQ ID NO:1254) Mouse coding sequence (SEQ ID NO:1255) Human genomic sequence (SEQ ID NO:1256) Human mRNA sequence (SEQ ID NO:1257) Human coding sequence (SEQ ID NO: 1258) Table 54 (mouse gene Tnfrsf6; human gene TNFRSF6) Mouse genomic sequence (SEQ ID NO:1259) Mouse mRNA sequence (SEQ ID NO:1260) Mouse coding sequence (SEQ ID NO:1261) Human genomic sequence (SEQ ID NO:1262) Human mRNA sequence (SEQ ID NO:1263) Human coding sequence (SEQ ID NO:1264) Table 55 (mouse gene Irf2; human gene IRF2) Mouse genomic sequence (SEQ ID NO:1265) Mouse mRNA sequence (SEQ ID NO:1266) Mouse coding sequence (SEQ ID NO:1267) Human genomic sequence (SEQ ID NO:1268) Human mRNA sequence (SEQ ID NO:1269) O Human coding sequence (SEQ ID NO:1270) U) Table 56 (mouse gene Morf; human gene: MORF) Mouse genomic sequence (SEQ ID NO:1271) Mouse mRNA sequence (SEQ ID NO:1272) Mouse coding sequence (SEQ ID NO:1273) g Human genomic sequence (SEQ ID NO: 1274) N Human mRNA sequence (SEQ ID NO:1275) Human coding sequence (SEQ ID NO: 1276) Table 57 (mouse gene: Runx3; human gene: RUNX3) Mouse genomic sequence (SEQ ID NO:1277) Mouse mRNA sequence (SEQ ID NO:1'278) Mouse coding sequence (SEQ ID NO:1279) Human genomic sequence (SEQ ID NO:1280) Human mRNA sequence (SEQ ID NO:1281) Human coding sequence (SEQ ID NO:1282) Table 58 (mouse gene: Bell Ib; human gene: BCLI IB) Mouse genomic sequence (SEQ ID NO:1283) Mouse mRNA sequence (SEQ ID NO:1284) Mouse coding sequence (SEQ ID NO:1285) Human genomic sequence (SEQ ID NO:1286) Human mRNA sequence (SEQ ID NO:1287) Human coding sequence (SEQ ID NO:1288) Table 59 (mouse gene: Arhgefl; human gene: ARHGEF1) Mouse genomic sequence (SEQ ID NO:1289) Mouse mRNA sequence (SEQ ID NO: 1290) Mouse coding sequence (SEQ ID NO:1291) Human genomic sequence (SEQ ID NO:1292) Human mRNA sequence (SEQ ID NO: 1293) Human coding sequence (SEQ ID NO:1294) Table 60 (mouse gene: Ptprk; human gene: PTPRK) Mouse genomic sequence (SEQ ID NO:1295) U Mouse mRNA sequence (SEQ ID NO: 1296) Mouse coding sequence (SEQ ID NO:1297) Human genomic sequence (SEQ ID NO:1298) Human mRNA sequence (SEQ ID NO:1299) Human coding sequence (SEQ ID NO: 1300) Table 61 (mouse gene: Mcmd5; human gene: Mouse genomic sequence (SEQ ID NO:1301) Mouse mRNA sequence (SEQ ID NO:1302) Mouse coding sequence (SEQ ID NO:1303) Human genomic sequence (SEQ ID NO:1304) Human mRNA sequence (SEQ ID NO:1305) Human coding sequence (SEQ ID NO:1306) Table 62 (mouse gene: Matn4; human gene: MATN4) Mouse genomic sequence (SEQ ID NO:1307) Mouse mRNA sequence (SEQ ID NO:1308) Mouse coding sequence (SEQ ID NO:1309) Human genomic sequence (SEQ ID NO:1310) Human mRNA sequence (SEQ ID NO:1311) Human coding sequence (SEQ ID NO:1312) Table 63 (mouse gene: Tnfsfl 1; human gene TNFSFI1) Mouse genomic sequence (SEQ ID NO:1313) Mouse mRNA sequence (SEQ ID NO:1314) Mouse coding sequence (SEQ ID NO:1315) Human genomic sequence (SEQ ID NO:1316) Human mRNA sequence (SEQ ID NO:1317) Human coding sequence (SEQ ID NO:1318) Table 64 (mouse gene: Itk; human gene ITK) Mouse genomic sequence (SEQ ID NO: 1319) S Mouse mRNA sequence (SEQ ID NO:1320) S Mouse coding sequence (SEQ ID NO:1321) Human genomic sequence (SEQ ID NO: 1322) Human mRNA sequence (SEQ ID NO:1323) Human coding sequence (SEQ ID NO:1324) C Table 65 (mouse gene: Fish; human gene: N/A) C Mouse genomic sequence (SEQ ID NO:1325) S Mouse mRNA sequence (SEQ ID NO:1326) Mouse coding sequence (SEQ ID NO:1327) Human genomic sequence (SEQ ID NO: 1328) Human mRNA sequence (SEQ ID NO:1329) Human coding sequence (SEQ ID NO:1330) Table 66 (mouse gene: Egr2; human gene EGR2) Mouse genomic sequence (SEQ ID NO:1331) Mouse mRNA sequence (SEQ ID NO:1332) Mouse coding sequence (SEQ ID NO:1333) Human genomic sequence (SEQ ID NO:1334) Human mRNA sequence (SEQ ID NO:1335) Human coding sequence (SEQ ID NO:1336) Table 67 (mouse gene: Sosl; human gene SOS1) Mouse genomic sequence (SEQ ID NO: 1337) Mouse mRNA sequence (SEQ ID NO:1338) Mouse coding sequence (SEQ ID NO:1339) Human genomic sequence (SEQ ID NO:1340) Human mRNA sequence (SEQ ID NO:1341) Human coding sequence (SEQ ID NO:1342) Table 68 (mouse gene: Pou2afl; human gene POU2AF1) Mouse genomic sequence (SEQ ID NO:1343) Mouse mRNA sequence (SEQ ID NO:1344) Mouse coding sequence (SEQ ID NO:1345)

O

Human genomic sequence (SEQ ID NO:1346) Human mRNA sequence (SEQ ID NO:1347) S Human coding sequence (SEQ ID NO:1348) Table 69 (mouse gene: Mef2c; human gene MEF2C) Mouse genomic sequence (SEQ ID NO:1349) Mouse mRNA sequence (SEQ ID NO:1350) Mouse coding sequence (SEQ ID NO:1351) Human genomic sequence (SEQ ID NO:1352) Human mRNA sequence (SEQ ID NO:1353) S Human coding sequence (SEQ ID NO: 1354) Table 70 (mouse gene: Map3k8; human gene MAP3K8) Mouse genomic sequence (SEQ ID NO:1355) Mouse mRNA sequence (SEQ ID NO:1356) Mouse coding sequence (SEQ ID NO:1357) Human genomic sequence (SEQ ID NO:1358) Human mRNA sequence (SEQ ID NO:1359) Human coding sequence (SEQ ID NO: 1360) Table 71 (mouse gene: Fgfr3; human gene FGFR3) Mouse genomic sequence (SEQ ID NO:1361) Mouse mRNA sequence (SEQ ID NO: 1362) Mouse coding sequence (SEQ ID NO:1363) Human genomic sequence (SEQ ID NO:1364) Human mRNA sequence (SEQ ID NO:1365) Human coding sequence (SEQ ID NO:1366) Table 72 (mouse gene: Cbx8; human gene CBX8) Mouse genomic sequence (SEQ ID NO:1367) Mouse mRNA sequence (SEQ ID NO:1368) Mouse coding sequence (SEQ ID NO:1369) Human genomic sequence (SEQ ID NO:1370) Human mRNA sequence (SEQ ID NO:1371) S Human coding sequence (SEQ ID NO:1372) Table 73 (mouse gene: Lmo2; human gene LMO2) Mouse genomic sequence (SEQ ID NO: 1373) S Mouse mRNA sequence (SEQ ID NO:1374) Mouse coding sequence (SEQ ID NO:1375) C1 Human genomic sequence (SEQ ID NO:1376) C Human mRNA sequence (SEQ ID NO: 1377) Human coding sequence (SEQ ID NO: 1378) Table 74 (mouse gene: Itprl; human gene ITPRI) Mouse genomic sequence (SEQ ID NO:1379) Mouse mRNA sequence (SEQ ID NO: 1380) Mouse coding sequence (SEQ ID NO:1381) Human genomic sequence (SEQ ID NO:1382) Human mRNA sequence (SEQ ID NO:1383) Human coding sequence (SEQ ID NO: 1384) Table 75 (mouse gene: Sell; human gene SELL) Mouse genomic sequence (SEQ ID NO:1385) Mouse mRNA sequence (SEQ ID NO:1386) Mouse coding sequence (SEQ ID NO:1387) Human genomic sequence (SEQ ID NO:1388) Human mRNA sequence (SEQ ID NO: 1389) Human coding sequence (SEQ ID NO:1390) Table 76 (mouse gene: Dpt; human gene DPT) Mouse genomic sequence (SEQ ID NO:1391) Mouse mRNA sequence (SEQ ID NO:1392) Mouse coding sequence (SEQ ID NO:1393) Human genomic sequence (SEQ ID NO:1394) Human mRNA sequence (SEQ ID NO:1395) Human coding sequence (SEQ ID NO:1396) S Table 77 (mouse gene: Pap; human gene PAP) Mouse genomic sequence (SEQ ID NO:1397) Mouse mRNA sequence (SEQ ID NO:1398) Mouse coding sequence (SEQ ID NO:1399) Human genomic sequence (SEQ ID NO: 1400) Human mRNA sequence (SEQ ID NO:1401) Human coding sequence (SEQ ID NO:1402) Ci Table 78 (mouse gene: Blm; human gene BLM) 0 Mouse genomic sequence (SEQ ID NO:1403) C Mouse mRNA sequence (SEQ ID NO: 1404) Mouse coding sequence (SEQ ID NO:1405) Human genomic sequence (SEQ ID NO:1406) Human mRNA sequence (SEQ ID NO: 1407) Human coding sequence (SEQ ID NO:1408) Table 79 (mouse gene: Blrl; human gene BLRI) Mouse genomic sequence (SEQ ID NO: 1409) Mouse mRNA sequence (SEQ ID NO:1410) Mouse coding sequence (SEQ ID NO:1411) Human genomic sequence (SEQ ID NO:1412) Human mRNA sequence (SEQ ID NO:1413) Human coding sequence (SEQ ID NO:1414) Table 80 (mouse gene: Ptp4a2; human gene PTP4A2) Mouse genomic sequence (SEQ ID NO:1415) Mouse mRNA sequence (SEQ ID NO:1416) Mouse coding sequence (SEQ ID NO:1417) Human genomic sequence (SEQ ID NO:1418) Human mRNA sequence (SEQ ID NO:1419) Human coding sequence (SEQ ID NO:1420) Table 81 (mouse gene: Mcm3ap; human gene MCM3AP) Mouse genomic sequence (SEQ ID NO:1421) Mouse mRNA sequence (SEQ ID NO:1422) Mouse coding sequence (SEQ ID NO:1423) Human genomic sequence (SEQ ID NO:1424) Human mRNA sequence (SEQ ID NO:1425) Human coding sequence (SEQ ID NO: 1426) Table 82 (mouse gene: Jak2; human gene JAK2) Mouse genomic sequence (SEQ ID NO:1427) Mouse mRNA sequence (SEQ ID NO:1428) Mouse coding sequence (SEQ ID NO:1429) Human genomic sequence (SEQ ID NO:1430) Human mRNA sequence (SEQ ID NO:1431) Human coding sequence (SEQ ID NO: 1432) Table 83 (mouse gene: Fusl; human gene FUS 1) Mouse genomic sequence (SEQ ID NO:1433) Mouse mRNA sequence (SEQ ID NO: 1434) Mouse coding sequence (SEQ ID NO:1435) Human genomic sequence (SEQ ID NO:1436) Human mRNA sequence (SEQ ID NO: 1437) Human coding sequence (SEQ ID NO:1438) Table 84 (mouse gene: Rassfl; human gene RASSF1) Mouse genomic sequence (SEQ ID NO:1439) Mouse mRNA sequence (SEQ ID NO:1440) Mouse coding sequence (SEQ ID NO:1441) Human genomic sequence (SEQ ID NO:1442) Human mRNA sequence (SEQ ID NO:1443) Human coding sequence (SEQ ID NO:1444) Table 85 (mouse gene: Pik3rl; human gene PIK3RI) Mouse genomic sequence (SEQ ID NO:1445) Mouse mRNA sequence (SEQ ID NO:1446) Mouse coding sequence (SEQ ID NO:1447) Human genomic sequence (SEQ ID NO: 1448) Human mRNA sequence (SEQ ID NO: 1449) Human coding sequence (SEQ ID NO: 1450) Table 86 (mouse gene: Braf; human gene BRAF) Mouse genomic sequence (SEQ ID NO:1451) Mouse mRNA sequence (SEQ ID NO:1452) Mouse coding sequence (SEQ ID NO:1453) Human genomic sequence (SEQ ID NO:1454) Human mRNA sequence (SEQ ID NO:1455) Human coding sequence (SEQ ID NO:1456) Table 87 (mouse gene: Tle3; human gene: TLE3) Mouse genomic sequence (SEQ ID NO:1457) Mouse mRNA sequence (SEQ ID NO:1458) Mouse coding sequence (SEQ ID NO:1459) Human genomic sequence (SEQ ID NO:1460) Human mRNA sequence (SEQ ID NO: 1461) Human coding sequence (SEQ ID NO:1462) Table 88 (mouse gene: Nek2; human gene NEK2) Mouse genomic sequence (SEQ ID NO:1463) Mouse mRNA sequence (SEQ ID NO:1464) Mouse coding sequence (SEQ ID NO:1465) Human genomic sequence (SEQ ID NO:1466) Human mRNA sequence (SEQ ID NO: 1467) Human coding sequence (SEQ ID NO:1468) Table 89 (mouse gene: Nr3cl; human gene NR3C1) Mouse genomic sequence (SEQ ID NO: 1469) Mouse mRNA sequence (SEQ ID NO:1470) Mouse coding sequence (SEQ ID NO:1471) Human genomic sequence (SEQ ID NO:1472) Human mRNA sequence (SEQ ID NO: 1473) Human coding sequence (SEQ ID NO:1474) O Table 90 (mouse gene: Dadl; human gene DAD1) Mouse genomic sequence (SEQ ID NO: 1475) 0 Mouse mRNA sequence (SEQ ID NO:1476) Mouse coding sequence (SEQ ID NO:1477) Human genomic sequence (SEQ ID NO:1478) C Human mRNA sequence (SEQ ID NO: 1479) Human coding sequence (SEQ ID NO: 1480) Table 91 (mouse gene: Lck; human gene LCK) Mouse genomic sequence (SEQ ID NO:1481) Mouse mRNA sequence (SEQ ID NO:1482) Mouse coding sequence (SEQ ID NO:1483) Human genomic sequence (SEQ ID NO:1484) Human mRNA sequence (SEQ ID NO:1485) Human coding sequence (SEQ ID NO:1486) Table 92 (mouse gene: Git2; human gene GIT2) Mouse genomic sequence (SEQ ID NO: 1487) Mouse mRNA sequence (SEQ ID NO:1488) Mouse coding sequence (SEQ ID NO:1489) Human genomic sequence (SEQ ID NO:1490) Human mRNA sequence (SEQ ID NO:1491) Human coding sequence (SEQ ID NO:1492).

Table 93 (mouse gene: Anp32; human gene N/A) Mouse genomic sequence (SEQ ID NO:1493) Mouse mRNA sequence (SEQ ID NO:1494) Mouse coding sequence (SEQ ID NO:1495) Human genomic sequence (SEQ ID NO:1496) Human mRNA sequence (SEQ ID NO:1497) Human coding sequence (SEQ ID NO:1498).

Table 94 (mouse gene: Map2k5; human gene Mouse genomic sequence (SEQ ID NO:1499) Mouse mRNA sequence (SEQ ID NO: 1500) Mouse coding sequence (SEQ ID NO:1501) Human genomic sequence (SEQ ID NO: 1502) Human mRNA sequence (SEQ ID NO:1503) Human coding sequence (SEQ ID NO:552 1504).

S Table 95 (mouse gene: Cd28; human gene CD28) Mouse genomic sequence (SEQ ID NO: 1505) S Mouse mRNA sequence (SEQ ID NO:1506) Mouse coding sequence (SEQ ID NO:1507) Human genomic sequence (SEQ ID NO:1508) Human mRNA sequence (SEQ ID NO: 1509) Human coding sequence (SEQ ID NO:1510).

Table 96 (mouse gene: Sept9; human gene Msf) Mouse genomic sequence (SEQ ID NO:1511) Mouse mRNA sequence (SEQ ID NO:1512) Mouse coding sequence (SEQ ID NO:1513) Human genomic sequence (SEQ ID NO:1514) Human mRNA sequence (SEQ ID NO:1515) Human coding sequence (SEQ ID NO:1516).

Table 97 (mouse gene: FzdlO; human gene Mouse genomic sequence (SEQ ID NO:1517) Mouse mRNA sequence (SEQ ID NO:1518) Mouse coding sequence (SEQ ID NO:1519) Human genomic sequence (SEQ ID NO:1520) Human mRNA sequence (SEQ ID NO:1521) Human coding sequence (SEQ ID NO:1522).

Table 98 (mouse gene: Calm2; human gene CALM2) Mouse genomic sequence (SEQ ID NO:1523) S Mouse mRNA sequence (SEQ ID NO: 1524) SMouse coding sequence (SEQ ID NO: 1525) Human genomic sequence (SEQ ID NO: 1526) Human mRNA sequence (SEQ ID NO:1527) Human coding sequence (SEQ ID NO:1528).

C Table 99 (mouse gene: Ncf4; human gene NCF4) SMouse genomic sequence (SEQ ID NO: 1529) Mouse mRNA sequence (SEQ ID NO: 1530) S Mouse coding sequence (SEQ ID NO: 1531) Human genomic sequence (SEQ ID NO:1532) Human mRNA sequence (SEQ ID NO:1533) Human coding sequence (SEQ ID NO: 1534).

Table 100 (mouse gene: Rac2; human gene RAC2) Mouse genomic sequence (SEQ ID NO:1535) Mouse mRNA sequence (SEQ ID NO:1536) Mouse coding sequence (SEQ ID NO:1537) Human genomic sequence (SEQ ID NO:1538) Human mRNA sequence (SEQ ID NO:1539) Human coding sequence (SEQ ID NO: 1540).

Table 101 (mouse gene: Mbnl; human gene MBNL) Mouse genomic sequence (SEQ ID NO: 1541) Mouse mRNA sequence (SEQ ID NO:1542) Mouse coding sequence (SEQ ID NO:1543) Human genomic sequence (SEQ ID NO:1544) Human mRNA sequence (SEQ ID NO:1545) Human coding sequence (SEQ ID NO:1546).

Table 102 (mouse gene: mCG10516; human gene N/A) Mouse genomic sequence (SEQ ID NO: 1547) Mouse mRNA sequence (SEQ ID NO:1548) Mouse coding sequence (SEQ ID NO:1549) Human genomic sequence (SEQ D O Human genomiRNA sequence (SEQ ID NO:1550) Human mRNA sequence (SEQ ID NO:1551) Human coding sequence (SEQ ID NO:1552) Table 103 (mouse gene: Rorc; human gene RORC) Mouse genomic sequence (SEQ ID NO:1553) SMouse mRNA sequence (SEQ ID NO:1554) Mouse coding sequence (SEQ ID NO:1555) S Human genomic sequence (SEQ ID NO:1556) Human mRNA sequence (SEQ ID NO: 1557) Human coding sequence (SEQ ID NO:1558) Table 104 (mouse gene mCG15938; human gene BATI) Mouse genomic sequence (SEQ ID NO:1559) Mouse mRNA sequence (SEQ ID NO:1560) Mouse coding sequence (SEQ ID NO:1561) Human genomic sequence (SEQ ID NO:1562) Human mRNA sequence (SEQ ID NO:1563) Human coding sequence (SEQ ID NO:1564) Table 105 (mouse gene: Iqgapl; human gene IQGAP1) Mouse genomic sequence (SEQ ID NO:1565) Mouse mRNA sequence (SEQ ID NO: 1566) Mouse coding sequence (SEQ ID NO:1567) Human genomic sequence (SEQ ID NO:1568) Human mRNA sequence (SEQ ID NO:1569) Human coding sequence (SEQ ID NO: 1570) Table 106 (mouse gene Zpf29; human gene: hCG27579) Mouse genomic sequence (SEQ ID NO:1571) Mouse mRNA sequence (SEQ ID NO:1572) Mouse coding sequence (SEQ ID NO:1573) Human genomic sequence (SEQ ID NO:1574) Human mRNA sequence (SEQ ID NO: 1575) S Human coding sequence (SEQ ID NO:1576) Table 107 (mouse gene: Kcnj9; human gene: KCNJ9) Mouse genomic sequence (SEQ ID NO: 1577) Mouse mRNA sequence (SEQ ID NO: 1578) Mouse coding sequence (SEQ ID NO:1579) Human genomic sequence (SEQ ID NO:1580) C Human mRNA sequence (SEQ ID NO: 1581) Human coding sequence (SEQ ID NO:1582) S Table 108 (mouse gene: Ppp3cc; human gene: PPP3CC) Mouse genomic sequence (SEQ ID NO:1583) Mouse mRNA sequence (SEQ ID NO:1584) Mouse coding sequence (SEQ ID NO:1585) Human genomic sequence (SEQ ID NO: 1586) Human mRNA sequence (SEQ ID NO: 1587) Human coding sequence (SEQ ID NO: 1588) Table 109 (mouse gene: mCG9110; human gene: hCG27579) Mouse genomic sequence (SEQ ID NO:1589) Mouse mRNA sequence (SEQ ID NO:1590) Mouse coding sequence (SEQ ID NO:1591) Human genomic sequence (SEQ ID NO:1592) Human mRNA sequence (SEQ ID NO:1593) Human coding sequence (SEQ ID NO: 1594) Table 110 (mouse gene: mCG2257; human gene: PRDM11) Mouse genomic sequence (SEQ ID NO:1595) Mouse mRNA sequence (SEQ ID NO:1596) Mouse coding sequence (SEQ ID NO:1597) Human genomic sequence (SEQ ID NO: 1598) Human mRNA sequence (SEQ ID NO:1599) Human coding sequence (SEQ ID NO:1600) Table 111 (mouse gene: mCG17918; human gene: hCG23764) S Mouse genomic sequence (SEQ ID NO:1601) SMouse mRNA sequence (SEQ ID NO:1602) Mouse coding sequence (SEQ ID NO:1603) Human genomic sequence (SEQ ID NO:1604) Human mRNA sequence (SEQ ID NO:1605) Human coding sequence (SEQ ID NO:1606) Table 112 (mouse gene: Lfng; human gene: LFNG) Mouse genomic sequence (SEQ ID NO:1607) Mouse mRNA sequence (SEQ ID NO:1608) Mouse coding sequence (SEQ ID NO:1609) Human genomic sequence (SEQ ID NO:1610) Human mRNA sequence (SEQ ID NO: 1611) Human coding sequence (SEQ ID NO:1612).

Table 1 SEQ SEQUENCE~te "SEQUENCE") CLONE CLASS GENE ID j1C jr T NO:{C T {C "CLONE "CLAS "GENE" 2} SIFICA \L 2)

TION"

MUTATION \L 2) GATCAAAGCAATCTCTATGTCT-fTCTCTG

CTGTCCTCCTCAGACATCTCCAGAGAGC

TGGGATATYHCT17CCCAMrGAGA-rI

ATGAAGFFGTTTCTAGAGTGCATGAGGC

AGGT7GAAGGATAAGTACACAGGTCCC AAGGAACCAAGCGT=fCACTGACGGTG ATGAGTCTTGTTCGTGAGA'G1TGTGA TTCTCAGCCTrCTCTrCCCCTGTGTGTG CTCTTCAT1TICTGGTrCTGTCTGCCTrAO PM000619 CACCTCCTGGGGAAGTGCTGTGCmT- p000632 A Spr GATIC'IrrGGAGCCCAGTI'Gl'rAATCATA

AGAGCTGATATTTTGAAAGAGTGTGTCA

ACCTAGATGCACAGGGAAGCCAAAGCA

2 EM000620 TTCAGCC p000633 D

ATATGACCACAAGGAAATAJ\GATAAAG

TGTTCATACTGAA1TrATAATGAAAAGT

GATC

3 1rM000621 p000634 C

GAACAGGCATGGCTTTACTTGTACAATG

AGGAAACCAAGGCAGAGATTGCAAAGC

GGGTCCTACACO MTGCTCCATGCCCTG C1TCTCTGACCACAGTGTACTGAGAATA

TGCTGAGCCCTAGTTCCTGGGGAGGAGG

CAGAAGAGAGCAGCATCCTIGCCCACTFIG

AAGGCGTGCACACATAGTTCCTGTCTGA

4 11000622 TC p000638 ID GATCAGGAGACCACACCCAGCTAGCCTl

CTCTGACTGGGTATCCTTGGTCAGCCAG

C='~CTrCACCTCATGTTCTCA1TrTGCA AACTCACATGAACACTAMflGACCTACA CACTTCATAAAGCTG1TAGAGAC

GAGATAATACAGGAGGAACGCTACAAT

IM000623 ATTAAATGATATGTATT7ATAT pOOO 6 3 9 D

AGTGTTTAGGTCAGCTGGTGCAGGAGAA

GCTTCITGAGGAAGACGACCATCTGGCA

AGGCCTGATGGTAGAAAATAATGGAC'fl

CTCTCCAACTGAGTAGGAA=~GATGAT

16 IM000624 IC p000640 ID F SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ED {TC {TC (TC

NO:

"CLONE "CLAS "GENE" 21 STFICA \L 2)

TION"

-MUTATION \L 2) ATCAGTAAG'rTAATCCTAAGAA~rACTA TGCA1TPTCCCCTCTIT1TIAACAACAT TCCTCCTfrAGC1TATATGAGGCTCTAGTG

CCCGGAGACMTAATACTGCCCTAACAT

GATGGTGGCTC1TGTCCCTCT7CTCAG

CCACTGAAATCTGACAGTGGGGAAGA

ATAATAAGAATAAGAAACTFAGATGGT

T1TAAATATAGATATAAAAACAGTrCTT CGACTATTCTCAATAAAGAAATrCAGTC 7 AAAAGAATTTCAGTCCTAACACAATGAT EM000625 c p000641 D

GATCATCAGAGTCCTGCATCTTATGTGT

GCAGTGTrCAGCAATACAGGCTTACC

TTCAACCTCTAACAGGCAACCAGATGCT

ACAATAGC'ITATA1TG1TIAGAAATCA

CTTGGACTACTCTAAACAACAACTTGAG

TGAAGGCTCTTGTATCTGATACTGGAG

TGTrAGTCTATGACACTTGTGGGGAG

ACATGTCTGCACAAGTAGCATATGTGTG

TACATGTATATrGTATACATATATAGTIT

TGCTCTATGTATGTATGTGTATATGTATG

8 TATGTATATGTATATGTATGTATATATAT 1M000626 AG pOOO 642

D

AAGGGACCTGATAATCGTGITGGCAACT

GGGCTACAATTAGTrATCAATrGC'FrGC

'TFGCCACCTGCCCTGCTCCATAGAGAAT

CATAGTCTGGGGAGTGTGGAGGAATAG

CGGAGTCATCTAAACACATCACTGCTGC

CCCCACCATTTGCCTGCCAGCAGGCCCC

9 1M000627 TGCCTTTCATI=GCATITCTCCCTCTTA CAAGCAAATGGCGCTCACTGATC p000643 D GTTrGGGGATTGTACAGAATGCACAGCG

TAGTATTCAGGAAAAAGGAAACTGGGA

AATAATGTATAAATTAAAATCAGCTI

TAATITAGCTTAACACACACATACGAAGG

1M000628 CAAAAATGTAACGTTAC1TGATC p000644 lK yc GATCTCATrACAGATGGTrGTGAGCTAC M000629 CATGTGG pO000647 R SEQ SEQUENCE{tc "SEQUENCE") CLONE CLASS GENE ID {TC {TC {TC

NO:

"CLONE 'CLAS "GENE" 21 SIFICA \L 2)

TION"

MUTATION kL 2)

GATCTCAGGAGGCACCGAGAGACTCAG

CATGGACTCAAATGAGTACCCTGGCAGC

CCGCAACACCAGCTGTGTAACACTACCG

TGAGGGATGTCT[CCCTGCCI'GCCTCCA

GCCCCTTCTCAGGCCCTGAGTCCAGTGT

GCAAAGCTCATCATGGTTAGTCCCCYTFC

12 IM000630 ACCT p000649 K Of]

AGAGCACCCGACTGCTCTTCCGAAGGTC

CAGAGTTCAAATCCCAGCAACCACATGG

TGGCTCACAACCATCCGTAACAAGATC

13 IM000631 pOOO 6 5O R

GATCAAATCCTGTCAGGGAGAGGGGCTC

CTCCCAG'fAGTGCCATCCCATAATAATA

AGAAGGACTCCTGGGCCTCAGTGAAGTC

AGGCTGACCACFACTGCAGGTTAGTCAT

GACCAGTAGCCAGAATGGAACGAAGGG

TGACCCAGTGTGAGGACACAGCCCCAG

GCAACTGCTTCTGCTTrGAGCCAAGTTG

T-TACCCCAAAGCTCGTCATTCCGCTTGG

TTrCTCATGTGTGTGAGCTGCACATATG 14 [IM000632 GAGGTCCCCCTTI'GTITCCCTT p000651 D

GTGAGGAAGGTCCCTCTGCATTCTAACC

TrCCTCAACTCCACCAGCCTCGGCGTl7 AAGGGAGAAATAITACCG~rCCCFFTGG GCCAAGTflGGAGCCAGTFGAAGTAGTCG GAAATGTACAGTCACAGGAAAT-rGCTGG

TACCAAGGCTGGAGGAACAAAGAGAAG

ACTTGTCACAAGAGGCCAGAGAGGAAG

TCACCCAGTACAAACTGAAGCGCGCGCG

CACACACACACACACACACACACACAC

1M000633 GCACACACACACACACACGATC p000652 D

TGGCCGCCTAGACAAGCTGACCATCACC

TCCCAGAACCTGCAACTGGAGjAGCC'ITC

GCATGAAGCTTCCGAAATGTGCGTGCTC

CACCTGTCCCTCACCTCACAGACATCAT

16 11M000634 rrTcCCAMI~AGCCCCTCCCGATC p000654 A i

GATCCCCTGGAAMTACAGTCGGTTCCA

17 1M000635 ACAATCATGTAGATG I pO00656 IC F SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID {TC ITC {TC

NO:

"CLONE "CLAS 'GENE" 2) STFICA \L 2)

TION"

MUTATION T12) GATCGGCTATAGCATGTCAATGTrfA CCCAGAAGAATAGCACAGATATATMrC ACATCAATGCTrATI'GCAGTATTATTCA

CAGTGGCTATGTAATGGAACCAACCTAC

ATGGCCAGCAACTGAATAGATTAAGAA

AATATATATACACAATGGTGCTT=C

GGCTATAAAGAAGAATGAAGTTATGTTG

M~GTTAGAAGATGGATGAAAGTGGAGA

TGATAATATCAAGTGCACAGTCAACCTC

TCTCTCTCACCTCCCCCGCCCCGCTCTI

CTCTCTCATATACA1TfGAGAGTAGCAG

TAAACTGTCTGAGAACAAAGGOGATTA

ATGGGAGGGGAGAAGATTAAGGAGCGG

18 1M000636 AAGGGTAGTAGGTAGTAT p000659 A Cr2

GATCGGCTTCTATGGACTGAGTGTGTAA

19 IN4000637 GAAAACATT pOOO 66 I D TrAGGAGGGTAGAGAACA1TCAGGAAT CAAGAACAAGCATIrAACACCCACTGA GCTATCCTGTGGATGGTGGTGG1T7r rG=1GT'rGG=rTGTIAGGAAGTCAG

GGATGGGGTGGGAATCTCACTCTGTGGC

TAGACTTGCAACAATCCCAAATTCTOG

AATGATAAGCAAGAGAGCTGTCTAGTCC

CAGTCrCAGATACATGCTGTTAATM~CT

ACTACTGCTATAACACATAGGCTCAAAT

GCGGTGGCTTACCTAACACACCCTGTGC

AGTTCTGAAAGTCGTAACTCTGGCACGA

1N4000638 TC p000662 D

ATGCTAAGCTGTGACTCCTCTCGATACG

21 1NM000639 AGACCCTGGCTGCCCTCCMICCCGATC p,000663 D

GATCGTCTGGAAGAGCAGTCAGTATTCT

TAACTGCTGAGCCATC1TGCAGCCCCC AGTCTTrGGGTTrG TTG1T TGGTrGGTTGG'ITGGTTrGGTTTAGTG GTTGGTTCAAGACAGGG1TTrCTCTGTG

TTGCCCTGGATGTCCTGGAACTCTCTTTG

TAGACCAGGGTGGCCM~AACTCACAGA

AATGCGCCTGCTAGGATTrAAAGCTGTGT CCCACCACTATATATATATGfGTG 122 1 M000640 I ,000665 IR I- SEQ SEQIJENCE~tc "SEQUENCE") CLONE CLASS GENE ID ITC ITC {TC

NO:

"CLONE "CLAS "GENE" 21 SIFICA \L 21

TION"

MUTATION \L 2} GTCACAGTG2FAGAGCCACAGACGGGG

GAACCTACTGGCTIGTICCTGGGTTCCTGT

AAACTAGGGGACAAAGCTGCCACAGCC

23 1M000641 AGACTTAGCTGCGATC p 000666

D

GATCGCTGCTTCTGTAAATCCGCAACGA

CAAT7GTTATCTrCTCCTTCTIrTC1T= ATTTGT1TYCTAT1TA1TrCAGAT

GAACTCTCATGTAGCCCAGGCTGGTCTC

AAAC'rCCCTCTGTAGCTGACGGCAACCT

TGAAC

24 1M000642 p000668 R ITCCTACACCATAGCAMrAGTTGTAGG 1M000643 CAGAAGCGATC 00O0669 D GATCGGCTCAAGGGCTCTAATTrAGTCT AGGAAGTCM1'AGGAAACATGAAAATCT

CCGAGATAAGACCCGGGGTAAAAAGCT

TGAGCCACGGAG'ITAGACATGCCCAGG

GTGGAG]CATGTTCAGAGGT-rCAAGACC CGAATCAGCTACGTAAATAAAGCAlTITG AGGCCTACCTrGGGCTACAAGAGAGTIATrc TlTAAATAAATAAGATGA7TAAAAAAA ACTGITICCCCTTrAGATGGATTAAAAA

AACAAGACAAAACAAAACAAAACAAAA

26 1M000644 ACCCGTcITrGc11ci'rAA p000672 D CTGTCCGTGTGGGAAACGn7rAGCAAGT CCGAGCGTG'rrTCGATC 27 1M000645 p000673 K Nrnyc ATGCGTTCGTATGACAGTrrCTCCAAATG

ACTGTCCCAAAGTCCCAGATJ'CCTGGAA

ACAGTAAAGAGTGGCTCAAACTGTrAGTC

ACTAGTCTATTATCTTAATCATAGTAAC

CAMTGGGTTTGAC1TGAAAACCTGTGA CAGGGAGATAAAT7I1TCTGCCACTGTAGG TGAAGC1TGGAAGGGCTAACCCAATGA 128 IM000646 ATATGGTCAGTCGATC W,000676 C SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE NO: (TC (TC {TC "CLONE "CLAS "GENE" 2) SIFIC \L 2)

TION"

MUTATION \L 2)

AGATGAAGCTATCCCCAGTCCCTAAGCT

GAG'TTCTGCCTGAGACTA'TI7GAAACAG GGTACCCCTGGGTCCCAGn7CAGTrGAC

AGGTAGTGGACGCATGAGAACGGCATA

CCTGGTGGCCGTGCCCGAGAGTGCTGTC

CCTGACCTGCCACTGTGTrCTCCAGAGC

AGCMTCCAATCTGCCTGCTCCTGTCTCC

CCTGCCTGTrGGCACCAGGCAGCCAGAA -FrCCATTTGn1TrGCTrCGCGATAGG CTC'FrGCCATGTAGTCCTTCCTGGCCTAG AACTTGATATGTAGACU7CCCCCCT7GG

ATC

29 IM000647 p 000678 C

CCGTGTCCGTGGGCATGTGCGTGTACAG

ACAGACATACATGCGCCGCATGAGTGT

GAACACCAGAGGTCAACCTCAGGTGTCC

TMGATGTrATCTACCTTGTrrGAA

GCAAGGTCTAGGATTGACCAATGAGCCC

CAAGTAGGGATC

IM000648 p000679 D

GATCCATAGGCAGAGAAGGCAGTATA

GGACATTGGTCATTGTACCTCATTTGTG

AGGGGTCACCTTGGAAATGTGCTGAGAC

31 1M000649 TAGGTI'CTAGGAGAAGCTCGCCA p000682 D

CTGGCACTGTGTGGCAGAAACAGTGAAC

AGTGTAGCGGTGCAGAATGTGTGTGCTG

TGGG1TIAGCACCAGGGCTGCATGAGA

CTGCAGACATGC'TATGACGCAGGAAGG

CTrCAGGACACAGCACACATGTGTGCTAA CATACATG I ITIACCTCAGACTCAGCTC CCATrGAC=IIAATrAATITIGGCCA 7rCCACAACAGAACC'ITCTGCTCCCT TTrTCAATCTrATGTATATATCTFCCTAC AITAGTrACAGGACTGTGACCTACAGT 32 [M000650 TTAAAACTCGGGGATC p000684 D SEQ SEQUENCE~tc "SEQUJENCE") CLONE CLASS GENE NOD (TC [TC {TC "CLONE "CLAS "GENE" 2) SIFICA \L2} lION" MUTATION \L 2) GATCCCTCCCCTCCCT7C1TI117CCCGCC

AAGCGTCGGCGAAGCCCTGCCCTTCAGG

AGGCAGGAGGGGAGCTAGTGAGGCGA

GTrcGGACCCAGCAGCl'GAGAGCAGCGC

AGCCCAGGGGTCCTCGGCCGCGCAGACC

CCCGGAATAA

33 1M000651 p000685 K Mc

CTACCACAGCCGCAGTGCTCTGGAGGGA

CTCTAGTAGCCAGGGGTGGCAGC'ITGGT

TGGGCCACJCATCTCACTATGTAGCCTA

G'GTCCTGGAA'ITGCTATGTAAATGT

GGCTACCCTCAAACTCATAGAGAGCCTC

CCACCTCTCCTGAGATTATAGGCACATG

34 IM000652 CTACCATGCCCTAAGTGGATC p000686 D

GGAGCAGGCCG'ITCTGAATCAACTFTGGC

AGAGTGAAGGAGGCACTCTCCACACAA

ACAGGAAAAGGGCAGTGGTGAC7ITCTA GGCAGGGAACTGGTTACATTT1TAT 'FUGAAGGTrGAAGAGTCc3TGACAT7CTGG

GAAATAGGCAAGATGGCCG'TTCCCCTC

AGCTACAACCAGCCATGCAGACCTCCTT

GCAGGGACCTGGCTATCTACACTGGAAC

CAGAAAGGCACGCCCTGCTTTAGCCTCA

GGCAGAACGATAATAACAGCGTGCTAG

CTCAGTAGTCTGTGTGCTGGAAGGGIFJT

ATGAGGAGGAAGTCCGCAATTACATATIT

TCTGGGCAAACATTrAACCAAGAT'rGAAA

CCTAGATIMGAAGAGAAGTAGCAGGT

GGATC

IM000653 IIp000687 D SEQ SEQIJENCE{tc "SEQUENCE") CLONE CLASS GENE NO: {TC {TC {TC "CLONE "CLAS "GENE"M 2} SIFICA \L 2)

TION"

MUATION \L 2) AGATGAACTrATAAATGCATCTGCAGTC

CTCAAATAAAGATGAATAGTAACCCAG

AGGCGTGGTAGTGCGCTCTTCAAACCCA

GTGCTCAGAAGGTGCAAACAAAAGGAC

CGGGAGTCCAAGGCTAGCCTTGACrAGA

AGGGGCCATGTCTCAAAGAACAACAAC

CAAGAGCrG=~ATGGAM3TCAGTCTGT

GTTCCCAGGGGGACAGCATCAGTCTAAG

rrGGCGGnGTTGTTGGCTGAGCATGCA

CAAATCCCTAACAGCACATAAAGCAAGT

TGTGTCACACACTCACAGTGCCCAGAyI- CACTGGATC Mm.1313 36 1M000654 pOOO688 B 36 GTCCATrGTGTACTGAGAGAGGAGTrAG GTAGAAAGCCITrCCTCAGATGTGCCCT

CAAAGAAGCTGCTACAAGTGCCCTCATC

CCACGT-rGCCAAGGATC 37 LM000655 p000689 D

AGCTGTAGGGAAGCCCAAAGCACAGAC

GACTGCTGCTGCTGCTGCGG'ITCCCA~r CTGGGTTGACCrITAGAAACGGGGTrCA

TCTCCTCCAGCAGCTCCGGGAAGGAGG

TGAAGGGGACTAACCATGATGAGO-ITG

CACACTGGACTCAGGGCCTGAGALGGG

GCTGGAGGGAGGCAGGGAAGACATCCC

TCACGGTAGTGTrACACAGCTGGGYIr CGGGCTGCCAGGGTACTCA1TITGAGTCC

ATGCTGAGTCTCTCGGTGCCTCCTGAGA

.38 1M000656 TC Ip000694 IK Oft] SEQ SEQUENCEftc "SEQUENCE") CLONE CLASS GENE 1{FC TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 2}

TION"

MUTATION \L 2)

GATCGCCCCAGTACCTCAAA'ITGTGTG

AGTGTGTGTGTGTGTGTGTATGCATATA

TGCATrACAAGCATATACATGCATGCATA TATATAATACACATAGACATrATATACAC ACATATAGACGCATACATGCA'GTATr

GCATGCATCTATGTATGTACATATCCAG

AACCAAATATACCAAACACGCAGACAC

AGCACACATAGGACAATAGTAATIGTGA

ATC'rAACTGGTGGGGYJ'TATGGGTCAAG

AGCCAGGGTAGAGGAAACTGGCTAAGG

CTCTAACCATCCTAGAGCAGGCACATrCT

ACCAGGAAAAGAAACAAGGAAAAGAGC

39 IM000657 AGAG~rGAGGGTTACTTAACATG p000695 D ACAGAATCTGTGGGTCAFlATTACG1TI' ATAGGAACAGGATITTTCTITTCCThETCTGA CTCTAC=~CTAGAAAGGCCGACThITA AATCCrCATGCTCVrGTCTAYFGACAGG 1IMOO0658 AAAAGATGGGcvr1cCACAcTrGATC p,000700 D

GATCAGGCTGGCCYI'GAACTCACAGAGA

CCCACCTGCCTCTGCCTCCTGCATGCTG

GGATITAAAGGTGTGTGCCACCACTGCCC

AGCTCACAAAGTAGTAGTAGGACTAGTA

CTAGTACTIAATAATAACAAACA'I1IACAA CAATCTrAAMTAThI=GTITCTACCTIT

AAAATCTCCCAACTGTCTIT=ATATTGC

CTCAAGTCTTCCCTCAGTCCCTGGCCTTC

ATAGCTTGACThTrGCTAGAGG'JTATC AGTGGCl'CATCTCTCTCCTGAGATrGAG

UI'GGCTAGACCACTATTCAGAGGGAGA

ATGTAATGTCTCAGACATCATAGCCA&I'

CCTCAGTrCTCCI ITTIGCTGACTGACCAC J-17GCCAAACTAGTTTTCCTAAGCCATA CCT7TTC TrAAAAAATAGTCM~C'Fr ATAGTGGGTGCTGGGTrTGAAC'n'CTGTr

CCTC'GCCTCACCTTGCACTGGTAGTA

141 1M000659 I AGTGA=AC p000702 1C SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ED {TC {TC {TC 0O: "CLONE "CLAS, "GENE" 2} SIFICA \L 2)

TION"

MUTATION \L 2)

GATCAAGAACGAAACCCCTGAAAACAT

AAAACAGTAAGATAACAATAGGGTGCC

TGATI=GTCGAAACCTTCTrGTCACCTG

TCACTGAGATTGTCAACTCCTI=CACCA

CCCTACATACGTrAGT7AGCTCAGTTrA

CGAGAG'FITGCAAAGGCCCCCACCAGTA

CCCTGCAAC1TfACCCACCCCTGCATGG

GACTGTGAGAAAATGGGACTGGAGAGT

AACCCTCTTCAGGCTCACAATCTGAGCT

AGTCAGAGCATCTCACGGGTCCCGGGAC

TCAGTGTGCTTTCCTCTrCGGTA-TTG

ACTTTAAACAATGTGTACCGATATGGGT

GAATAATACAACATCCATGGAGAAAjTA 42 1M000660 AGCCAAATCAAGACACT7CTTCAGAGG p000703 D

GATCAAAAACATCAACGTAAGGAGCCC

TAATGACGCTGTGACGGMTAGAAT

GGTCTACCCAAACGTAGCCAAGTCTAAC

TATGTrATGGAGGTGGTAAAAGCAGTTA

ACCTAAACATCTGGGACACTCACAGAAT

GATAGGTAGOTAGGTAGATAGATAGAT

GATAGATAGATAGATAGATAGACAGA

CAGACAGACAGATGT-rGAATAAAAAGT GACGTrACAGTGATG1TAGCTCAAGGC AGGGC1TICAGGCCATITCCCCTGGTCT 43 IM000661 CACCC pOOO 7

O

4

D

CTACTAAGTCCAGAGCAGAGAAGGAGG

CGCCGCCTGTGTGCACAGCGGAGTCrGG

GAGAGACCACCGGCCCAAACCAGTAAA

44 11M000662 CACAGGGCACCCACCGTGCTCCGATC Ip000706 D SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE NO: {TC {TC ITC "CLONE "CLAS "GENE" 2) SIFICA L 2}

TION"

MUTATION \L 2}

ACAGTAATCTGATTATCTTGCAGTAGAT

AAMhGTCTACCTGTPAATGACTCTGC'IT crrGAACTACGTCCCAGTAGATGCCATG

CYICAGCCTGGTAAGTGACACTAATAC

TACCTCCAAACTGTCACTTGGA7FGTCA

GGGTTTTGGTGTGGTGATGATACAGGAG

AAATGTAAAACACGGAGTTGATGATAG

AAAGGAG'rCACIrAATACA'T1TrG1CTAGG

AAAAGTCAAGTGACACACAGCAGAATC

TACCTGAAGGAGCTCCGCCAATAGGGCT

GGAAGATAACTCTCGCACTAACCTGCT-T

TATTAGGAACTGTAGGAAAGGCAGGTCT

GCAGCACAGTFGAAGMIAGGTJGC'GA

GAAAGTITfCTGGTCATA1YIATTCACCA

GTGATGATC

IIM000663 p000708 D 46 IM000664 GTIAGCAAGTCCGAGCGTGTTCGATC p000709 K iy

AGGCAAACCCATGTGAGGCM~CTCACA

TCMTCCT'rGGATGCCTGCACACACCTG ACTTGACAGAMTCAAATCAGAC1TATC AACTCACCTCT7CAGTCCTGGGCCTC1-TC CTGTATCAATCTrAGATIAGAAAAIIG GT-rCCACTGTGTACCAGCC'FrGAACCAG

GAATGCAGAGCCAACCACCCCTGGGGT

GTCCCAGGCAGCTGGGCTGGATGCTACC

TGTCATGCTCITGATC

147 1M000665 1 p000710 IC I- SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID{TC {TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2) ATGTATGAGTGTGGGGCTGGGT17TGAAC

CTGTGTCACCTTAGGACTCTCTGAACCT

CGGTCCTATTAGACGGAGGGGCTATT

CGGAGTCCTCATCTAATGGAGACACT

GTGGGTATCAGAGGGCAACACTGTGGTA

TrGGGGGTGGGGGGTrGCTGCTrAGAGC

TCAGAGAAGAGGAGTTGGCTTGCTCTA

CAGAACATGCAGGCTGAGGTGTGGGTG

CAGGGT1TCCCTOAGGCCCCGGCTCTGA CCCTCTCCCCACTCGAM1CCTGCGCAGG TGAGCGACAAACGTTCCAACAGCTTrCCG

CCAGGCCATCCTTCAGGGAAACCGCAGG

CTGAGCAGCAAGGCCCTGCTGGAGGAG

AGGGGCTGAGCCTCTCTCAGCGGCTCA

TCCGCCACGTGGCCTACGAGACTCTGCC

CCGGGAGATTGACCGCAAGTGGTACTAT

GACAGCTACACCTGCTGCCTCCGCCGG

TTCATGATC

48 1M000666 p000711 C GATCATnTCTCTCGAGATGGATrAAA

GCTATGCTGCAGAAGGACCCGTGTGTGT

CCTGTGTGTGTGTGTCCTCGCCOGGCGAG

ACTCCTTATCACACATGACAGCITCAAA

GCCCCCAGATTCAATAGGTrCCAGGAGT TCACA1TAACACTCATGGGGTCAAAGT

GCAGGCAGATGGTGGAGCCTGTGGAAG

GTCATCAGACAAACAACCTGGTGGTrGC

AGCAGAAATCACCAGGCAAGTAG

49 11M000667 p000712 R

GATCTGGCTAGCAGGGAGCCATACAG

IM000668 CCAGACATCTATCATCCrrA p,000713 D SEQ SEQUENCE{tc "SEQUENCE"} CLONE CLASS GENE

ID

NO: {TC {TC (TC "CLONE "CLAS "GENE" 2) SIFICA \L 2}

TION"

MUTATION \L 21 GATCATGTACClCACCTGTCAG'lFTGA

CAGGTGGGAGGTGATATCTC'TVFCATT

CATGTA'ITCTITGAA.AGT'17GT-rCATGCA TATAATACATrCTGGTTCAJLrrCACCACT

CCACCCTTTGTATCCCCTGCGTACCGA

GCCCCCATTCTCACCAAGTC'IT'ACTGTI

TfATCTCAGTTIGGGGC'TAGFT-TGT TGTC'1T17FG'rGTIT=GAAACAGG GTCCCGrrATGCAGCCCTGGCCCTGAAC TrGCTAAATAAACCAGGTGGCrGAA

TTCAGAGTTCTGCACACCTCTGTTACCC

AAGTGCTCAGATTAAAGGCGTATACTAC

51 1M000669 CAC p0007 14 C GATCAAITCAATCTA1TlGCAATAXCC'[G

GTTTII'-TITCCGCAACTCCAAGATGGG

GGGGGUGGGGCCCAGTCAGGAGAGGTT

TCAACACAAACGCACTAGTAT~rACACA CAGAATCTCCTCCACTGTTCTTCT-rCTrT GC'TrAAAAGTCT1T7GTTCCGGAATCTAT

AGATAGGGAGACAGATGGCTAGCTCCC

CAAGGCTGAGAGCAGAGGAGAGTA'IAA

ACAGGGAAGTCAAGGGGTCTGGGAG(G

52 IIM000670 CAAGGTAAGGAAGCCACAG pO 0 0 7 ]S D CAATGCCnrCCCCGCGAGATGGAGTGGC

TG'FATCCCTAAGTGCTCTCCAAGTAT

ACGTGGCAGTGAGTGCCGAGCATm' AATAAAATTCCAGACATCGTrTCCTG 53 1M00067 1 CATAGACCTCATCTGCGGFUGATC pOO0716 K Myc 'rAGTA'T7CAGGAAAAAGGAAACTGGGA AATTAATGTATAAA'TAAAATCAGC~rF

TAATTAGCTTAACACACACATACGAAGG

54 IM000672 CAAAAATGTAACG1TACTTTGATC p000718 IK Myc GATCAGAAAAACAGCCCATrATTCAAGA 1M000673 TTCAGGT p0007 19 D SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE {I TC {TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MTATION \L 2)

TAACTFCAAMTAATAATTATCACATGCT

AGGAACTAAAGAGGTGCACAAAACAAA

CCAACAGTGGTTCCTATCCTGTCTAACA

GAAGAAACTACAATTGTGGTGGGATG

CCACATAAATGACAGCAACGGGACCTA

CAGAAAATTAAGTCACAGAGAGAATGG

ACCA1TCTGCAGAGACCTGGAAAACAG

ACAAGGGAAGAAACATGGTGTGTCTAA

GTGATGGGGCAGGTGGTGCAAACGCTA

GAGGCAAGCAGAGGGGATATGAAACTG

TGCTGGACAGCTGGACAGAAGGGAGGC

rGGAAGGGAAGAGAGGACCCTCTGFTrr

GACTCAATGGCTAGATGCCATGTGCCAA

ATAAGAAAGCACTrGGGGGGTTCTGTGG

GAAATCGGAACAGAGGGACTGGAATCA

AACCTCAACGTTrCCTTGCATACTCCAGA TAAGAACCAGGCTT7GAGCCAGGGCCTG GGAAGAGGGCTGGCCTACATATCTCA1T

TAGAGATGAGCAAACAGGACTGGGAG

CTCTAGGTCTrCAGTGACACGCTI-GCTTr 56 IIN4000674 GGCCCGCAGGAGACCCTGGc1TTrGATC O02D

GATCATGTCATGGGTCAACAGAAATAAT

TCTGAAAGGCTAAGTCAMTCT-rCTACC

CCCAAGAAAAATCAAGAACACCCCACA

TACAAACCTrCCGTAGTAAACTGAGAA

TGGAGCCATGGCCAGAGCCCCTCTGCTC

TCCCATCCCCCAACCAAGAACCAAAC

57 I1M000675 p000721 D

ATATAACTTCTITTAAAAAAGAAT

TAT-rTAT=1ATGTATATAAGTTCCTTAT AGCTGTATrCAGAGACGCCAGAAGAGA 158 1EM000676 iGCATCTGATC pOOO 722

IR

SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID J T T NO:{T C {C "CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

IMUTATION \L 2)

GATGATAGCACAGTGGGGTGCCATCTGT

CACCCCTAGACAAACATCn7TAACCNGC ATCTC'TCCTGAAGCCCACnrGGACCAC

CCM~GGAAAACCATCACCAAGGCCAGT

AAGGTACCCGTGGTGACTCACCTCAGCC

TAGCCCACCATAGACGGTTrAGCAGAGCA

GGTGTGTGTAAGTCAGAGCCAGACAATC

AGAACACTrCTCCCTGCTCCAAAGTAGCA ATGTAAAAAA'IFFGAACCCAAAGTrG 59 1IM000677 p000724 D

GATCAAAGTAACGITACAITPGCC'TT

CGTATGTGTGTGCTAAGCTrAATrAAAAG CTGA1TIAATTTATACATTAA'flTCCCA

GTITCCII=CCTGAATACTACGCTGTG

CATTCTGTACAATCCCCAAACGTATACA

TACACACUrTATATATACACGATAATCT

AGCYI'AIAACCAACCAGAAACATGAGT

C1TTGCTCTGTGCA'ITGG17TCTAGAM~ AT7ATATAATGCATA'ITCCCTCGGGAY1r 1M\000678 GCTTATCC p000727 K IMyc GATCATTrGATGCT'rCAGATAAATATGTr Mm. 1278 61 [M000679 AAATOGTGAC p000728 B 181

GATCAAGATAATCCCCCACAGGCATGCC

CAGAGGCCCA'TrTCCTAGGTGAGACTAT AGTCTGTCAAGTrGACAATGCTAACCAT

TGCAGTGAGGGAGAGAAAGAAGGCCAG

GATGGTGGCTCTCTGTrACTCTGCTrACC

CACGGGGTGCAAGGACAGTGGGGGATG

GGCCTGAGCTTCCTCATGAACACACACA

TGAGAGCAGTCAGCACATGGCCTC'ICC

TCTAAGCT-rCACAGTGGCAGCCGCACCT CTGCTG1TAAGACCTAACATGTGGCCGG

GCAGTGGTGGCACACGCCTTAATCCCA

GCACTCGGGAGGCAGAGGCAGGTGGAT

TTCTGAGT-FCGAGG*2CAGCCTGGTCTCC

AGAGTGAGT-FCCAGGACAGCCAGGGCT

ACACAGAGAAACCCTGTCTTGAAAAACG

AAAACCAAAACCAACCAACCAACCAAC

CAAACAAACCATCTAACATGTACATCcTr

ATCCATGTGCACGAATCATAC

62 1M0006H0 p 000729 IR F SEQ SEQUENCE{tc "SEQUENCE") CLONE CLASS GENE ID T T T NO:{T {C {C "CLONE "CLAS "GENE" 2) SWFICA \L 2)

TION"

MUTATION \L 2)

AGACCAGTGCCGGAGCCGTCCTGGCTG

AGGCAGCCCAAGTCCTTGAAGAGCTTGA

AGAGGTCGCTGCGGAACTTGACGCCGAT

GAAGGCATACAAGAAAGGGTrGACGCA

GCAGCGGACGGAGGCCAGGCTGTAGGT

GACGTCATAGGCAATG~rGAGCTGG CTGGMTCGCAGCTGCTATTGGTGATGfl GAAG77GGCCACCGTCTGAGCCAGGACC

ACCCCATTGTAGGGCAGCTGGAAGACTA

63 rmo00681 TGAAGACTACCACCACGGCAATGATC p 00 07 30 A Cmkbr7 CCCTCTCAAGCCTrCCTUGTTACTFAGCC

WTATAGGTCTGTCATATACCATCAT

CTT7AAMIACAGCTAATATCCAMTAT ATATGATTATGTACCATATTGCyJMG

GGGTCTGGATTGCCCTACTCAGGATGAC

CTITTCTAGTrGATC 64 EM000682 p000731 D GATCATGATG7GTrGAAGCACAGAA

ACTATAAGACAGTGCCCJ&AGAGCCTCTC

TGGAGATAGCC

J1M000683 pOOO 7 32 D GATCGTG1-rAGACACAAGTAJAGAATG AATGAGTCTTCCTGATI-=~AAATrAAC

T'TCTCCCCATATTGGGTGTCACAC=II

TAAATCAGAAAGGAGAATCTGGACGGT

TCCAGGCCTGCAGCGCCATGCrrGCAAA AGGTTrACAGAATCGCTCTGc3ACACT 66 IIM000684 pOOO73 4

D

CTACCACAGCATCTI=GAGTGTATATA

GTCAOTGTMCACATGF1ATCTATGAAC ATATGCAAATGAGGT-1GAGAATTAAG TGCTGATAGACTCATGGO'rrAGGGOTn

TGATTGCCTGCTAATGATC

167 1LM000685 Ip000735 ID F SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE NO: (TC fTC {TC "CLONE "CLAS 'GENE" 2} SIFICA \L 2)

TION"

MUTATION JL2)

GATCACGAAACGGTGACTAAACAAG

ACTGAACCACAGGCAGATACCAAACCC

AAAGCTCTATGTCTAGTGTCTAGAATAC

ATAGG'l'GGG'FAGCCATGCCCCTGTIGA

GCCTGCCACGTGCAGCAGACATAAGACA

ATACTATAGACAACCACTCTAGTCAG

AATTGCAATGATGTCTrGGCAAACTAC

TCTAGTCTCCTTTGGCCAGGAGCTGCTA

AGTGT1-'CAGGCTIGAGG'I'ACA~rACC TAGGTIAGGTGGGACTrGTGTGCCCC'TGTG CTCCTGGGTGCICCTrCATGTCTGCTATGC rrGCCCn7~ 68 1M000686 p000736 D V

GATCATGTCAACTATACCTGGACACGGA

CCITCATCCTTGCTGGTrCACTACCTCT GGCACCCTGCAACATCrGCAGTfTG

GAACCCTGTGCATCTATCTCCTCACACT

GGCAGGGAACTTGTTCATCATTGTCTlG GTCCAGGCAGATrCAGGGCTGTCCACTC CCATGTACTrCT-FrATCAG'GFCTCcTCC

TCTGGAACTCTGGTATGTCAGCACCA

CAGTGCCCACCTI'GCTGCATACC'ITGCT

CCATGGGCCTTCACCCATCCCCTCGTCT

GCATGCTTTrGTCCAGCTGTATGTCTTCCA

CTCCTTGGGCATGACCGAGTGCTACCTG

CTAGGTGTCATGGCTCTGGACCGCTACC

FI'GCTATCTGTCGTCCACTGCACTACCAT

GCACTCATGAGCAGACAGGTACAGAAA

GAGTrAGTTGGGG1TACATGGTTGGCTG

GTITFCAGCTGCCTGGTGCCTGCAGGT

CTCACTFGCCTCFJTACCTrATTGM1GAA 169 1M000687 JAGAAGTGGCCCAYrACfT p000737 C 1

I

SEQ

ID

NO:

MIUTATION

1 IMI000688 SEQUENCE(te "SEQUENCE"}l

CTGTCAATTCATCCAGCTCTAGGCCGGT

GTCTGGCTCGATGCTAGGT7ACA GTGCCGATGCATAGGATTrTACAGTCAG

AGTGGCCTAAGCAACAGCTAATATTGT

MCTTGCTG77CTGGGAACTAGATGTTC

AAGGTCAAGGCGTCAGTAGCTTGTTAT

GAGACCTCTCTGCTGTCGGGCTGTGTT

TCAAGTTrrCCCCCCTCGTGCATGTG TGTTCCTA1TrCCTCTGCATGkAAGACC

AGTAGAGCCAAGTGGTGGCACACACC-

TGATC

GATCATGAGAGGCGAGACCCAGACA

TCTCTAACTC7CTTGCCACTCAGGAG

CCACCTGTGGCCCCAGCTGGCCACCAGC

CGTTCCTCCCTCAGAGGCCTICCATm.CCA CAAAAGGCCIT[CCTGGTrGnrCAGGACA GAGCCTGGnrCCCTGATACCCCTT~CTCJ.

CAGTGGCCACTGAAGUTACAGGGATGCA

GCCAGCCGTGGTTGCCATGTCTGTATAT

GAT-rTCcAG G M GTCCGCATGAGTCCCAGGGACCAC TCAGAGTGGCTGGCAGGCAHrGTGGAGT

TGFTGCAGCGGGACGTCTGTG.IM

GGGATGATC

GATCACCTGGGAAGGGGGAAGGACA

AGTCGAGCTCCCAGCCCACA'I-TCTCCT

AGGGTAGCAGCTCCCTCACP~'AGTGT

'CLONE

(TC

"CLONE I"CLAS \L 2) SIFICA \L 2}

TION"

\L 2)

CLASS

TC

GENE

ITC

"GENE"

p000738 ID I-- 71 ITMOO0689 p000739 ID I-- 72 JIMOO0 690 000740 ID I- 73 73 I 4000691

D

SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE NO: {TC {TC {TC "CLONE "CLAS "GENE" \L 2} SILICA \L 21

TION

MUTATION \L 2}

GATCAGTI'CTTA'ITAAACAATACAGACT

TAGGCAAAATGAGTCAGAAATAAGGAT

ATCGCATATCCCGAGACCAMTGAACTC

TAAGAAGTATI1'fCTATTATrAAAGTAG 17CACCAGGCAGTGGTGGCACACACCYI'

TAATCCCAGCACTCGGGAGGCAGAGGC

AGGTFGGATTTCTCAGTFI7GAGGCCAGCC TGGjTCTAGAGAGTGAGTTCCAGGACAGC

CAGGGCTACAGAGAGAAACCCTGTCTGG

74 ACAAACCAAAAAAAAAAAAAAAAAAAA LM000692 AG p000744 R

GATCATCACAGATGACATAGAACCAAA

CTGTAACI]CTAGACTACATGTAGCAG

ACATIT

1IM000693 p000745 D

GATCATACATGAATACAAGCAGGCTI'CT

GGTATACTCTITAAGTTGAATrCTGTTnC T]GTAGTCGTAGTCTrGTCTI-frCCAGTIhr 'rAAATTCTAGAACAGGTATACTGTAGAG CACCCGCCTCCCCTTrGCTCFGGAGGTAG GGTAGAGTGGGAGITrAAGGTCAGT1 CC AA65702 76 IPM000694 p000746 B 18 ATICTCYI7GTAAAACTCACT1CTG1TC ACCCATI=GTCTGTGTCCTI'ACTAAAT7r

AT'ITCTATATAGGAATICTTTGTATCTTCT

GATATAAGCTAGCGCATGGGTACCACCA

GCACCCAAGTCATCTGCTGAGGTGCTTC

TAACC'ITGC'ITGATTCAGTGTCTrCAACA

GAAGGTGGAGTAAACAGGTCATVITTA

77 P400O0695 CCCITAGAGAGI1TCAGATC p000748 D

GATCTCCGGGTGCCAGACYI'GCCCAGCA

AGCACTrCl-ACCTGCTGAGCCATCCTGA GGGCCTFGGAMIA AA AA AAAA AAATATT 78 IM000696 GACATATTGYFC Ip0007 4 9 D SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID {TC {TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 21

TION"

MUTATION \L 2)

GATCTCCTAAAACTCCCTGTGTCAGGAA

ACMTCTGTGC1TIGTAITGCGTTCCTG TGTrCGTGGAAGGCCCCCACGCCTrCAT CCTTGCTAATTC1T=~GGATAGCTTGT-r GCTrAACTAGATTGGCCCMTTT'TGGCT AGTA=r~CTGCTGTACCTATGAGTGGT

GTGGGAGAACTGTGCAGACITCCAGGA

AGCGCAGCCATGAAGCTACATGTGCCTA

rGTGTAGACACATCATGGATI=CTTACT AG1TrACTAGTGGGTGATAATCTGTCCT

TITTGAGCTCTCCAGAACGTTCTAGAAGG

TAAGGAc3AGAAATCACTTAAGAGAG 79 1M000697 pOOO 7 52 D

ATCTGATAGTAAGTAAAAGGACAOCTA

AAGATGAAGGGAAAGCAGGAGAOTCCT

GGAAGAAGAAACTAGTGTTTCTAAGAGT

TCATCAT-rGATAAAATGCAAAAGAAGTC AMCATACATG1TAGGAAACTGAAT CCTCTrG1TITGGGGATGTTTG1TrGA GGCAAAGGCTCTCTrACAGAGCCCTGGC TG11TCTGGAGTrrCTGTATATCAGGCTCTG

GCCTCAAACTCAAGAGATC

1M000698 p000753 D

ACATCAAGAGGAAGTTGGAAATGTATC

1TrrAGCTATCT-rATATCCTGGTAGCI~rA AGAM~CC1TrTGTGTGACTlTATAGT'rCT

CAAAATAT=~AAGGGTCAGGGGAGGA

AGCACTFTCAAGAAATGAGATGGGAGA

GGGAATGTCMTGTGrrGGCCTGGAGAT 81 I1M000699 c p000755 D AGCTATACCTGAAAT1TrGGCCAAGAACA GAAGCTCAGGAAATAGTGTGATT'rAAAA ACCAAAACCAAITrACAAAAGGAAGAC 82 IM000700 TGTGGTGTAGATC pOOO 7 5 6

D

CCACAACTGAAAGCAACACACACAGTA

ITI=CTGTGGG3T=AGGATGTATCCAC ACTCCCGAACTTCCTrCCCTGAAGCAC CCCTCAGTTTACTCTGAAGCATGG'T7G

AGTCCCAAGGCCAGTGTCAACTTTCTGC

CAAGTCTCAATGGCAAAAGTCTOTI=A

83 IM000701 ATCTGCTCAGGCTAATGTAGATC p000757 D

SEQ

ID

NO:

SEQUENCEftc "SEQUJENCE") ICLONE IULASS jF(2 1 fTC "CLONEI" 'CLAS

GENE

(TC

"GENE'

\L 2) \L 21

SIFTCA

TION"

\L 2)

MTATION

34 LM000702 CTTCCAGTCThITIAGCTA'T[FA'IGATA TGAA'FFCCCTCCrrA'IGTATCATCCA GATTCTACCTAA4TACTTCCATAAGT ATCAAGGACCACTCAAAyT-CATAT-r

GGACTFAGAAGCTCCACTTTAAA~-A

GA1TCTATAGAAAGAGCCTGATGGG GGCATGAAATGGG3TCCATC-FCCACCATC

ACGCACACATGAACAAAGAAAAGGAGG

AAATGGTGIT7AAGAAAACTrACATCA1'A CTAFT-lAAAAATAAGGAGGAAG

GAGG

AGGGAGAGAAGAGAGAAGCI'CATG

CTTAGGCAAGAGTGCTAAGAAAA1IAC

AGTTAACAGATC

GATCTCCTAAAACTCCCTGTGTCAGGAA

ACMTCTGTGCTr[GTATTGCGTTICCTG

'FTCGTGGAAGGCCCCCACGCCTTCAT

CCTTGCTAATC~rrTGGATAGC7GT GCTTrAACTAGAl'FGGCCCTITCTFGGCT AGTATTF7CTGCTGTACCTATGAGTGGT ~3TGGGAGAACTGTGCAGACTrCCAGGA

&GCGCAGCCATGAAGCTACAITG'I'GCCFA

I'GT

p000758 I IM000 703 D000759 D

I--

86 JIM000704

GATCTGAGTGCTGGGAACCAAACCTGGG

TCCTCTGCAACAG'ITI'GTGCTC-AGCTG

CCGAGCTTT

GTAGGGCGATGGGCACAGGC'ITCGGGA

CAGTCCGCGCGACGCTCAGGCGGACAA

CGGGAGGCGGGCGGGGAAGGCAGGGGC

TGCAGTGTCAAGTCCCTGACCCGGGAGG

CTCGGjAAACTTCACTGCCTCTGCGCA[FC CGGCATGGCCCCTCCCAC7CGGACfl-CG

TCAAAAAACCGCCACCGTGGAGTGTCCC

AGTATGTGCGGTrGTGGGACACTATCG CACTGlITGCCCTGGCTCTTCTCCTJAGACC CCCMhGTGAGCCAAGAGAACGCTG

GGCAGATC

p000760 IR I-- IM000705 D 00076 I IB Mm.2739 3

U

SEQ SEQUENCE{tc "SEQUENCE") CLONE ICLASS GENE ID T T T NO:{T C C "CLONE "CLAS 'GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2) GATCTCGTTACGGATGG7GTGAGCCAC 88 IN4000706 CATGTGG1TGCTGGGATAA pOO0762 R CTGGGTGACCTrAGAAACGGGAGTTCA

TCTCCTCCAGCAGCTCCGGGAAGGAGG

TGAAGGGGACTAACCATGATAGCMG~

CACACTGGACTCAGGGCCTGAGAAGGG

GCTGGAGGGAGGCAGGGAAGACATCCC

TCACGGTAGTGTTACACACTGGTGflG

CGGGCTGCCAGGGTACTCAMTGAGTGC

ATGCTGAGTCTCTCGGTGJCCCCTGAGA

TC

89 1M4000707 p000763 K Gfil

GATCTCAGGAGGCACCGAGAGACTCAG

CATGGACTCAAATGAGTACCCTGGCAGC

CCGCAACACCAGTGCGTAACACTACCG

TGGGTTTCCTCTCTC

GCCCC7TCTCAGGGCCCTGAGTCCAGTGT

GCAAAGCTCATCATGGTAGTCCCC'C

ACCTTCCT-TCCCGGAGCTGCJTGGAGGAG

ATGAACTCCCGTrCTAA0GTCACCCA

GAGTGGGAACCGCAGCAGCAGCAGCAG

1M000708 TCGTCTGTGCMhGGGCUFCCCTA pOOO764 K Gfil

GGAAGAAGTGTGTGCAGGCCATGGTCA

AGTCCTGCATGGCTCCCATCTGGGTCCA

GCAGCACCCAGCCTCCAGTGCTnGCTCC

TGATGTCCCAGTGAACTCAGGTCCTGAG

CAGCAAATCCCAGGGGCCAGTCCTAGG

GAGAAAAAGAACACACTGCCATTCAG

TGCCTCAACAGAAGCA4CCAGGCGTC AGTCATGTCCT'rG1TACCCACATCACA CCTAGACTCCCTGGGTATCATGCTCTGT Mm. 1535 91 1rM000709 GTGAGATC p000765 B 12

GATMTAGGATATATCATMAGGAGA

CAATGTF1rrMAJ&TATGGCATAGC

CACAGAGATAAAAATAAGAAAATAGAT

ACATCGAATTCAGTAAATGAGGAAGT

92 1M00071 10 TCTTArACGACpOOO766 A MtpnJ SEQ SEQIJENCE~tc "SEQUENCE") CLONE CLASS GENE

ID

NO: {TC {TC {TC "CLONE "CLAS "GENE" 21 SIFICA \L 2)

TION"

MUTATION \L 2}

GAGGTAAGTCTGTTCAGTGTAGCTATCC

TAGCAGCTAACAGTCCTCAAAACT=T

TAGAGATC

93 1M000711 p000767 D CTACAGATGCATrATrAATATTACWFI AAAAAAACCCAGTATACTGCT-rGAAAAC

AGTGAATGCAATGGG'ITCTCATTCACCT

TCCTGCTCTCAATCAATCTCCATCTCTAA

AGCAAGAAGTGGGGGCCCTrCTGGCTGA

GCGAGGGGTGAAGGGAGGGGAAGAGAT

94 1LM000712 cI p000768 D GATCTGGAGAAGATGITCAAGThrlI'AAAA 1M000713 TGAGGCAG p000769 D GAG TGAAGCAAGAAM~GGAGCCCAGC

TGCCGCAGCCTI=CCMTCAGCAAAG

CTCGGGAGTGATAGATATGCATGAACCA

AAGCAAAGCCTTGAGAGTGCCACTTGGC

CCTGCCTCCTGAGGGTCTCAGGGCATCA

GCTGGAGACCACCCTGTGACCCACACAT

CACCGACTATGAAAACAGGTCATCAGAG

96 1M000714 'IAATAAAGATC p000770 D

CAATGAACAGGACACATGC'ITCACACGA

CAGTCCAAAAATGCAAAGTGTGGAAGA

ATCCACAGCCATAGCCrrCATrACTAG 97 1M000715 ATC p000771 D

ATGCCTT-CCTGGTAGAAGAGGGCCATGC

TGTGGCGGGGAGGGGCCACTCAATTTT

CCTGCTCCCT1CCCTGTCCCATATTCTC AGG0AGCTI7CTAGAAGCGTAOCCTIGCATrc TrCATGCCCTGACTITGGCACCAAATGC'ITr GCTrTGTATCAACACCGCTITCTC7TrCTG

CTCTTCCAGCTCGCAGCCATTCAAATA

ATACCACCCGGTACCCGTGGAATCAGGA

GCAGAGATTCCAAATTGAGTCCTAAAAT

98 CAAATCCAAATGGGCCCGTCAGCTAGAT IM000716 c p000773 D

SEQ

ID

NO:

SEQUENCE{tc

"SEQUENCE")

CLONE

[TC

"CLONE

CLASS

{TC

"CLAS

SIFICA

TION"

GENE

ITC

"GENE"

\L 21

MUTATIOIS

99 0TO0717 100 IM000718 AGGCGAGCGAnTACTAAGGAC'1GAA GACTCCTAAGAC1TGTCTCCTGCTCCCTG GCCAGCGGTGGAGCTCAGCAGATnG

CAAGCTCAGCTCAGGTCTCAGTGATGCA

AAGCACCCTCGrACTCCATGTGTGTT ACCTCGTGGTCTCA1

TCAAACACCCGCACACAGACCTCCCA

CCGTATCCAGAGCATTGnCGATGCT

TCTGGAAACTATGCAAGCCC'J.A

ATATCCAATCAGATC

GTGTGTGTGTGTGTGTGTGTGTGTGTGT

GTGTGTnACAAGGTCTCATACAGAATCC

AGGCTGTCTCAACTACTGGAGTCAAG

CCATCTTCTCACCTGGCTnAGCTGGGGT

CACAGACTTGTGCCATCATGCCCAATGG

AATGCTGTCCTTGGAAAGCCTGCTA

CTGTCATATACTGTCATAGGAGTTAGCG

ACTGCTGGCrrATTCCTTCGCTP..GCTTG

GAGATC

F

CCCCCTTCCTGTCACCTCCTGACCCCTTG

CGCAAAGGAGGCTCGTGGCCCGCTGTCC

CACTGGGGGATGGGGCTOGG3OnGAGA

AGGCAGTGAGCGCJ&TACGCCAGG

AAGTGAAGTTrGTGGTnGGGGGCTGA GCTCCGAAGGAGAflAAAAAAAAAAAA AAAAAGTCAGAGAGACAGATC p ClTrfGTATAAGCAGCAAC&AAAGCCA

GAGGCAGTCCACAGATC

p 4 ATACAACAGGAGCAAAGC1'GGAGGGGA

ACAGATATAGAGGACAGTTCAGGGCAT

CTGCAGAGGTGCTGTGGAATGGGGAGG

GGACAGTGGATAGGGGACflACCCTG

AGCATCTCGGTAATAGCATGGGTCACA

CTGCGGAAGCGCTCCTGTCCTGCAGTGT

CCCAGATC IpO \L2} p000774 ID 000776R 101 JIM000719 000777 ID 000778 JD 12 IiM000720 103 Rah37 1 M000721 00780 070A Rb SEQ SEQUENCE~tc "SEQUJENCE"} CLONE CLASS GENE ID IC J T NO:{T {C {T "CLONE "CLAS "GENE" 2) S1FICA \L 21

TION

MUTATION \L 2}

GATCTATGTCATCMCCAGGACTCAGAG

'fl7AAGAGAGTTACCAAGTGAGAGCTCTC ATCACCTTCTGAAGCAGTGAGAArrGG AACCCAGAAAGATGCACATfGCACGGGC

ACACACACACCCACGGGCACACACCCA

CCCACCCATGCAGAGAGAGAGAGAGAG

AGAGAGAGAGAGAGAACTCACACTGGT

104 ILM000722 ACTGCAGTAAACGGGAGCTTGThr p000781 D GATCTTCMTCTCTGCTCAATTAGTrCAC YTCTGCTrrCATCTCc'I=TC'TIGATA

AACCATGAGITUCATTAGGGCTATTACA

105 IM000723 ATCACATGCAG'ITITICC17ATAGTA p000782 D

GAATTAGGCCTAGAAACAJTAGAATCCA

106 1M000724 GACCACGGAGCTCCCCAGATO pOOO 783

D

GAT~~rCTI7GYCTAGAACGACCCTGAAGGC

AGCAGAACAGAGCAGGACTGAAGGGCA

CCAAGGGGA'TrTCAACTC1TFCAGAAAAA ATAAGTGACTCACCTTCTCACAAAc3AGC

AAGAATCACAGAGGTCAGATTGTCTCCT

CCTGCCCATCAGGGACAGAGTCCCCCAT

C]TrGCCITGCTCCATCTGGCAGGTAAG

AGAT'GGGAAGTICTICCITT-]CCCTCGGTCT

GCAGCATCCCTGGCATCCCTGGGGAGTG

107 [IM000725 TTGGCACAGAACCCCCCTCCCAA p000784 C

GATCTGTGTGGGCAAAGCCCATGTGCTG

CAGTGTGTCTGGGTAGAA-ATGAGTTGTG

TGGTGCTCAAATGTAAATGAAGTCCCTG

108 1M000726 TGTT p000785I D

GATCTCATTACAGATGGATGTGAGCCAC

CATGTGGTI7GCIGGjGAAITGAACTCAGG ACCT1ITGGAAGAGCAG'I'CAGTGCCC'FFA

ACTGCTGAGCCATCTCTCCAGCCCCCCA

CCrTnTI=AAAAGATI-ATTATAG TTI1GCTITTIAACAGTACTGGAACAT CrCAGTAATTIGCTAAGTTGTCCTI-GCTCC

AGGTGAGCAGTCATATITCTCCAAFFC

TGGTITrCCTACTTGTGTCAGAGACCAA

AATAGCTTGTTTAATCAGTTAGAGCTCT

109 1M000727 TTAGTTACCGATATCTGTGTAGTAA P000787 R

U

SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE

ID

NO: {TC (TC {TC "CLONE "CLAS "GENE" \L 2) SIFICA \L2)

TION"

MUTATION \L 2)

TAAGAACATAAAAGCAAAATTTGGAGG

CTCAAGATrCAGTITTAGTTGCTAGAGGG

CTCACATAGCATGCCCTCCCCACCCGGG

ATCA1TCTCAM~ATCGAGGCATAAG

GCCAGGTGTGGTGGGATATGTGCTGGGA

TGCATAAGATC

110 1M000728 pOOO 7 88 D

GAAAGGCACACTGGTGAAGGCTGAGGA

CCACCAAAGCTGCATrCTGCTAGGCTA

GGTAGAACAAGAATGGTGCTCCACTAA

GAACTCAAAAAGCCACAGCCCACCCCTG

AGGCCCTCCATCTGACACATGCCGGTCA

CCTGTCCTCCCACAGCCCAGCACAGAGA

AGCCACCATCCCTCCC M CCCACCTCCT

GCAGCTGACAGTGTGCATCTFCCGCAC

ATTCCTCTCrCCTCAATCAGGTCAGAAT 11 1M000729 GTA'TTCCAAAGATC pOO0789 D

CACTGAAAATGGCTAGAATTCTGGTGAT

GGGTGAGCCGATC

112 1M000730 pOOO 7 93 D

GATCGGAGTCCCGMTCAGAGGCCCC

ACTTCTATGGCTCCTGCCTTCC77GGCTA CATCCA1TCCTGCTGAGCTCCTG3AAAC CTGTGTATCAAGTCTTJCCAGT7AGTGC GTrCTGAGTGGCTCTAGAAACCGCT'rCC CATrACAGCGAAAGACCCGTATAAACCA

TGTTCTCITCCTCTGTGACAAGAGACAA

CAGAGACCGCACAAAGGACTGTCTGGCC

TGGGGGGGGGTCCCTGGTTCACAGCTTC

113 1M000731 AGTCCTGA p000794 D

GATCGCTCAATATAACAGCAACATGCCA

AGTGCCACT-rGTAAAATrGTTGTTGAG CAGTCTCA~rATCAACTGAAGCACAATG TCAGGCTAGCAAGAGGCAGGn7CAG~rG TTrGATTAGCGATAGCACACACAAGCCAG CACATGCTI=CrGTGAGITCTAT 1114 1M000732I p000795 D SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE NO: {TC {TC {TC "CLONE "CLAS "GENE" \L 21 SIFICA \L2}

TION"

MUTATION \L 2}

GATCGCTGAGMTITACAGAGCAGGG

ACGGCTCAGCTCGGATGCCAAAGCTACC

AAGAGCTGCAAACGCAAJACTrAGCAGA 115 1IM000733 AGCACACGTACTCCC p000796 A Cited2

GATCGCACAGGTAAAATGGGGACTCACF

TAGCTAAAACAACAACAACAAACAGC

CTGATGAGTCGAAAGTCTCY-ITAGGI-IG

CCCTCTGTTCTCCAGCCCCACATCCTGA

AGGCTGTLGCATrCCTCCCACAGCAGTCT

CAAAATAACCATAGTGCTCAAGTCCCCT

G3TATCAAATGGTGGTATCTGCATCCACC CTACAGGTGTCTGArFTCMhC'M-rc TI-rGTAAGTGTGTCTGGOTGTMnTGCCTG

AGCGTATGTATGCGCCTAGTACCTGCAG

116 IM000734 AGGCCAGAATAAGGTGTCAG p000797 D F

GATCGTGAGAGGCGAGAAACCCAGACA

TCTCTAACCCTT"CTUrGCCAACTCAG

GAG

CCACCTGTGGCCCCAGCTGGCCACCAGC

CGTFCCTCCCTCAGAGGCCTCCAMTCCA

CAAAAGGCC'rrCCTGG'rG'n-CAGGACA GAGCCTFGGT-rTCCCTGATACCCCTTCTCT

CAGTGGCCACTGAAGTTACAGGGATGCA

GCCAGCCGTGGTTGCCATrGTCTGTATAT

GCTAATCTCCGAATTCCACTTCCTGTUTA

117 LM000735 GA1TCTCGG p000798 D ACTGTCCGTGTFGCiGAAACG'I-rFAGCAAG TCCGAGCGTGYJ7CGATC 1118 1M000736 pOOO799 K Nnzyc SEQ SEQUENCEltc "SEQUENCE") CLONE CLASS GENE 0O: {TC (TC (TC "CLONE "CLAS "GENE" 2) SIFICA \L 21

TION"

MUTATION T2) AMrCr11TGAGTACTFCATATA~GAGC TTCGCATCTACACCACTCT1TGCTCGCCAC TCCTCr1TCTrCCATTACTACTGT

CCACTCTCCAAACTTCATAATCTCTTAA

TTACTATTGTTA1TTrACACACACACACA

CACACACACACACACACACACACACAC

GTATATGTAACCTACTGAATClACTA

ATAGCMACTATCTCCAAGTACAGG

CACTTGATAAATCT-cTGTCAATCTCCCA' GAACAGAA0CCTTAAGAGTCAMAA 4

&GT

TCT=ATCTCAGGCTGTnCTG1TCTATG 119 IM000737 CCTIIGCT=~AATCCATCACCGATC O01D

GAATGTCTAGATGGAGACTGGACAGAG

TUGOATrCCTAGACACCTAACAGAAGCG

AAAGCAGGGGATGGATAAGGTGGGTGC

CTCGTCCTACAGCAGGTTCTGAGTGTCC

GCAGAGACTCCCATGGCT.GGCACCATG

GTrGAAGC1TCCATCGATC 120 1M000738 p 0 00803 C CTA1TICGTTCTCTCCGATC 121 EM000739 p000804 D

GATCCTCATGTCAAGGCAGGGGCAGACC

AGGGTCAAGGGAAAAACACCI'GCT-1.CC TGGGT7GTAAATGCCAGAAAGGGAAGG

CACGGGGTGGGTAGGGTGCJAGAACATG

122 IM000740 GCCCAGACCCCTGTCTCITCTCT pO 008 06 D GCACCTGAC1TCCTCATATAAGACACA

ACATCTTGAGTGCTGCGCAGGTGTACCA

GG3ATACAGGTGAATCCAATCTGGTGGAG A1TGCCCCTGCTGCCCTGATAGCTGA

AGCTGCGTGCCTGGTGAGGTGGCATGGC

CTGCTGTGCGTGGATGGGAACTGAGAGT

ATAAAAGAGCGAGAGGCCCGGGpT'AGA GGAGGATrATTATrCGAGAGAGGATTGT

TATATTGGGAGATATGAACAAGGGAG

ATATAAACAGGGGAGATATA&ACAAGG

GAGATATATGGAGAAAGAAGJAACAGG

123 M0004 1 ACTGAATAAATGTGTGCAGJ&AGGATC pOO08O8

R

SEQ SEQUENCEftc "SEQUENCE") CLONE CLASS GENE ID llTC (TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 2}

TION"

MUTATION \L 2}

GATCCTTCTCCTGTCTTCTC'ITCTGGAAG

GCTGGGCTACATGCCAACATGTCAGAGT

TTrACCTGGGTrCCTTGCAGAGG1TfGA AcrCAGGTCCTTGTACTTrACACAGGAGC 'rAC1TrGCGTAT7GAGTCAATA=F~GTG

TGTGMTGTGTAGGTGTGITCATGTCTGT

124 1M000742 ATACTTG p000809 D GATCGTGCATrGCATGGGTGTG'ITIGGG 125 1MO0743 GAGAGG'ITCTGTCCTI'GCTAAG O01D

AGCTCAGCTFGTCAGGCCTGATTGTGAA

CACTTCACCAACCGAGCCATCTCGTCAG

CACAGCCCTGTYITMrATTCCCA1TFCYC[ T-CTGTATrCTG1TGAATTTCrCACAT

ACTCTCCTFITCTCTITCTGCCTI'CTTCTGG

'IMCTGCATCATI1rCTATA'I7GACATTrA AACAACCCCCAAAATJ1CAAGATACATCA ACAAAAA'ITrAVrCAACTAGTC1TTG1'TA C'ITCCATATCAATAATGAAAGAAAAl7A AAACC'IMCAAA1TCAACAAATCCCTAC

ACTACATATAATCACTITCCTCTATGCTA

AATCCAAC'ITGAA-ATTATATCC'FCAATA

CCC'fGCTGGTAT1TIACTGTCTACATCA 126 IM000744 CrGCCTAGTc'rrcG3ATC p,000812D

CTGGTATATGAACGAAGTTGGTCTGTAA

AGGCCGTCTAGAACAAGGGTrCIrcAAcc

CGAGGGTCGCACCGGGGTCACCTAAGA

CTACTrGGGAAAGCACAAATFA=~ACATT ACGACTCATAACAGTAGCAAAA1TACAG TTATGAACTAGCAACAAAAAATAGrn1 ATGG1TGGGGATrACCACAACATGAGGA ACTGTA1TCAAGGGTCGCAGCAITAGGA AGGTI7GAGAACCACCGATC 127 1M000745 pOOO 8 1 5

R

TrCTAACCTGCTAGGGI-rCTCACGTGG GTrCfTCIGAGGGCTCTCTGGCTTCCC

TACTGAGCTGTAGCTGCCAAAG'ITGAAG

GGGTGGGTCTCCGTTGCGTCTCCCCAGTC

TTrACAGCTCCTGAAACACACTAAGGTA T'17A1TICAAATCCCTGTIFGTGI'GCGAT 128 1M000746 c p000819 ID I- SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE NO: {TC {TC {TC "CLONE "CLAS "GENE" 2) SIFICA \L 2}

TION"

MUTATION 2) AGGGCCCTrCCACCTCTrCTAGAATTrCG

GTAAGCTAAAAGTACATGTATCCGATTA

ATCTGAAATAATIGTAGACAG'ITTGG

TGACGGGTGc3AGGGTGTGTGGTrGCGCG 129 1IM000747 ATC p,000820 C GATCGGCGAGACCACGATrCGGATGCA ACAGCAAAAGGCITrATTGGATACACGG

GTACCCGGGCGACTCAGTCTATCGGAGG

ACTGGCGCGCCGAGTGTGGGGTTCGGAC

130 1M000748 CAp000823 R

TGGGTGTGGAGATGAACGTGGGAACCG

TGGAAATGACCCTAGAATGGGGCTCAA

ATGTGAAAGGCATGCCAGAGGTrGCTCT GTrGTT=AAGTCCCTGCCGAACATTAG AATITrAGCCTCAGTMIAAAAGCTGT7A CrGCCTAGTTGGGTGCTrCTrCTrAAAA AGCAACCAA AA AAA AAA AAGCCGFIT

CACTCTGAAATGTATTAGAAAITITGCAT

TAGCCCAATGGCTAATAAGCGATC

131 IM000749 p000824 D GTrATAAGGA'rrGCATACAAATGGCATC

AGGACTGGATGTGGTGGCACATGTCITG

TATCACAGCACTrGGTGAAGAGAGc3CAG

GGGAATCTCTTTGAGTTACAGGCTAGCC

AGCATGACACGGTGAGACTCTGTCT-'AA

ACAAACAAACAAACAAAAAAACAAACA

132 IM000750 AAGGTAGCATAAGAGCGATC p000825 D ACCTGAATCTTrGAATAATGGGCTGTTr 133 1M000751 TCGGATC 00O0827 D

AACTAATACCITTCCTTCCGCTGCGATGT

TTrCATGAGACTCTGGGTrAGTGCATGGT* CAGGGGCCCAGGCAAACAGTGGCAGT7 134 14000752 ICTGCCCAGGATC Jp 000831 ID I-- SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE {D TC I TC (TC

NO:

"CLONE 'CLAS "GENE" 2} SLFICA \L 2)

TION"

MUTATION \L 2) GTTrAAAGAGCCGGTrCGACCCGCTTrC CG'I1TCGCTCCGGGTCAGCTAGTACTGT

GAACCGCTCGGTCGGOTCCGGCGCTGCT

GCGCACClrACTCGCCGGGACCCTGAAGC CCCCCAACTACATATAGGGGFCTrCCCG

GAAAGTACGCAGGAAGTCGCGTTCGGC

CCCCTCCCCCCAGCACCACACCCAOTCC

135 IIM000753 CTTCCACCCCCCGGGATC p000832 D

GATCCCAGTAGAGACAGAAACAGTGCC

TGGYI'AAGAAMTCCAGGCAGOATGGT

ACAGGATTGCAATCTCAGCATGGGAGAC

AGAGGCAGGATMCCAGGCCAGCCTGG

GCTACAGTATAAATGGGACCCTGTCTCA

AGTAAYIX3AAAAAAAAACAGAGAAAGA

ATTTGGAGACTGTGACTATAGCYFGGTG

ATGGAG'rCCGITU-IGCCTAGCAGAGTGAA

GCAGCTGTGCTCC'IGTGTTCACACCACA

136 WM000754 AAATAA p000833 D V GATCCAGTGAATrCTGGGCA'GTGAGTG TGTGACACAACTTGCTCTATGTGCTG1T AGGGA'TrTGTGCATGCTCAGCCAACAAC AACCGCCAACTTAGACTGATGC rGTCCC Mm. 1313 137 1MN000755 CCTGAGAACACAGACTGACAA p000834 B 36

GATCCI'CCCTACCGGTCCTCGGGCAGAC

CTCCAGCCCTTCGCCAGACACTGTTGGA

AAGCAGGCACGCCTTCCACAGTATGGTC

TGAGG'TAACCCATGACAGCACTCTGGG

TFGCCTGGTGGTG'TTCCTGGTGGGGACGT

CAGTAGC'rGTAGCTCTGTCATJTGGTCCT[

GCAGCGTCTCATI'CCAACTATVFCITCCCAIP.

9138 11M000756 ITCACTCCTCT 0835 ID SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE IDIT T IT NO:{T{C

C

"CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L2) ATATGTG'IMTGTGCGTGTGTGTAGATciT

GCATGCATGGCATGTATGTACCCATATA

AATATGTGTATGTGTGTGAAGTGCTGAT

GTATTTCACACAGCATrTGGATrrAAT

GGAGAAGGTAGCTCAGATGTCAAGTGT

GCCCTCCTGTCAGGAGAGGAAGCCTGAT

GTGCCTGCTGTCATAACTCTGGTT=GAT

AAATACAGCACGAGTGA'TI=GGCTGT

TGGGTMTGCCGTGTATGGATC

139 1M000757 p000837 D GTITrGC1TGCAACA1TGTCATAGCTrAGT

GAACAGTATAGCATTGTTCTGGCTCAAG

AAGCCCTGGTrCrrCAAAGCTCCTACFT AGATGAAATTATMrGATCACAAACAAA AArrTTTTGCAITrTrAGATAATGAAG

GATC

140 1M000758 p000838 C

GATCCTAGGCCAGTCAGGGCTACCAATA

AGAACCTGCCACACACACAAAGGA

GCAAAFTITGCAAAAACTCTAGTCTCA

TGGTGTGACGGTCTI'AAACATCTrFGAG

GGGCTCGAACTGGTGAGGTGOGTCGGA

GGTAAAAGGGC'TT7GATGCACAACCTGA GTrCAACCCCGTGTIArAAGAC-TrTCTG

CAATGATTCTGGTCTGCAGTCCTAGCGC

AGCACAGTCAAGGAGAGATTGAGGCT

GAAACGGAAGAATGGAAGMrGCATAA

CAGCTCAGTGGCAGAAATAACAGGAGA

GACCTGACCTrAAAAACAGGGTGTAAG

GTGAGAAATGATGACAAATGACATCCA

CTTCAACTGTGCTACGAACAGCTACCTG

TGCACACCCCAAACACACACACACAC

141 ITMOO0759 ACA p000839 D

GTAAGAGGGAATGTACTCTCTGCCATCG

GGACACCCAGTOGAACTGCTCACCTGGA

GTCTTGCCTCCACGAAGACTAGGATC

142 1M000760 p000840 D SEQ SEQUENCEftc "SEQUENCE") CLONE CLASS GENE NOD {TC (TC {TC "CLONE "CLAS "GENE' 2) SIFICA \L2)

TION"

MUTATION U, 21

GGGAM~CAGGGCATAGAGCTTAGTTCC

AGACAAAACCAAAGTTAGCAGTCGCCTC

TCTC'ITAAAGACGTTCTCTCTAGCCGCA

GATGACCTCAGAAGGGGCTFCTGGGAGC

CGACTCCCACCCTrCC]TCTCTG'flAGA

GAATCTGGTTGGGCTGTGAGGAGCGACC

CACGAGACGGGCTCCCTGTAGTGAcrITA 143 1rM000761 GGCCAGTGGGAACCAACGAGGATC p000842 D

ACACACACTAACACACACTCACTCACAC

ATACTCACACACACTCACACACACTGUC

ACACACAGACACACACACACACACACA

144 1M000762 CACACACTTTCCACCAGGATC p000843 R 0ATCCCTGC3ATATGGCAGTCTCTACATG

GTCCATCCTAGTCTCAGCTCCAAACTT

TGTCTCTGTAACTCCYITCCATGGGTG MT TGTTCCCACT-rCTAAGGAGGGGCATAGT GTCCACACTTCAGTCTTCATrrFFCITGA GTIT7CATGTG'TTAGCAAAI1TGTATC1TA

TATC'ITGGGTATCCTAGGTIMGGGCTA

ATATCCACYI'ATCAGTGAGTACATATTG

TGTGAGTLCCTGTTCAAATmCATITC TATrCACCA'ITGTGTGTATATGTGTGTGT

GTGTGTGTATGTATATGACGTG'I'GTATG

TTrGTGTGTrGTIATIATATAACGTGTrG'L'AT'GTI

TGGGGGTCAAAGGCATGCTCATGCCACA

GTGAATGAGTAGACATCAGAGGACAAC

1T~CAGGACTCAGTTCTC7FGTTCTACCC TGTGGTTrCCAGGACACTAACCCAGGTCA

TCAGGCATGGTGACAAAGG=IIGACTC

AAGGAGCCAFFITACATGccFrCATAAGA 145 1IMOO0763 AGGGCC p000844 R GCACI'AGGAAGGAAA'ITIGACCCGTGTTrG 1TGG'ITrGTG'ITCTGGITTG~rCGGTGGT GCTn=GTITr=GThrGTTTG1T=r 146 LM000764 ITTGTATCAGGATC p000845 R SEQ SEQUENCE(tc "SEQUENCE") CLONE CLASS GENE, ED (TC {TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L2)

TION"

MUTATION \L 2) GATCCTGGITrTCTCTTGACACAGAAC AC1TCTCCTGATTGACTCTGGTCCAGAC ATTTC1TTCAAAGGCAGAGGACTCTGGC

TAGCTGTGGATGACT~TTCAGATGAAG

TCATrGGTTGCGATTGGAAACGTAATC

AGAGCAGG

147 IiMOO0765 p000847 D GATCGCATTAGGGTITTr=ATGGT1TrC TCATCTrCTC1TCAAA1TAGCATAGAAG CCTCTrCCTAAAGAATGGATACTTAAIT C'ITAACTTGAAAATATC1TICTCTGTGT

GTI=CCTCTCCATTGACTGTTCGCTCTA

TCTATCTATCTATCTATCCATCTATCTAC

TGAAATAAAAATAAGGGAACGCCTrCT TCTCTCATTCTTGTTrGTTGTrfGMTGT TTTGT1TIGAGACAGGGTrTTTCTG

TGTAGCCCTGGCTGTCCTGGAACTCACT

TTrGTAGACCAGGCTGGTCTTGAACTCAG

AATCTGCCTGCCTCTGCCTCCCAAGTG

CTGGGATrAAAGGCGTGCACCACCACCA CCTGGCTrCTCTrCATTC~TAAAACGA

=GAAACCIT=~AGTGAGGTCAAC

ATTGTGTACTCCAGTCCCACTCATCTrCC TGTCCCTfCCCTCTrAGGCCTGCCTGTCT GGTACCTCACTCATG'ITTGTGTAT7CTCT OTGCTGAGCCTCTrCTGTG=-TCCCAGC ACATGGCTGCTGGCTCCAG'IMCAT-rCC 1148 1 M000766 AGTCCCTTGTGATGTGAGCCTAGTrCAG O05IR SEQ SEQUENCE~tc "SEQUJENCE") CLONE CLASS GENE NO: {TC ITC (TC "CLONE "CLAS "GENE" 2) SIFICA \L 2}

TION"

IMUTATION \L 2)

CTCTCATGGCATGGGTCTCAAGGTCCTG

CCAT1TCTGCTCCATC1IACCCCAGCAC ATCCTGTAGACAGGACAAATrGTAGGCC GGAGG=T-GTGGCTGGGTrAGAGACCC AGT-rCTCCACTGGAAGCCCTGCCCGGT

TACAGGAGGTGACCAGTTTCTGGCTCCA

TGTCCCCCATTGCTAGGAGTCTTAGCTG

GGGTCATTCTCACAGATfCCTGGGAGAT TACTCTATITATCTCCTTG1TCAAAGTG

TTCCATCAGATATTAATTITCTCAAGAT

TCAATATrCTCAAATATTA'ITCTCAAGCT ATGGACCC'FFCAAATTrACAGATAGAT17 TATGAAITGAAAAGT'rGTGTGG3TFGAAT

ATGTAGTTGAGGGTGACITGAACTTCT

GG'I ITIICCTGTGTCTACCTI'CCAAGTGC'I'

GGGGTITACAGGTATGAGCCATCACGCCA

GT7TCTGTAGCACTGAGGCTCAAACACA

GGGCTTCTGTCTGCTAGGCAAGCACITCC

ACCTACCAAGCCAAATCCCCGGGC'=A

CTGCAI'CT'ITGTGTGTATATGTATGGTAT

GTGCGTGjTGTATGI'AAGGATATATGTAC

CTGTGT

149 M000767 p000854 R

GATCAACACCTGAAAAGTGGCGCCGCCT

ATACACATCCG'AATI'GAGAAGTATGTG

GAAGATrCCATCCGTGAAAT'rCAATTrAT

CATGCAAGCCAAGTGGAAGCGCTTCCCT

GGGGAAGGAACCCAGCAGCCGCATCAA

AACGACCCCACCTGTCTAY1TCATGTC AAAAciAG'rGAGAAGTCTGGGTGATGAA

ATAGAGAGCATACATCAGCTTAATGAAA

ATTTCCAGGGGTCCCTGGCTGTAATGGG

150 ILMOO0768 AGTCCCAT p000858 D

GATCACCACCAGGGTGTTGAGAAAAAA

AAAAAGCAAGTI7AGTAGATGTTAG 151 IM000769 p000860 D GATCTGACAAAACCTACCTGTT=hGAA CACATGTrGGGACAGCAGTCTGAGAGAA TCTATGAATfAAAAITCCYF-FCTGAG'ICTG 152 1M000770 IGCACA'TTGGTACAC Ip000861 ID F SEQ SEQUENCEftc "SEQUENCE") CLONE ICLASS GENE IDIT T T NO:{C {T C "CLONE "CLAS "GENE"M 2) SIFICA \L 2)

TION"

MUTATION \L 2) GATCAl7ATACCCCAAATGGTACTGTAT CTATATATACCTCAAACATGTCATGrrA

AAGAAAATACTCTGTTGAACTAA'ITCAC

153 1M000771 ITGTIT p000863 D

GATCACAGGACTGAATCACATI-TATGCC

154 IM000772 AT p000864 D GATCAT'TrACT'rGTTTrGGTGTrrC ATGM~GTGGCTCCTTrATGTAGTCTAGAT

ATTAACTTGAAGTCTGAAGTGGAACTAC

155 IM000773 CAAAGATTTTCTrCCATCCTCATCT pOOOS 6 5 D

GATCAACCGCAGATGAGGTCTATGGAGG

AAAAACGATGTCTGGAATnITTAA~AA T-rGCTCAGC 156 1M000774 p000866 K yc

GATCATCATGTCAAACCTGACACGTGAC

GAGACAAATCTGTGTGCACAGAGGTGTG

ACATCCTAAAJAGTACTAACAATACCGC'

GGGCAGGGACACACGCGGCAAlIJCCAG

TCCTGGTATCCATGGCTCAAGCTCTGCA

CGGAGAGCCCGGCACACGGCAGGAG

AGAGCCACAGGCTAAGGAGAGCAATGC

157 IM000775 TAACTAACATGGCACCCGTGTTAG p 0 0 0 8 67 D

GATCTGGCTCCAAGGGCCTGTACTCAT

GTCTACAATGCTCCTACACAGATATAT

158 IM000776 p000868 D SEQ SEQUENCE{tc "SEQUENCE") CLONE CLASS GENE ID {TC {TC ITC

NO:

"CLONE 'CLAS "GENE 21 SIFICA TL 2}

TION"

MUTATION kL 2)

GATCAGCCTTCCTCCAAAGGTACCTGCA

TAGAAGAGACCTCTGCTCTCACCTACTC

TCCTCTACAGITCAGCCCATATGGC17C

ACCTGCATCCCCTAGAGACACACACACA

GACACACACACACACACACAGAAACAC

GCACACAGCACACACAACAGACACAAC

ACGCACACTCACAACACAAACAGACAC

AACACACACTCACAACACACTCACACAC

ACACACAACACACACACACAACACACA

CTCACAAACACACTAGTACACAAAGACT

CCAACACACACATrCCCATGCACTACTC CCTCAGTATCCGCCGCA'nGTGTTCAC

ACTCATCCACACTCTCACACATGTAGCA

CACACACATCAT'rCCTACACAGGCATGG

ACACACACATGCTCCTATACAGGCATGC

CCAGTACTCTCACATGCATGMIGCACG

TCCCAAACAGG'FrCCCACAAGGG1TrG

GCAAAGTACATGCATCCTCACACGCTAA

159 TGCAAGCCGTCACACCCCATACCACAAG 1rM000777 CATGCAC p 000870

R

GATCAGATGTGGAAATTAGAGAGAAGT

T1TAACGCTCATGCACATrTCTGAAA

ACTCMIIGCGAGGTATACTGGTAGATAA

ATGAACATI'GGTCAGACTCCTCTAGMh

AAACCACTCTCTTCCCCGCTATGGGGOG

AGGCGAGAGGCAMrCTAAAGCTTATAT GTAG17GCAAAGTGTGTGTGGTGTGTGT

GCATGTATGTGCATGTGGTGTGTGTGTG

TGTGCATGTGGTGTGTGTGCATGTATGT

GCATGTGGTATGTGTGTGAGTGGTGTGT

GTGCATGTGTGTGCATGTrA'TGTGCACCG

TGTTGTGTGTGTATGTGTGCATGTGGTGT

160 IM000778 GTGTGCATGTATGTGCATGTGGTGT p000871 R GTAACATCTACTAACTGCTrFThIT 161 EN4000779 TCTCAACACCCTGGTGGTGATG 00O0872 ID

SEQ

11D

NO:

SEQUENCE~tc

"SEQUENCE")

CLONE

(TC

"CLONE

2}

CLASS

(TC

"CLAS

SIFICA

TION"

\L 21

GENE

{TC

''GENE''l \L 2)

MUTATION

162 PJM000780 163 JEM000781I 164 IMOo 0782

GATCATAAGGACTGTAGCAGGCWAG

GCGCGTGCCCA4rAAAGATGGCMC CTCTCCCACCCCAGC M JGATGCTCTGAT

TATCCTAA

GATCAGGCTGGCCm'J&CTCAGGGAGA

G

C rCMCMCTTC T~f-[JJ 0 GAGACAGGrFCTCTGTATAGCCCTGG

CTGTCCTGGAAITCACGTAGGCCAGGA

TGGCTCAGTCTGC7C'ATAGACCA

GGACCACCAGCCCAGAGATAACACCAC

TCACAGTGGGTGGTCCTCCCCACATTG

ATC

GATCACACACTCATGTGGCTGTCAA

CTGTGATTGCTGATACAGGGCTGT

ACAAGTCAGCTATAGCTCCGCAT-GCAG

CTGCAAC p

GATCACMTAGAGAAATCCCCACAG

CTGGATCGTGGAGGTATCCCCAAC

TGAAGCTCGTCTCTGTGATAAT-rCCAT CCTGTGTcAA4GnGACGAACCAGCC

AGTACACAAGTCGACACAAAACTAGCC

AGTACACAAGTCAACACACAACGCGCA

CAAGCTGAGGCAAGAGACCAAGCA

TCTACCAGGCCTCAGT-GCTATGTCCAC

TTCTGCAGCCACTCCAAAACACCTGTCA

GAAAT-rCGGTTrTGATAGAGAACTCACCG

AGGGAMCCCTACACAGGTCAACCA

GrGCACAATACAACCTA

PC

GATCACrTGATAAAGATGCTCTGAGCAG

AGGCTCACAGGJ&ACCCAGCCCTGTGTGC

TCCCCAGGAGcGAGA'n-CAGCAGTCAC

AGTGCAGTGTTCACGTGACCGTGCGCAG

GCCATGAGCACTAC

P

p000874 ID Ip 00 0875 IB NIM.8363 000876 JR 165 JIN4000783 '000877 'D I- I 116 ILM000784 ~00878 _JA ICctS 167 B A1615991I 167 4000785 SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID f T T NO:{T {T C "CLONE "CLAS "GENE" 2) SIFICA \L 2}

TION"

MUTATION \L 2)

CTCCTITTTCAGCAAGCTCCTCACATCAC

AGGCCTTCTC11TGGGATGGCAGCCGCCT

TCTATCTGGAAAGTATGTGACAGCTCAC

ACAATCCTGTAAGTCTrCCATGTAATCA

CATI'CGACTGCCTCTCTCTGAACGTGCTC

CATGCCAGGGCCATG'IGGAGGGAGCAG

CAAGACYFGAGCTCAGCTAGTCTATGAA

GATGGTGGCAGAACAGGCTCTGCTGCCT

TGATC MMU767 168 1M000786 p 00088 1 B 154

GATCAAGAGTTCAAAGTCATCTTCAGCT

ACAAATGAAGTTGGAGACCAATCCAGA

CCCTCTCTCAGAAAAAAAGGAAAAAGG

AGAAAGCAAAAGGAAAGGAGGGGGAG

ACCGAGAAAGAGAAGAGGGAAGGAAA

GGGAAGTCAACAGAACTCAAGGTCAGC

169 CTGGGAGGGTGAATGAGGCArrGTFGTC Mm. 1388 11N1000787 T p000882 B 09 GATCACCTCCACMrATGGTGGACAGAG

GATGGCAGTAGTAACTGCCCCAAGGAA

ACAGAAACAACAACAACAACAACAACA

ACACCTCCAAAAAGACCAAAGCAGTAA

GCTGTAGAACAAATGCAAAGAGCCAAA

170 IM0007 88 c p000883 R

GTTCCACCTATAAGG'FIGCAGACCCCYP

TAGCTCC1TGGGTAC2ITTCTCTAGCTCCT

CCATTGGGGGCCCTGTGATC

171 1M4000789 pOOO 8 8 4 R SEQ SEQUENCEftc

"SEQUENCE")

NO:

MUTATION

GATCACATGGACCGATrGCCGCGGGACA

TCGCACAGGAGCGTATGCACCACGATAT

CGTGCGGCTI=GGATGAGTACAACCTG

GTGCGCAGCCCACAGCTGCATGGCACTG

CCCTGGGTGGCACACCCACTCTGTCTCC

CACACTCTGCTCGCCCAATGGCTACCTG

GGCAATCTCAAGTCTGCCACACAG3GGCA

AGAAGGCCCGCAAGCCCAGCACCAAAG

GGTG~GGTACAGACA

GGACCTCAAGGCACGGAGGAAG&GTC

TCAGGATGGCAGGGCTGCTGTGAC

AGCTCGAGCATGTGTCGCCTGTGGACT

CCCTCGAGTCACCCCATGGCTACVI7GTC AGATGTGGNCTCGCCACCCCrCrCCCC TCTTCA1-rCCAG GACTCCAGA CrCTA ~3ATATAATrATG-fTAGAGGGAACT !rT=AAATrGAAGTTCA1TrfATTGTAT 3AAA1TA1TTTGATAA 172 jJM000790 pO00885 IK [Votchl 173 JIM00 0791 pOO0886

GATCAGCATGGTTACAGAGTAAGT'AC

AGGACAGCCAGGGCTCCGTGGAGAGAC

CCTTGTCAGAACACACAA

A

4 ATrAGAAAGAGACCCTCTCTCTGAT-J-

GACCAATCACCCGTGTCAATCTTGCCA

CAACCGAATCACCACCA&AflGCCAGAC AAGCGGCTATGCTGGGMT'1ltJGAGGflG

GACTCCTCAGGTAGCCCGTGTCTAGGCA

GAATGATGCCAGCAGCTACAC I II I AG AAAGTAGCAG~rCGC ACCTAGGAATGCAGC IRp 087 174 175 ~IM000792 W1000793 GATCAGTCATGTCCM~AGACGmrACUr TCATCCCAACTrroGA~cA-p.CAAGC pOO0888 p000888 SEQ SEQUENCE~tc "SEQUENCE"} CLONE CLASS GENE

EID

NO: {TC ITC {TC "CLONE "CLAS "GENE" 2) SIFICA \L 2} TI ON" MUTATION \L 2) TrACAAAGGCAGAAATATCAGAAAGAG CCTGAAGTAGCAGCTGTrAACCTGTACC AGGAACTGGCCGAAGTACACACGCGTr AACTCAGCCCTAA~rATTCTCGGGAGAT ACAGTrGATTATCATACACATGTCAAAA

TGGAAAATAAATGGGTAACTAAAAATT

GAGGAAAATAAGATTAACACJ-TAAACA

176 1M000794 ACCTAGTTCATTATGCCACG*JTGATC pOOO 8 9O D F 177 1IMOO0795 GATCAGAGTGGGACAGATTAAATGT-rA p000891 D

AAACAAATACAAAGTGATAATGTGTGA

CATCTGAAc'I~i'CAATGAGATAGGTAA TrATCTCTGGGCAATIGG3TAAATGTGCT

GGCCAGGAAACGTCACAGCCAGAGTTCA

ATCTCCAGGAACTrAGGTGGGGAAGGA GATAACTGAC'rrCCAAATGCTCACCCCC AAATATACAATTrAAAATAAAAATCTTCC 178 1M000796 FI1ATGAGTAGCAACTGATC p,000892 D 179 JIM000797 TAcccci'GGTCGTCCAACACTCCGATC p000893 D GATCATGACATAGACTrGAGTCAC1-TCT

CTGCAGTGTCAATAAAAGCCCCTAAG

GGACAGTGTGGACThrAGAGATAAC 180 IM000798 p000894 D AATGCCAGCCATAGTGGCACACAC=hr AATCCCAACACTCAGGAGAAGTTAAGTr

TCTCTTAGCTCAAGGCCAAGTAGCT-FGG

GCTACTCCGTGAATTCCAGCCCAACTAC

ATAGTAAAACTAGCCT'TAAAAAAAAAG

OCACAGGGAGAGGGAGATAACAAAAAT

GCCCAACTCCTAGCTACAGTAACTGTAG

181 GAATI'AAGATAGAATCTGTAG'TFGTFT IIM000799 ATCATrATCGTGATGATC p000895 A l GArCAITGGCTTGAT-rGTAACATrTATCAA AGCTI7CCTTGGCACACTGCAGGGCTGTC TTCGGGAAACTGCGTA17GTGCTCTTCA

GGTACAAAGCATAGAGCCC'IACATGAG

AAACGCTGGGGTrAACTTrC3-rCTAG'rC cc'[CTGCCCCACT'rGTGGCGC1TCCCACT 182 IM000800 CATGACTTCTrCAGTGTGTATTrCACTT p000896 D SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID T T T NO:{T C {C "CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION TL2}

GATCATGCTGAACTCUGAAAGTATTCT

AGCAAAATGTGGCTrAAAAGAAAGAAC AACATrAACTAGGTATGCMIGAuA.AA 1TACCTGTGGTAAAAMTCCACAAGCAT 183 GAGAAGTrTG'ITTCTTITGTrGAACC'ICA EM000801 GAG p000897 D GATCATATATCAATITATTI=AACTn 184 GTTrGTI17G7TGTfITGTTrGTGTfCG 1M000802 AGACAGGGTTCTCTGTGTAGCCCTGG p000898 R AT7GTGTATCCAGAGTGTGACAAGGTAT 185 EM000803 ATATGGTrGTGTGATC p000899 D GATCTCTGTCTGGAAGAGTGCTrGCTG GTTCCGACTAC1Tlrl-rli-TI III ITII r Tr-GCTTGGGTrCANATTGGCTTCA GG'rrCTGGGCCCTrrCGTGGGTTGTGCT 186 IIM000804 GCANAGCCCCA1NACAATGTCTrGGQ p000900 R

CAGGAAACCAGGGGAAATGGGACACAG

TGACATCTGAGTCC1TAGAAGAGGTCCC

ACAAAGGTCTATATGACCTAGCAACGTC

ACTW'TGAGWrA1TfCTCAGACACAGTO

GATGMTGTCACAGCACACTGTAGGACA

TCCCAGAACAGCACCATGGGAGACCAT

GGT'rGGTGCAACAGAGAACATGCACACT GAGACAGTACAAGAGTrCCCAAGCAAG

CAGACACAAACAATGGACTCAATACAC

187 JIM000805 ATACAGTGGCAGATC pOOO9O 2 C

GATCTGCTCACCAAAAATCTTGTCCTAG

188 GGAAGTTGAGT'TGAACTGCGTGCTrAC JIM000806 TGGCAAACACGCGGTGCCCPAAFFI'AA p000903 D ACAGTrCCCCCTGGAAATGGTCCCTGTA 189 1 M000807 CCAGAGGAGCAGATC p000904 D SEQ SEQUENCE{tc "SEQUENCE") CLONE CLASS GENE ID (TC (TC (TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 21

TION"

MUTATION \L 2)

GTGGGGCCCAGACTCCAATCCCGAAATA

lCATTAGCTGCTGCGCACT7CTCCGAGG AAGTh[rACACCAGTACCC'I'AAGTYFCAAG

TCTCAGAAGCCTCCAAATCCTCGTTGGA

CCCCrATAMICAC~rrGGTCATCCGACTG

TAACTCACTCACCGACAAGACAAAGAAT

ATCTTAGGCTCCGTCGTAAAAGAACGAG

CCCGGTTCACCGCAGCTCC1TPATAGTC TCC M GTGCGAGATC Mn.2 179 190 1M000808 p000905 B 18 GATCTGAAGATrAThIGACAACAGCTAA AAAAAAAAAAACCAAAAAAA4~ACCCC[TT ATTACTAACCAAGGGAAAATrGCAAAAA TAAT'rAAAAGTTCCTCAATTAAGTAA

ATATCCAAAAAGATTGGTTOTATAACAA

AGTTGAAGAGTCAAACAGTATFI'GAATA

191 IM000809 A p000906 D AGCTCA1TGCCGrrAA3TrCCTCAGCCT AATGAGAATCTAAGCC'T7GA'rTl'GTATG TACCATAGCATCTAc3ATC 192 1M000810 p000907 C CCT'rGAACCTAGT-rCAGGGAATAGGCCA

CC'IGGG'IGGGACTAGTGCTGGTTGGGGA

,rGAAAAGACAG'FrGGCTCAGGTGAACCC

TGCTCGCACCCTGGTCATCGTCTGAGAC

TGCYITGATTGCTGACCCCAGTGCTCCA

GCAAGAAC'FrGCG'rTC'rrGITCTCTCCAC

TCAAGCCGGAAGAAATCTGAGGAGAG

GTGTGAATCCTGAGCCAGGA[FGTCCAAA

ACAACGGAGTTGAGCCAGAAGGACGTC

TAGTTGGGCAGAGTTAGCTCAGTCCCCT

GACCCCCAGTCCGTGCAAGCTCOAGGGT

GTTATATAGTGATACAGATC

193 1M00081 1 p000909 D GATCTCTrCTflATCTCTACCTI1TGGGGC ACAATC3TATCTGGGGACACCACAGAGC

CCAAGAAT-TGTCCTGTATCAGAAATFUG

GACC=TCTGTGGCTATCTGTAAACCCC

ACTGAC'ITAAAG=IAAGTAGAAAAGG

ATATGCCT-flrGTAGCATGGTAAGGTCT 194 10008 12 Y-rATGGCACAGGAGGATIGTrCATCCATGTF pOOO 9

I

2

R

SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ED {TC {TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2) CTTCCTFCCITTrGAAACAGGGTl-rC

TCTGTGTAGCCCTGGCTGTCCTGGACCT

CAATCTGTAGACCAGGCTGGCCTCGAAC

195 EM000813 TCAGAGATC pOOO 9

I

3 R

GATCTGGTCCACMTACACAGCTGACCA

196 IM000814 TOAGACCATGTNCACATAG p000914 D

ACATGACATATCACCCTCAITCAGAGTT

CAGAGTCTTCAGAAAACTGGGCGCCTGA

AAAACCTGACC1TrAAATI=CGTCCAT AGTrCTrCTG'IrGAATGAATATT-CAT 197 EM000815 AAAAGC1TCATAAATGCCAAGATC p000915 D 198 1M000816 GATCTrCACAGCGCACCCAGGGATC p000916 D CTITrCTTGGTATTTAGGGAGTCAGGA AAAGAAAAACCA'TGGG1T]TACATTA G='~CAGGTAGGGTrGTGGCT=rGAG

CAACAATAACGTATGACM~GTGGTCGG

199 1M000817 TTGTAGATC pOO 0 9 17 D GATCTTC1TATATCTGGTTCCTGGGCGC 200 1M000818 UTCCGGTAT p000919 D

GATCTCTGACAGGGMICAAAGAACTGT

TACTGATGTTAGATTGCCTCTGAAGAC

ATCACATATACTGTGCTACTCTGC =TGT

CAGAGTCCCGGGCCCTGGGCACCCCAGA

CGGCAGCAGAGGAAGAGCGGGGTATCA

CTICTATACITCGGTAAAGTCATTGGG

201 ILM000819 ATATGTGCCCT p000920 C T CTCCTCTATCATTATC1TCTrCCT 202 1 M000820 TCUCCATCTGTTTGTTT 00pO0921 D SEQ SEQ1JENCE~te "SEQUJENCE") CLONE CLASS GENE NO: {TC {TC (TC "CLONE "CLAS "GENE" 2} SIFICA \L2}

TION"

IMUTATION \L 2} GATCTGCTCACCAAAAATCTrGTCCTAG GGAAGTTGAGTTTGAACTGCGTGCI1AC TGGCAAACACGCGGTGCCCAAA'I1TAAG

GAGTGCCAACGACTTCGCGGGCCAGCA

AGGTGAAACCGGAGCOCGCACGAGTGA

GCAGTGGCCAGGAGGCCTGGCCAAGAG

GCCAGGGTCCCTGAGCATGACCGAGAG

CTGjGCGTGCTCTCTGTAACCCCCAATCA GTrCACCTAATCTrCGGGTCGAAAC'GA

GCCCTGCAGGAGGCGGGGCTGAGACTG

CATCCCAGCTCCTGGCCCGCTCCAGGGG

CGACCC

203 IMOO0821 p000922 D 204 IM000822 CCAGGCATCTCCAT-ICTT'AATCCAGATC p000923 D CATAGACTCIT-FCAY1T'AGAATAAAGTG

TTCCACCTAACATCCTGTAGGAAGTGAT

GAAACTAAAAAGAAAAAI'AAACGCATT

ITCTC1TCTCTCGTrACITICCATTCA CTAAACAAAATFGACTMfIr=rTCCAT

GAGAGTTCACACTGGGTCTGCCTCAGTA

AGAGTCACACTG17CAGCCCACACACGC TGTGATATGTTA'T7ACTCATTCTCTTCT

CAGGAACCACTCTCACATGTGAACCCTG

205 1M000823 AATACCAGCTCCCTCCCTC1TCAGATC p000925 D

ATAGGTTCTGTCTCAAAACAAACAAAAA

ACCAAAACATGTCCACAGGGTCCAACA

GACACAGTCTCCGCCACTCACAACTAAT

GGGTACACAAATACACACCTCAGCCTrA

CATGGTTACAGAGAGAAGCAGGACCAC

AAGGTAGGCAGGC2ACCTAACAC'ITIGCIT- CTrGGAAGTTGGAGCACACACACACACA CAGAAACACACACACACIrUCTCACACT

CACACACACATTCTCTCTCTCTCACACA

CACACACATGCACACATGGTCTflGTACA

AGGTCCTCCTGGGATGGGCACACACAGG

GGTAAGAGGACTCCAGATC

206 1IM000824 p000926 D I- GATCGAACACNCTNGGAC'TrGNTAAACG 207 1 N000825 NTrCCCACACNGACAGA p000928 D SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ED (TC {TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L2)

TION"

MUTATION \L 2)

GATCGTCTGGCCCGACCGCGCCTCAGTA

GATTTFGGGTCCTGGTCTGAGCAGCCGGG

CTGGTGCGGGTGTCGTCACTAGGATAAT

GAATACAGCTCCACTACCTATACTACCC

AAGACGACCCCTCACACGCTCTGCGAGG

AAACCGGTFC I IGGAC 208 1M000826 p000930 D

GATCGACCGCAGATGAGGTCTATGGAGG

AAAAACGATGTCTGGAA1TrATTAAAA

TITGCTCAGC

209 1M000827 p 0 0 0 9 3 3 K Myc

AGTAGACTGAGAMTGTGAGCGCTAAGA

TAAAGATGAGCAAAGG1TGGCAGCTCT

TAGGTATCTGAGGGCCACCGTCCTCTAC

AAAGCAACGAGAGGCACGGCGGATTAG

GATAGACTGGTTGCATCCAAACACTACC

TTGCTGCCTCAAAGGC'ITATrGGACACC

ACAGAAAGACCTCTGGTGGAGGCAGAA

210 OEMOO0828 GTCACAGGACTCCTCGTCAGAGACGATG 00O0934 D

GATCGGCCTTCCTGCAAAGCTACCTGCA

TAGAAGAGACCTCTGCTCTCACCTACTC

TCCTCTACAGTTCAGCCCATATGGCTTC

ACGTGCATCCCCTACACACACACACACA

GACACACACACACACACACAAACACAC

ACACAACACACACAACACACACAACAC

ACACTCACAACACAAACACACACAACA

CACACTCACAACACACTCACACACACAC

ACACAACACACACACACACAACACACA

CTCACAAACACACTAGTACACAAAGACT

CCAACACACACATTCCCATGCACTACTC

CCTCAGTATCCGCCGCATrTGTGCTCAC ACTCATCCACACTCTCACACTrGTAGCA

CACACACATCATTCCTACACAGGCATGG

ACACACATGCTCCTATACAGGCATGCCC

AGTACTCTCACAT6CATGTrGCACGT7 CCCAAACAGGT-rCCCACAAGGGTTTGGC

AAAGTACATGCATCCTCACACGCAAATG

CAAGCCGTCACACCGCATACCACAAGCA

.211 1M0 00829 TGCWk p000937 R SEQ SEQIJENCE~tc "SEQUENCE") CLONE CLASS GENE ED ITC ITC ITC

NO:

"CLONE "CLAS "GENE" 21 SIFICA \L 21

TION"

MUTATION \L 2)

ACACCACATGCACATACATGCACACACA

CCACATGCACACATACACACACAACACA

TGCACATACATGCATFACACATGCACACA

CACCACTCACACACATACCACATGCACA

TACATGCACACACACCACATGCACACAC

ACACACACCACATGCACATACATGCACA

CACACCACACACACTTIGCAACTACATA

TAAGCT1TACJAAATGCC'ICTICGCCTCCC CCCATAGCGGGGAAGAGAGTGGTlTAA ACTAGAGGAGTCTGACCAATGTTCA'fl'

ATCTACCAGTATACCTCGCAAAGAG'IT

TCAGAAATGTGCATGAGCTGTTAAAAAC 14s. 17043 212 IM000830 ICTTA'fCCTCAT p000938 B 4

GCTGGACCCCGGTGACAGACTGTGCAGA

213 1M000831 TGGATC p 000939 K Pimi 214 [M000832 TTAGCAAGTCCGAGCGTGTTCGATC p000941 K Nrnzyc 215 1M000833 ACTGCACACATTrGCCGGTTGTCGATC p000943 K Notch] CAAGTGTAGACATrGCAGGAAAAAAA'r

ATGGTGACAGTGAACAAAGCCCGTGAA

GGTGACAAAAGCCAGTTAAAGTAGGAC

AAGGCAGAGCGAGGCGGATGACCGGGA

CCAGGCCCAAGAAAATAAACGAAGGCC

AGGAIC AW32 14 216 1M000834 p000944 B 168

GTCGGAGGAGCTGGCTGGACCGGTACAT

GCCCTGGCCATCCAGGCGAAGACCCCCG

CCCAGTGGAGAGAAAACCCACAGTTGG

ACA77AGTCCCCCCTGCCTAGGTGGGAG CAAGAAAACTCGAGGGACC'TCl-AATAA

ATACCTGGATTGGGAGAACGATC

217 1M000835 p0009 46

IR

GATCGCGGGGCTATCTATAGAGTCCCCG

CIGATGTrCTGAGAAATGAGCCCTAGAAAT

GACTAGAAAGAAAATCGAAGTATTCT'G

GCTCCTGGAGAC~rCCGCAGCGA0AAGT CACAGA'I7CAGGACACAGATT'GACAGG

AGCTGCGGGCGCTGGTAG

1218 11M000836 I p 000950 ID I-- SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE NO: {TC {TC {TC "CLONE "CLAS "GENE" 2} SIFICA \L 2}

TION"

MUTATION \L 2) GATCCCAGGAITrGGGAGGCAGAGGCA 219 1M4000837 GTTGGCCCCA p000953 R

CAGGCTGGCCTCAAACCTGCAGAGATGC

TCCTGTCTCTGAGTGTAGAM~AATA

AGGGGTTCACGATC

220 1M000838 p000954 K Lck GTTGCTGGGCCCTAAGCGCCCACA77C

ACAGCTCCGATGCTCATCAGCATGACTC

TCCTGAGCACAT'rATCTGGTGGTGGCTG

ACACTCTCTTCAGTACCCCCCCCCCTCCC

AAAAAAGAAAAAAGAAAAAAAGGACTG

GrrGCTAAAAGAAGTAAAAGTCAAGTC

ATCAAAAACAATGTAATATCCTGTGTGA

AAGTCACGAAGCCTTGCGGMhGAGTCC

CTCGATC

221 1M000839 p000955 D

GATCGGCCGGCTGTCCAGCGACCGGAG

AAAGGAGAGCACTCGAATCGCAGAAGC

TATCAGGTGAGTCCGACCTCrCTCTGJ&A TGAACG;rIGGGGAGCCTGCCAACGGT GACCAAAMIAGCCAGTrFAAAAGTACAG

GCTGCCCAGCTGTAACGTACATCAAAC

222 IL000840 AATGTGCGATTTTAT=IrAGTGTG&A pOOO956 D

ATAGTAACACTTGGGAGGAGCCATCCC

AGTGAGGCTCGTATAGCATAGCCCTGTC

CAATAGAGCCTCTG1TGCACTCTGTGTA CACTrAGCTCC17GCTFAGGGATIr=

TACATOGGGACACAGCACCCCAAM'

CACATrGGACAGACTCCAGGACACCCCT

CGGTGTCCTGTGACGCATACAACAGCCC

CCCACGGGGCTGCACCGAAAACGCCAC

AGTACTGAGGCTGCACCTCACTCATCA

CACACACGTCTATGGCTCAACGTCCTGG

AGAAAAGGCTGCGACAGA7TCCCACATC

TGGGAATGCAGTGAAAAAGCACTCACA

CTGGGGGTGGGGTGGGGCTGGGGGGGC

ACCCTGTCT-rCCCGTCnrCCCATGACCCT C'CCC1TCCAGGAGACCATAGCCAGAG CTGACAGGAGATrCAGTCGCAGCTGCAC 223 E1M000841 ACGCTGCTGCCI'TGCCGATC pO00957 ID F SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE NO: (TC {TC {TC "CLONE "CLAS "GENE" 2) SIFICA \L 2) lION" MUTATION \L 2)

GATC(IGGCAGGACACACATI'GGGGAGG

CCCATCAAGCCCGAGCCTGcciTG'rGAG CCCCCGGAT7GGCAGGGCAGAGAGGAA AGCTGCTGC0TGCT=ATAGACT'rGGG

GAAGTCACAGGCTCCGCTTGCTTGGGGG

AGGCAGGAAACCCCCTCCACCTAGGCGT

CTGCCAGAGCACCCGCAGGCTTMCTr

GTCTCTGTCCCCCTCCCCAGCACCTCTTC

CCCTGAACAGCTTCCCTCTCCTGGCCCT

GCTGTCCC1TrAAAGGAACTTGAATCAG AGUrGAGAATGATGGTGACTCAGGGTGG

AAGGGGTGGTCACTTG

224 1M000842 p000959 D

CCAGGGCTACACAGAGAAACCCTGTCTC

GAACAAACAAACAAACAAACAAACAAA

CAAACAAAGT FAAAAATAAAAT'rGATAT 225 1M000843 ACGATC p000960 R

GATCCAGGACATGGCAGAATATGGTCAT

CTC'LTF'GCT-rGCATGTCACACGAATGG ccTrCTGGCTCCACCCCTGAffGCTTGCTC CCCITGGAAGCCTCTTrGAGCCTAGCTAA C1T1CCTGTTCACCTIlTGTAYrATGTGC TCCCACCATGGCCCACCAGGCTCTGC1T

GCAGCACTGCAGCCTGCAGCTCCAGCGG

CCTMTACATGGCTCCTGTAAACAAGTCC

CAGAGGCCTCAGTGTCATCATTTCAGCA

ACCGCCTCACTFCIGGTGCCGCCTTCCT

TTFAJTACMr~CATA1TCTGTGACCGAAA

TACCCCCAAAGAAGCTACTCAAGGAAA

GCAG'rATGTGTGGGCTCACCA7TFAGAGG

TCAGTCCCCTGCAGCAGTGGAAGCATGT

GCTGGTGACGC

1226 1 M000844 1 p000976 ID F

U

SEQ SEQIJENCE~te "SEQUENCE") CLONE CLASS GENE NO: (TC {TC {TC "CLONE 'CLAS "GENE" "TL2) SIFICA \L 2)

TION"

MUTATION \L 2) GATCGCTAC~fT]CAGAGACGCCTiCA TAAGGGGAGAATGGAfiAGATGCTGGT TGACTrGAAAGATITrCTCTCTGATrGTr TrACAGGAAGTGCATCTGTACACATGA

GAGACTCCGGGTGGAGAGGCATTGTGG

CGGYFGAGATGCACCTGGGAGTGCCAAC

TGCCCGGGCTTGTACCACAGCTCTGCAT

AGCAGGCTGGAGCAAGCAGCCAGCp

CCAT'TGTGCCCTAGCCTCATCTCCTCCAG

AAGAGGTTATCTGGGCTCTGTGTAACCT

CTGCTCIIIGGCTATGGTATTCCTTCT-G

GTGCTFMTCTGTGGTCAACCTCCAGGTAC

AC1TAGGGCCTATCCTAGACAGACTGGG AAGAAAGAATGACATTCCCATrGACCTC TGTFIIATITCCTGGAAATCCAGACCTr GTrCCAGTTAGTGGAGCATGGGGT7AGA CCAACCACACTGCTAAGAG=r~GGCCT 227 1M00845 GTAGACATATCTGG0

C

TAGCAAGGTAAGTACTrGTCTCAAITC

CAGGTAGTATAGAAGAAACATATATG-

ACAGM'TAACACCAGAACAATCACACA

GTGTTGTA1TJAGCTAAAATATGACTCT GTGG1TrCAAATGGCATAGT-rGTGGAC AACTTrAATTAAGCACGCTCI-ATAAGAC

GTGATAGAGTATGTGCCATCCAGATACT

AAGAACTGTGTCCAAAGAGCTTrGGGAC ACACACTAAGGGGCCTGCCTCTrCATA ACGGGGATGAAAATGACTGAGGCTrCA 228 DM000846 CA1TIGCACAGTACGATC p000988 D AAGCCATCTGGGTCTCAAGyrGCrM.A&A CT'fAATAACTCCCTCCCTGTG=ffGTCCT

TTATCTAATGGTAAAATATGACCTAATG

AAATAGGTrCCTAAGGC1TTGATATAG GCATGATGITrGAAGGATGGAGGACAGA

GTGGATGGAAAATCAGAGMCCGACA

GAAAACCACAAGCAGCTAACAAAAGTC

CACAACCAAAGCCTGTGCCTGAAATGTC

ACCTACAATGCAGTGGACTAITCATATG

229 M000847 CCAGCCTGGTCCTCATGCGATC pOOO 99 1 D SEQ SEQUENCE~te "SEQUENCE") CLONE CLASS GENE NO:{C {T {C "CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2} ACCAAc3AACAGAcICCCCAAACTAATAG GATGG'TGi-rGCACGTGTACATGTGTA

TGCATGCGTGCATATACGTGTGTGTGTO

TGTGTGTGTGTGTACACCCACACGTGTG

CATGTGTGTTGTGTGTTITIAAGCAAAC

CTCAGTFGTGTCATACATACTCTCCTATAC

TrCCCCTCCC'1I-'G'IrcCATATGAGGGTGC CTTCTrATCTCACAGGG1TG'TFTG3T-r 1TICTATAACAGAATGCCGCTGATGCT CTTICTATATGAACCCTACAT1TAAT ACT-rATCCATAAGCAAAGGAACAGTATC TrATCTTGCGGATC 230 1M000848 p000992 R

CTGGGGGCTCTGCTACGCGTCAAACGCC

TGGAGAACCCCTCGCCCCAGGCGCCGGC

ACGCCGCCTCCTGCCTCCCTGAGCGCTG

CTGCATCCTGCACGCCCTGGAACCCAGG

AGCGCCCCAGCGACCCTGACTCCCfGCC

AGCACGTCCAAGGCTGCTTACCCCAGCA

ACCTCCCATCCCCTGAGCCCTCAGTAAA

TGCCATCTGTAGCAGCTGTTTGTCTGAG

CGCCCTGTACTAGGGGGCCGGTGGGCTG

GGTGACAATGATAATGGAATAGTGGCTG

TCCTACTGAGGACAGCACAGTACTGYI1'

GGGACCTGTACTGGTAAGGAATACATGC

CTGCTTCCTCTGGACT1TGCGGGTCTCAC CGGGTGCCTGGGCTACCCT-rCTAGGCTT CACTGAGGCGGGTTCccTrGGGAGGCTCT

GAGGTI'ACMTCAGCGTCTGCCAGGGGT

CCACAGCAC7ITAGCCAAGGGGCTrATGGA 17CACTCGTGGTCTGCCAGGACCAGGCT

TGTTGTGAGGGCCCCAGGTGGATC

231 1M000849 W0O09 93 A Saas SEQ SEQUENCE~te "SEQUENCE") CLONE CLASS GENE ID {TC {TC (TC

NO:

"CLONE "CLAS "GENE" 2} SIFICA \L 2)

TION"

MUTATION \L 2) GTGTTrCTTTCT1Tl=IT~CTITI=C TT=Cl I I C'ITlI rITI AAATCT AAGTAAGGTGCAACAATGTAATrCGAA GGGGCAGTGTC1TrCCTTrCCTGTAGTCTC TGCTrAAT-TCCTGAAGMTGCCAAACCA

GGAGTTAGGAAAAGTTGGAAACCTGCA

GAGAGAGCGTqTGAGAGGTIlTGAGATGT

TATAGGAGAGGG'TI'GGCAATGTGTGGA

GTACAGGTAACTTGCGGTKArG1TJTCT

TGGCCCTCTATCTTCATCCT=GTGM~G

232 1M000850 CTA=TACCT-rGCTGTCGGATC pO000994 R GATCCTTGAGTCTGTACrrAGCCTGAGA

GCGCTATAACACTATATACAAAGTACG

ACTAGAAACTCCACACACATGTTGAC

TGACTrAATGTGTAGCCCTGCAATGGTr GACAGTrGGGGGTCAGGGGGCTC'ITGCA

CTGAGGGTAGTGTATAGCCTAAAGAGAT

AATCAAGATGATAAGTACATCCACACTA

GGACAGGAGCTTTAACAAGAGCTTAG

TGAAGGGAACTCTGGGAGCCTCAAGG

233 1M000851 AAGGCATAT pOOO 9 9 5

D

AGCAACACCTCATGTGGGAATTCATACA

rGTAGGTAATCAGTCTACTAGCTGAAC TATATCTCCAACCCAGGAGGTCAGG1T

GTFGTIGMAACAATCTAGTI=GAA

ACAGTCATATCCTAGGCTGGCCTCAAGT

TATGTAGTCAAAGATGGCCTrAAAAGAT GACTCTTGGTTrATLCCAAGTGCTGGG

ATTATAGATATGCACACCACCACACCTC

ATGTCTGCGGGGCTGGACTGCAAATCCA

GAGCTrCATGCATGTGAGGCAAGCACTG TACCAACTCGACTTGGATACTCGAT-rG AAAGTCA'TI1ATAACAGGATC 1234 FN000852 I p000996 F SEQ SEQUENCE~te "SEQUENCE") CLONE CLASS GENE ID TIT

IT

NO:{C C C "CLONE "CLAS "GENE" "1 2) SIFICA \L 2)

TION"

MUTATION \L 2)

CTACTI'ATCTATCATCTATATGTCTATCA

TCTATCTATCTATCTATCTATCTATCTAT

CTATCTFATCTATCATCTATCATCTATCAT

CTATCATCAATCATCTATCTAGCATCTAT

C17CCAGAGCTCATG17GTGGCTTGGGC

'FTCTCATTCACCATCATCGAAGGTAGIT

GCATFI-rGTATFGGMTCTrAGAAGCA

GGAGGCACATGAAACAACTTGCTAACCC

MFCCTGGTCTTrTG1TGTTGT(GTGGT

GGTGGTGGTGATGGTGGTGCTGGTGGTG

GTGGTGATGTGCACAGGAGACCTGTCC

GGTATGGAGATATGGAGAGCGTCTACGT

235 1M00O0853 CCTCATGGGATC p000997 R

GTGGGAGGCGGAGGGTGGAGATGAITT

GAGAAGCAGTT1GTCGATTCCTCCTTCTT

CCAAACATCAAAGGCAGCGGTGGATGA

CAAACTGAAGGACAGAGGG1TTGATGA

TGCAAGAGGAGCCAGCAGCAACCAAGG

CCAGCCTCTFGCGGGTGTGGGCAGGGCC

TC'TrACAATGAGTTCACACACACACA

CACACACACAGAGAGAGAGAGAGAGAG

AGAGAGAGAGAGAGAGAGAGAGAGAG

AGAGAGACTGCTCMICAGAACAGCCCF

AGGAGGTTAGCTTCAGACTAAGACAGG

AGACAGAGAGTCCTTGA'F1GCCAAGG

TTGCACAGCTGGGGAGAAACCCAGCTAT

GGC'TTCACCTTGGCCCTrGTfrAGGACTC CTrCCTAGTCCGGTrGCAGTCTCCTGGA'r 236- 1M000854 c p000998 R GTATrAGAGGCCAGGCCAFYCAGAAGAT

GTGGCAAGA'ITGTCATGTGGAAAATATT

TGAAACCAT7CTAACCTAGTCATrCCAT

CATCAATAATAATAATAATAATAATACT

ACTAAAATGAAAAAACCTAGATAYT=G

AGACTGTACTGCTGTATITTAAGAAT

CACGGAAAT17AGCACTGAAATFTAGTG CTAGrI=AAGAATAC1TTrGTACCGTTAC TrGGACCCACAA FrGCTTAGAGCAAGGG 237 1M000855 ATC 1POOO 99 9 C SEQ SEQUENCE~tc "SEQUENCE")

ID

NO:

IMUTATION

GATCCTGAGACAGTACAGGAACTAAGA

AGCCCTGGGCAAMTGCAGTGTGCACAC

CCAGCCTGAA'1GCCTGGTrGTCACCA

GCCTACCAATAGAGCATI'GTAGTGGCAG

GGATGTCTGCTGGTGTCTCGCAGACAAC

YTMGAGGTCCTGCTrCTCCAGAAGTGT GCAGCTGGCAAITAGCAGCCTGGTCT17

TCCTGTCGCCAAGACCAGTGCTTCCACC

AACCTGGTCTCT'rCCCACAGCCCAGCCC I ITCTrCCTCTTTGACACCCACTTCCT CTAAATGGTGGTCACATGCTrTGTCTCTT GAAAAAAAG1TTTATGAGTCAGGGTATT TTCAACGCCGGGACAGAAAAATrGAC

AACCTGGC'T=~CAATTAACCACTAAT

GGGTTTCACTTACAGTCCTGACAAATAC

CAGGCACAATrCATCCAGGACAATAGTG

AAGAATTTCATCTCTTCCCCCCAAGCCA

GTCAGTCTGG1TIAATATGCACGGTGG

ATAGCCCATAGCATGCAATGAACTGTGA

GCACCCCTCTGGGAGTCAGCAGAGACAC

ACACACAGGCACCCATACCACACACTGT

GCMTGTATCA

238 1NM000856 "CLONE "CLAS "GENE" 21 SlFICA \L 2

TION"

\L 2) p001000 D I L L SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE NO: {TC {TC {TC "CLONE "CLAS "GENE" 2} SIFICA \L 2)

'LION"

MUTATION \L 2) GATCAAAACAATA'fl'CAAATAATGACAT CAGTCAAAGTrATGATITFGATGGCCATGA

CTCATGTCAATAGGCAACACATAAGCCT

GAGAGTAAGrPAAGGAGAAATTCAGCA

ATAAACAAATTGACATACTATGTCCACT

ATGAGTAAAACCTGCCTCTC'ITAAAACG

'TI17rACTGTACTCCATGGCTCTCCCCCAA TGTGCGYI7CGTGAGAGTCCCCACCCCTG

TGACTCCATCTGTGTGTGGGTTCAGGAG

AGACTCCTGTGTGTA1TCAAAAGAGCCC

CCCATGTGTGTACACACAAGAGACCCAG

TGTGTGTACATGAGAGGCCCCACCCCAT

GTGTGTTCATGAGAGACCCAACCCCTGT

GCGTGTACATGACTCTCCCCATGTGTGT

TCATAAGAGACTTGTGTGTATGGGAGAC

CCTGCCTCTCCITGTGTATATGGAAITACCI'

TCAGAGTATCAAATATT'FrCAGCCCACTG

AGCCATCTTAGAACTTCTCTCCCTT

239 IM000857 p001001 C

ATACATATGTACACACACACTCACAAAC

ACACATATATACACATACATACATACTC

ACACATATATATACACACTAGTACACAC

ATACOCAAATACACACATGCATATACAC

GTACTCACACATACATACCCATACTCAC

ACAAACACATATATACACACATACTCAC

ATATACATTrCATFACATACACACACATAT

ATACATACACACACTTGCATACACACAG

CACACACTCACACACAGAGACACACAG

ACACACAGACACACACACAGAGGAACC

CAAAGGATTGGAAGAA'I'AA'ITTCCTGTG

CTCAGTGGGAAAG'ITACCAGAAAGAC

240 IM000858 AAGTGGTCATGTGGGATGATC pO01005 C

GATCAGGGACCCTGTACCCTGCCCCGTG

241 1 M000859 CAGCCTGTGATTC POOI 006 C SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE m TCDC

T

NO:{T {T (C "CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2)

GGACTGTAACCAACTCGGAGAGGAAAG

GGCTTAMrCATI=AGTCTTrACAGTCC

ATGATTGACGGAGGTTAAAGCAGGACG

CTGCT7ACTGACTTAGCTCCCCG-ITGCTr

TATCAGCTACTITCTTAATACAACGCCA

CCCCCGCGGCCGCCACCTCCCTAGGCAA

GACCCACAGGTCAATCCAACAGAGAGG

ATTCCTCAAGTGACACCCTATGTC&AC

GCTATCAATGGCAAAGGTATATTGAGCT

242 1IMOO0860 AAGAATTGATC pOOlOO 7

D

GATCTCAGGCTGCCCGTGGGCGGGGCTG

ACGGAGGGAAGCAGACTAGGCCTCTAC

CATATCCGTGGGAGGGACTrCCAAGGAC

CGAGACTGAAGAAACAGCGAAACAG

GAGACACTGGGAGGAGAGGCGGAGACC

GAGAC'frAGTAG Mm.7675 243 1M000861 pOO1009 B -3 AGAGAAAAGACTATCTTGAC=rIGGAT

ATGCGGGTGCAAAAATGAGAAGACCAC

AGTGCAGCTGTGTGCCCTGCACGGGGCA

GCGAGAGGAGAAAGAAGCAITIACAT

GAAGCACAGAACACGCCTGACAGTTCTC

AACAGCAGCACGTCAGACCACCGCAGC

ACTGCTCGlII=CTCAGCAGACCCCCA

GGAAGCACCACCCAGGATGGACATGTA

GGGGTGCATCCGAGAGAATCAAAATCA

CACAGGGGCCATCCTI=GGTrCGGCAT GAATGATGGGGGCCGCCrGCACTGGCCT CCACCTTCTATGGTrGTrCTrCCTI'GTAT CAATGT1TCAAAAAAAATCCTTGGGCTC

ACAACTGCCTAATGACATCTTCAGGAGT

CAAGTCAAGAAAGAGAAAAGTAGCCGA

CCTGGCACGTGGTAGATAAGACTCAAGG

GTGCAATAAGCAGATGAACTGGCTTAGT

TGGGCTTrCTATTGCTGTGATAAAACAC

CATGACCAAAGCAACTGGGGCGGGGGG

CGGGGGGTGTCATGTTACACTTCCATAT

CACAGTCTATCACTGAGGAJAGTCAGO

AGGATTCAGGCAGGAACC

244 IM000862 p001011 R SEQ SEQLJENCE~tc "SEQUENCE") CLONE CLASS GENE ID {TC (TC {TC

NO:

'CLONE "CLAS "GENE" 2) SIFICA \L 21

TION"

MUTATION \L 2)

GATCGGCCAACACAGGATAGATACCAC

ACAGGATAGGAGGTACAGTGTC'IGGAA

GATTAi-rATCGAGCCCCTGAACGTAGTA

GAAGCTGGCTGI'CG'ITCCAGTGCAAGCT

245 IM000863 GAGCAGATGGTCC p001013 D GATCCACATGAAAGCCAAGCTGCACATr TGCTrCATATGTATGGAGAGGCCTAGGT -rAGCCCA'TGTATrGTTCTTIGGTTGGTGG

TTCAGACTCTAAGAGTCCCAAGGGTCCA

GGTTAGTTGAC71TrGGTrC1TCCTGTG

AAGTTCCTATTCCCMTGGTGCCGCI'CAAT

CCTTCCTCCTATrC'FCAATAAGAGCCCG

CAAGCTCCATCCACTG'IGCTTGTGGG

TATCTGTAA

246 1M000864 p001015 R GCCTCAGCTACATrAGTCAATTrCCCATCT

AGCCTGGGTATCCGAGATGGCAGTAAA

GACACTAGCTGCAAAGCC'ITACTGCCTG

247 1M000865 AGTTTGATC pOOl 0 18

D

GATCCAGTCACAGGAGAGCAACTGGGG

GAGGGAGCAGGACAGAAGCACACCATA

GCCCTTTCAGGGGGCCGGGGGCGAGGG

G'IX3GACAAGAGAAGACAGATAATGACT

CACAGGATGAAGAAGCCTCCCACAGCC

CCTCCGTGAACTGGCCATCTGTTICTGGG

GCCCCAGAGCAGGCGAGTACCGTGAAG

CTTGGGGACTAGCAGCCGGACCACTGAA

CAAGGTCAACCAGCCAGTGTCCCACGA

GGGGAGAAGGTACCAI17GAACTGTCACT

TTGGAAAGTAGCCAGAGCCCATCCCTGG

TCACGACCCAAC

1248 1M000866 I p001 0 19 ID F SEQ SEQLTENCE~tc "SEQUENCE") CLONE CLASS GENE ID T T T NO:{T {T {C "CLONE "CLAS "GENE" \L 2) SIFICA \L 2)

TION"

MUTATION \L 2)

GATCCCTAGAGCTGCTGGTCAGCTGGCC

TGGCTGAAACTACUrCTGTGCAGTGAGA

GACCCTGCCTCAAAACACAGATAATGGA

GACAGATAAATGACATCGTCCGCTGTGT

GTGGGTGTGTATATGTAACACAACACAC

AGTATACACACATACACACCACACTCAT

ACGGTCACACATGCACTCTCAGTGCATG

TGCAACACAACACAGTGTACACACATAC

ATAGACACCACACACATACACATACCAC

249 1M000867 CACACACGCGCACACACACACATAA p001020 R

GATCCTGTGCATCACTGAGCCATCTCC

CCAGCCTACAGTGTAAGTATTCTATACA

TATTAA17rAATCCTGCCGGGTGGTGGT

GGCGCACGCCCTTAATCCCAGCACTCAG

GAGGCAGAGGAAGGTAAA M CTGAGTr

TGAGGCCAGCCTGGTCTACAGAGTGAGT

TCCAGGACAGCCAGAGCTACACAGAGA

AACCCTGTCTCAAAAAACCAAAAAAAC

AAAACAAAACAAAACAAAACAAAAATC

CTATGGAGTATTCTAAAAGTAAAACCGT

ATCATrAGCACTOCCAAATAACAGAAAG

GAAGACCAAAGCAAA

250 1N4000868 p001021 R

GATCCTCTGAAAATGGAGTTACAGATGG

TGTGAGCTGCCATGTGAGTGCTGGGAA

CrGAACTCGGGACCT-[TGGAAGAGCTGC

TGGTGCTC=AACAGCTGAGGTGTCTCT

CCAGCCCCM~GGGTGTGTI=G1TGT TrGTIMG1TrGC I I I CAAGACAGGG 1TrrCTCTGTGTAGCCCTGGCTGTCCTGGA

ACTCACTCTGTTAGACCAGGCTGGCCTC

GAACTCAGAAATCTGCT'CCCAAGTGCT

GGGATTAAAGGCGTGCGCAACCACTGCC

251 1M000869 p001022 IR L-

GATCCAATATAFFCATATGOAGATACAT

252 IM000870 GTATATACATAA p,001023 ID I- SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID ITC {TC {TC

NO:

"CLONE "CLAS "GENE" 2} SIFICA \L 2}

TION"

MUTATION \L 2}

GATCCAGGTCC'ITTCCCCCTTATGGTCCT

ATACACGCCTGGGTACTTAGAGGGTC

AGCTCTGACTGGTGGTGTGGGGAGAAGT

GAGGGG11TACACATGTGACAGAGG'TcCT

AAAAGCTGTCGCCATTGGCACATGACCA

TCCTAAG'I*CTGTGGCAGAAGGCTGCTCA

GAGCCTCTGTCCAGGAACAACCCAACAC

A'ITGCAGAAATAACTGTGCATCTGGGCA

ATGGGGCAACTACTACCTGTCCATCCAG

ATAGCTCTTCTAGAGGCATTCGAAATAA

CACGTAAAGTGGGGTGGTGATGAACAC

ATATAATCTCAGCCCCTGGGAACCGGAG

ACAGGGGAGTCACAAG

253 IM4000871 p0010 24 D GTrCACAGTACYFGCTCACTTGCCTGTC1'C ATGGTITACTCGCCGCTCCYJ7C

[CGTACC

CCC=fCCCCTACAATCCTCCTCGTCTA CTrCATGCGGTATATGTCAAACACCGT

CATATATAACAATGTATGCATGCAGCAT

T-rCT=TTTFCCCATCAGCCTCCCTI'G CTCCCCATCCTCCCGCCCT7CCTCCTrCC 254 1IM000872 TcccAGGATC p00102 6 D AG7FFATGCTTGCAGACAGGAATGTAGCA

TGGCTATCCFCTGAGAGGTTCCACCCAG

CAGGTGACTCAGACAGATACAGATACCC

ACAAGCAAACAGTGGATGGAGClITGCG GGCTC'rA1TGAAGAATAGGAGGAAGG ATTrGACGGCACCAAAGGGAATAGGAAC

TTGACAGGAAGACCAACAAAGTCAACT

AACCTGGACCCTTGGGACTCTrAGAGTC

TGAACCACCAACCAAAGAACATACATG

cGCTAGACCTAGGCCTCTCCATACATA'r 255

GAAGCAAATGTGCAOCTTGGTT'FTCATG

IM000873 TGGATC Ip001027 IR SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ED ITC ITC {TC

NO:

"CLONE "CLAS "GENE" \L 2) SIFICA \L2)

TION"

MUTATION \L 2) GATCGTGGTCTCTTCTC II ICCCTCT ACTTCTTCTTCTIC1TCTrCTTCTrCTTCT TClrCT7CTACTGTCTCTTCTTCT7C 'FrlCTrCTCTTC'1TfCTTCCTCTC TCTCTCTGTCTTT7CTCTGTCTGTGTGTCTC

TGNCTCTCTGTCTCTCTCTATCTCTGTCT

TTCTCTGTCTCTCTGTGTCTGTCTCTCTTT

CTCTGNGNCTCTCCCTGTCTGTCTGTCTC

'fCTC1TrrCTCTCTCTGTCTCTCTCTCTCTG

NCTCTCTNTCTCTGNCTCTCTCTGNCNCT

CTGNCTCTGTCTCTGTCTNTGTNTNTCTrC

TCGCTCTCTNACACACACACAGATGTAC

ATGCAC

256 1M000874 pOOl028 R GATCGGCGGTATCATA1T=ATGTG1TI ATTTCTGTGTCAGAAAG1TIAAAAGGCC

TCAGATFGGAAGTCTGGTGCATGGAA

TGCATATGAGCTI=rCATCTATTGCCC AACAGAn7IAGTCTAAGAACCACCTCTA TrATATAGGGTATGATAAGTAATATAGG TAAGGGAATGCATCCCATrGATAAGTG AAAGTTGAACACACATAGAGT-rGGCTCA

GCCCGGGGTCTAGGCTCTAATGCGCTGG

GGATACCCAGGCCAACTAAACGCTATAG

CAACAGGCATrFGGGGCATGAAGATACTT TTTGTrGHTGTCTTGAATITATATAGOG

GCTTATATCTCAMTACAATTAATCATGA

GTrfGCAGTCAATAAATC7rCATTGCTCA ACATATTTGTACCCTCAAATA'lrI=C TI GTGTGATAT 257 1M000875 p001029 C CTTGTAAACACGATrAFTAAAGATAT AAATGGCTCT1TrACTCTGT-ITAAAAA1T GTrCTTrACCAGTTCTTCGTGTACATrG

GTCTCCAMTCACATGAAATAAAATATT

T-rGMTAATGTrAGATTTTCAATACCAGC TGAGTG7TCGATGTGTGCCTMGGACA 258 TATATFTGTTGTAAAGTGGTCAT17GGG IN4000876 ATC p001031 D SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID {TC tTC ITC

NO:

"CLONE "CLAS "GENE" 21 S1FICA \L 2)

TION"

MUTATION \L 2) GATCAGATTCAACTCCCGCAT7TCTAGC

CCCAGCATCGTGGAAGGGCTACTGTGTC

=CAAGCACTATGGTGGATACACATA

ATGCCAGCFFCCCTCATfACTGGTGATG TGAGCTGIFl7GCCTAAGGTCcTTTCTrGCC AGGCTT1CTCTGCTGCCAAGGCTCTGAAT TCCCTI17GTAGCTAATGCGTAGCCCTAT TGGCAGACTCTTCCCGTrGGCTGAC'FrCT

GCGTCCCGTCACACAGCAGTACC'ITGYI'

TGTTGTCACCTTGATGMTCTTATATGCA

TTGATGATGGTGAACAGCCCAGCAAGTG

CGCCTGTTTCTCCCTTCCTCCCACT1T GTTCTCAGYI7GTACATGGCAAGGAAAAC

CAATTCCFIT=CATATTTCTFCCCAGAA

AAAAAATCCTCThrFATAAGAGTTCACAT

CCTTGAGCACACATGATAGGAGCTGGTA

259 IM000877 GCCAG p001032 D GATCATGATA2TGTACTGCTGAAGACAA ACATATrAAGATATAAGACTrTGGAGAA ATCAAGTrGGTATUFGACATTGGAGArTA ATCTC1TIGGCTAGCl-M-TGTAGAGCrA GAAGTTrGGTATGTAAGGTATAAGGAAG AGAAGTATI'CATAAGAC17ACCCAGTTG

TCTCTCCTGTAAGCTAAGACCAGCCTFAA

GAAGCTAAAATTATCTAATGTAGiAAC CACAGAGAAAGAAATTGTGGTATGAA1T TTGC'FrG1TCGTGGACATrAACCATnAA CTCAATGATAATCAAATGACAATACATrA

GAGACAAAGATATGCATACTAGTAAAA

260 IM000878 TAGTGATAA Jp001033 ID I-

U

SEQ SEQUENCE~tc "SEQUJENCE") CLONE CLASS GENE NO: ITC {TC {TC "CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2}

GATCGTGCTAGAGAATGGTACACTTGGG

TATATTAAGAAATCTrGGTTGAGTGGT GGTGGCACCCTCCT7AA77CCAGCACT CAGGAGTCAAAGGCAGGCAGACAMrGc AGTrAAGGCCTGCCTGGTCTACAAAGT

GAGTTCCAGGAAAGACAGGGCTATAAA

GAGAAATCTrGTCTGAAAAACAAA

AAAACAAAAAACGAAACAGTAACTGAA

ACCGAA AkAA AAAGAAAGAAAGAGA

GAAAGAAAGAAAATCTTACAATGTGGG

AGCTGGAGAGCTGGCTCAGTGGTFAAGA

GCATTGGCTGCTCTrCCAGAAGACCCAG GTTCAATrTTTAGCACCCACATGGTGGG TCACACCTGCCTGTGGCTTCAG'TrCTAG

AG'IMCTGACACTCACACACAAACATAC

261 1M000879 ATTCAAGT p001034 R GATCTTGTA'ITrCTrCTTGGCTTGTCTCC

ATAGGAACAGGCAGCACAGCAGAGGTC

TGGGAGATGGCTCCGAGGGTAAGGGAC

CAAGCAAGGTCACCTGCGCTCACTCCCT

GGAACCCACACAGTGGACAAGAGAGAA

AGACTCTATGGCCTCCACGTGCGTGCGT

GCGTGCTGTGGTGTGCACGTGCCCCTCC

CCCAAATAAAGAAAACTAACGAAAAA

AAATTAAAAGTAAAAAAACAGCACTGC

AGTAGCTCCAGGAATCAACTGGTCAATG

AGTGTATCACATTTGACTATCCGATGAT

GGTTffA1TTACATGTATGCACGTrTr

GCATGTATGTGGGTGCACATGTACAAAC

ACATGTGCCAAGGCCAAAGGACAACM

GGGTGTCCMTCTCAGGAGTCATCGACC

T"TATITTCTGAGACAGGGCCTCTCACTG

GAATCTGACTGGCCAGCAGCCTCCCAAG

GATGCTCCCCAACCTCAGAAGGATGCGC

CTGTCTCTGGCTCCCAGCCCCGGGGG'rr ACACTGGTGGACCACTGGGCTCT1TCA m18 1262 1M000880 ICCTGGGTG 1 0 0 1 0 3 5 B 134 SEQ SEQUENCEjtc "SEQUENCE") CLONE CLASS GENE ID TC {TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 2) 'lION" MUTATION \L 2) GATCTCTCTrAAAATrACATTACAGTA GAAAATGTTTATGAGGCCG I I I IATCT CTAATA~rA1TrATTACCACTCTCCTACC CCCAGAGTCTI7ACAGGCATCAGGGAGJ'G

GACAAAGGCCGGCGGTACTGAATGGTG

ATG3TTA1TfrGAAATAATGAAAAG 263 1IM000881 pOOl 036

D

TACCTGTITGCTCCAACATGGTCAGAAAT

CAGTfrGTFCAAVI=AAGATACAATG AGAGTAACACCCTAAAGACTrCACA'IT

TATGCATAMTGCTACTCTGTGAGCACA

264 ILM000882 TGAACGCTCTCCTrGGGCACGATC p001066 D

GATCGCAGATACTGCAGGTATGTAGTAA

TGAAGTCTGTAAACATACAGAATGGAG

AAGGCCAGAGAGGAAAGTrGCAGGCA17 265 IM000883 GGGTAGTCAGTAGGTAAAATAT p001067 D GATCGCAGCITCTT"CCTrGGTGCTU-rCCC

GTCAGTTCAAGTGCTGTGGCGGGGACIGA

CTACAGAGACTGGAGCAAAAACCAGTA

CCATGACTGCAGCGCCCCCGGGCCCCTG

GCCTGCGGGGTGCCCTACACCTGCTGCA

TCAGGAACACGGTAACTGCATc3GGTGCTF

GGATGTGAGGGTCACCCAG=TGCCAAA

CACTGcccTrCACTCTGCCCAAGTGGAGG

AGGCAGTGGGAGTGGGTGGGACGTGGT

GGCCGGGGCTGAGC7TTGCCTrAGACCAG GGGCCCTAGCAkATGGGAGATGAGTGGG

CAGCTTCCTCTGGGAGTGTGTCAGTGAG

CGTGTGCGTrG'TGIGGGCCTGGCCCAGGC GCTTTGGTTGTAG'FrACTTrGGTTCVrACA

ACAGCT[GGAGGGTCTCAATTGGGGTA

GTGTTGCTTTAGCCACTTAGGGGGACTT

GCCCAAGG'TTGGCAc300CTCYTCCCAGC

AACAGAGAGCCAGAGTGCCCGGCAGGT

GCAGCAGGCTCTACCCAGTCACTGGAGG

CAGAGTACAGTGCAGGTGCTGTGAGCAC

TGGCAGCAGAGCCCTGGGCAGCGGCAT

GCGGTAATGTAAATQ' Mni.281 1 266 1M000884 p001069 B .2

U

SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID T T T NO: C {C {T 'CLONE "CLAS "GENE" \L 2} SIFICA \L 2}

TION"

MUTATION \L 2)

CCATGTCAGGTGATTAACCTGTGAGTCT

AAC1TCCAGGAATGCAATGCCTCTGGCA

TCTACAGGCATAAACATAM~GTGGCTT

ACACTCAAACTGACACACCAACACATAT

GTGCACGCGCACACACACACACACCAA

ATTAAAAATAAAATAACCCT1TAAAA AAAATATAGAACCTATAGATAATTGCT7 267 IM000885 TACTGCAGTCACAAACATIMAGGATC p,001070 D

GGGGCACATAGTGAGTTCTAGGATAGCC

AGGGTTATAGAAGCTATAGTGTGAGACC

CTATCTCAAAAAAACAAAACAAAACAA

AAAAACAAAAAAAACCTAAGCCCGTGT

GGTGGTGTGTCTCAGTCTGAGCGC'ITGG

AAGAGAGAGGGAGGTGCATCTCTGAGC

TTGAGGCTAQCCTGGTCTACATAGAGAG

CTCCAAACCAGTCAAAGTAACAAAATG

AAACTGTCTCAACAATGACAACAACAA

ACAAACAAGCACTAGAATAAAAAGAAG

CCAGCATGGTGTCATGTGCCGGTCATCC

TACCACTrGGAAGGAGAGAAGCCAGTG

CAGGAAAATTAGGGATC

.268 1M000886 W001072 ID I SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID ITC {TC {TC

NO:

"CL ONE "CLAS "GENE" 21 SIFICA \L 2}

TION"

MUTATION \2) GATCCCAGGC3TCCTGTAGGCTAGGCAA

GCCCTCTCCCCACCCTGTCCTGGTAGAA

-ErGATCCCGAATGTCAGCATTCCTTCAGT

TAAAGGAATGTGCTCCCTCAGGCTCTCT

CCCATGGTrGCAYIN3CTTCAGCACGCAGG CAGACAC11TGTCCAAGCTAGGcTrcCCTG

TCTCCCATCTGTAGGAAATGCTTGGTAT

GAAGGCCGTGGTGGACCTGGCTAGATGG

GCAGCGCCCAGTGAAGGGCTGTGTCTGG

AGCCTGGGCTGTAATTAGTGGTTTGAAC

TGGGTGCTCTGGGGAGAGGCAAGTAAG

AATrTGC7FrCTG1TFIAGAGCAGGAGi

GAGCTGGCGGCTGGCTGTGCCITAGCCG

GCTGCTCGAAGAGCATh-rGAGGTG'rrCG CCATCTrAATGGGTTAAGACTCTCCTGT GCTAATCTIGGTGGGTrGCT'IMAGGCAC GGTGGTCCCAUI'GTGGlTGTGTGAACAG TACCTrAATGCCAACAC'T[OGGAGGCCT AAGGTATCCCCATCTGCAGGAAcTrGGGG 269 WM000887 TGCACA p001075 D

GATCCTCACACAAATTGAGTAGTACTAA

CAAGAGTGTGAT'CACATAGTCAATAAA

GGTATAGGCCATCTGTGCCCTGGCTTGA

CCTCCGCAGAGCAGAAGCTAACAAAAC

CAAAACAGACTCAGMTCTGcATGCTAA CTrAACCATGATTrCCAGACl'AnMTY

TTATCCTGTGAAAAATATATTAATCI'CT

ATTCTGCAGAGTATCCCTT=TIAAGAG

AACATGAT~rCACTGYTrGACAATAT 270 GCCTAGACACAGAAAAAAATCATITAGT AA793 1M000888 Trp001078 B 16

TTGAGTGCTCAGTGAACTACTUAGGG

CAGCCTAAGGAATACAGTGACCCACCA

GGAAAI'GCCTTGTG=TGGCAGTCTGA

TAGCATCACTCACAGCTGTCGGTCGTGA

271 [M000889 C'11'CATTGGATC p001079 JA Edar GATCCAGGGACAAAGAGCCCATlTCTCCT G'rrCCTrCGTAT 1272 1IMOO0890 I pOOlO8l D I-

U

SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE IDITIT

IT

NO:{T C {C "CLONE "CLAS "GENE" 2) SIFICA \L 2}

TDON"

MUTATION \L 2) ACTITCAGGCAAGCTCT-1rGCTCAGTGA

ACCTGCTACCACACACAGACTCCTCCTC

CCTGTrCCCGTCGTTAAAAAAAGTI=A

M~GAGGMTAGAGCAATGGCTCAGTGC

TCAAGACTACTfGCTGfCTACAGG ACCTGGGGCTAGTrCCAACACCCACATG ATGGCTrACAA3TCTCCAGTCTCAGGGG

TCCAGAACTCTI=CTGGCATTGAATG

CACATGATGCATATATAGACAAGCAGGC

ACACACACACACATAAAATAAACA

TCM~TGAATGTAA1TAAAAAGAMA TrAA1TIAATF=ATGTGTATGAATGTr TrGCCTGCATGTATGTCTATGCACTGCAT

GTGTGCCTGGTGCTCAAGGTGTCTGATA

GCCTGGTGCTGGGCTTGGTTCACTCAAC

AGCTGGCCCTATGAAGGCCAGCCGTGAG

GACACCTATCCATGCTGACAGACACAGA

TGCTCAAATGAGACAGCCCCITGTCTAT

GAATGCCCTCTTGAGAATGAACAACCTC

CCTGCAGCAGACCTCCTrCTGGATACCC rGCCCTITCCATAC=ICTGGGTGTCTAGT rcTcrrcc 273 IM000891 p001082 R SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE NO:{C {C {C "CLONE "?CLAS "GENE" 2) SIFICA \L 2}

TION"

MUTATION \L 2)

GATCACACGCTTCACCTAATTACAAATG

ATTrTCTTAGAGGGGTCTGTATATAACA

GAGATGATAAAATFCAACGGCAGCGCTC

CAACTGCATTrGATATACAGGAAGTACTC ATGAAATrGGAGACACTGATrATCTCTT

TGTGTGGTGTCCACATATGTGGCCATCATL

ATCATATTATTA'FrATTACATGGCTAAA

AAATGGGGTCATAGGTTTCATGACCAGA

ACCAAAATATTCCCCTGTAATITACACA

GGATTGATGGTAAGAAATGAAAACAGT

TTACAThMGAIAATFACTTIACT-rGAC ATAAAATGTGACTrTCATFCC'I1IGCATF CC'TTrCACAGGTAAGGCTACGACAATA GATTCTCAGTTCTCCACCTCTrCTCTATCT

TGTCTACTCTATCAGCAGCAATAGCAAC

AGTYT'CCATGGTCC1TCCATCTGTAAAA

GCAATAAAAAATAACAAAGAAAACCAT

ACAAACCAYI'AGAATATGAGTTGGTATT

CACAACTCTCCTCTCAATAC'CATAT~f

TAAAAATTACTAGAAATATTCATCAATA

274 ATATTTCATrrGTTAGCTCTAGATAATGT 27 PM000892 PFfcCAGG 1001083 ID V SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE IDITIT

T

NO: C {T {C "CLONE "CLAS "GENE" 2} SIFICA \L 2)

TION"

MUTATION \L2) GATCATGGTTATITIGTAGGG1TrATTr ATACATGTCTACATGAATfATGTGCAC

CAGATGTGTGCAGGTGCCCATAGAGGCC

TGCGAGGATGCCAGATACAGATAGITAT

GAGCCACCTAATATAGATG'TGGGAA7T

GAACCCATGTACTCTGCAAGAGCAGCAA

GTACTCTTAACTACTGAGTCATCTGTI-rA GCCCTCCTGTrGGGATTTAATGGTCAGT GTGAAATACTATGAAGATAGAAGGG"17

CCTAGACTCTGGTGTGTAGGGGTGGGGT

ATCTGTGAGATGGGTAAGCTCTGTrGGC

TTTCTAAGAAGGAGAATGAGCAGAAGG

CACACATAGACAIT-rCACACTrCACACA

CATGCATCCAAACACCACACATGCACA

CCACATACCACACGCGCCCTCCTG~rTC TACTATGTAATAATGTrC'TGTAATAAC

TAGTACTCTGCTAATGAAAAGGTCACC

ACTAACTAGATGCTAGCCTTCJ&ACTTTG

GACCAGAACTATGAGCCCAAATAACCT

CTrGCAnrTATAA'FrrAGCCAGCATGTA 275 GAACTGTGTCAATAACAATGGAATAGTG 27 M000893 rGpOOIOB5

R

GATCATCTGGCTAAAATI=ATAATATG

ACTC'TrAAATrCCTTAAGAATTCACAA GGACCTITATGTTGAAATrACTCATATG

TAAGCTI'ACTGGAATGAGATGGCTCCCC

AGlTGAAAACACCATTCTrAAAATACTC

AGAAAATAAGAACGAGGCCAGCCCQGT

CTACAAAGTGAGTrCCAGGACAACCAG AGCTATACAGAGAAACCCTGTCTCAjAAA

CAAAAACAAAAACAAAAACCAAAAAAA

AAACAAAAAAGAAAAAACAA4CAxA&

CAAAAAGAATGTAGATATAAAGAAGA

ATAGTG1TGCTGGAAATAAATAGTAAT ATAAACTTAACAGCAGCCTGTCAA'TrGC AGGGTI=GCACTrGCAGCTCAGAAAG

AAGTGACCCTCCTCAGGAAGTAG

276 1M000894 jp001086 IR I- SEQ SEQUENCE~tc "SEQUIENCE"} CLONE CLASS GENE ID IC (C J NO: C {T {C "CLONE "CLAS "GENE" 2 SJ.FICA TL2)

TION"

IMUTATION \L 21 GTGGG17TGTGTGACTCAGAGAGCAAGCT

TCTACCTCCACAGGCAAGGATGCCTGTG

CACACAGAAA~TGAGATGAAGTCATATGT

GGGGACTGGAGTTGCAGTGGCTCCCAGA

AGGAGGTGTGCAGAGTTCAGGCTGGAG

TCCAGATGAGGAACATCAAATAGAGAG

GCCMTGGAGGGAGTGGGTTCTC17GAT

AAGTAGGACTGCCACCCATATCAAGTAT

AAGACTGCCAATCATACTGAATCTCAGG

TAThrCCCATGTAGCAUrGGGAACATA

TAGCATTTGTCACACTGCTATAGCAAAG

AATCTGTGATGAGGTTGGGAGTGGAGG

GGAACGCCTTTGGTCCTrAGAAAAAGAAC 277 1M000895 CAAAGGTAGGCTGATC p 00 1087 D

CCTGCCCTTGCCAGACCCGACCGCAGCT

CATCGAGGAGGTACCCTCTAAAGTCGTC

ACCTUGAGGAGACAAGCTIC'I'GTCA:I'AGT

GCTCGCAGCCCCGCGGCCCCTGCGCCAG

GTI'GCGGACGCCATC'CCCGCGCCGTC

GCCGCCATCTCCTCCTCCTCCTCCTCCAC

CACCTCCCCCTCACCTGCCACTGACCT

TTCCCCCAGCT-lGGAJGCCACCCTTA

GGAAGCAGAGTCGGTCGGAGACCCGCT

CCTCCTCAGAGCAGCGGCCACCAGAGTC

AGGAAGGGGGGGTCCAATCACGTGATC

278 11000896 p001088 R GCTCAATAG'Ffl'MAfACAAAC AAAGCTAAAAGCCTGATGTGTCACJ-rGC CTI'CAGCAGAGCTGrn1TGGGGCCCATTG

TTAATGTTGTGAA'ITAAGTTCTGATGTA

AGTAACCAAGCCACTCCCCACACTTTA

CTrGCAAGAGT[CCAGGCAGATGThAG 1279 1 M000897 jGTCAACCCACCTGACTCTGATC p001089 D

U

SEQ SEQUENCEftc "SEQUENCE") CLONE CLASS GENE ID T T T NO: C {C {T "CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2)

GATCACAGTGMTATCTCAGCAACAGAA

AGCAAATGAGGACACACCTGGGTCTCAC

TGATATACTTGGTGATATGTGTAGTrAYr

ATGTCTCACAGTAATTGGACAAGGAAGA

GAGTTCATTGT-rrAGAATGTTGTAACT

GGCATTGTTCTTCTCTCTCTTGTTTTCAT

AAAATCTCACAATATCTACAGCTGTGAG

GTCCAAGGGGCTCATrFGGTGATACCCAC TCMCrTA=~IGTGTGACCAACCTCTITr 280 1M000898 TGGATGTCAAGGGT p001091 C GATCAGT7GCTATTGCT7fGATrGATrGC GAGACTrTAACAAGAGTC1TGTCT

CCTCTCACTCCCTAGCTTCATCITAGAAC,

TTAAACCCACAGCCCAAATGAGTAGTTG

TATGTCATATGCCTCGGCCAGCACGA

CTGAAAGGAAGAAAGGCAGACACTG

GAGTGCAGGAAGAAGACACAAGGCAAA

GCCCAGAATrCAAAAGTAGAAGCACAG 281 1M000899 pOOlO92 C GTACCCTGCATCCCCGGTGTGCC7TcGG

AGTCTGATGCCAGCACTACAGAGCCAAG

CCATAATACAAACCAAATAGAAT-rAACA 282 1M000900 AGAGCTCCATATGATC p00 1093 D

GATCACCTTCCTAGGATGAACGAAGAAG

GATGGCTGGAGGTTAGGGACCCAAGGG

ACTrCCCCCTAGAGCTGGCTGTGTACCC

TAGGCATGTGTGACTGCAGCTGTACAAG

CAGGGTATGTGGGATTCACAGTCCTCA

GGATAAGATGACACTACAGATTAGC

TrTATACCCAACATGGTGGAACCCCATG GTCACACTCTfTCACAGATGGTCACTCC CATrGCCCGAAGCCCAGCCMIATCCAA 283 1M000901I G pOOlO9 4

C

GATCAATAACAGGAAAAGAAAAA\AGA

AGTrACT1CATGTAGCAATGTGGAT AA'rrCCCATCCAGAGAAACAAAACCAGT 284 1N4000902 TCCAG p001095 C

GATCAGGGAAGATGTCACCTCCAACCCA

285 IN4000903 GCCTAGACATGGTGCTGTGACCA P001096 D SEQ SEQIJENCE{tc "SEQUJENCE") CLONE CLASS GENE ID {TC {TC {TC

NO:

"CLONE "CLAS "GENE" 2) SLFICA\L 2)

TION

MUTATION \L 2)

GATCAAGGAGCAACCCAATAGCTTCTAT

TCCCCCCCTACTAAAATATGACAGTG

ATGGAI-rCTIGGOGATGCACAGATIG'H'CT

CAGAAGYI'ACTGATGAACACACCATGCT

CTAACAAATAGTATCAAACCCACAGTCA

CAGATGGCCCTAGTTAAGCACAGTGCAT

CACAAAG.CAAAGCAAAGAGCCTTGACT

GTGGGAAAGGTACTI7GTGGTGAGGACTA GTOGGGTATGAAAGAAA'1ITAGAGAGGA

TGAAGGTAGTGATAYFCAGTGTGTGTGT

GTGTGTGTGTGTGTGTGTGTGTGTGTGT

GTGTGTGTAAGACTATTAAAGAACACCC

TIrflAAAGAAAGGC1TrCTTGAGTGTC 286 LM000904 ACC p,001097 R GG1TAATAAGCTAGATTATCGTGTATAT

ATAAAGTGTGTATGTATACGMTGGGGA

TITGTACAGAATGCACAGCGTAGTATTCA

GGAAAAAGGAGACTGGGAAATTAATGT

ATAAATTAAAATCAGCTITFAATTAGCT

TAACACACACATACGAAGGCAAAAATG

28~7 M000905 TAACGTTACTIGATC p001098 K IMyc GTGAACGACAGCAGAATCGGGT-rGTACC TCAAAGCAC17ACC1TrTCCCAATACACC

TGATC

288 IM000906 p001099 D

GATCAGTGACAATGTAGCYIGCCTGGA

289 IM000907 AGGATAC'JTGAGTC pOOllOO D

GATCAGCAAAATGGGACATCGAAGTFIG

AACCAAAGTCATAATAAAACATCCTGAG

GTACATAAACACTCTGTAATAGACTAAT

ACAGTTCCTCCAGGCACCAACAGAAACC

7TGACTACTTCCCTTGACTACTTCAGTCA

AATCTTCTGATAAAACCAGACCCAACTI'

290 IM000908 GGAAACGTCCATGTATACAATG p001101 D

GATCATCTGCYFCTACGCCCAATTAAAA

GACGGACTAAGAACATAAAAAGAATCC

AGGCACCTAGGMIGCAGA-AATCTAAAG

291 IM000909 GTTGAGTTCCTTf pOOl 102 D SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE NO: {TC {TC ITC "CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2) GATCACAAGTrATAGTTGAATAACAAGT

CCTGTGTGTGTGTATGTATCCGTATATCA

TAITLC1TATCTGTrACTCATTrCATG GAAACTAGGTGGATGTGTTAACTrGGCT 292 1MN000910 ATrATGAGITrGCTGCTAT p001103 D CTACAATGGTTCAGGC1TGGAATATCA

CTGTATAGGCTGTGTGCCGGCCACCACC

CTTCAGACTGCCACTCACAGGTGCCCGT

GAAGGCTGCCGAGAGGCAGTCCCCATC

AGCCTGTCTCCTACACCCACACACTCTG

TGTGGAGACCACAGGCGCCCAAAGGGT

ATGCTAGTCTCTGCTCTACCGCGTACCCT

CTCCTGAAGGCAGGCAMTCAGAGATTC

CAGMTCACCAGGAAGCTCAGATC

293 1M000911 p001104 C GATC1TTCCCCC1TGTAGTATCAGAGA

GAAAAGCCATGGCATGCATGGCACATG

CTAGGCAAACACTCAAGCATCCTACTCT

GTGATGCAG=TGAAACAAACT1Tr'TT TC1TI1CYI1CTIrG=TITH1CYTT CTTrrCTrrCrrwi 111111111111-i--ri 294 1M000912 TTGAGT pO01l105 R

GATCTCTCCCCATCCTCCTGTGCCTCTT

GTCTGTCATACCTCTACTACTCCATCAGT

TTrGCTGCCTCTGAGTCCCTCTTC117CCTC TCCTATCCCTCCTCCCATCTrCCTCATCT CCAGGTCTCTCGAGGTCT'rCCTTCTTCCC TCTFICTTCCCCTTTCCTCrCACTG rC'TGTATTCCGTTCTTCTCTGT'rGGT CGCTTGCCTCGCACCTC1TCCTCCTGTC CCTCCFI=CATGTACCATAT1TCTCTTC CTCTICTGTGTCTCCTCTT7CCTTCCTCC 1TrACIT-rCCTTCTAACCTTCCTCTIMCTC CTCCTCCGGCAAGC='~GCT-r 1295 JIM000913 1 p001106 IA lGatal SEQ SEQUENCEftc "SEQUENCE"} CLONE CLASS GENE ID (TC (TC ITC 'CLONE "CLAS "GENE" \L 2) SIFICA\TL2)

TION"

MUTATION \L 2} GGTTGT'rCCAGTYFAAATTGGCTCTCTAC AGGAACATGGCTTAGTTCTCCCTlAGCC M~CATGAcccTACACCTCAGACACTAG

TCAAAGTCTAGCTTAATAAAGTG'ITCAG

GATG1TGGTGGAGGGGGGGAGAFGHrA

ATACAGATC

296 1M000914 p00 1107 D V

GGACCACYFJ'AGTATGGGTCATATGTTC

T'AAC'C'ITICATFITCTAATT-Cl'rCC ATCTGCAT7GATTGTGCCCAGTTATCATT

AGTGACIIT]TAGTAAC'ITAAGGGAA

AGTTGTCTFATGCTCTACTTAGTGTCGATT

TAACTTACTCTCCAGACATGGGAGTGCT

TATTMGTTrGCCTACCTCATCCAGGA 297 IM000915 GCTTGTAGATC p00 1108 D 298 11M000916 GATCCGATTrATGAAACCGG'CIAAC p00 1109 D

GATCTGTGGAATGCTATCCAGCTCYIFCC

299 1M000917 AACAAATAC p001110 D TrrAGTATCTGCATCTGACTCTTTCAGCTG 'iTCGYJ'AGGCC'TrCGGAGGGCAGCCAT GCTAGGC-TCCTGTCTrGCAAGCACACCAC AACATCAGTAACAGTCTrCAGGGGTC1-]GA 300 JIM000918 GCCTCCCCTTGAGCTAGATC p00 1111 IR

GATCTGTGGTAATGATTCTGTAAATACA

GATAAACAACGTACACATGGGAATTGTr CCCTGTGTGAAAGTGTrCATCATAAGGT

G'T=ATITATCTACAATATC'ITGGG

301 ITMOO0919 'I AG p001112 D

ACTGCCACA'TTCCCTAACACCTCATCAA

AGAAAACAACACCACAGGTCTCAGGCT

GCCACTCTAGACCTCCGAG7FrGACTCTG

GCTCCTGCTCTCTGCAAGCAAACACGCA

TCCCTCAAGTCTCATGCTGGTTCTCTCA

AGTCT-rCATGCTGGCTCTCTGTAGTTCTG TAAGCITACCCT'rTCAGTGGTGATTrGG 1302 1M000920 GGAGATC P001113 ID I SEQ SEQUENCE~tc "SEQUENCE,)} CLONE CLASS GENE

ID

NO: {TC ITC fTC "CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2}

GATCTCCTGGC'=GTAGATAAATGAAG

AGAGTMCTACCAACTGAACTAAAGAG

CGGCACAGGAAATTAAAAAAAACAAAC

AAACTGATAGTTAACTCAATrGAGTAAG TATGGAGTI=GGGACCAAGACATATrA

GGCAAACAGACAGTAAGGCCTAG

303 1M000921 p001114 D GTFCCTGTACTrTATCATGTC1'TACCCCT

ACCTCCCTCCATI=AATCATGTITACTG

GGATGTAATGCATTCGTGTCCA~rCCA

GGATGCTATAACAAGATACC'TFCAGCCT

GTAAGCTATAGAAGAGTGTGGTCCTCAA

CCTTCCTAACTTTGTGACCCTATAATATA

304 1JM000922 GATC p001117 D CCANCGTGCCANACTCA1NANGGArrr TA77CATAGATTCTNTCANACTGCTGTCC

CACATGTGTTCAAAANCAGGTAGGTCTT

305 EM000923 GTCANAT p001119 D

GATCTCAUTGCACAGAAGAGTTAGAAGA

AAGAAAGAAAAGCAGACTGGGAAAAAT

TI=GGAGCGAGCA'FrCAGAGATrGAAC

ATCTATCITAACTTATGCAAAATTCCTATC

AAAAGAAAAAAAAAGCTrCAACAGCTG

GGTAAGTTAAAATGTAACTATAAGGCAA

CACAAGGCAAAGTGTTG1-rCTFGC1-r G'ITTCCGAGATGAGCTCAA'VrAAAATAT

CAATAGCGACAACAATTCTGAGCTGGAC

rAACAAAGAGTAGAACAATACTACCCA ACGCTrGTGGTTAGGTAACCTTACACAA rArrnCCTAATGCTATTCGGCAATAAnT 306 IEM000924 GTCAAGAAAA pOO 1 2 1 D GATCTITrCCTACAAGACTrCTGGGTGA

CCTTGCCAAGCCCAGCCACTGGCTGTGG

TACCTCACCAGGACACTCGGTGGACA'jT

AGGTAGTGCTCCCCA)AGTGCTAGGTGAC

1307 JIMOO0925 IAGTTTATGCTrCAAAGTGACTCCTGCAC p01122 ID I-- SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID {TC (TC fTC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 2}

TION"

MUTATION \L2) GTGCTGACGCGCCCTrGCAMTGGGAGA GCAGTCAAGCTATCTGTACCTrCACCGT

AAGACTACAFITGTCACTGCTGGC'ITCCC

TCCTGTGCAAGGGACGCA'FITGGGTrCAG

ACTATGCATGAAACAGGACAACAAAGG

TAGGGCCATTGGTAGATC

308 JIM000926 p00 1123 D

GATCTCACTGAATATAAAAAGACATCAG

TCCAAGGGTGGAAAMhAACCAAAATAA TACAAT7GTTFGTTG 309 1M000927 p00 1124 D

GAMCWTCAGGAACTAGAGTTACAGACA

310 IM000928 ATGCCCGCCTTGTATr pO01 125 D

GTGGCAGTGACGTCCGTGTGGGAAACG

311 rMO0929 rTAGCAAGTCCGAGCGTGTTCGATC pO17K V~

CAGGAGAGTGTCTCAAAAAGCAGCAAA

GCACCCAGCACCITAGGGTGAAGGACC

A M.CTGGAA'rGTATCCTCCCAGTTGCA

AATGTACACTGTCTCATTCACTCCTGTG

ACATAC'FMGTTTGTGAATGCTAATATC

ACATAGITTCGATC

312 1M000930 p00 1129 C

CCAGCAGAGACCAAGCATCCAAAACAT

GAGCCCATrCAGGCTFCAACCATAGCA GCTCCCATICT'CAATCCTGTTrCACCCCCCA CCCCACCCCCCGCTTCTCTAT'IrAAATCA

CCACTCTCAGTGACCAAAAAGATGCTCA

TGGCAAATGGACTCTTGGCTCTCT=TAC

CTAATACTGAAGGTAACAAGATAATCAA

CTGT17CCTCTCCTTCCCGGGGACCTCAT

CATACAACAT'TCTCCCACATGAAATTAT

CACCACGTCCAATACCCACATCCTCCCC

GTCCTGTAGAGAAACCACATGCCTAGCA

GCAG'I'GGTi-irCCCACCTCTGTGCTCCCTT

CCACCTCGATC

313 IM000931 p001131 D SEQ SEQTJENCE~tc "SEQUENCE") CLONE CLASS GENE

ID

NO: (TC I TC {TC "CLONE "CLAS "GENE" 2} SIFICA \L 2}

TION

MUTATION \L 2}

GATCGCTOTGGTITGGTGTCTGTGTATAT

GCACTGTACATACTAACCAGGTACACAC

ATAAATAMIAATATATAAAAAATAAAG

TGCTTCTAAGAGGCCCCTAGGCAGGGA

CGTATAAAACATICACAAAGCAGCAA

AACAAAATTGATACAATCAAAAAAACA

ACACTATAACCAACATAGGTGAAAACA

GCCAAACACATAATGTACAATCTGGTGT

TCCAGGACAAACATCGTCATATACATG

314 GTATATACATACATACTITICACTCAAT Mm.3 669 IN4000932 AA p001 132 B 2

GATCGCTAAGTGTGCGCGGCCGCCGTCT

GCAGAATGAATGGAGGGAATGAATGAG

GGTGCGCGCGCCCGAGGCCCGGCTrTGCG

TCAGCCATGCGTGCCCGGCATGGACACG

GCCTGGCCTrCCTGGGAGGATGGGACCG GATGCAGTTAGTCCAGGCGTfCAGCATC CCAGGGCCCTrCCTCTGTTGCGTGGTCT

GAGTAATCTGTCTCGCAGAAGATACGCT

M. 1515 315 [TM000933 p001133 B 128 GGAGGTCTCTrGTAGGTGCTTFAGACTCAC GTTACAGTCAYrCAGAGGAGGGAGMT CAGCrGCTAGMTCTGTGCACACCGATC 316 IM000934 p001136 D

GATCGGCTGTCAAGACTGGGGAAGGGT

317 1M000935 CCTCCTAG p,001138 D

AAGCAAGAGGTAATAAAATACATGTGG

ATGGATGACTCAGGGGI-rCAGAGCATAC

ACCGATC

318 1M000936 00O1139 D GATCGGGGACCTrGCATAAAGGGGTCCA AA70964 319 1M000937 GGGCTCTCAGTCCTTGGGAAGG Ip001140 -B -7 SEQ SEQIJENCE~tc "SEQUENCE") CLONE CLASS GENE ID {TC (TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2)

GATCGTGATGACTTCATAACCATCACGT

GTGAAAAGACTTAATGGCGCTGAATTCA

CATGACACTTAAAATGCACAAAGTAACA

AATMTATGTCACATGTATrAAACTACA

GCTAAGTACATGGGGAAAAAGPTAGAC

'lIAGAA'IAACTICATCCAGAGTICATAI'GG 320 1IMOO0938 TAG p001 141 C

GATCGAGGAGTAACCCAATAGCTCCTAT

TCCCCCCTTIACTAAAATATGACCCACTG

ATGGA'FrCTGGGGATGCACAGATG'FrCT

CAGAAGTI'ACTGATGAACACACCATGCT

CTAACAAACAGTATCAAACCCACAGTCA

CAGATGGCCCTAGTFTAAGCACAGTGCAT

CACAAAGCAAAGCAAAGAGCCrrGACT

GTGGGAAAGGTAC'FIGTGGTGAGGACTA

GTGGGGTATGAAAGAAATTAGAGAGGA

TGAAGGTAGTGATATTCAGTGTGTGTGT

GTGTGTGTGTGTGTGTGTGI'GTGTGTGT

GTGTGTGTGTAAGACTATTAAAGAACAC

321 CC3I'-Tfl'AAAGAAAGGc'nTCrrGAGT 114000939 (3TCACC p001144 IR

GATCGGGCCACATCTCAGACACTCCTAT

AGCITACAGAC3AGATACCGiTi~ccTGTTA TGTrGCAGACAACT-rFATCTIGTT-ACTCA

GAGAAAACCTCCAGGTGCCCCTAAAGA

AACTGGGCCCTACATCACATACCCATAC

CACACACATGCAACATGCAAAACATAC

ACACATACATAGACACACACACCACAC

OCACACAGACACATACAGACACACACA

CATACTATACATACAGACACATATGCTA

CACACATACAGACACACACAAGCACAC

ATACTrCACACACAGAGACACACACACC

ACACACACACAC

322 1IM000940 p001 149 R

GCCTGCCTCTGCCTCTCGAGTGCTGGGA

ATAAAGGCGTGCTAGAGCCTFCAC'GG

CTC i cl CTCTCTCTCTCTCTC1-1TIAACCT CC'I1TCCTITAATGAGTTATI1'ATr ATTI1ATGTGCATTTGTGT1TGCCTGTA

TCCGATC

1323 1M000941 Ip001 151 IR I- SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE

ID

NO: ITC I TC {TC "CLONE "CLAS "GENE" \LJ 2} SIFICA \L 2)

TION"

MUTATION L2)

GCTTCAATATTCGAAAAGAATTAGTAAG

324 11M000942 AAAGGCTGTrCGATC p001 152 D CTACCAGGAAGTCAGGGGT17rCCAGGAA

CCCAGAGTTGGCTTCCTCTGCACAGAGG

GACCTCATACCAGTAGATGGTGATATG

CFCCCTTGTTCCTGAGCCTCAGTGGAAG

CGACMTCTATGGATACTCCCTCCCTCGT

GCCTCTCCTTC1TrCCCTCfCTGCTCTCC 325 1M000943 CCCCCCCCCGTCGCCCTCACGATC pOO11 5 4 D

ATACACACCATCAGATATACCTCATTCT

GATATACCTACAGGTACACCAATCACAC

ACACACATTrACTCACATGTACATGCAC

ACACCACATCGGTTAGAACCAAAGACCT

CACACACACCCCTCACACATGT17CATC

TGCATTATCAGTGCCGATC

326 1IMOO0944 p001155 D 327 [M000945 GATGGTCAGGTTATGAATGCCAT pOOl 156 C

AG'JTCTCAGAACCAGCTACTGMIACAC

AGGGCCTCATGCAGCCTTGCTGTCCTCC

ATTCTGCAAGCACAGGATACACACCCCT

328 GAAGGCCAGArrGTCAGGTCAGCCCGAT M000946 c pOO11 57

C

CTrCAAACCGGTCCTGCGAGGAGTCCAC 329 1M000947 AACCTCTGCCTGCCGATC p001158 D

GATCGAGGCCAGCCTGGTCTACAAGTG

AGTCCCAGGACAGCCAGGGCGATACAG

AGAAACCCTGTCTCAAAACAACA&AC

AAACAAGATTCCATTGAGGAACACCCA

GATGGAGACATGGGTGTTCTCCATAGAA

GGGTTAGGGGCTTCCACACCGTTGACAC Miii.8136 330 11M000948 pOO1l59 B 6 GATCGGTGTGCnTCTGCAGTrrTCAGCG AGGACTCTGGGCCCAAAATG1T=AAAG

CAGAAAATTGGTAACACTAGAGATATTG

TCAAAATACGATJfTCCTCTGGTrCAGAA ATGc3CGAGAGGGAGGGCTGGAAGGGTG GAGTGGGAAGGAATTGTCATCAAAGCA AA40894 331 IM000949 TTGflGATAC p001160 B SEQ SEQUENCE~tc "SEQUJENCE") CLONE CLASS GENE ID (TC (TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 21

TION"

MUTATION \L 2)

CTGTCTCAGGCATGAAAACACTAAAAGA

TGACCAAMJCAATAAAGATGAGCTGAA

TGTCTACTCAATTCCCACCATAAGGTCT

332 1M000950 ACAAGATGTAAATGGGCCGATc p00 1161 D GATCGTGGAAACAGAGCCT-rGAATATAA TrGAAGAAACAGAGGGCAGGCAGCAGCC

GCAGCACAGCAGGGGCAGTGTGAGCAG

333 IM000951 GCAGCAACAGGGGG p00 1162 1D CTCcCTACTACCTTCGITCCTGGACNTC

CACTGAGATGAGGCAGGATAAAGGGTC

AAAAGAGACCTGACCTTCTCTGCCAAAG

CCAGGGATTCTGGAAGAATAGAAATG

G'TFCTGGAATTFCACAGATGCAGTGGTCT

AGGATC

334 IIM4000952 p00 1163 C GATCCATAGGTCTCTGCThFCCCCAT7CA

GGGCTGGAGTTATAGATAI'CTGITC'I'ATC

ACCCAGCTTTATGTAGGTTCCAGG

335 1M000953 p001 164 D

TATGTATCTACAAGCCAGAAGAGGGCAT

336 11M000954 TGGATC 00O1166 D GATCCGAG1TCTCTCCGGCCACGTAccTr

TCACATCCCATGCACCCTGGTATGTAAG

AAGAGCCCAGCTCAC

337 IM000955 p001167 D 338 JIM000956 TCCCATAATAT-hFCCTCAGAAGGATC pOO11 6 8 D AAATGTGTATCG'TTrCTGGGTCAGAGCT TTCAGGAACTGAGCATGACrGcrCTACA GTGTC'TrCTCCTTCTGCCTGCTGAAGCC

GTAGGGGACAATAGAACCACAGGATGA

AAGGACTCGGGATC

1339 1MN000957 jp00 1169 ID I--

U

SEQ SEQUENCE{tc "SEQUENCE") CLONE CLASS GENE NO: {TC (TC {TC "CLONE "CLAS "GENE" \L 2) SIFICA \L2)

TDON"

MUTATION L2)

GATCCAATGGCAGCTAGCAGAGTCAGA

GAGCCCTCACrCCAGTrAACTAGGGGAC CCACATGAAG'TrCAAGCTACATATCTGC TACAAATG1T7GAGGGACCTCCTAGCTC CACGCCACATGCTGT1GGTTGGTGGTT

CAGTCTCTGTGAGCCCCACTGGGCTCAG

GTTAGTTGACCTACAGTCT-rCTTGTGGTA TCC'rrGACCCCTCTGACCCCAGAGM~A

ACAATAGCCTCTGACTCTAGAAATCT

ACCTACATTrCCACTAAATrCCTC 340 1LM000958 GGCTCACATAATACCAATGAACT pO001171 R

GATCCATCTGCACAGTCTGTCACCGGGG

TCCAGCAAGTAGCAGCC1TCTGCTGCT

GTCTGTCAGACCCTCCAGGGAGGGAGA

GCTrGTCTTGTGGCCTCCCAACAGGACC

CTGCGTGACGATGCAGGGACAGCAATG

ACAACTCAflCCAGACTCCAGGTCCCTG.

GAGGAGCCTCCCACAAGGGAAAGAGAC

TACTCACTGGTCCTGGGCCCCTC'=GC

GCGCCCCGCCCCCAGACTCAGCGTCTAG

TGTTGCTGGGCTCCCCT

341 11M000959 p001172 K I n)yl

AGGGTAACAGGCTTAGTIGGGGCC-=

CTGTrACAGGAAAACCATGAAATGTCCT

GAAGTGCTCAACAAACAGGGAATATAG

AAAATCATAATGGTrCCTCCCTAGCACA AGGAAGCATGTTrAAAAATrGCAGCAA AATAAAAAAGAACAGATC1TAAGATTG AGGGA=fIACGGGGTGGTACTI=CTr TCTCTrATAAACATTrATTTACTI=GIT A~rCAAGACAGGATC 342 154000960 p001173 D GATCCAGCTGTGCTrAACATACGTAAA

GGTATGGATGCTGAGAGAGTATCTATCG

AAAGCGAAGGCACGCTCCCCAAATTCAA

GAAAGCAGCTGTTrCTAGAACCAAAGAC

ACCACCGCCGCCGCCGCCAGCACCACCC

GCGAGCGCCCGGACCCTGT'rACAGAGTG 343 1M000961 TO pOO 74 C SEQ SEQUENCE {tc "SEQUENCE") CLONE CLASS GENE ID [TC {TC ITC

NO:

"CLONE "CLAS "GENE~ 2) SIFICA \L 2)

TION"

MUTATION \L 2) GATCCTGAAAT7ATCACA'TrrGAATCAA

ATCATGCCCTGCCGAGGATAAATAACCC

AAACGACCGAGAAAACCGAGAAAAAGA

344 1M000962 ACAM1ACTGACCATCCTfC p001175 D GATCCAGTCCAGAGCAATGTrCAGGTCT 345 [M000963 GTGATGGTAT 00O1176 D AAAGGTGCTCrFCAATACTTAACAATCCA

TAAGCT[GTGCTCTC'ITAGTCGTAAAGG

TGGGGTCCATCAAAATCCCATGACACCA

CAGCGAGACCAAACTCCTrCTCTTAC

TCCGAATCACCCATCCCATGTGGGAGAC

GAATAAGAACACAAACTACATCTTCAGT

GACATAGAGTAGCATCTGCAACAGAGG

AAGTGGATGGAGACCYIGcTCTCTGGTCA

AAGACAAAGCATGTGACAGCTGAGCCT

GGCACT7CCTACTrGGGTCACAGCTCAA

ACCCACCTGAACCAACAGCAGAGCCCC

ACAGGGATGGGACTCACATG1TITCCCTC ,irGcCCTGGAGCTTCGTGCATGITGTrA

GAAGCTAACTGGCTAACACGCAGGGGA

ACAGGCAATGTAG'I7GGAGTATGAATCG

AAGTCACTGGGCATGGTCC'TCAGTCAGC

346 1M000964 CAGGATC p00 1177 C CTAGACTAGTATGGCAGAACCTATC17C ITCTAATCAYl'TAGATGAATACTCCACA

TGAGAGAGCCCTGAGAATATCTGTAAAA

AGTAATCCAGGTrCTGTrAC3TCTAGCT

AATC'ITATCTAGGTAATAATAGATAAGG

AATCGGGATTCACGAACACAAATACCTG

TACAAAGCATGTTGTCTCACACGGGACG

AACACITG'FITCTGCTGTGCT-rTATAACGC

TGGGACATACAAAACTAGACTCTGCCTA

AGAAGTGMrGGAAACA1TTGGGTTAAA 1TATAGTCAGATAAAACAACAACCATGA

GTAAATCGAAGAATATAAAACTAGGGA

347 IM000965 TO Jp001178 C I- SEQ SEQUIENCE~tc "SEQUENCE") CLONE CLASS GENE EDIT T T NO:{T {T {C "CLONE "CLAS "GENE" 2} SIFICA \L 2)

TION"

MTATION \L 2} TTCCTGGACAATAATGrITCTTCA'ITA AA'TrFACACTTAGAGCATTGTCTTAATC

CATGAATAA'TCCCAGCTCCTAGCTCAT

TACGTGTGACACAGCAGGGATTCATACA

T7AT7GAATGAATGGATGAGTGAATGA

ATAAAAGAATGAGCATATCAAGAGGAT

348 1000966 c p00 1179 D 349 LM000967 GATCCCTTCTGTC1TIGGTTATCTC pOOl 181 D GATCCACCACTGAGCCACTTCTrCAGCC TGTGACTGTCATTC1TAATCATCCACAC AGACTrCTCCrrGGCAGAJIGCCCAC CTCTTAAGAG1TCACAAAGGTITr=C

TCTGCAGGGCACATGAGAAAACAACTC

TGTCATAAAGAAACCCAGGAAGAAAAC

CAGCAGAGGCAGGTGAGTTAAGCCTGT

GGTGGACA1TCCTTCTGGGGATGACCAG ATGGGAACAGTAAT7CACAGAGGCAGA

GGGGTCTGCAGTCACTCTGCATGCCACA

TGTGTAACCCITAAGAAGTGAGGAATGC

TCTCAACAGGAAAAACACAGCAGCAAA

TGCTATGATACCAAAGCCACAACTCCAT

GGGTCCCTGGAGCCTCTCGAACTAAGCT

GCCAGCTAGGGAGCTAACACTAGCTTG

GATGAAACACAGCTCTGGTAGAG1T 350 1M000968 ,OO 1182 C

GCTGGGAT[TTGAACTCAGGGCCTTCAGA

AGAGCAGTCTGCTCTTACCCGCTGAACC

ATCTCACCAGCCCCCTTCCGTrCTnCC' TCTrCCTrCCTITTr-JTCCACAITGTT TrCAGACTGCACC'-G'TrAGTAGTCTA GGCTGGCTrCCAATrCCCCAATGATTGA

GCTATGGGTATACTGTCTTCACCTACTI

GA1TrMGMIGMTATTTGTT!TTGT 'TTrGAGACAGGG1CTCTGTATAGC CCTGGCTGTrCTGGAACTCACTITGTAG ACCAGGCTGGCC1TGAACTCAGAAATCT GCCTGCCTCTGCCTTrCAAAGTGCTGGGA 351 1MO00969 TC pOOll 8 3 -R SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID {TC {TC {TC

NO:

"CLONE "CLAS 'GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 21 GCTrrCA'IAATATACATCATFACCAG AAACCACAGACATCTTrGTACCAACATA

TAGTAATATI'AATCACAATAGCGATCAC

TC'ITATGTAAGiGAITGAGjAAGACTCCCAG crAATrA'TGCTAATQTlGTAGiAAGAT'GCCA

GATGGATC

352 PM000970 p00 1184 D GATCCCTGC117CTGTAAATCCGCAACGA CAATrGTrTATCTrCTCC1T~TrT A'rT-rGlrITATCTATfATm=CAGAT 353 1M000971 GAAAA p001185 C GATCCT'CCrGcc'i~cTGCCTCCYI'CAGCAA 354 ATCCTACCGGCGTGCGCCACCACTACCG ILM000972 GCGAAAAA p001186 R F GATCCCCC'FrTCTCTCTGTICI'ACGGCCTrC TGTCCTGTG117AGCTGTAGGCCTACTCTG TATGAACAGACCTCAGCcK3AGGGGT]17G GACTTGGGCTrGTGTTTCTTAAGAGAAT GGGGClTCCATGACTGTCCCTCTGTCCCT TfCATCCTAACCCTGCCTCCCGCTAACA GGCAGCCTGTATGMTrGCACTGTrCC TrCCTCCTGACGGTCTGAGTICG'i-i-cccT CAGAGACTGT7GCTGCTGCTTCAGC'FM

CTCTCAGCTTCTCTCAGGGCTTCCGCTCT

GGAGTITCTCCTGCTTCTCTGTITTACn7r TCAAAGCTCAGCCTCCATCTrCTGCACC

TGCGGAGTCATFCACTGAYI'CCCAGCTGT

GGCCTGTCACCC1TCCC1TrCMC'CC

TCCTGTGCCACCACCATGCACCCTCCCC

TTCTGTCTGTI'GTGTrGTCCTAACCTT7C TTCTCCCCATGCACCCTCCCCT-rCTGTCT G11'GTGl7GTCCTAACCITrTCTTCTCCTC

TCTGTGCTCTGCAGGTTTAGGGTCTCI'G

TATGAMhGTACCTGCA1TrA'ITGAAGC

TCCACTCTTCTCMJCCCTCTCTTATC

355 1M000973 pOOl! 87

D

SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE

ID

NO: ITC {TC {TC "CLONE "CLAS "GENE" SIFICA \L 2)

TION"

-MUTATION \L 2) GATCCTGCAATACCTCjTCGTGGGCATAT

ATCTAGAAGATGTITTCAACTGGTAATA

GAACACATGCTCTACTATGTTCATAGCA

GCCTTI7TATAATAGCCAGAAGCTGGA

AAGAATCCAGATGTCCCTCAAGAGAGG

AATGGGTACAGAAAATGTGATACATTrA 356 IM000974 CAA p001188 R

ATCTAAACTATAATAGT'TGCAGGGCTAG

TTCATTGTCAGGTGCGTGGCGAAAGAGT

GCAAATCCCGGGGGTTCTTC-FCAGAA

TCAACGAGGCAATACACTrGAACATGTA

TGYTTGTAATCTGCGGGGCATCACCC

GTCCTCCAGGATC

357 IM000975 p001190 D

GATCCCCCAGAAGTGATAGTAACAGT

GAGGTGAATGCAAGCAATAAGCTACCT

AAATCATTAAAACTTCCTA=TIATAGC

ATCTATTAGTrGCACACAGCAGTGATGG 358 ILM000976 GTrCATT p 0 0 1 19 2 K Irf4

GGACCTCTGTACAAATGTCGGGAGATAA

GGGAAGAAAAAGACGACAGAGATAGCA

GTCAGGATGTAATGTGTACTAGATGAGT

GGTTCAAGCAATAGGATGGAAAGGGCT

TAGCAGGAGAGAT=~AAGGATGGAG

GCAGTAGAT'rACATCTGGGAAATGTCAC 359 JIM000977 TGGAACTGGATC p00 1194 D

GATCACCAGGCTGGGGAGGCCACCTAA

GGAAGTGGCACGGGCACGGGCAC1rCC

CCAGAGCACCCTCTGGGCACTCTGAGAG

GGGCAGAGATGTACTGCAGTAGGCTGQG

360 [M000978 CGCGGAGGAG p00 1196 D

ATATAAAATATCGAACGTCCTCTGGCTT

GTAAATATCATGTTAACCTTCAAAGCGT

TCGAAAGCGCAGGAAATCTGAGTCAAC

AGAATAGTATGTAAG FrrATTnTATAG

AACCTGCCTGAACTGCAAGGGAGGGGC

GGGGCGTGGACCCAGGCCTGGCTGCCAA

361

TCTGCGCTGCCAGTGAACTAAGCCTGAT

IM000979 c pOOll 9 7 D SEQ SEQUiENCE~tc "SEQUENCE") CLONE CLASS GENE, ID T T T NO:{T {T C 'CLONE "CLAS "GENE" 2) S1FICA \L 2)

TION"

MUTATION \L 2)

GATCAAGTCCTGGTCAGTACCAAGTTAA

AAAAAAAACTATATAAAAGCTATAYLAG

GGGACAGCTGTGGC1TTTFGTAGAAAAGA

AGGTCCTGGTGCTATGACCTGCAGATGC

CCATGTGGAAGTCTTCAGATGAAGACTT

TCTCATGGAGTAAACATAC1CTGTITGTTT GACCATGTGGACTrGGTTCAAAA'rGCCC A'TGGATGCTCCTI'GGGTACCAGGC1TC

AGTGGGAGTCCCAAGCCCATGTCTI'AT

TTGAGCATGAGCAGTACTGATGCT-rACC TAGTCTI'An'Cll7CCTTGCCCCCTGCCT GGACCGTCTCTGG'I7ACAAGGATGCTGC AGTGGGAAGCGGTATGACCG'TACC7IT[

ATGGGACTGAGACCAACTAAGGGGAGG

CI'GAGGAGGCTGCAGTGAAGY[ATrGTT

GGCACTGTGGGCTAAGATGGAAGATAA

CATGTTAACAAACT1CAAGTGCGGAGGTC 362 LM00980 TCAGAAGTAAAATTGCCTGGY[AGTAD

GATCAATT'GGTAACCAAGCCTTGAACTG

GTATCTCCCACCTGGCTCAATATAGGCT

CTM~CAAAGGCTAAATTrAAGACCAAGG ACACAGAAGGGTAGCTCGCrGGGCAAA 364 LM000982 CGTGATCCCTGCTGATAGTGTAG pOOl202 D CTCTCGTGTGGAGATAT7AAAGGTG

[GA

365 IM000983 ACCACTAAGCCCTGATC p 001203 A lgcp2

GATCAAGCAGAGGGGTAAAAXAAGGGC

AAGCTCAGTGTTAGACAAGCTCATAAGC

CAAAGCTGTGAACTCTCCAACGCCT

366 IM000984 -1p0012 05

D

SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ED {TC {TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2) GATCACTrCAACATCAAGAAGTTACCCA GCCCCGGGAAGAAGTACA1TCGAGGA AGCAGTG1TrCATI=GAGTCTGCTC

CCATCCCGTITCTCTGCAGCTGGGTAAA

CTrGAAGCTGGGCTAGCCTCTGGGTAGA

AGGCAGCTAATGACAACTACCTTGCCTG

TCCCACGGAGCCCGGACAGAACCTGAG

ATAACACACCTAGCTTGCTGAGTAAAGG

CAGGTrACTGTGTGAATGACTGTGAGCT GTTCCAGCTCTGCAGAGCAGGjAAGTCTG 367 IM000985 ACTGTGGAGATAAGAGATAT 0001207 D GTCATGAM~GTAATrCCCTGTCCAACTC TCArrGCTTAGGTCAAAATGGC-FAACT CCTAGCCTACTrCAGTGTAAAAGTCATG 368 1M000986 CGTAATGATC p001209 D

GATCAGGCTGGCCTCAAACTCAGAAATC

CACCTGCCTCTGCCTCCTGAGTGCGGGG

A'ITAAAGGCGTGCGCCACCACTGCCTGG

CTGC-IC1TI1r=CTT1TC1GTGT

GTGTGGGGTAGTGGTGGTGGTGGTGGTO

TrCGAACC 369 EM000987 p001210 A Hsc7Ot

ATGTGTGTGTGTGGGATGTGTGTGCCAT

TGTGTGTGTGTGAGTGAGTGTGTGTGTG

TGTCTGTGTATGTrGTGGAACAGATTCC TGTGTATGrICCTTCTTCACACATGTTr

TCAGAAGTGAAACCAGOCTATGAAGAC

CGCCAGGCAGCTCTGCAAAGCAGTACTG

AGAAGGTGGGACACTGCGGGGGTGAGA

370 11M000988 ACAGTATGCATGATC p,001212 R GATCACACTCCATGAAGCTrCTCTTCTG

CAACAGGAAACAAATAGCAAGCAAAAC

CACTGGTAATCATTrATGTGGTGTCTAAC

AGAGAGCGGTGACAGGGGTGGAAAACT

GAATGACA M AAAAGGAGCTGGAGAT GT'rGG1TrAAGGCGTGTGGGGGCAGCCT 371 M4000989 ACAGCATGGAATrGGTCCATAA p00l213 D SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID ITC {TC (TC

NO:

"CLONE 'CLAS "GENE" 2) SIFICA \L 2

TION"

MUTATION \L 21 AACCATCATGGTAGCTrCTGcT-'c~icTrcc ACGAAGATGGTrGMTCCACAGTTGCCC TCTCTACAGAGTGGTCCTGTAT7AAGTC

ACAGGTGCCATCCI'GGTGATC

372 1IMOO0990 p001214 D

GATCTAACCACCCG'TITCCTGCCCGGTC

TTAGATAGACCTCTTGGCCCCCACGCAC

GTAGACAATGGAGTAGACAAGACTTCG

AGGGGAAAGAGGCTI'CCCAAGATGACC

CAGCTCAflGGC'ITGACTCCCAACGCCA CCCAC7TACACAGTGAGTATCTCTGGTC 373 1M000991 'IGrCTGT p001215 A lFarp

GATCTATGTCATCTTCCAGGACTCAGAG

'rrAAGAGAGTrACCAAGTGAGAGCTCTC ATCACC17CTGAAGCAGTTrGAGAATTGG

AACCCAGAAAGATGCACATGCACGGGC

ACACACACACCCACGGGCACACACCCA

CCCACCCATGCAGAGAGAGAGAGAGAG

374 1M000992 p00 1216 D

TAGGTTGTGCCTGGCCTGTGCAGGACAT

GCCTATGGGGTCTTCATCCCTCTCACTrA CTAATG3TCACTACTGACAAGCACTA

GTAAGAAAGTAGGTGCCTGTAAGAGAC

TGGAGCAGCCTGCTGCTGAC1TCAGCAC

CTGGGAGGCCTCAGTAGCAAAGCYI'AGG

G'ITAGCAATCC'n7GGGGCTGTGGCTGGC

TGAGCTCTGGGGTACCGITIAAGAGGAA

AGCTGGAGTCCAGGFTCTCCAGGCCCTG

GGTGCATCCCACAACCTCTCTCTCTCTCC

TACCACTCGCAGCCUTGGCTAAGGAT

GAGGACCGGGACCTGGAGTTATC'FGAG

ATC

1375 1M000993 L-pOOI 2 1 7 A Snn SEQ SEQUENCE~tc "?SEQUENCE")} CLONE CLASS GENE ID {TC {TC ITC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L2)

TION"

MUTATION \L 2)

GATCTCTCCCCATCCTCCTGTTGCCTCTT

GTCTGTCATACCTCTACTACTCCATCAGT

TGCTGCCTCTGAGTCCCTC1TCTTCCTC TCCTATCCCTCCTCCCATC1TCCTCATCT CCAGGTCTCTCCAGGTCTTCCTrCT-rCCC TCCTTFCCGCCTICCTC1TCCACTG TC1-TGTATrCCCTTC1TCTCTGTrGGT CCCTTrCCCTCGCACCTCTITCCTCCTGTC CCTCCTT=CATGTACCATATTTCTCT7C 376 1M000994 CTCT17CTGTGTCTC p00121 8 A Gatal

GATCTTAGATGGCCAAATGTTGTGAACG

TCCTAGATGTGTCGTGAGCACTCAGG

GTTrGAGAGCCCTGGTTATrAGCAAGTG

AAGTGGATGTATACACAAGCAGAAGGC

TGAAAGTAGACCCCGGTCTCTAATCCTA

TATAAAAACCAACTCCAAATGGACAATA

GAAATAAGTGCAAGACTAACTCCAGGG

377 1M000995 TCACTGGAGGGATACAAAGGGAGATGC p001219 D

GAATGAATATATATATGGGACTAAATGC

CATGCCATAACCAAGAGAACTIAAAGA

AGAAAGTGTYITAGTTATGMIACTC1TrC

AAAGAGTCCAGCTGCCAAAGGGATGCT

GTCAGGAGTAGCTGAGAGCATACATCTG

GACCCATTAACAAAGAAGGGATGCTTCC

378 E1M000996 CCAGCAAGATC p001220 D 379 1M4000997 GGAGGAGGGGCACCTTCTCAGAGATC p001221 D

GATCTTAAAGCI'AATAGGTGTGTGTGTG

rGTGTGTGTGTGTGTGTGTGTGTGTGGTC

AGTGGTAAAATTGTCTACCAAGCTCTAG

G'rTCACCCCTCACAGAGCCGGAGAGAA

AAGGAGAAATCAACTCAAGTCAACCCA

AACAAAACAAAGGACTCAACA

380 JEM000998 I p001222 IR SEQ SEQUENCEftc "SEQUENCE") CLONE CLASS GENE ID {TC (TC (TC

NO:

"CLONE 'CLAS "GENE" 2) SIFICA L 2}

TION"

MUTATION \L 2) GATCTG'ITCCCAAATCCTCAGTrACTCTrc

TGGGAAATGGCTI'CTGTATGTACACATG

TTCTCTAGCTATGTAATAAAAGACCTCT

C'ITCCTrGGCAAAACUrAACTCTACCTTA

GAAAACTUTGATIGAGTACTAGAAAGAT

GACATGTCCACAAACGTC'FrAAGTGAT

TCAGGGTTCACAACAAAGAAGGAGATG

CTATATTGTCTrTCATGACATAGCGTCTA AGTCCCATrAGCATAACT-TCTATAACACA 381 1lM000999 CAAGTGGG[ p001223 ID ACACTAGC'ITCGAAAC'F7TTAGT'TGTCT GTCCCTGAGCCCYI17GTGGTACTI'CCTCC TCAGAGCCCA6CTCCAGCAGTCCCCT7A

GCGGGTGTTTTAGCAACCACACCCTCT

GACTGTGGGTTGCTCTGCAGTGGCTT

AAGGTrGAATACGAAATGCCTTrCCACA

AAGAGACACTACAGAATCT]TAGGTGTCG

AGACAATGGGCATrGAGAAGGAATTG GAACC1TCAGATrc 382 1IMOO1000 p001224 D I-

GATCTAAAGGGAAACCCTGTC'ITITG

AATCTGAGCCAGCACAATA'TGTATrTC

C'FCAATACGTGGTGAATGTTGTATTAG

CAACAATAAATGGAAGCAGGGAATCTC

TCATCTCATGAGTGATATrACAATGTCT

GTCTGGAAACAAACGGCTAATCAAGTTA

GTCACT'rACTGTrrCThFAGAAAACACAG

TACTFIGAAATGCATACCTAGCAGAGAA

TATAAAGTA'TFACTG'rrGGACTAGACT 383 ILNM001001 GGGCCCCCGGGTGTGAGGG pOOl2 2 5 D

GATCTATCTCATCCTGT'ATAGCCGGAA

ACATGATAGGAGGATTGGGCAACTCTCC

AGjTCCCYI1l'CTCT7GGGTAAAGTCTGAA Ac3CAAATCGCCCGGACCCALrCTCCTGTC

TCTGCAGCCTGTCCGAGTTGCCTCTIGCC

ACTCACTAACTTCACTCCTF]AA1TTAAA 384 EM00 1002 AAGCCAGCACAMTATFGACCGTCT pOO 122 6

C

SEQ SEQLJENCE~tc "SEQUJENCE") CLONE CLASS GENE NO: {TC {TC {TC "CLONE "CLAS "GENE" 2) SIFICA \L2)

TION"

MUTATION \L 2)

GCATGTCTCCAGACTCTCAGCTGCTTCCT

GTCTGCTCCTGCTGGATGCT'rCATGAAG ATGGAGTGAAGCAGTGGTCAGCTrGTCT

GTCTCAGCTGTTCTATGTGCATGTGTGC

ACTTGCTGGAGC'ITATGTGCACCACAAG

CACGCAGGTGCACACAGAAGCCAGAGA

385 1N4001003 TC p001227 D

GATCGAACACGCTCGGACTTGCTAAACG

386 MO~l004 TTCCCACACGGACAGTCACTGCCAA 386____EM001004______ p001229 K Nnyc

GATCGTGAGTTCAAGACCAGCCTAAAAT

ACAlCAGTGAGCCTCTGTC1TrTAAGAAAc

AAACAAACAACAACAGCAAACAAAAJ

ATAT'rGCTCAAGACCCAATGTTCCTCGG ACTA ATAGGAATCAGAGTTGCTGTr CTTCTCAGGGCATGCCAGTTrAA-rITGAA

AGACAAGGTGTAGAGGCAAGGAJAG

TGATI=ACT-rGGATAACCACCTCATGG

AGCAGTCAGGGGAACTCTAGCCTCAAA

GCTCT'rGCAGAAGITATAT 387 IM001605 p001230 D GTAGAAGC1TFIAGAAATACGTTrGIT

ATCTATCTATCCATCTATCCACCCATTAT

CATCTATTATCTATAITrAACATCTrATCT' AAGTATCTG1TTATCTATCTACCTGTCTA

TACCTACCTATCTACCTACCTACCTATAG

CGATC

388 1M001006 p001233 R GATCGTGCATGCATGGGTGTG1TTGGG 389 IM001007 GAGAGGTrCTGT pOOl 23 5 D GTrACTAT'rCATCTGAGGTrCTCTrMGT

TGTATITGAACAGGAGGAAGGAACCAG

GAGCTCAAGGATGTAGCTGGAAATGCTA

TAAAACTGGGATGCCCTAGAGAATCACA

CGGACAATCCTGCTAACCCATGGAT'rGT ACACTCCAATATACAAGATAACATG1TTT 390

GTGCAGGCATGCCACCATGATGTTCGAT

IMOO1008 c pOOl 2 39 D SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ED {TC {'IC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA \L 21

TION"

MUTATION \L 2)

GATCGACCGCAGATGAGGTCTATGCAGG

AAAAACGATGTCTGGAATIT7AAAA

TTGCTCAGCAACTCACTGCCACGTATAC

391 1M001009 TGGAGAGCCAC'fl'AGGGAT p001240 K [yc CCAAGTATACGTGGCAGTGAG7ITGCTGA GCAATFlTAATAAAA7TCCAGACATCGT TIMrCT'GCATAGACCTCATCTGCGGI'CG 392 1iM001010 ATC pOO 1242 K Myc

GATCGTAGAGAGATIGGACCCAAATATC

AGCCAGAGAATTrAGACCAGAAAATGGA

ACCAAAGTACCTGTCAGTCCAAGGATGT

393 M001011 AGTGGCACTAC p001244 D F

GTCCCCAAATGTAAACAAAACTATCAAA

AGAAATTGGGCATGCCAGAA=TrC TICACATTAAGGGAAT-CTGAAAT-rGAA ATCT7GCTAAGGGAAGGGTGGCTTGAGA ATA'FrAACAGAATCCTAGGTrGAAGGAG

CAGGAATAGAGGATC

394 1M001012 p00l2 4 6 D

CAGCTAGCCCATGGAGCTGCTGGGACAC

GAGGCCGCAGGCTGAGCATAATGGGGA

AGAGATGGCAGATI'CATTCACCCACTTG

AGGAGACCACAAT7AGTCAGAGGCATG CTGGGCCTGGTCAGAGTlGCTCAAATAAA CATfCACAGGACCAAAGTAATAAGCAYI' GGTG1TACAGAGATAAATCC'ITAGCAG

GGACACGGGACCCCAGAAAACCGGA-AG

GACATCOTTCCCATCATGAGAACAAGGA

CAGCAAACAGTCACTGAGGGTATACTAC

TGACCAG'FrCCAACAGGGATGGTCAGAA

G'TGAACGCTGGATATATCATGAGCTCT

GACCTAAATATTCTGAGTATTCCCCATG

flTGAATGGACTGAATACTCACATTTTCT

AAATGCTGAATACTGAA'TICATAGCA

ACCATCATAAGGCATGGTGGCAGAATA

ATATCTCTCACTCAGAAAGCAAAGTATT

CTAAGTflGGGGATC 1395 1rM001013 I p001247 ID F SEQ SEQUENCEftc "SEQUENCE") CLONE CLASS GENE ID (TC {TC ITC

NO:

"CLONE "CLAS "GENE" T\ 2) SIFICA \L 2)

TION"

MUTATION \L 2)

GATCCCGTGGGGACTGAGCCTGCAGCTC

AGTGGTAAAGCAGATGTCTAACGTGGTA

CAGGGTCCCAGATGAGATGACACAAGT

ACCTGTCAGTACTCCGGGAACACTGGGT

GGGAC1T=ATATGMTAMTGTATrCTT 396 IM00I014 p001248 D AGTCCATGT3TACTGAGAGAGGAGTTA GGTrfTAGAAAGCCTrCCTCAGATGTCCC

TCAAAGAAGCTGCTACAACTGCCCTCAT

397 IMOOlO15 CCCAAGTTGCCAAGGATC p001249 D

AGATITGCGTGAGTTCTGATGCATGCTGG

CCATGATGTGAGGCAGGGGCAGTGGTrG GATTCGGAGTCAGAAAACMrCCCGTCT ACTGCCGTAATCCCAGCTAAATTrCCTA 398 JIMOO 1016 TCCTCGTTGTAGCTGTTGGTGAGGATC GATCCTTCCGAATCTGCCATrGAAT A1TrrAAAACACACCTCACTGCAGACTAA

ACACATTGCAAGCACTGGGAGCAGAGG

TGGCTAGTGAGCACCACTCTAGATGGTC

399 1M001017 CTTC p001253 D GATCCTCCTGCGTCTACCTrCGGGTGGG AT'rGCAGGCATGGACCACCATGCTrGGC 1TGTGTGGTACTG3ACATTGAACCCAG AACTC1TTrGAGCACTAGGCAAGCACATC CrGAACACCAGTAAAACA'II-CAAAGA

GAAAAGAAAAMTAAAACATACACCTAT

CTACATCCATIrrCCACCATGTTAGTAAA CCAGGGACA1TrGAAGTGTGGTCInrA

TAAAAACACCCGGGTGCTTATCTCCCAC

400 IM001018 GCTCT pOOl 2 5 4 R

CCAGCGGTGCTCACTACTGCATGTAACC

01 IM001019 AGCTCCAGGATC pO01255 ID SEQ SEQUENCE{tc "SEQUENCE") CLONE CLASS GENE ID (TC {TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA\L 2)

TION'

MUTATION \L 21

GTCTCAAAGAACAAAAATAAAAGAGGA

AATrAGTAACGAGTCCTGAGAGATAGA

AGAGTA'TCAGCCTGGGACCAGAGCTCT

GTCT1TACAGTC17GCCATTCTGTGGGGC CTGGGACACAGCATCCTYFGGTrCT1AGA ATGCCATAGGCCTCCTGAGGGAGCCTrT

TCTGTAGGCACTTCTCCCACATTC'ITGGA

TGGATGCGATI17ATTCTGTGTCAGGGGA CTAGGGTrGCTGGATGTGTGGGTCGAATG ACTGTT1GTTCTGTCACFI'GGGAATYITGG

GATAGGAGAATI'CTGAGTGCAAGGCTA

GTCTGCACTTGAACGTACATATCGGGTT

'ITAAGCCAGCCTCTGAGCTACCACAGTG

AGACTCTCTCT'rAACTfAAAATCAACATA AATAGTCTTAGTATGGAGAGGTrAGGGG 402 M4001020 ATC p001257 C CG'IIccCGGAAAATGTGAAAAGAAG

AAGCACGAGACGAAACCCCCTCGAGAA

TGAGAAAATTAAATCTAGAACCCAAATG

GCGTCCAACAAGAACAYI7AGCTCT7GAA

AATGAATAITGCGCCTGCGCAGCCACCG

CGCGGCCAGCTGCTCAACTGCAGCTAGA

403 ITMOO1021 GCCCGACCCCAAGCGATC pOO1 26 0 C

GTGTCACATGTATGAACAGCATCACATG

GTATGAATGGTATCATATGGTATGACGT

GAATGTGTGCACCGGCACTGATC

405 IMOO 1023 ATACCACCCACTCCC~aAAGAAAAIGATC p001263 D GACTGATATTAGTAGGiTrGTTCTGTAAG GGCCGTGAAAT1TIAGCTAGAAG7FrCT

TGCTTFCATFAACAGTGGCAAGTATGAG

TCCATCTCATGGGGTGGGTC117GAATA

CAATCAGAAGGTGGTGAGTTATCGCCAT

AACATCTGTGCCGCTATTGTACCAGTGG

ACATAG'VrGCCAGGCAGGCGAT7ACTGT AG(-CTTAGGTCATiiccTGAAGCTCTCT

GGGGTCTGTTAGGTGAGACTGATGATAA

CTCTrCTCTTCCcYTrAGTGTACACAGCAC

CTITAGCACTATGAAAGCGAGGCAGTA

'TGATC

1406 M001024 1 pOOl 264 ID I

U

SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID TIT

IT

NO: C {T {C "CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 2} GTrCCGATGMTGTATCTCGTTrGAATTA TCCATCAG1TGATTAAGTTGATGGTCAT

CTAGGCTGATTCCCCTACATGGCCATCT

CAATATTGCTFC=~IAATAAGACCTGGA

CAA1TAACAGCACCAGTTGACATGCCAA CITGGA'rrGGGGGAGGGGTCTTAAAGGG CCCCGCCClTAGATGAAGAGCTATACGC

AATTAATGACTGTCAGAAAGGGAGAAT

GGCTICCCAGAGATGAACCCCCTAATG

407 IM00 1025 GATTACCCAGTACCAAGTGATC p001265 A RadS2

ATCAACCTATGGGGCCGT-AGACCCCT

GGTCTrGGGTGGGGTGGATATG7TAT'rC ITTTrGCTGTGGTGGCAGCAATI=GTT TGCMTTG1TT=GATACAGITCTC GTCATGTAflCCTGGT'TGCCTGGAATrC AC1TCTATAGACCAGAATGGCCTCAAT

TACAGTGAACCGCCTGCCTCTGGCTC

AGATTACTGGAArrACAcGM~GTGCTA

FCTCACTAGTTGGTGTGTGATC

408 1M001026 pOO12 66

C

GATCAAGTCCCCAGTTAAATGCyrTTr-TT GATAGGTTGCC1TGGTGATGTCTCTrCAT

AGTAATAGAAAAGCAACCTAAGACAAG

AGGAGAGAGTOGGGIMAAGAACGAGGA

GAGAGAGGAACTCAGAGGGTCCTGGAG

GTCCCGGGAA

409 IEMO01027 p001267 C

CTCACACATACATTCATACATACACACA

CATATATACATACACACACTrGCATACA

CACAGCACACACTCACACACAGAGACA

CACAGACACACAGACACACACACAGAG

GAACCCAAAGGATTGGAAGAATAAT'17JC CCGTGCTCAGCGGGAAAGTrACCAGAA 410 IIMO01028 AGACAAGTGGTCATGTGGGATGATC pOOl 270

C

GATCATCACCAGTGTAGTGTTGGCT-IA

ACGGTGCACGCCTITAATCCTAGCACT-r

GGGAGGTGGAAACAGGTAGGTGTGCTT

ACT7CAGTGAGTGAAT-rCCAGGCCAGGC

AGGGATACAGAGTGAGAACCTGTTATCT

AAATAAATAAATAAA

1411 IIM001029 p001271 -C SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE {D TC {TC {TC

NO:

"CLONE "CLAS "GENE" 2) S1FJCA\L 2)

TION

MUTATION \L 2) CACCCACGGCTTGCTrCITTFCTCTATGT

GTAATTGAAGCACATACCCGGTGGGAGC

CATGTAAAGCCTGTGTCCATGATC

412 1M001030 p001272 D GATCATGTGTrAATGAAACTGTCAGGGG

TGGGTAAGATGGCTCAGTAGGTAAAGG

CAC'rrGCCT~CTAGCCGGAGACCTGAG GTrCCTCCTGGGGCCCACAGGGAAAAGG

AGATAACCAGCTCTCTGTCCTCTGACCT

CCTGGGCCCCTCCCTCACAAACAAACAA

ACAAACACACACACAAACGACCAGACC

Al1TCCCACAGTAGCTGTGGTGCGTTAC AC'FGTAACGGGCACCATGTGAGGGYlTG

GGC'IT'ATCACATCTCCGCTAGTCATACT

TGGTGT-ITCCTGCGTCT'rGCTTACAGTTG

T-I'CTAATGGGTGGGCGGTGATATCGAAT

TGTGGYT=AGCATGTATITrCCTGTGCTC 413 1M001031 TGCTAAGACCACTrACAArACAG pO001274 R CCTrAACGCTCCCTrGATGTCCACTCCCG TTrTCTGCAGCGAT'rTA'FrGCTTAGTC

TATCTATAAGGTGTATGCAAGCTGCAAA

GTCAAGTATrCC1TTGTACTrGAGCAA GTc'ICCTIAAGTA'IrIATOCI-rCATAACGT-r GTGATATGCTrGAGcAAAT-rrGAGI'C'IA TrCATAA1TAAGCCACTGT7CTGATAA 414 1MOO1032 AAGACCCTAGAGTGCTATATCTGATC p001277 D

AAA-AGAGTGTCAGATGTCAGAACTGACT

AGCTGGGCTGACACTGAGGAATGAAGG

TTGGGGATATATGCACCTCCTGAAAACA

415 IM001033 GGAAGCCTM~GTTGGTFGATC p 0 0 l 2 79 D GATCAACC'ITAGTACACAGCAGAGTGTTr TTCTGGGAAGCTCATGGAGACCCAC1TI' TGTCATCCCATAGAGGTrACTACAAATC TGAGCATGAGAATAACTACT7GCTG=r~

AATACAAAGAACCATTAGCAGTCAATGC

CCCAAGT7CTAAGGGCACAGACTTCATA

CGAGAAAAAAAAACAAAGCAAAACAAA

AACTATCACATGCTACTATCTGTACTGG

GGAATGCATACAA=GrTTAGGTAT 1416 1M001034 I p001281 ID SEQ SEQUENCE{tc "SEQUENCE") CLONE CLASS GENE ID {TC {TC (TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA TL 2)

'RON"

MUTATION \L 2)

GATGAGTAGAGAGCAGAGGGGTCTATG

AGGGAGGTAGAGCAGCCTGGGAGGCCT

GAGGAAGGAGGGACAAGGGCAGAGTCT

TGGTCACTGTrGGTCTAATTGCCTrCAG AAGGCTTGCAGACTCTGG'T17GGAGTTC

CAGGTGGGTGGCTG

417 1EM001035 p001282 C

CAAGTAGGGTGTGTGTGTGTGTGTGT

GTGTAGCCAGTGTC1ICTCAATCACTCT CCACCTrAATATITTrTGAGACAGAA TCTCTCACTGAACCTGTATGCTGTCAA'rr

GTCATGGCTGACTGGCCAAGGAGCCCG

AAGAAT-rTATCTCTATGCTCAATCCAAC 418 EN4001036 CCCCAGATC pOOl 285 R

GATCACATGGACCGATTGCCGCGGGACA

TCGCACAGGAGCGTATGCACCACGATAT

CGTGCGGC1TIGOATGAGTACAACCTG

GTGCGCAGCCCACAGCTGCATGGCACTG

CCCTGGGTGGCACACCCACTCTGTCTCC

CACACTCTGCTCGCCCAATGGCTACCTG

GGCAATCTCAAGTCCGCCACACAGGGCA

AGAAGGCCCGCAAGCCCAGCACCAAAG

GGCTGGTGTGGTAGCAAGGAAGCTAA

GGACCTCAAGGCACGGAGGAAGAAGTC

CCAGGATGGCAAGGGCTGCCTGT1TGGAC

AGCTCGAGCATGCTGTCGCCTGTGGACT

CCCTCGAGTCACCCCATGGCTACTTGTC

AGATGTGGCCTCGCCACCCCTCCTCCCC

TCCCCATrCCAGCAGTCTrCCATCCATGC

CTCTCAGCCACCTGCCTGGTATGCCTGA

CACTCACCTGGGCATCAGCCACTrGAAT

GTGGCAGCCAAGCCTGAGATGGCAGCA

CTGGCTGGAGGTAGCCGGTrGGCCTG

AGCCACCCCCGCCACGCCTCTCCCACCT

GCCTGTAGCCTCCAGTGCCAGCACAGTG

CTGAGTACCAATGC

419 PM001037 pOOl 28 9 K Notch] SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE pIC {TC {TC "CLONE "CLAS "GENE" 21 SIFICA \L 21

TION"

\L 21

GATCTAACTCAGGCTGTTCAGCTTGGCC

AACAAGCTCAAATATCCATrCCGCTGTC

ACATCGGGCCCCATGTGATGCTTFATAT

ACTAAATAGAACAAGCAAArrGATACTA GATGGGACAGTCTGCTIACCCAGM1'GG

TGTITGGTGGGGGAGGTGAGACATATCC

CACAGTCCCAGAGCAACTGTCACTGCAG

GGTICCCAGGGGAGGAGCCAGGTGTGAA

GCTGGCAGTGTGTGAGGTACCCTGGGGA

AAkATGAAI'GGTrTACT p001292 D

AGGCCTGGTAGTGACCAGCAAGTACTGA

ACGCTCGCTCTATGCCAGACACAGACCC

TCTRFCCTCGTC17ATCCTA1TATCC ATACTGAACAGACAAGGAAkATGAAGGC

TTAGATGAGTCACCCGAC'ITGCTGAGAT

c p001293 D

AGTGGGGCCTGAAAATCACATCTGGGCA

AACCCTGAGGCCTGCCAAGTCCTCATCA

GAGGGATGCCCTCTTCATCCCAGGTGCT

117CTGACTATAAAATAAGGTGAAITAC[A CCTCCCCTGAGG~rACACCTFCCAGiGG'F[I AAGCTGGIfTAGAGAACCCAGGGACACA

CTGGGAAACAGCCCACAACAGCAGGAG

CTGGAGCACTCACCCAGGGATGTCCATG

GGGTCCAGCTCCCTGCGCTGGCGCCCAC

GACTGGTrACCAGGAAGCAGTGAAGAGG

TGGCCCAACCCACTGTAGAGCGCTTGAT

TGGGTGCTTGCGCAGCTC1TCCTCOTGG

CCATAGTACGGGAAGATC

EM00 1040 pOO1 2 97 tMoichi AGTGGAACCAGATlCCTCCTACGCMTG CACTGCACTTFCGTITCTCTrCTGTACC ATrFCTAATGGAGGCCAGAGTAGCAACTG TATAGACAAATCAAATCG7FITACTCTTC CAGIC'TTGCGGCTAACAGfCII-CCIF GTTCfCCTC'TAGCCTCAYI'rCC1ITF 423 IM00 1041 CTCAGATC p01298 B A1604147

U

SEQ SEQUENCE~tc "SEQUJENCE") CLONE CLASS GENE ED ITC (TC {TC

NO:

"CLONE "CLAS "GENE" 2) SIFICA\L 2)

TION"

MUTATION \L2}

GATC'ITCTGCTITCATCTGAGTAGGCTTA

GACTGGTTGTATTATTATATTA'rrACT TGTTGTTGTTGTTA1TIGGTGGGAGTAG

TAGTAGCAGTAGGTGTGTGTGTGTGTOT

GTGTGTGTGTGTGTGTGTAGATGTCACA

GCATGTATATGGAGGCCAGAGAACAGC

TCTAGCGGTrGC'FrCTCTCCTTCC1TCC

ACTGTGGTCCAGGGAATAGAACTCAGGT

CATCAGGCTGGGCAGCTGTCACCI7AA

TGCTCTGAGTTATCTCACCAACGTTAAT

AAAAGGCTrCAAACAGCAG-TrTGGGC TGGGCCTGGTrGTGCAGACCTGGAATTG

CAGMMC~AGGATGCTAGGCAGGAGG

ACTGGAAGCTCAAGTTGTGTCGGGGAAA

CTTAGTAAGTCCCTATTCTCGTCCCGCAC

GCGCCCAAAAAGCCAAGACCAAGACCA

AGCAG17GGTACAGCAGAAAAAGCAC GAGAGTCTCCTCCTCCTCCTGCTCCTGTrF

TAATGATGCAGAACCC

424 1M001042 p001300 R GATCTGTGCATrA'JTCTGTTGGAAATGT GACAAGATrCTGTTGAGAATCTCATACT CTATGAACTCTTAAAAAAAAAAGGTrTC TGCTGTrnTGAGACAAAATACTrATAL AGG1TATGATGTAGrrAAGGCCCTGAA TGTCCCCCAAAGACATGTGTGT7GAGGG

TGGTCTCCACTCCGTGGTCTITGGGA

GGTGTI=ATGTrAGCTGGTGAGGCATA

GTGGCAGGGGAGGAGAGTTGGGTCATA

GTCCTM~GAAGAGGCTAT-FCAGGC-1CT 425 EM00 1043 GGTGCCTAA p001303 D

GATCTGACTGTGATAGGAGGGTCCTGGG

GCCACCCTGACATAGGCCTGGTCTATGA

ATGCTCTCATGGACTGGGCCGT17GTC 426 U%4001044 A p001305 D SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID ITC {TC ITC

NO:

"CLONE "CLAS "GENE" 21 SIFICA \L 2}

TION"

MUTATION \L 2)

CTGCCTCTCTCCCTGGTCCCTCCTGAGG

TTCTGGACCCTCAAAAGGCCC'I=CCCA

CCCCAGCCrrCAGGCCTG'rAACCCAGCC TCGGTTTCICTrCCCAITGCCAAAGCACA ATGGCTGTTATAATTAACGGArrATCTC

AGCGCGACAGCTGCGCCCCTGAAAAT

427 1M001045 TAG&I17GAATAACAAGATC p001306 C

GATCTTGGACCACCACGTCAAGCCTCT'T

GTACATTTCMGAAAAACAAAGCTTGG

'TTCCCCCTAGTCACCACGGTGAAAAAAA

428 1M001046 CCCAGGACAGTAAAGGTCCCAA pOOl 3

O

7

D

7AGTACCTCTGGTGGAATCACCATGCC TGACCTAAAGCT17ACTACAGAGCAATT

GTGATAAAAACTGGATGGTACTGGTATA

GTGACAGACAAGTAGACCAATGGA.ATA

GAA'rFGAAGACCCAGAAATGAACCCAC

ATACCTATGGTCATCGATC

429 1M001047 p001308 R

GATCGCACCGATTGCCAGTATAGTACCT

AGAGTGTCAAGTTGGCCTCTCAGGGAAG

AGAGAACATGTA1T'AGGGTAAGACGCA 430 IM4001048 AGCCCCAGTAAAAACATGTGAG p0013 ii D GATCGC'ITCACCAAGTGTGAACTGTrGG

TAGGGACAGAGCAGACCACAAGCCCCT

cT-rrGCATACATGGGGGCGTCCTAGT

GTAGGTGGCTAGGGATGGTGGACAGGA

GAGGAGGGAAGACAGTATCACATA.AGA

ACAATAGTrGGAGGGCAGGGGAGGAAGC CMrCTCATGGCTGGGGTGAAGTCACTTC

CGTAGCCAGAGCTGACTGAGAATATCAC

TGCTICCTAGTAAGGAAACACCGGAAG

TCGGAAGATGATAAACGCGAAACTCACT

ACATCATAGACACCA'ITCTGTC~rCATC AACAGAGAAA1TrATAA 431 PM001049 p001313 D GATCGGTCCAc'ITcTGTGTFGCTAGGCCC

CGGCATAGTCTCACAGGAGAGAGCTATA

TCTGGGTCCTTTCAGCAAAATGTTGCTA

432 1M001050 iOTGTATGCAATGGTG pOOl 3 l 6

IR

SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ED {TC ITC {TC

NO:

"CLONE "CLAS "GENE" 2} SIFICA \L 2}

TION"

MUTATION TL2) AGGGTACAGCGAAGC1TGAAAAAAGCA

AGGAGTGCTCTGGGACCGGGAGTGATG

GAGAAAGTCTGAAGCCCCMIGCACACC

CCTACAATGGGMTGCGCCAAGAGAGGC

GCCGGCAACTCTACGCGGCGTGGGOCTC

TCCCCAGCGCTCTAGGTrCTACTGTGCT GAGCCACACTAGnCTCTCCCTAGACC

TGAAGAGACCCCAGAAGTCTGAGAGTC

CCMrGG'FrCTCCATCTCTCACCACCCCC CACTCTCGTGCTlTAACTCTGAGGAGGG

CCACTCAAGTITCATTCATAAGAACAAGG

GC1T7GCTCTTrAAAGGAGCCGCATACCG

AAAGCGTFGTGTGACTGAGGGTTCACA

TGCACAGAGCTCCGCGTGTCTCGACATC

CTCTCTCTCCGATC

433 IM001051 p001317 D

ATCTCAGGAAACTCCTAGCAGCTITAGT

434 ACc3CATCGTGCTG'=CCAGCTGTCGGT WOO01052 A1TIACACAGGTITGAGCGATC p001318 D CCTrCAGGATrrAC1TGGATGA17CATrA GAGAATCTTGTC1TITAGACTATAAAGCA CTTGTrGAAGAAGGTTACAATGTAGCAA GCAACCTrGTI=GGAATGTAT1TGGTA CA1TGTGCTCTrCCCTGGTCTGGTGCMT CATTrCACATATIrGCTCTrAATAGAAG TAGGGTrCAGTGCTGGGGA'TT7CATrG CTGTTrCTCCA~rGACCTC1TrGAGCTGA AGTTATTrC1TATrAGAAAGTCAGGGTAG 435 IMOOI053 GCGATC p001319 D

CCAGCAGGCAGCGAGACGCAFI=CGCG

TGGCGGTGGTGAGCTCTGTrCGAGGG GATGAGCCCC17GCAACGGCACCGG'rrG

GTCCACGAGGCACTGTCGGAGGAGCTG

GCTGGACCGGTACATGCCCTGGCCATCC

AGGCGAAGACCCCCGCCCAGTGGAGAG

AAAACCCACAGTJ7GGACATFAGTCCCCC

CTGCCTAGGTGGGAGCAAGAAAACTCG

AGGGACCTG'TrAATAAATACCTGGATTG Mm. 1045 436 ]14001054 GGAGAACGATC p001321 B 31 GTI I CCTGCATAGACCTCATCTGCGGTjo 437 'Irvloolos CGATC 01322 lK SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID ITC {TC {TFC

NO:

"CLONE "CLAS "GENE" 21 SIFICA \L 2)

TION"

MUTATION \L 2)

AAACTAGGAAAGGGTATAGCA'IMGAA

ATGTAAATAAAGAAAATATCTAA'TT'AA

AAACAAAAAAGAAAGACAAAGGAAAAT

TAAAAAAAAAAAAAAAAGAAACAAAAG

CCACTGCAGGACTGCCCAACAGTCTACT

GAAAACTGTGAGCCflA7IFCCTAGATGA

GCCTCTGATGCCTCCACTTACAAGCTAC

CYTCACTCCTCCATCTATCTCCT=[G11'

ATGTCCCGCGATC

438 IEM001056 p001324 R

GATCGGACTCGAAGAGCAGAAGAAACA

AAACTCAAAGCAGGGA'ITlAGGTCAAAA TTAAAAAGGGThrGCACACAAAAGGAA

ACCATCCGAAGAGACAACCTACAAAGT

439 IM001057 GAGAGAAACTTG~hrGAAC p,001325 D GTCTGAGAAATTGTCTFrAATGTAGTGA

CTGTGGAGCCTTGCAGGGAI'ACCCACGA

TGGGGGTGTCATTCATATGTCACTGCAC

440 1IMOO1058 CTGGAAGACCGATC p001326 ID GATCGCACAGCCTGCYI17CTCAACAGTA

GGTAGGACCAACAGCCTAGGTGGCACC

ACCCACAGTGAGCTGGGCCTTCCACATC

AATCATCAATCAAGAAAAATAGCACAA

AACCCTrTCCCGAAGGCCAATCTGCTGG AGGCA'IMICTCAG'I1GAGATFrCCCTCTT

CCCAAATGACTGCATAAAACTFGTGTCA

441 TGTTGACATGAAACTAGCCAGCACAGGG 1MO01059 TGT p001327 K lPvtI GATCGGGTAATTTAGTAATAGTrCATGA TATrCATTACTCGGCGTAAATCAGGAAA AACAnTrCTAGATGAATGTGGTATCTC 442 AGTGCACAGM'IT(YTFAGTfAGAAAAC 1IMOO1060 AAAT p001328 D F GATCGAGGAGGGGAAGTCCIT7CCTTCCT 443 IM00 1061 TCGT-rCCTrCCT-rC 00O1329 R SEQ SEQUENCE~tc "SEQUENCE"} CLONE CLASS GENE NO:* {TC fTC {TC "CLONE "CLAS "GENE" 2) SIFICA \L 2}

TION"

MUTATION \L 2) GATCGGGGGTrCAAGGTCCTCCTCGGGG

TACCTATTAGGAGGGCAGCCCAGGCTAC

GTGAGACrCTGTGTCAATAAAAATAAAA

ATAAAAAGCTGGGTGGTGGTGGCGCAC

444 11M001062 GC p001330 R

GATCGACCTGCCTCTGTCTTAAGCAAGA

AGGGAGATAGATATGCATAGTA'IMAGT

GTAATGAAAGTTACGTTGTAT-rACGCTG 445 EM001063 AGGT17ATCACA p00133 1 D

ATCTAAGTAGTATAATGTAAGACGAT

446 IM001064 C 00O1332 D GATCGTCGTCTAACTrAGCTGGC'TrTAT

AGTGATATAACAAAATATTAGAGGATGC

=GGTrGAAAAAGAAG=hATTrGCAT 447 IM001065 CACAGTTC Ip001333 D GATCGAACACGCTCGGACTrGCTAAACG 448 IM001066 TTCC p001334 K iNyc GATCGTdATCA1T1TATAACAGTAGTG

AGGAGATGTCCCCTGGGGCCGCCCTGGC

TCTGGAGAGGGAAGCCACATGCTCCAA

GGGGCTATGGTGAGGACCACAGCCMTA

449 Irm00 1067 CAMTfGCTT p001338 ID

GATCATGCACTGTCTGGGATAGTGATGG

GCTGTGTCCTITGTTGGCCAAGAGGAAG

TGGCAAAAGGCAAAG77GCTGTFGGCTC

CAGGAGTCAGTCTGGGGACGGGGCTGA

GATGCTGTGGGACAGACTCTGGAAAGG

GCAG

1450 I1M001068 pO10l 339 ID V- SEQ SEQUENCE~tc "SEQUJENCE") CLONE CLASS GENE ID T T IT NO: C {T {C "CLONE "CLAS "GENE" 2) SIFICA \L 2)

TION"

MUTATION \L 21 GATCGTGGCCACTGAGAGACC1TTCT

GGCCACCAGATGCACACAGCTGCATGA

ACATCTGCATACACAMrAACACATACA AAGTTGAAGAGAAGCACGTGTGTC7FrGT

GGTCTGACCACTTCCTGGGCACCACCAA

GCTGCTCTGACAACGGATTCCCACTGGG

TTCGGCCATCTTGCTTCCTCCCCTCAGAG

'IfnGCCCATGTCCTCTGTCTI=CATAGC

CACAGCCTTGCCCAAGATAAGATACATC

451 1M001069 CAACTGTACAGTGCTCCAIl p001341 D

GATCGTACCAGGAGCTCCAAGCGTACCC

CTGATGCTACAACCTCAlITCCTGAGCCT

TGATTCTGTGGACTCTAG

452 P1001070 p001342 IC

GAACAAGGAAGGAAATAAAGAATAAAG

GACATCTGACACTACCAAAGTI'AGGTCA

GGATGTGTCTTACAGATGGCCACTCAAC

AGCCTATAGAAAGCACCGCACAGACCA

GCACGGTCT1TICTCCCAGGTGTCTCTG AGGTACTGC1Tr=rCCAGGGATC 453 IIM001071 p001344 D

GATCCCGAGTCCT=CATGGTGTGGTTCT

ATTGTG'CCCTAGGGC'1ITCAGCAGGCAGA

AGGAGAAAGACACTGTAGAGCAGCCCC

454 LM00 1072 CAAp001345 ID GATCCTGGGA3T=CTGGjGCAATrGGAG

GCCACAA'ITAGATAGMTCCGGAATCG

ATGTCCCT-rAAAGACCAGCGCCTGGACT CTACTGAGTAAACTCCCArITCAAG1TC CTCCTC1TCCTCTAIT-1I'GAACAACGTGTA TCATTAAATTATAAAATTGTGI'rG'frGT TGTrG7rGITrCAAAAATTrAACTAT'rG

GGGGAGGGGCAGTTGCCCGAGGACAAC

ITc3TGAGAACCAGGThITGCCTrCCACA 455 CTTAGGGGTCCCTGGAA'TGGAACTTATG 1M001073 T pOOl34 6

R

SEQ SEQUENCE~tc "SEQUENCE") CLONE CLASS GENE ID {TC ITC {TC

NO:

'CLONE "CLAS "GENE" \L 2) SIFICA \L 2)

TION"

MUTATION \L 2)

AGAGGAGAAATGGGGGTGCGAGAGGAC

AAAGTCTGTGCCCCACAGCGCTGGGGCC

AGAGCCCAGGAGGGCCTCATGGGAGAG

GTTGCCTGAAGGCAGTAAGAGAGGCAG

AGGATGCTI7GGGCCAGAGAGGTTCCCCA CAA~rGCTTGGATC 456 1M001074 p001348 D

GATCCCAAACAACTGGAACAGGGG'ITAT

457 B4001075 CCCAAAAGCTGTrGCCTG p,001349 D

GATCCAACTCCTCTTCACAAAGAGACTA

TGTGCAGGATGGAGAAGAAGATGTATC

CAAGCATATCCTGTGAAA1TrATGTCAA TGCTGTGAAA1TrGTCCCAGCACTCACA ATCCAGATTTCTGCTrTMAGGTGGCTITr TrCTAT-TCAT-rCTGGCTTGATAGA AG1TFGAGGTGACAT1T=AAGACCTGT Min.1238 458 1M001076 GCCACTAAAAT1TCAGACCCTATTTG p001350 B 02

GATCGGTTAGFJTGACCAGCCATACTAT

AACTrAGTGCAACCCTTTACTTrGGTGG GTGGTACTAGGAATrAAACCCAGGACCT TCACATATACTAGTATCATrGAGTFFACA TCTAGCCC1TIAACCAATrCCC'TTT AACCCTITIATCC1TG 459 [MOO 1077 p001351 D V- CTCAAGAT-TCTGrrGTCTGAGAATCTCTC

CCTCTGCTTGGGGACCCAMTATAATGA

GGTGATACTTCATCTGAAGTAATGGCCA

GGCCACGGTGTGAGACTC1TGAATGTCA 1460 1MN001078 ICATGCTGGATC Ip001352 ID I- Breast TABLE 2 SEQUENCE {tc "SEQUENCE") SEQ ID SAGRESH CLASS. GENE CATGTGAGACTTG'I1AATTTAGATTT A'rrCTGTAGTGIT[GATATGAGTAT AAATAAGACAA1fTAAATITCTATA'ITA GAAAGTGGCTT'TACATrGAATATG

CITCAGGATATGCGTGAGAATTTGG

IM000127 CGATGTGTAATC 461 D

CCTTACTGCAGAGATGACTCGGCCAA

CGGCTNCGAGCTCCTGACCACTTCCT

CAGGTTTGG=ITFGTrAGTTICTC

ACAGCAATGGGAAGCATAATCAATA

CAACTTCCCAGAATGCGACCTGTGAC

AAGACCAATGAGCAGACTCAAGGCT

GGGCACATAAAAGCACCAAAAAAAA

AAAAAAATTCCC'1TGCAAT'n'ATrGTT 1M000 128 CATO 462 D

GCTGCTCATCACCAAAGGAAGTCAGG

ACTGGAACTCAAGCAGGTCAGGAAG

IMOOO 129 CAGGAG'I17cATGCAGAGGCCATG 463 R CATGGCAAGATGGAGACTTrGTCTAC FgI3/Fgf IM000130 CAGGGCCACTCCAAGCACCCAGCTG 464 K 4 GTGAAAGGGCAGAAATAAUfCCTGA IMOOO 131 AGGTTGTCCTCTGCCTTCT'ACATG 465 C

CATGACTATG'ITTCTFJTTAGGTATATC

TGAATAGTATGGATCTAAATGATGAA

GTITACACCATTCTACAAATGGGCA

CAGAACACAGGGCATAGATACAAAT

GGCAAGGTGAACCCAGATCTCTGTGC

ITATCTGCAATATAACAACACTAAGA

AATA'ITAGGTCTCTCTGTGGIITCCT

IM000132 TAAATrCTA 466 D

GTA'ITTCCTGTCAGAGGAAAAGAGTT

1TCAAAAAAC1T1AAAATFITfTAT-IT

GTAGCCTGGACCAGFITCATAGCAA

CCTGTCATCCATATCCTCAGATTCACT

TATGAGFITGTCTGCCCATTAAGATC

TIFTAAAATGGTTCTAACAGCTTACTT

CAT7GTTrCAITAGTAAAGGG'ITTATA TCTACACTfTGATA MTIGCTFACTCCA IM000133 TACATG 467 D LMOOl 34

CATGAGATGAAAAAGAAGCCFTIGGA

CTTGAA11TTGCUGCAAATGCGTA

CTGCAGTTGATGGAAATI'

AGGGTCCCTrCAACTTCCTCAGAGCC

AAGGCTGACT[TACTACCG'ITCCCCAA

IM000135 GATCTCATG 469 D

CATGCCTCTGOAAAGTACCTTAAACA

IM000 136 TAGAATCCGCTCGTAGTG 470 K Myb CCAGATCCCATT'AACAGATGGTrGTG IM000137 AGTCACCATG 471 K WntJ CATGACTrCTTTCAMTUCTGTGTG TCTGTCTTCCTGTG'TFrGCCTGCCCCT CTC1TTCTCTTCTAACAGCCCCCT"TGA

ACCAAGTGATGCGCTGTC'ITCGGAAA

TACCAATCCCGGACTCCCAGCCCCCT

IM000 138 CCTCCATFTCTGTCCCCAGT 472 K Braf

CATGGGAATGTAATGTA'TAATGAAT

AT-rATATAAAAGAGGCTAAATAGC1T

GGCT'ITAAMTCTCACTTGCCTACTC

AATTGAGAAGT'TTATGGATCACCAAA

IM000139 AGT 473 D CATGTCCTTA FTCTAGGAAGCCCCCT 7TITUACCCCTGCCTCTGAGAGAAAC IM000140 AG 474 D

CATGAAGACCCAAATCCATATGAATA

CACACATAAAATATM~ATITCTCTA

IM000141 TAA=TATGCCCACC 475 D GAAAGCATFrGAAATATACTGGCCTFrA IM000 142 TTAATGGCACATG 476 D

CATGTGCACACACCCCACAAATGACC

TCAGATGTCAGTGGTACTGAAACTGA

GAAACTGATGATAGAGCCAGTAAAA

ATAGTGAAAGTGCCTGTITTGAGAGT

TTATA1T'ACAATAC1TrAATATCTA

ACTACACACACATACACCTGAAAAG

GGCTCAGAATACACAGGCCTGAGAT

EM000143 GGCTCTCAAGAACCAGCCTC 477 D

GGCCTTCCACTGGTCAAAGCTGAGAC

TGCAGAAAAGGTTGATAGCCTCCCAG

GGGCAATGACACCCTTTCTGCTTGAG

CTrCCCCCCGCCCCCCTCTCAGGATGT IM000 144 AGTCATG 478 K Wntl

CATGCCAGTCCACATCTGCTTCTATG

ACAAATGCCACATCCCAACGACAAA

CTCACTCATTCTTCCTGTATCAATTrA

CGCATACACATAATAC=ITGCTCAA

GGTACATrCATATTrCCGGCAAACAG IM000 145 ACAGCTATAG 479 D

CATGTCACTCACTUGGAGAAAGAGTT

CTAATrATTTATCACGGCATFIrCAC AACTATAGAAATAAAGTTAATTTC1T Mm.605 52 TN4000146 TGGAAATAAAGTT7GAAGTrTGTAAMF

CCAGATGGGCTCAGGTTGCTGTT

CTCCTCCITAAAAGAAAAAAGGAAA

GAAAAG2FIAAACCTGCAACAGCATC

AGCAGAGCTCACCCCTCCTCACCTGC

AGCCCTGGTTGCCT'CTCTTCC'ITTCAT

IM000147 G 481 D GAAAACACTFGTITCTGGGIfTCAGGGGT TACTTAGCCfl'GGAATCAGAGTCTAC CCAGAGTCTrACCTGCTTCTACCCAA-A

GCAGGTGGAAGAAGCTGCCCAGGAC

GGGGCTCAGAGTCTACATTFGAACTC

CCTGTGCCAAGAAGTCTGGATAGAGT

ATAGTGTCTGTATATTCTAAACTTITCT

GGAACAACCCCTGCFI'ACAATACTCT

IMOOO 148 TTCCAACTCTGAGGCCATG 482 D ACCTCTGTGCCAGCTTCTCGGACATT Fgl3/Fg/ 1M000149 TAACAACTCTGGATCATG 483 K 4

CTGGCAGTAACACACTTAAACTGCTA

GCACCTrGGGAAGTGGAAATAAGATC

AGGAGCTCAA'ICAAGGTCAI'CCTCAG

CTAAACAAGACCCCCCCCAAAAAAA

AAGAAGAAGATGGCCTAGAAAGAGA

ACTCAGCAGCTGCTGATCTPACAGAT

GACTAGAGTTTGGFITACCAGCACCCA

IM000150 CATG 484 D

CATGCCTGGTCCCTGCTGAGTGCAGA

AGAGGGTGTCAGATTCCTTGGAACTG

GAGTTATATACAGTCGTGTGTCACTG

TGGGTGCTFGGGAACTGAACCTGTGTC

CTCTGCAAAAACAAGAGGTCTTGGIT

GTTGTTGTTTTGTTTGAAACAGGGTTI'

IMOOO 151 CTCTATrGTGGCCCTG 485 C

GCAGGAGCCCTTGTGCAGGCCACAAC

CTGCACAGCTGTACAAGGCCTGCCTG

ACTGCCTGAACAGATGTGTGGGATCT

TGCCCCCCTTGTGCAGGCGTACAGAT Fgl3/Fgf IMOOO 152 GCAGACTGCTCAGAGACACACATG 486 K 4

CATGGGCTAGACCTACACTGAGFTGT

IMOOO 153 GCTAAAGAAGTGAC 487 D

CATGTCCTCCACAGCTGAGCACCCTC

AACTGTCTCCCAGGGCCTCTGTFTCTA

TCCAGGGTCTGCAGGGTCTCTGCCCC

ACGCCTAGCCCCTGAGAAATCTTAAG

CAGTCTGAAAACTACGCCACTGAACT

GCTAAAACCCTGGAGTCACTGATGGA FgJ3/Fgf 1M000 154 A 488 K 4 IM000155 TAG'I'GCTAGACTCTGCC'1ITCACCITG

GCATAGATTCACCTTCCAGATAT

U

CCAGGGCACTTGCAAAGAAGCCAGG

CATCATCAGGGGTITrGGACTrCCAGC CAGAGTCTGAG1TGTCACTTGAATGT

GCTGCATTTGTTGGATTCAGCCCCA

GTCTCCCGACTCTITTGTGAG MTAGG

ATAATAATCACAACAGCACCCCTTCT

TATTTGATGGCTAATAAGCTCTAGGC

CAGTGTCTTIAGCTCCATTCATG

CATGTA'1TCTGAGAGTAGAATITATA

CCCAGAGAATACCTAAGAAGTGAAC

TGACGCCGGGCGTGGTGGCGCACGCC

M[AATCCCAGCAGTTGGGAGGCAGA

GGCAGGTGAATTITCTGAGThrGAGGC

CAGCCTGGTCTACAAAGTGAGTTCCA

IM000156 GGACAGCCAGG 490 D

GCCTGGTGTGGTAGCTCACACCTTTA

ATCCCAGCACTCATCTCTGTGATTTG

CTAGGCCAGCCTGGTATACACAGTGA FgJ3/Fgf IM000157 GTFACAGATCAGCCATG 491 K 4

CGACATCCAACTTCTGGAAGGAGAG

ATGGGAAGGGGCATTTGGGGTGCTA

GGAAGGGATGGGAGGTGTCCCTAGA

IM000 158 GCAGTGCTCATG 492 K Wnt3

CATGAAATAATGCCTITCAGAACTGCA

TTAGAAATCACAAATAGCCCTGAATG

CCCTCTAGATGCTTCTTGAGAACA

ATTATGTGTTAAAGTCCTAAGGCCCT

TGTCAGCCGACCATATGGAAAGGGA

IM000159 GAACTAAGTGAAATGGGAGTF 493 D

ACTGACAAGAATAGAGAGAAGTTCA

IM000 160 GTCATG 494 D

GTGTCCTGCTCCTGTCTGGGTCAAGG

TCATAAAAGATGAGCCAAGGCTGACT

TCAGTGCCCACCTGGGGAGACTGATG

TC7ITCACAGGAATGCTCACCTGGAAG

GTGTCCTCTGGGTGCATCTGTGTCAC

ATTrCGGTATAGAAGGAAGAATGCCA ACAATACTCTAAAAATATfAGAGGCC FfGAGAGTCCTCAGTGGTAT'TCCACC

AACATCAAAGCTGCATCGTAATATGC

CAGCCTGGTCCTCACCTTTCCTGCGCT

TCCCAGGAAAACATCAGCCTTTAACC

IM000161 TCAGCCCATAGGGGAGATG 495 D

AGGATCTITATAAAAATAACAGTGACC

CAAAACATAATTIIGCCATCAAGAA

TCTCAAAATCAAGTCTCATCGAAGTC

TACTCTTCTI'ATFGTATCTrAAACAC

ACACACACGCACACATCACACAAGC

ACACACACAAGAATTCACACACATAC

1M00062 49 Wnt IM000162 496 Wntl CATGGTA7TCTGATGA'TAGTACCAAC

ATACTGCTGCAGCTAGCTGTATCTGG

AAATCCCAACCTCAGCCAAGTATI[G

TGGITTGAAATAACCTATACTTCTCAC

IM000 163 ATCAAACAC 497 D ACTGTGACCTGAGCACTFCThTGTCFI'

ATCAATAGCTCACGTGCCCAGGCCGG

GTGACCAGTCTCTAGGATGYFCTCCA Fgl3/Fgf 1M00I14 TG 498 K 4

CATGCACACAAACTGGCCCTGAACTT

TrGACTFCCAGGCCICTGCCTfCTCTGC

GCGCACACACACACTCGCACTCCTGT

ATATGAAGCGTATATGTGYITCTGTG

GGAACTGTITTTATCAGGTGAAGCAC

TITCCTTTGTITCTYIGCTACCCACCTCCA

GGGCTCCAGGATCTCCAGACAGCCAA

GCCTAAGACAGGCCCAGCTTCCTCTG

TATCTCTGTGATGAGAACCTJ'GGCAT

AGAGCTGCCCTCACCCTCGGGATAGG

GCTYITTCCCCGGAACGAGCCAGG

CACCTCAACAGCTCCTGGGGAGGAAT Fg/3/Fg/ IM000 165 AGGGGACT 499 K 4

CATGGCACTATGAAGGAAATGAAGA

TACAAAAGArI-FCCCATACAAAGGGT IM000166 CAACTGTITCAATTJ'GGCAIIFTAYI 500 D

CATGATAGAAGACCACGTCI'GGGATG

GGGTAAGGGTTTCTCAGAGTACCTTG

CCCTGGGGCCACATCCTAAATCTACA

IM000 167 ACAAAGCT 501 D

CATGCAAAAGAATTCCAAATGAITI

ACAGATCTTAGCCCTCTAAGAGATAG

ATATAGCACAAGTCCTGACTCCTGAG

GTAGGTACACACTGACTTCCT'TCCAC

AAGCAcTrGCCTCAGCCCGGAGATGA

AGGTCACATCAATAGAGACAAGTCA

GGTTAACCGTGAGCAACCTCAAGACA

AGGAGGAGCACAGCATAGGTCGGTG

GAAGTGTITGCATAAGCCTAAGGCCT

GGGCCCAGTCACCAGCA'GCAGAG

GAAAAGGAAAAACAGATAGTAGGTG

IM000168 CCTTGGTGTGT 502 C CATGCAGTITACCAATCTF['rCCACT CTrrAAAAAGACAAAAAATATTAGA

ATACTGGGCTGAGGAATGGCTCATCA

G'1TAAGAGCGCTGCTCTTTTGAAGGA CTCCCGTrCTIGIf[CCAAATGCCCACCT IM000169 GGAGGCTATCCTGTAGcTrAGAGGT 503 D AGGAAGTGCTGAATFAGAGAGGTnTG

GGGAGAGCCCAACAATCTGACCTATT

TATACCCTGCCAGGCCCTGCCCATG IM000170 Sl OOa4

CATGGTGCTGGAGGATCATCCATCCT

IM000 171 GACATTCTGGGA 505 R C2ITTAACCCA1TITATGGTGTGACCAG AAACCACAGATCTFTACCTAGGC1TCA

GAGACATGACCCGAGGAAAGCTCCAT

IM000 172 TAAAATCCTCATCATG 506 D

CATGTAYFCATAAGTGGATAITAGCA

IM000173 AGAAAGTACAGGCTAAT 507 D

CCTCTGGAAGTCAAGTGCAGCMTGC

TTATTTG1TTAAGCCATCCACCATCCA

GTTATTAGATCTGAATTCATCTTAG

GGTCAGCTTTGTTGTAGATTTAGGAT

GTGGCCCCAGGGCAAGGTACTCTGAG

AAACCCTrACCCCATCCCAGACGTGG IM000174 TCTTCTATCATG 508 D GII ITCM1C II1TI IIIIIrAAAAGAA

ACAGTCTCAAGTAGCCCAGGCAGTCG

CTAAACTTATTATATAGCCCAGGACA

GTCTITGAATTfCCTGAAGGTCCCTCCTC

TACCTCGTAGTCCTGAGACCGA'ITGC

IMOOO 175 ATG 509 D

AGAGACCCAGAAATACCAAGGTGAT

TTCCAACTGCCTGACCTGGGAGGCAA

IMOOOI 76 GCATG 510 D CATGTAAGATGTTCAC=1JCCAGTGT

CTG=FGTGCTGCCTTCAAACTGTTGA

CCTGATGTAAAAATGTTTGCATCAGC

TCAGGTGTATAGAATTGGACTGATITC

CAGGAGAGTCAAATATAGAGAATAT

IM000177 CTAGTGTCCAAGAT 511 D CATGCTAATGGAGTTTAT-rCTTrAGGA CTGCCTCCTGCATCCATITGATTGACTr IM000 178 AAATATGTGCACACT 512 D

ACTAGGTGACTGTCTCAGGGTCTCAC

TGTGTAGTCCTGGCCTAGAACTCTCT

ATGGAGACGAGGCAGAGCTCACACTC

AGATCCAGATGCCTCAGCCTCCTAAG

TGCTGGGATTrAAAGGCCAGTCCCAGC ATACCCTGCCCCTGTrCTGACArITG

AACCCCTCCTTTAGACAGTAGGGAAA

CTGAGGCCTGAGATATGAGAC=IJ

IM000179 AGGGGCATG 513 R-

AAACTTCAGAAAGCGGGGGGTACCA

AGGAGACTCAAT7IAAGATCTCTCCTC

GATCTTGAAACCATCCCCAGCCCTTC

GCAAAGCACAITTfGACGGACAGGGTT

CTCTTGTCTTGGGCAACACATCCCGG

CTACGCTCTGCAGGGTGAAGCTGTTA

AGAACGTTCCATG imoool 80 54514

GATAAGCCTCTACAAAGCTGGAGAG

GGCAGTCCAAAGAAAC'ITGAAAAGA

TFTAAAAGACAGTGCCTAAGGACACA

AACGTTICCATAAAGAGCCTATGA

CATFATITI'-ACTGCTGCTAATGAAACT

GACC'rrGAAGGAACAAGTGTTTAGGG

TTAGCCTAAAC'TFGGAAT'GGTGAA

GGCAATGTGTCAGCTAGACAAATTFAG

AGAAAGAACTCAACAGATGAGTCAA

TGAATT'TCTAAACTAGCTTGACYF

AGGATTITrCAGCACAGGAACAAAAG CACATACTGTCCCTCTGGTrTGGCATG IM000181

CATGGAAAATGATAAAAACCACAGT

CTAGAACATATrAGAGGAGTGAGFFA CCCTGAAGAACACAHrCGYIGGAAAC IMOQO 182 GGATATTGTGTAA 516 R CATGCCCGGCTCTArJ'ACTATTrC'T C'F1TCTIr=GTTTCAGGATCCAGIT

TCC'FIGATAAATITTCTI'GAATGTFG

T&L'TGT1TTC=IGCTGAITrT CTTCAATACTGCTGCTT1TTCTCTCCA IMOOG 183 GGFFCAGGA'IGAGA 517 D CATGCTGTCACTAAGcTrGTGCTCUTC CAAGGAGATGAAGAGACTAGcTrGGT

ACCCTTGCTATGCCAGGCTITTFCTT

IMOOO 184 GTTrATACACACCTAATG 518 D

CATGATCTAATCTGAAC'YI'GTATCCC

AACCCTTTATAAACAAGTGAATGrG'r

AATCTAAACTAGTATAAGCTCU'GAA

TAATAGCTGAGTGAATTGCCT1rTGAT IM000 185 ACACGTMFCCAAATTAGTAGCC 519 D

GTCAACCACAGCAGTACTGTITACTFI'

CTGTGGGGGAGACGTCTCCCCTCCTC

IM000186 ATG 520 D

GGCAGTGAGCTTGCCCACTCTGCTACAGGACC

TCGGTGACCCACTATATACAGCCCTCTTCACT

ACGGCTCACAATCGGAGT17AAGACCCAGTG

AAGTAAACCCAGCAGGACCCTTI'ACAAAGCG

IM000 187 AGGACATO 521 D

CIUGTCCAAACCAGCTTAGTCAACAG

CCTCCTATGTGGGCTCCATCTTACCCT

CCTCATCTAGCTGATGAATGTACCTG

CCTCTGTTCCCI-FCCTCCITGGTCTGA

GCTGAGCCFFCTTJGGGACTGAGAGCC

'1TCATCCACCACAGGCAGACTATCYT

TAGATCATCATAGCCCCAGGTC'ITCA

TTGCAGTGCAAAAGTGCAGACVFITAC

AM11CCATITTATGCTCCCTflTGTAA

CGGCTCCTTACCGGACTGCAGCATAA

GTGGCTGAGTATCCAATCACAATAGA

IM000188

ACACTTAGTITGTTTGC'TTGTCTAACTC

TCTCAGTTACACCATTGAGTATGTTA

CACAGGGCTGCTTrGTAGCTGTCACT

GAGGCGACAAGGCAAGGGGACTAAG

GCAGGACTCAGATGAGCCTGT1TIA CT1TCCCGTTGTCCC M CACTTTGGGT

TGAGCATG

ATATAGACTCAATCAAGGTATTATFC

TGGAACAAACAACTAGTAACAAAAA

TAGTGCAATTGCAAGTATGATAACAC

AAGGCAGCCTITACCAGGTL'TGTCGG

AAGGAAATTGTTCTTTGAAATCTGAA

TTCCAGAGAAAAAGTCAAATGTAAA

IMOOI 189 CTAGAAGTG17IGCATG 523 D

CATGTATGTGCGTGTGTGAGTGCATC

AACACAAGTGGATAGATGCGTGTGTG

T-fTGTGTGTCTGACTGTTFAAGTAGGT GGCATCTGTCCTAGTCCTGACTTTrrG ATAAGTCTACACGnrrGATAAGAGGA

TCTCTCTCACCACTCAGGYTCCTCCCC

CCACCTCCACCCCAGTACACAGCCAT

GCCCCTCTGATCCCATTTTAGGGACA

TAACACCCGCTCCCAGACTGAGCTA

ATGCGTITGGACGCTCCAAAACTGATC

TGAACCCTCTCTGACCCTGCCCTCCTC BF 1638 IM000190 CCAGGACAGGGCAA 524 B CATGA=]ECAGTITICFGCCATATr CCACGTCCTACAGTGGACATMfCTAA AT=TCCACCTfl=CAGTTICGTCG IM000191 CCATATflTCACGTGCTAAAGTG 525 R

AAGTATGTCTGCTATGAGTCAAAAGT

IM000192 CTTATITTGCATCACATG 526 D

CATGCCGCAGTGGCCAGCAGCCCTGG

TrCCAGGATTCTCAGAGATAACAAGG

AGCCAGTGACCCTTCTTCAAGCACC

AAAGAAAAGGTAACCGACCCCACAA

AGACCTGAGTATGAATGG'TrFCTGCA GCTAAGGCACTFTCCTMfGAGGTCAGC

GCAGTTCGGGGCTGAGAAAAGAGCT

TGCCCTGGCTTAGAGCC1TTCTCTGG

CTCACTGTCCCAGCCAGGACCCATCC

ATCAGCCCACAGTGGGGTGGCATAGT

GCAATCCTAGAGAGATGTrCAAAGG FgI3/g 1M000193 GACATATC 527 K 4

AYTCTCTGGGTTFCCTGTGGTGCTCT

GGACCCCTCTCGGTCCTACAATCCTF

CCTCCCCATCTTCCAGTGCTCTGCCTA

GTATITIGGCTGTGAOTCTCTGCATCT

GT'CCATG IM0001 94

CATGCCCCTCTCGACCCTGGGAGCAT

TCACCATCTTATAAACTGA'ITCTTFTC

IM000 195 TGGGAAGATGATG 529 D CATGAAACACAC'ITTTAACT1TCCAC ATACThITAAAAGTGTACCTTCCCAT

T-FICGCCCCTAGACCCAAATTGGA

TGTTTCTGGCTCCCTCTCGTI'CGTAGC

TTTCCTGTGATGTAGAAACGCIT-AG

IM000 196 AAACCACACC 530 D

GTTTCCCACGGTGGAAGAGGCAAAC

AAGATCCCTTGGGCCTGCcTrCTTGT IM000 197 GGCACTAATCTTACTCATG 531 D

ATGTGGTGTTI'AAATGAGAATGTGGC

CCATAGGCTCATATGTTGAATACNTA

TJrTrcCAGTACTTGGAAGTAMTGGG

GAGGACTAGAGGTGTGACYITITGAA

GGGGGTGTAFITATIGTGGATGTACTAA

[M000 198 GAACCTTTAAATCCCTCTGACCATG 532 D 1M000 199 GCATCATAGTTGTACCATG 533 D CATGGGTTAACAGTG GGCCCTAAACT IM000200 TGAACTAGAAAACTTrAAAGATG 534 K WntJ CAAGTCTGTCTGTCTCC7ITACTAGCCT

=FIGCTGTTCTGACTCTCAAATGGTTC

CTrAATTGGCCATITrGTCCCCTAAAT

AGGGGCGATITAGGATCAACACTCAA

GCAATGTTCCAGATGGGGTCTIGACGT

TCCTCACTGGGGTCCCAGGGCTCCTC

TGACTTrGGTCACAGAAAGGTCAGCCC

TCTGACCTGGGATAGATGTCTGGATG

ACCTCTGACCTCAGCTCATAAACCTG

ACTGTGGAGATTGAGACTGGAGGGA

CTCAGGGCAGTGGCTCAcLrGGACAGT

GCCAGGGTGTGCAGTGGTAGGCAGA

CTTCTATGTCAGGTGCTCCTGTGCCTC Fgt'3/Fgf IM000201 CATG 535 K 4

GCACATATCTGAGCATCTCAAGAAGC

TGAAGCAGCAGAATCATCCGCTCGAA

GCAAGTGTAAGCCAATAAGAAGACT

CTGTCTCAGAAGAAACTGAAACGAA

GAGAGACAAAAACAACTITrCTIGGGGC

TGAAGAGATGGCTCAGCAATTAAAA

GCCCAITCTGCTCACTCAGAGGCCCT

CTGTGAGCTGTCTCCAGATG'ITTAAC

IM000202 AAGCACAGCTAACA7FJTGGCATG 536 R

CACATTCATTAAAGAGACTTTATTAA

AGCTCAAAGCACATATTGCACCTCAC

ACAATAATFJGTGGGAGACTTCAACAC

ACCACTTI7CATCAATGGACAGATCAT G IM000203

GGGGAGAGGCTTCAATGAGCCCCCTC

ACATTTFGCA1TIAAATAGCAGCATCA

AGCGCTTCGCGTGCCACACACCAGTG

GGCTCCCAGATGTCAAGCCGGAGTCA

GTCAGATGGCCAGTGCCCAGCTGTCC

TCCCTATGTCGTGCGGGAGCAGGCAG

TGACCTTAAAGAGAGAGCGCTCACG

CTCCTGGAGCCCGACTCTGGGTCCCT

IM000204 CATG 538 D CTfGTCCGCCACCCCGCCTGCCTCATT

ACCTGGCTCACTCAGTAACGTGAAAG

CCTTrACAGAAATCTCCAGGTCCTCAG

GGGGAAAGGAAGTCATCTTCTTCCTC

ATCCTCGGAGGACAGAAGTCGGATG

GTAAGCATCTGTGCTGTGCTCCTCTA

ACTGTGACGCCGGGTTCCCATGACAT

IM000205 G 539 K Braf

ATATAGTATGACTGCCTCAAAACAAA

ACAACAACAAGAAAACCCCAAGATA

TCTAAAGGAGGAACMTCCAAAAGA

CAGAAATG TCCATAGACCrrGACAAA IM000206 GGAACATG 540 C GTCAAGTGGATGTTTCTCATFTrCAAT GATTITrGAGTIrTTTGACATATrCA

CGTCCTACAGTGGACATFCTAAATA

TTCCACATII IICAGTITCCTCGCCA TATTTCACGTCCTAAAGTGTGTA1TrC TCAFITCCGTGATI=CAG=r~CTC GCCATATrTCCAGGTCCTTrAGTGTGG AM~CGCAT-TTCACGTTr'AGTG ATFI7GTCATTM~CAAGnTGTCAAGT IM000207 GGATGTTTCTCATFJTI ICCATG 541 R CATGAAGrAGAATAATFGGGATAAA

GCTIIATCATTATCAATI'GGT-=GA

AATTrATTGTATrGATATCTTGTAAACT GAATATTTfATTGGTACATAAGTCTGG 'ITATGG'TTGACTACTTn'AAGTT-AAG AG1TIGAT-rCTTCCAGGTAAATGGG IM000208 TGTTfGTAATG 542 R

CATGCAGCCGGGGTGGGATTI'GAAG

AT-TATGCCTAGTGAATATTTAATAT

AAACACGGTGTGATCGAA'ITGATAGC

IM000209 ITG'1TGAAAACTAGAGCGAAACC 543 D

GGACAGGGTCTCTCTCTCTTGU-GTTC

AT-rGMIICATATATCATCGTCGGCCTG

CTITACAGACTGCATTGTGTTCCCCTGT

CTCTGCCTCCCATCTCACTGTAGAAG

TAATGGGATTACAGATAGATGCTACT

GTGTCTGAAAG'ITAAATTrCCTAGGCC

CCATG

IM00021 0

AGTGGGAGGGAGCGCCACTCTTGGA

GCTAGGCAGGAACTGTIGTTACTTCA

AAAACTAACAAGACAATCTCACATTC

CTGAGC'TGAAGACCAGATGCAGCCA

GGGACAGGGTTCTGCCCTGGCCACTA

GATGGGCTGCIGGCGCTGCTAAAGC

ACTGCACAAAACTGGACGAGGTGCA

CCAAGAGTCCCGTGTI17GGCCCTCAG

GGCAGACTAGAGAGCAGGACJTITCTC

CTGGGAGCAGAAACTGAGCCTGGGG Fgf3/Fg/ IM000211 TCTTCATG 545 K 4 CATGCTCATAA'rrCTGCAGTrGCCT7CT

CATAACACAGGATAAAACACTCTAAC

C1T-AACATTATAC1'TGAAAACT'TAT

GTGGTFTITCCTACCAGAGTCATATC

AAACCAGTCTCCCTCTCCACTCACAA

IM000212 GGATCCAGTCACAATGGCCTITITA 546 D

CTGTAGGACCTGGAATATGGTGAGAA

AACTGAAAATCACGGAAAATGAGAA

ATACACAC3TITAGGACGTGAAATATG

GCGAGGAAAACTGAAAAAAGTGGAA

AATATAGAAATGY7CACTGTAGGACA IM000213 TG 547 R CATGGCGAGATTrCTGTGTCCAAGCTG

CCTCTACTCGTGACAT-TCCAAGATGC

CI'CTGAGGTGGGAACTGTGAAATAGG

IM000214 -ACAGAGCCCCACAGTCCCCTCTT 548 K Wnt3

CATGGGGGGGGGTACCAAGAAGGGA

CTGCTGTGA'ITGGGATGTAAATAAAT

AAATAAATAGAATAAACAAAACCCA

AAAACAAACAGAAACCTAAACTCAA

TAACTGCAGAAATGACTCTTGCTCTT

TTCTGGTAAGGTFTAGAAGCAGGTTAC

AAATCTATATrAGAGATGGAGGCATT

TCACACCAGCATAGGTATAGGAAGTA

GATGAAATGAGGACTACACTAGAGT

CTGThITGTCACAACCAATTCTGAGTG IM0002 15 ATTTrCACTGAGATAT 549 D

CTCTGAGAAACCTACCCCATTCTCCC

TCCTrTCTCCCATAAGCAACCACCTC

CACAGCATTATCAAAAGACTGCTGAC

AGATTGGTGGCTCAGCAGGGAGAGT

CAGAGCTGTTTC11TAGGTCTAAGTTfG

TAGCTCCACAGTAGTATG'TTCTCCAT

IM000216 G 550 D CATGGAACACTCAAAGcTrGGCCAGG GCCCA1TTACCAGGTATCCTTTGCCTT CTCAGCTGATGGGCATCAACACATrA

A'TCACATATGACTCGMJGTGTCAT

ATCAATAGTAT IM000217

U

GTGGT1TITGTGGTAGAGAGACACAG

AAGAAACTGAAGTCCTTGGAACATA

ATTATCACTGTGG1TGAATGTFITGTGT

TCCTATAACATCCTATGTAGGAACTG

AACCTATAAAAGTAGTGGCTCCGAAG

GTGGTGTCCTFAAATGTGAACTGGGC

TACAAGA1TTGGCCCTTGTGAATGGC

TT'TATGGAAGAGGCTGTCACTIT

GTCTCTTCCTCCATTATCT-rGGAAGAC ACAACAGTfCAAGGTCTCATCTGGGA

AACAGAGACCTT'TACCAGACCCTAAA

TCTGCCAGTGGTGTCTTGATCCTGGT

CTTTCTGTCCITAGGAGCTATAATGC

ATG IM000218 552

GGCCACAGCCAGTCCACCTGTATGCA

GCTGGGTGCTTGGAGTGGCCCTGGTA Fg/3/Fgf IM000219 GACAAAGTCTCCATGTITGCCATG 553 K 4

CCTTAGGGCGCAAAATCCTFTCCTCCC

ATTC'ITCCATAAGAGTCCCCAATCTC

CATCCACTGFI7CACCTGTGGGTGTGT

GTATCTGTCTAAGTCAGCTGCTAGGT

IM000220 GGAGATGCTCAAAGGAGAACATG 554 R

GACAGTAAAGAAGACAAAGAAGTGA

GTAGAGCTGGATGAAAACTAGGAAG

TTrCAGACAAAGACTGCGGGAATGAN

GTGTAGAGTCTAGAGCCCAAACAGTT

IM000221 AAACATG 555 D CTGCTACATFTCTrAGCTCTAGCTAACT

AGCATCAATGTCCCAACCCF-CTA

TGTATGACTCCAAAGCCAGTGTCACA

IM000222 TG 556 R

CATGGTCTCTAGAGCTAAGAGATACC

AATGCTGCGGCAGGCAGTTYITTA

CAATCATITACAGT1TGACAGTGTCT

GGCCGTGTGCCAAGGCTGGCCTTCAT

CCCTGAGCTCGGTGATGCTTCTGTCC

TGGTCTTCTGGCTCGTCACAGCTTAA

IM000223 GAAAGTAGCTGCTTCTC 557 D

GATGGAAAATGATAAAAACCAGACT

GTAGAACATATTAGATGAGTGAGTTrA

GACTGAAAAACACATTCGTTGGAAAG

GGGATTTGTGTATATCAATGAGTAGT

IM000224 TA 1558 R

CATGGAAAGATAATGTGTAAATTTGG

GT[GCCGTGGAAAACTITFGGTTTCT

CCATCAATGGTAATTGAGAGTITGGC

TGGGTATAGTAGCCTGGGCTGGCAIT

TFTGflCTC'ITAAGGTCTGTATGAAGT CTGTCCAGGATC'FrCTGACTCTCATA

ATGTCTGGTGTAAAGTCTGGTGTAAT

IM000225

TCTGACAGGCCTGCCTTTATATG-A

CTTGACC'FrUITCCCTTACTGCTTTTA

ATATTCTA

GGTAAGAGTGGGAGAAAATGGGGGT

GGGGGGTGGGGACACTGCAGAA&JCC

TGGGAGAAAAAATCCAACTAJA

1M4000226

TCAGGAAACACATG

CACCCCCATCCCGCAGTTCCCAGAGG

1M000227 GAACAGTCCCAGCAAAAATACATG

CATGGAGATGCAATGAAAGCACACA

ATFATFGCTGAACCAAACAGAJ4AGCTC

AAAACTAGGCACAGAAAAGAGATAC

AAACACAAATCTGAACAAAy]TGACCT

TCTGCCTATAGCATAACTAATATCTC

AGAGATAAAAGTGGTCThPATATACC

AGGGCGAAAGAGGTCTAAAAAGAGA

GGAATAAAAAATATGGCATAMflCCT

GTCATATGCAGAACCTATATGAGT'CT

TITGTTTMGTTTCITrrCAAITACAGCCT

ATGTAGCTCTAGCTGTCCTAGAACT

ACTITrjGTAGACCAGGCT IM000228 CTGTTCTACAATGCCGG'I11CCAACG

TATGTGTFITI'CAGTGTAACTCACTCA

TCTAATATGTCTACAGTGTGGTy= 1M000229 ATCATTITfCCATG 563 R

GACAGGCTCCAATCAGATATACCAAG

GGCAGGAAGCACGTGACAAAATCAG

ATGCCTGGAGACAAGTGTAATAAAA~

GAAGCAACAGAAAACAAGGTTAC'IT

GGCATTGTCACAACCCAACTCTCCCA

CCATAGCAAGTGATGGATACACCATC

ACACCAGAAAAGCAAGATATGGATC

IM000230 TAAAGTCACTTCTCATG 564 R

CATGGGTCCCTGAAGGGTCTCTCCT-

TAGCAAACCCCTGTACAGTrGAAGTG ANTTFCAGGTACCCATTrGGTCTTAG IM000231 c 565 D

CCCCACTCCTCACAGGGCTCCCCACA

TCTGCCCTGGGACACCCCACTrcCTCA

CAGGGCTCCCCACAI'CTGCCCTGGCA

CCCCTCCAI1TrCAGGCACCTGAAG~ TCCCTACTFFTCTAAAGGCCA~j'CyrCT ACCTCAGGTCTTGCTCTAGGACTGTC FgJ3/Fgf IM000232 AACATG 566 K 4

CAGGACAGCCAGGGCTACACAGAGA

AACCCTGTCTCAAAAAACAAACAAA

CAAAAAAAAGACCATTATGCATTCCT

1M000233 GCGGCTCTGACATG 567 R IM000234 1M00234CATGGGCAGCACCTCGTGGAACACTA

U

TITATAAGTGTCCTCCAGTCAGGTCAA

_______CAGCGTAAGAT

CCTGTACA'TCTGTGflAAGGACAGA FgI/Fg/r IM000235 GGGCCTGCTGCATG 569 K 4 CATGGA GGCGCAGGAGTTATTGTCTA

AAGTTGTGAAGATGAAGCCTAGATTG

IM000236 TATTGGAGATCCGGGTAT 570 D GCAGATATTrCCACCTCTGCCTTCCA IM000237 CAGTCCTTCGTCCCATG 571 C CATACGCTTACAATGTGTTGTTATTrrC

TGG'ITCTCGTCTGCCTTCMTATAAAA

ACAAATCCAGTAAGGTGGAGTAGGC

AGCCTITACTCAGGGACTGTCACCAT

IM000238 G 572 D TITCTGTATATATrGTGTGGTCAGAAA ACCGTGGTITCCTGGTGTCAAiAcjT TAACAC M CAGTAATCACTCATrCT

AAACCAGACAAACCTTTAATGTTTCA

TCTGGAAAGGTACTCATrCAAACCAA TGCTCTCTfAAAACCAGAc3TAM~AA ACAGCCAACTGCATGTUTCAGGcrITrG ATAGAAAATCAGCTrGATCTAAAATA GTCACTGAA2ITCTGATATCATAGACA IM000239 TG 573 D

TCCACCCACCCACCCACCTGCCCACC

CAGACAAATGTTGACTGAGCATTCAT

ATACTCCATTCACTTCTAAGTAGAGA

GCCTAAGAATATGAGAAAATCCTCAT

AGCAAAGAAATGCCTCT-ciCAACTCci

AGTAAAAACTCGAGTATGGGATGGA

AGAGTTGAGAAAACAGATGATAGTA

IN4000240 TGAGAGCCTATG. 574 D

AGGAGCCTAGCAGAATTGCCCTCTGA

GAAGCTCCACCCAGCAGAAACAAAT

GCAGAGACCGATCGATAAACACTGG

ACAGAGCACAGAGTCTTGTGGAAGA

GTTGGGGGAAGAATTGAGGAACCCA

AATGGGATAGGGACTCCACAAGAAG

IM000241 AAAAAGAGAGTCAACTAACATG 575 R-

CATGTCCTACAGTGGATATIMCTAAA

TI=CCTCC ITIIIICAG1TrCGTCGC

CATATITTGAAGTCCNAAAGTGTGTAT

TrTCTCATAT-rCTciTGATTTCAG=m

CTCGCCATAT'TCCAGGTCCTACAGTG

IM000242 TG 576 R

CATGTGGAGGCCAGAAGTCAACATAT

AGTCTCCTTCCCAATTACTI-GTCACTG

GAGAGC

IM000243 G~rCAGTAGCCAGCAGGGGGGATAG

GACCAGCCCAAATTCTCCCTTTGCTT

GGCCTTGACTACTAGTCTGGGAAGGG

ATAAGTGGGCTAACCAGAAGTCTrCC

ACATCTCTAAGTGATTAAAAATGGAA

GACGTGATCTCTGGTCMTTCATAAAC

AGGCN1TI'CTCAAAGTTGGTCTGTGC AGT-fTGTGGGAAAAAATGAAATGTAC IM000244 TICATG 558 D

CTACAGAGTGAGGTCAAGCTCGAGG

ATAGCCAGGCAGGGATGCACAGGGA

AACCCTGTCTCAAAAATCAAAACCAA

CCCAACAAACAAAAACAAAAATGGA

IM000245 AGGATAGAAGAGAGATAATCCATG 579 D

CATGTACTGAATCCCTGAAGTTGATG

CTGAGCACCATCTTrGTGCTGnTCTAC IM000246 CGCAMhACTGGGG 580' D

CATGTGTCACTCAAAGGCTGCTGAGA

ATCAGGCTGTACCTGTATTCCTAAGC

CATCCACAGCCATCCTGACCCACAGC

AAATGCTGGCAGT1CGCCCCACAGCTG

GACTCCG'TCCTCCCTCCACTCCTATA

GCCGAGGCTATCCACACAGGCTATTT

CAGTGCCCTFAAGCCTTGCTACCCTTA

IM000247 TGTATACATTGAGGACAATGAT 581 D

AGAAACCACTGCCAAATCAATACATT

YI'AATTGGAAGTG'T'ATGAAGCCCA

GGAGAGATCCCTAAATGTATTAATTG

CYI7CCTGAGGAAATATAAAACTCACA IM000248 G'TACTAAAGCCATG 582 C ATC'31CTACACAGATGAAACTGACAA

AGTACAAATAAAGATTATATACCAAA

ATGAAAAAAAGTAAACAGCACACAT

TrATAGATGCATCTAGCATCCCCCAA

AGCTCAACACCATCCATAC'ITGAAGA

CTGCAGTGGTCCCTCTAGACAGTATG

CTCCAGGTCAGCCCTCAGCACJ'rGAG AATAAACAGC'ITCATIMACTCAGCCT FgJ3/Fgf IM000249 GTrGTCAGGATCCATG 583 K 4

ACTGCCTCAAAACAAAACAACAACA

ACAAAACCCCAAGATATCTAAAGGA

GGAACATTCCAAAAGACAGAAATGT

IM000250 CCATG 584 C

CATGAGCTGTCGATAGTGACCTGCAGT'CAAGG

AAATCTGAGGGCTTCCTAATTAACAGAGGAG

CTCTAAATGAGAGTAACGCGCTCCACAAACCC

CCTCACACTCGGTAAG'FGTCACGGTGCAGATA

1M000251 IAT 585 C IM000252

SGCCGCG'IA'IGTGTTCTITCA:FAGAAGAAT

TAGCACATAATGGAATGTGCGTATCTGAAGITG

CACAACTGAGGAGTAITrATrAI'TACATACCT

'TACAAGATATCTI=CTGAGGGAGCAACCTG

AAAACATAAGGAGAAAAACATAAGAACTGCC

ACTCTAAGGGTTGGTGAAATGGCACAGCCTG

GCGGTAGGACACACAGATG

CATGGAGAAACCTGGGCTrATTCAAGCAGMT CCTrGITrACCCTGCCCAGGGTrGCCAGTGA AGGGGCTCCTCCATCACTAACTAAAGGTCTrA 1M000253 TCGTATGCTGGTTCCTCTCCACCCCACCAT 587 D TATAGGAATAGAAATCAGAACTATCAGTTr G=nGC'rCAAATGTCAACACATAAM~AAA IM000254 MIACAAACGCCTrGCACAMTGCATG 588 C

GAAGACAAAAGATGTGTCAAATACCTOGGCA

AAAGGGGGTGGTGGTGCTCTCGCAACTCC

TGAAAGACACCTCTGCTCAGCACACTAGM~C

CAGGTTCCTGGGTTAGGA1TGGGTGAGATTG GTCGGCGATGGMTGGTrCCTCCATTCTGCTG C1rCTCCCTFGATACATTGAGTTACAGCAGCCC IM000255 ACGCGTACACACTCTCGCACATG 589 K Wntl

GAAGAGGAAATAAGOCAATAGCTAGACTGGA

AAAACGAGCCAGCCTAAGAAGCTGCAGAGTA

GTCTGTGGGGTTCTG='~GG1TAGCTGCCTI IM000256 AGTGCTCATG 590 D CATGGATAGAGGATGGAAGTrfGAAA~

ACCTGCTATITAAGAACATAGCCCTGT

IM000257 CCATTAGTGAGAGTG 591 D CATGTGGCCCAGGGGCACTrGGAGCCTrAGAT AGCTGCc=rATGGCTCCTGGTGGCCTTGGAT

GTGGGTGGGTGACAGGAAACAGGAAGAGCTG

GATAGTGGGGGTCCCGAGGAGGAGCTAGCT

GTGCTCTCTATGCAC11TGCTCTCCTGGGGCTA

CCCCCGTCTCAGGGGAAGGCCTGTGACTGGCT

AAGCAACAAGTGTGGGCTGAGACCTI-CTCTG

TGACACTCTGGTGCTACTCTGGCCATAGCACA Fg/3/Fgf IM000258 GATCTCTAGGAACGCACTCT 592 K 4 TATATGGATATGT17ATGTGAGGGTAGGCACT CCTGGAGGGTGGAGGCATTAAYrAGATCCTCT IM000259 GCAGGTGAGCCACCTGACATG 593 D

ATATGTGGACTGTAGTCATCTTGAACATCTGT

AACAAAATATATAGAT-rAGGAGG'LMAGACA IN4000260 IGCAGACATG 594 D

GTGCCTCTTGTCTGCCAAGCTGGTAT-GTAGC

1M000261 1TG 595 D A'ITrGTGACATCT-TAGGAGC'ITAGGTTGGTCT

TCGAGACACAGGGCTGTCCCCTGTAAAGCAG

GTTCCATCAGTGACTCCAGGGTI=AGCAGTT

CAGTGGCGTAGTMCAGACTGCrA.AGATy-

CTCAGGGGCTAGGCGTGGGGCAGAGACCCTG

CAGACCCTGGCTAGAACAGAGGCCCTGGGAG

IM000262 Fgf3/Fgf 4 206

ACAGTT'GAGGGTGCTCAGCITGTGGAGGACAT

G

CATGACGACTTGAAAAATGACGAAATCACTA

IM000263 AAACA597 R

CCTAAGTCTGACCGTGCCACTTCCCAGTCTTC

CC'TACACTTCAATGC'ITIAGGCACAACAAAT Mm. 102 IM000264 I TGTACCCCTCATG 598 B 899

CCCCCCAGCCTGCTCCCTCCCCGGAGGGAGTC

IM000265 CCCAGTrGTGACATG 599 D GnTFAGGTGATAGGGTACTGCCCAGCAG'rAG GTGGTGCCCAGGATrcTrATicCTCAAAA'fI'GCA IM000266 CAAACAGAACATG 600 D CATGTTGTGTAGATACCTACA'rAATfATAATr IM00 0267 CATIAACTGTAAMTGCTAC 601 D CATGGGMTGAGCCTTrGTCCTGAGCTGGAGGA AGAGAGTGACCCAAAGGGACCTrGGTAGCAG

CCAGGGATGTGTFGGGGAGCAGAGAAACITI

TATGAACTTCAGflTAGTACTGAAACTTCCC 11M000268 TTICCCTAGACTTCCTIG 602 D CATGGGACAkACTCCTTTCCTTCTGGGTCAG

GGGAGAGAGACCTCCTATCTAAACTGTATAG

GCCATrGCTGTAGCCCTTAGGTCACTUCCGGG IM000269 GCGGGGAGGAGGAGGTTAAGACCC'IAT 603 D CA'GXAAAFGAAAGAACAGAGTAGCAATfTGG

GGAGAAAAGCCTGCCGAGCGGACTTAATCTTI

IM000270 CCCAAGTGCTATCAGT 604 D A'I'GC7FFG'r1'YITCCCGCCCAT-rACCTGCTITrTG T'ITGAGATAATAG1TFFGTTAC1TFTATCAACTrA GTAGCGACTAGITTACA'IT'GG1TTCATAAAT

AAGATCCATTTTAATCTGAGTMLCCATCCTTG

ATiTA11TGATTCATATTTrAATrGTCTAGT7

CCCATCCCTGGGCAGGACTTTTGGGAAAGTC

TTGCAGGTGACTATG'L1I'GAGAAMGA1'TTATGT

TGTATTAGCACAGGTACAITCGACAGTGCTGG

TTCCTTCTGGAGCGCCTCGGGTGTGGGTCCTT

1M000271 TTCCTCAGC 605 D CATGAGFIGATFI'ATrCCTGAATTCTACCTCT 1M000272 CTTGGGTCTATFrCTITCTITTGTrCTAGAG 606 R

GGGATAAGACTGGATAGTAAGCCGGGCGTGG

IM000273 TGGTGCATG 607 D

CAGAAGGTAGTG'ITTCACAACAGTCCTCCCGA

TGATCAA'G'ITACACTAAACCATATAGGA

A'[FCACCCTGAGAGGAGTTrCGAAAGCC'lCA

AAA~CTGTACTGATATAAAGCAAATCTCVIIFT'

GGATTCCCAATCAAAATGATFI7rGGCAGAACIT

TAAGGCCACAAAAATTGTGTCTGAACAACCCC

TCTGAGCCCAG=hFGTTAGCfl'AAATTAAGG IM000274

GCCATG

CCTCAAACTAAGAAGCATCCM1TCGAAGCTG

CTGGGATTAAGGGAGTATGCCACCACCACCA

GCTATGGCA1TTTTTC1TrAA1rACTAT 1Tn'GCTTrGTATATrATGG'1TCCAGYITGTG IM000275 GGTI=ATAAGCM~GAGTGTGMhCTGCATG 609 D GTCCACMhAGOACGTGGAATATGGTAAGAA IM000276 AACTGAAAATCATG 610 R

CATGGTCAGCTCTCACTGCCCCATCCCCTGTC

TCCAGTITCACGCACTGTATCCTGTGTCTTrTCTC TGTGGCTAGACTCTTCTCT'rGGGGGAGGGGAG TCTrGTATATCGATGTGTGCTCACGCACATAG AGGCTAAAGATrAATCTAGGTTATCATTCA IM000277 TCGTCTCATTGX2 611 D CATGTGTrCCTGATnTAG~rGGATTnr

CTCCCAGG=CTGCAGTGTCCCCACCCCCCA

IM000278 Ic 612 D ATGGTGTCTGTrCATAGCAGTAAAACCFrAAC

TAAGACACTGATATAACTCACCI=CCCAGCC

TCAAAGTCTCTACCATCTCAGGATCCACTCAC

TCATTCACCAAACTTCATCAAATGCCCACTGT

1M000279 GCTATCATCAGTACAGAATAAAITCATG 613 R

CATGAGACTGTCACAAGCTCCTGGGATGGGG

ACCTTACCAGAAAGCCACCAAATCAGAGGCA

TCCGTGTAGTCTTGTIrC CAGGCCCTGAGTGCCAGGCAGGAGCAGGCAA Fg/3/Fgf IM000280 AGTrCACCTGGGAGGATGCCCTGGAT 614 K 4 GTrGGTCTMCAAAGAAAACAAAGGTC ATrGCAGC'ITIGTACCATGAGGTGATGGT AGGAATPrGAGATATATAATCTA=~GAAGATA 1M000281 TATATTATGGCATG 615 D

CCGCTGCTCTCTCACCAACCCAGTGTGTCTGC

TI=AGCCCAGACGGGGGAGGGGGTAAGGGG

IM000282 GTGGTCTGTCTCATG 616 K Wntl GTGTCCCTCCTGTCGrAGGCAGTACCCA IM000283 ATCAAACCATG 617 C AGCTGGTACAATGGT7AGAGCAGAGCTGCAG

AAGCAATACAAGAGATCCTGQCTCAGCTAGG

TGCAAGCTGGAATAGACTCCTGACAGn7GTCC IM000284 TATGAACTCCATACACAGGCATG 618 D

ATGGATCCCTGGGOGCAGTCTCTGGATGGTG

CTC~CGCCGACAAA-GCC

IM000285 GTAACTCCTTCCATG 619 R CATGATGCACTrAGCAATCCTCAATTGAGACI TCAAGTGAGCCTAGGCTGTGACAAAATGACT Fgf3Fgf IM000286 GT7fAAAACT 620 K 4 IM000287 10087CATGTAAAGCTAGTrCAACATACTATA rrICAGTGTAGAAGAGGTGAGGTTATCTCAC''

GCCAGGATAAGCTA'ITGAACAAGCAAGGG'ITI

CTCACTTACTGTAAGTGGAAGTGTT=CTTA

CTTCAAAAAGTCATAATGAAYI=AAGCTGC

ATAAATAThFTAGTTA1T

TAAGC'TTTCTCTTACACAATCCCCCGGAAAC

CCACAGTrTAGGTGACAAAGACCGAGGCAGCT ALrTCCTAGGCCTGGTAAGT'GGGCACCCACCAT 1M000288 TFACAAAGAGCTCA(GGA'ITTGGCTCACACATG 622 D

CATGAAGAI'GAACCOGGCTTCTCTGGCA

ACTAGGCrCAGAAAGGATAGGACCACCAc3CC

GAGTAGCTGTCAGATGGAGCTGAAGACCTGA

GGGAAAGAATGCTTGTGGGAAGAAGCTGGCTr CC-fFrGGTI-1-GTTG'rrGCTGG3TIGTGACC IM000289 GGATC1TGCTCJTGTGACCCTACCTIAACATr 623 K WntJ CATGGAM'IAMTrACTGCAmTGAATTrATG GAAAAI'ATATIAT'GAAAAOTC'rr1rAGAAAAAG GCAGAGGACGAAAAAAACCAAAGAAU['FTrAA TTrATCTGAGACCAAGAAAACTCT1TAAGAAAA AGCAGTAGMTFAAACTACGTG'FrGTTAAAAT

AGTCCTGTAITAGATATAAAGTCCCTCAGAGGG

AAGAGATrTGTTGAATAAAYI'CAGACACTCAA IM000290 GAGAA 624 D ATTAAACAc3CCCAGTGCACTCAG3AAGTGAAT G'I7GAGAAGTGGGTAATCTGGGGACAAACAG AGGGAAGAATAGTGCCCTTGGCACGTGCAAA Fg/3/Fg/ IM000291 GGAG'TI'GGGAACAAACATG 625 K 4 CATGTATrGACAGT'GAGGTCAGGAGTGCCCAG GGAGCT-rGCATrGGCAGAACAGCC71TCCTGG

CCAAGCCTAGTGTCATCAAGTATATATTGGAC

CAGACMTATAAAACTTGGGTTCCACTCTGGC

TGGACCAGCCTCAAGGCGTCGCCTCTCCAGGC

CTACCTCCCAGAGAGAGGCAGCATTI'GGA

IM000292 GGA'JTGAA 626 D CATGGG3AACI1TGrcCAAGCAAGGGACTCTGC TACACCITCAAGGGACGCTFGCTrAATACIGGGIT

TCAACCTTGGGCAGCGTGCACAGCAGGAGTG

GOAGGGCTCTGATGAGGAGAGCCACCCACAC

IM000293 TGTGAGATCTAGGAGATAAGGTCACATCCAC 627 D

CCCTCCAGCAAAYITGAAATACGAAAGACTCA

AACACATTAGAACCATTCCAATAAAAACTTGC

IM000294 A'J1GCCCCCAGGCCCCTCCCACCACCATGj 628 D

CAAGAGTATATATCCAAGAAAAATACAGCTG

IM000295 IAGTrOACTGTPAG'F-FCTGTM~GGCCrF7CATIG 1629 D

GGTAAAAACTCTACCAGTFTAAACTAC

ATTFCCCAGCCTGCCTCCAATGAATTT

AAT'FflGTGTFTMrAGGGMTCTGI1TAT TGTI'G'TI=GAGACAGGGATTrCACA AAGATCTGCCTGCCITCTGCTTrCCTGA IM000296

GTGCTAAAATTAAAGGTATGCATG

GTAGTAACTGrI=CTGTATTAC=r1GTTG AAAATrAGATTGTrCCTGGTGAC=IGTGTGC 1M000297 TATATTCTCTGCATG 631 D CATG'1CTGCTTCTAC1TrATCCACCCTGCAC ACACTGACTGCTATGT-rCCTGTACCTrTTCCAT CTCTCCATrGAATATTCACTCCAACAGTGGCA IM000298 TTGGAAArrGCAGTGGAGATACC 632 D

ACGATGGTCITGCCCM~CTCACACCATCAAT

AGTCACTCAGAGCTGTG1GTrATCTGAAGT IM000299 GTGTrGCAGTCCAACIr7GCCCCATG 633 D-

GGAGTGTAAGCGTCGGTGTGTCACCCGTGAG

IM000300 A'rrAAGTCAAAGTGTACATG 634 K Wntl

TAGACGCAGTCTTGCACTGGCCTGGG

ACTCGCTITATI'AGG'TrTGACTG'ATC

TGGCCAACAAACACCAGGAAATGGG

GTGACAGGTGGTTGTGAGCCCTCTGA

AATGGGCAYJTGGGACCTGAACCTGGG

IM000301 TCCTCTGTAAGAGACATG 635 D TCACCCCAGCTGGGGCTGTGCTGAAGACTCTG Fg/3/Fgf IM000302 AAGGGGAAGATAGGCCTATGGTNACATG 636 K 4

GTTGGGCTGAGCCACAAGTACACCTCCACTCA

CTGAGCCATCTAGCAGGTCCCAAACAAGGTG

AC=IIGTCATCCAGCAAGACATAGCCATCTA Fg[3/Fg/ IM000303 TGCCAGTCATCCT7GTCATG 637 K 4 TAACATATTTGC ITG'FATGAAGGAAAATGTf GGATGTGTGTGCCTGTGG1TGAGTACTGCAAG

TAGTGTCAGGGAAGAGAAACCTAGCTTGAAC

AGTCCCCTCATCTCCTrCATATCCTCACTCCTT

GTCAGGCCCTGTATTAGGTAGTGCTTCCCTAC

CTCCCTAATGCTGTGACCCM7CAATAGA IM000304 G1TCCTCATG 638 C

CATGTGAGCACAGGTACCTATGGAAA

CCAAAAGTGTAGGATCCCTrrAGAACT GGAAT'FATAGGCAGCTGTACGCTAT'r

GATGTGGGTGCTGGAAACTGAACTCG

AGGCTTCYrGAAGAGCATCAACTGCT 1M000305 CTTAGCTGG 639 D

CATGTAGAGACTGCCATATCCAGGGATCCACC

CCATAATCAGCATCCAAACGCTGACACCATTG

CATACACTAGCAAGA11TATrGAAAGGACCC

AGATGTAGCTGTCTCTTGTGAGACTATGCCGG

GGCCTAGGAAACACAGAAGTGGATGCTCACA

GTCAGCAAATGGATGGATCATAGGGCTCCCA

ATGGAGGAGCTAGAGAAAGTAGCCAAGGAGC

TAAAGGGATCTGCAACCCTATAGGTGAAACA

IIN000306 A 640 R IM000307 1M00307CATGTCCTAGAGTTGTTCCAGCACAGAAGCTI'

TTGGGAGAGACCACCATTACTGAAACGCAGC

AGATGCTGCAGCT

CTGCTrGTTGTGGGGACGAGCCAGACACCCTC Fg/3Fgf IM000308 CACAGGTGCAGTGGTGCAACATG 642 K 4

CATGATGMTGTGCAGGAATAGAAACCCTGAC

TAAGACAGAGGATATTrCAAGAT'CCAAACTAG IM000309 CAGG'ITAGCT'GTGGTTCC 643 R

CATGAAGCACACATTACCCTGTGACYTGC'TT

IM00031 0 'IIA'TAAT 644 D CATGTCGTCCTCT-rGTCTrGTrAGTrCTCTATTCT TGTGATTCCGCAGCTCTCCATAGAGTGCAGITr CTATGTCCTGCCTGCAAGGTCCA'flGGC1TAC

TAGGGTCTGCCCCTCCCAGAAGAGTAGCTCAT

TfAGAATGCAT'TACTGGTGTGCTGTCTTGCAT IM000311 CITTYFACCCAT 645 D ATCTATGTATGCACTACTAATrACTGTITAG TTE7ATATATGCCCTAATAAT[rACCCCArrGAA AAC'n7AAA'Ir1TG1TrlCAAAAGTGTGGTCTCA TTGGAGGTGTlAATGTACAATGTC1TICTCATI IM000312 IG 646 D

CATGGCCAGCTGAGCGGGCTGCJAACCTGCCCT

TCTGC'fl'CCTGTCCCTGCACCT'CAGCACCGCT IM0003 13 GTGCACTrGGTACTAGACCTCAATCACCGCAG 647 D

CATGTGCGTCCCCCCCAAACACGCAAGCGCAC

IM0003 14 ACCCACAAAGAGAAGAGACAGGG 649 D CATGGCCACTTrGGAGAGAAGGGGGAAGGGAA LM0003 15 TGCGGAGAGAGCGGGAGCAAGAG 649 C

CTTAAGCACTGATCAATGGCCAAGGTPTGCCG

AC'FIGGGATCTGGGGTATAGACATCCACCCAC

TGAGACCCTCTAACAAAACCAGATGTGGAGG

TACGAAGCCTGGCTCAGGGGCCTGTCCTTTGT

CATCAGAAT-I'CACCAGCTGCAGCTCCTGGGTC FgJ3/FgJ IM0003 16 AGCTIFYG'VrFrGGCAMG 650 K 4

GTGTATTGATATGCAAATGTGTFAAAATATGAI

IM0003 17 TyrAAAATT~ccCCATG 651 D GCAAAGTrGTCCACAC=rGGTCT-rCGTTCTTCT IM000318 TGAGTrCATG 652 R ATAGCAGGT CTGGATACCCCAACATACCAG AAAAGCAAGATTCAGATCTAAAATCAC-1TCTC IM000319 ATG 1653 C IN4000320

CATGTCCTGGCITTGTAAAGGGTCCTGCTGGG

FTrAMYCACTGGGTC1TAAACTCCGATTrGTG AGCCGTAGTrGAAGAGGGCTGTATATAGTGG

TCACCGAGGITCCTGTFAGCAGAGTGGGCAAGC

TCACTGCCTGCTACCAGCAGTTCACTATGT1T ATGGTCTGCTGCCTGCTGGTGGT-rTATAGATG CTGTGTCGTAAGAGAAAAG'FrCAGGGTAGCCT

GGAGTGAATGGAGT'TGGGGTATCAGGGAGGT

CTM GTACACTGGGGTGAGCTAGGCCTGTGGA

AAGCITTCTGGGGGTITCCCC

CATGCTCCCAGGCACCAGGCTTGCT1TrGCATA GGTG43GACAGGGTCCCAATACTCAGCCTGGG

GTGCCAATGAGGCTCAGGCCACACACCCTCTT

GGTAGGAGTCACTGTAGTGGGGTCTGTGAGA

GCCAGTAACTrGTGAGGGTGTGAAC-ITAGCTC AGGACAGAGGCCAGCAGGAAGCTrCCCTAC AGAGAGTGTTTrCGTC'TITCCYTrCTGGTT TGT-ITCTTrGGGAAGGGAACAATMTCGCTI-17 AGT1GGCTrGTATATCCTACTGAAACC1Tr IM000321 AAG 655 D

CATGTATTAAGTCCCTCGTGAGGAAG

1M000322 GGT -656 D

CATGAGTCAGAGGCTTCTACTCCATAAAAC

TGATCTGGGTATAGAATrGTGTrCTCAAGAAA

TAGTAAGTTATAATCAACTAAGTCATCTCCTG

TCTCATTITMCTCCAAATCGGGTCCTCGAA

TTGTITATAAGAAGATTCAATCAATCAAGAGTA

TCCCTIT7CCCAA1TrrGTGTGCTAAGTGGAAAC AGGTC1TAGCACATCAATCACATAAAGITCAA IN4000323 'TAAGAAGGAA'TrTAAAGATCAG 657 D

GCTATGAGTCTCCACTTGTAAACAAT

TATACTCAAACATAITCAGGACACAC

TTGGGCTTCCTCCATCAAGCCAGGCA

GGTTTG=h1CTTGTTfGTF=GAGAT IM000324 AGATGGATGGGCCAGCTTCATG 658 C CCCACCCCTAGCAACCAGTTfCCTCCTCTGAAT GGAAGACATCTGATACCAAC=rGAGCInrCA IM000325 CATG 659 D ATCNNCGAATCATrCTAGGCTTIGTGG 1M000326 GACCATG 660 D ACTATTCTCAACAATAAATGAACTrCTGGOGGG AATCACCAATCCTGA T7CAAACGGTACTGTA IM000327 GAGCAATCATG 661 R CCTAGGCACCCACCACAATAG'rAATCCATCT T-TGAATI=GACCCAGTGT'rGCCAAGTATTC ATrGCAACAGCI-=CAAATG=rI-ICI-JC IM000328 CCAAATAAA1TCCATG 662 D AGAGGCTACCCCTTCAAGTGGC17GCCTAGTA TAGGTATrACAGACAGAGAAC'TCGAGTAATr IM000329 TCCTCAAGCCACATG 663 D ACTCTGAACTITGCTTrGCCTGGTATrrGCC TCTC1TATCCCATTGACCCTGTACAGAA&AGC

TGAGGAAGCAGGTGCAACCAGGCATCTCAGG

CACCCAGTITAAGAAGTAGATGAAATACTGTA

ATGTACATG

IM000330 CATGATrITCAGTMTrGCCATATTCCACGT CCTACAGTGGACATTTCTAAATMrCCACCTTY 17rCAG=nCCTCGCCATAITTCACGTCCTAAA IM000331 GTGTGT 665 R CATGAGACAGTCCCAGATCCCTCACCATAiG IM000332 AGCTACCATATIAC 666 D

CATGCGACCATCCATCAGGAGTTGGAGGTGCC

A'TCGGCTCT'GCCTTACAGAAAAGGAArcI'GAG A1TFAGAAACCCCAGGTGACCCACTCAGGGCC

ACCGGGGCAGTAAAAAGAATCTAAGATGTAA

AGTCAGTGGAAACTCCTCCCAACCAGCAGAG Fgf3/Fgf IM000333 ACTCCTCCCAGCCAGCTCI7GAT 667 K 4

GGGAAGCAAGAGGCAGTAAGAAAGGGGAAA

IM000334 CTGGGGAGGTAACCAAAGTCACATG 668 D

CATGCTAACAAAGAATGGGGAA.AGCTCTCTA

GGCTFCCACCT[AAACAATGAGGAAG3GGAAG IM000335 AAGGAAAG 669 D CATGT-rGGTGGGACTTATGGGTA7GCTJ7CT

GATATFI'ACTAGGAGGCACAATCTCACAGAAA

AC'rCCCTG3ATCTTACAATCC'rrFCTGCCCCCTCT

MTGCAATGTTCCCTGAGCCTCAAGTATGGAG

TTA1TrATAGCTGTATrCArGAGACCAGAA IM000336 TCCACAGGTATGC 670 R IM000337 CTCACACAGATATGCATG 671 D

AGAAGTGATCYICTTCTGTGTGTCCCTGITCAC

IM000338 CGGGAGGCAATCAGACGGiTCCCiCATG 672 D I I CC I i IGTIGGACGAATATrATTrGAAA IM000339 TATGTAGTGTGCATG 673 D CATGAGATATGATITrAGATCTGAATCTTGCT TTTCAGGTGTCTrGGCATA'TCAGAACTCGCT GTGGTGc3GTGAACTGGoG1TCTGA'I'G3ATGCCCA A159706 1M000340 T-rGGTC3CTGGTTC 674 B 2

CATGGAAAGGTAMIGGAAATAGGCTGTITTG

IM000341 TGTGTAACTC 675 D

CCCTAGGACTCACCTGGTAGGAAAGAAGTAA

1rCTTCCAAGTTGTCCCCTGACATCCACAAGC 1M000342 ACATAGTGTCAGGCATG 676 D CATGCCA'TrCATACATACTGGCAATGGATATA TAGAAAATGAGACTCCTTrCAATATTrGTGTGA IM000343 TGACAGAT 677 D

AGAAACCATTITACACTGCCAGGTUTGGGGCCT

LIM000344 GGCTATGCATG 678 D GATCCCTInAACTTCTTGGATAGTT-rCTCTAGC TCCTCCAi-rGGGGGCCCTGTGAT'CCA'TCCAAT

AGCTGACTGTGAGCATCCACTATGTGTITUGC

TAGGCCCTGGCATAGTCTCATAAGAGACAGCT

R IM000345 ATATCAGGGTCC=rCAGCAAACTCTrGCTAG TGAATGCAATGGTGTCATCATrT7GGAGGCTGA

TTATGGGATGGATCCCTGGATATGGCAGTCTC

TAGATGGTCCATCCTITGTCTCAGCTCCAAA

CTTTGTCTCTGTAACTCC'TrCCATG

AGGGTGGTCTGTGCAACCCAGGCTGGAACCC

AGCACAATAAATAGmrTATITACATAACCGA

ACGCGTGGCTCTGCGGCCACATTMCGGTGCAA

ATTAMTACACAGTGATGAGGAGGCAGGACA

GGAAGGGGTGGGAGGAGGCTGAGGGAGGCAT

IM000346 G 680 K Wntl CATGTGTGTrCT1TrGTGATTGGG7rACCTCAC IM000347 TCAGGATGATA1TrCT 681 R CATGAGGCCAAGGGAGAGGCAAATrCCTGTG M000348 TGAATCAATTATCATCTCACAGAGAACATAcc 682 D

AGTAGTATGCCACAGGGAGAAAGGGTATTTA

TCAAAGGGACAGGAGCTAG'ITGTGGTGACCTT

ACCTATCTGCTrGCCTCTGCCTCCACGGTGCT GGGATTrGAAGGTGTGCACCACCACACCCAGC TICAGA1T1TI1ATTrATGNGTATrCC 1M000349 TGM~CACCTGCATG 683 R CATGCATATACAGGATATAACCTfGTAAGTA AGAATAAAGCACATAAAAAATAC1TCAGTA IM000350 ATATrGTCCAAACCACTT 684 D CATGTGTGTGYTGTG1TTGCGGAGTGTGGGG GCGGGAGGGAAAGGTGGCCAGGCTGTCACTC FGF8 AGAGATCAGGATGACAGGCGCTCCCTCATCTA

{TC

GGCGCGGGAGCTCTGATTGCAGATCGAGJA

AACAAAATAGCAATTG IFGF8" \L 2} IM00035 1 685 K CATGAAGATGAACCGGGCTTGTTrGTCTGGCA ACTAGGCTCAGAAkAGGATAGGTCCACCAGCC

GAGTAGCTGTCAGATGGAGCTGAAGACCTGA

IM000352 GGGAAAGAATGcTTGTGGGAAGA 686 K Wntl

TCAGTTCCAAGAGATGACACAGCCGC

IM000353 AGTGATG 687 R

CAGAGACTGAAGGAAAGACCATCCAGTGAGT

GGCCCAACTTrGGGATCCATCCCATrGAAAGG IM000354 ATCAAATCCAGACACTATfACTGATACCATG 688 R CCCTACAGTGACACTrACTCCAATAAGGCCAC IM000355 ACATCCTAGTAGTGCCAGTCCCCATG 689 R GGCCTCTATTGCTCGGITCAGATrAAGTACCTG GCT'rGACTGAGAGCGGCTCMTCATTCCTAAA 11M000356 ATGGTrcTCATG 1690 D IM000357 1M00357AGTAGATGGCAGAGAATAATCAAACTCAGGG

CTGAAATTAACCATG

CCAACCCAACAGCTGGGAAGGGTTGGAAGTA

GCCCCGAGGCTGG'IAGTCCCCT'TCCAGATGG

GGAGGTTAGACTGGGGCTAGCCAGGCTGCTC

CAGATAGACTTrCCGATTCGCAI-rAGAAATGAA

AAGAGGAGAGGAAAGOGAAAAGGAAGAAAG

IM000358 GCTACAAGCATG 692 C

CATGGGGT'CTGGAGCCAGC'I'ATICAAACCCAG

GA'TGTCYFAACTGTGGTGGCTrGGATGAGiAA TGGCCGCCATAGGCGCATAGATI1GAATTCIT IM000359 GGTCCCTAGTI' 693 R ACGGTGGGCTGATA1TICTAGAITCTCCTAGT IM000360 GCCTATCCCCTATTATCATrG 694 C CATGAAT1TI'GAGATAT-fCTCTGAAC IM000361 cAAAcAATAi-r 695 D

GGAGAAATTATGCCTTAAAITAAAAAGCAAA

TATTGAAAAATTAAATATAATTCCATrFAAA'r

CATAATGGACCAACAACAGAACACATCTATCT

ATGTATCTATCTATGTFATCTATGTA'ITI'AT'CTA

1M000362 CCTATCTATCTGAAAAG3CAAAAACITACA'L'(G 696 D GCAAGGACAACTIGACAGTGAAGCAAC'rAT T-ITCATCTTGACTCTCACTCGGC1TrAACGTIC IM000363 CAITCAGGAAACAGGCATG 697 D

CATGAGAAGTCACAATTCCACCACTT

AAAATCAGTGCTTGGAAGGATACTGT

AGGCCAAGAGGTAAGTAGAGGGGAC

AGCAGTGCACGTT1TICAAAGTGTGG

GTGTGTGTTGTGGGTGTGTGTCTGTC

TGCCTGTGCGTGTATGTGGGTCAGTA

IM000364 CAGGAAAAGC 698 D

CAAGAITAAACTCTTAATGGGAI'CTAGGGAGT

CAY[CTGTAGAGAGCACYTGACTAGAAGGT-rA

AGTCTTAGATCCAGATCCCAGCACAAACATAA

TACATCGTATACTCACACACACACACACACAC

IM000365 ACACACACGCAGTCGTCATG 699 D CATGTCTCAA AA A AA A AA AAGAATCACTlGG ATrGTACATAGTAGTTAATAATATGTAATTAG TCTAACTGTGAAGGGGCAC117ATTAG'IMCTA

CTFATGTAGTGTAAATGAACTATG'FCGCTATTA

IM000366 GAAATTC 700 D GAAGGTTGAAATCTGTAATcrATrC'TTCTATGG

CATCATTCACCTCTCTAATACAGCTGTAGAGA

AAAATGTCTGAAGATrCGGTrCTACTCTCG'Fr IM000367 CTFFGAGGTCTGCCAACCCATG 701 D

CATGGCTGGACTATAGAGCTCTAGCTTCAGTT

GCTGGGATGTTCAGTGCATCACCACAGAGAG

IM00368GGT-rC'rAAGTGGTGATGG'Y'GGTAG'rGGAAAG 1M00368GTGGACCCTCCAGACAAAGGAAGCACTCACC ACGACCCTGCTCACCTGTGAACCTTTCCTrITC

AGACTGATTCCTGAGATCAGCCAGGCAGGGC

TACCAACCAGGGACTCGTAATGAAAATTrAG

GGATATGG

CATGGTCTGGTGAGTATGGCACCAGATAGGAT

GTTATGCCCG1TrTATTCAAGAAACAAGG AATCTTGTT7CTATCATAATAGGAAGAATA

GAGCAGTCCTGGCTAAATGAAAGGTGGNAAA

IM000369 GTTGGMTGAGTATCTCMTCC 703 D IM000370 AAAATCCAATACACA1TCATG 704 D CCCTTTGTrrGTGCAMTCAGCTAATCTCATCCC TGTTTGGGTCCTGGAACCCTCTTGCTfCCCTGG

CATCTAGGACTTGCTAGTGGCTACCCCCAGCT

CCCCAnCCCCATTGCTACACACCTCTGTrCA AA'FrCCTGACCCTGTGTATATCATCGCAGTCTC

TTCTAATACCTGACCTGAACCCCCTITICCCC

TCCTCTA1TCTCTTCC17GCAAGTCCCTCCCA IM000371 CCTTCTACC'FrCCATG 705 R

CATGGGTCATCTGATGTIACCAAGCAACA

GTGATGAATCTATAAATAGAACCATCAGTTCA

AGAAACACAACTAGATrCC1TrCCATACCT TGCTIMG1TTCTTACATCTCCCCCTGCCCTG TGOTI=C=rAATCTG1TI=ACAATCCA IM000372 AATFGTATCCCCTrCTCTGTC 706 D TrGGOCCTITrGCATACCCTGTTCTGGCTAAGA IM000373 CAA17GTCACCTGACTGGGCATG 707 D IM000374 AAGTGGATGT-17CTCATI=CCATG 708 R TATAAGCAATCCCAAAAA1TCTACCTGGGAAC TCCTAGAGCTGATAACACCTrCAGTGAGCCAA GTATCTGGGTATAGGA'ITAATTr1AAAAAAAT

AGAAAATCAGTATCTCTCTTACATACAAATAA

CAAAAGGGCTGAAAAAGAAATrAAGGAAATA

AAACC=~CACAATAGCCATAAATAATATAAA

CTATCTTGGGATAACTCTAACCAGGCAAGCAA

AAGACCTGTATGATCAAATCTTrGAAGAAGA

AAATTGAAAAAGGTATCAGAGGAGGTAAAGA

IA4000375 TCTCCCATG 709 R IM000376 CATGGGCTCTGCTTAAGAAACCCCGGAG 710 C CATGC1TrAGGCC=F~CACGATCTFrANNGG

GGACCGNGAGAGNT*NGGTGCTGGATGATCTC

ITGAGAGAGCITATCGTCCTCAAACTcICTGATA

TTCAAGCTGTTCGCAGCTGCAGCAGCAAAGT

CCCGGTCT=GTCACCGATCTGTGAACAGCAA

CAATGAGCACG'IMCATAACAGACAGOAAAT

IM000377 GGATGCT 711 A inDall IM0003 78 GGCGTACCTGTGTATATGCATGCATG 712 D

GTGCTAGGCTCACTCAAGATAAAAIT

1M000379 ITGCTAITI'CAGCTCCCTGGATAATAA 713 D

AATCTATCCTCTCACAGCTIGITGACTC

TCACAGGGGTGCAGGCAGGACGACA

TCAAGAGAGTGATGGCCTCTAACAAG

TGT-rCTGCCCACFTCCTCYITCCGGGTC

AAAGACTAGATCTAGACTGGTGGGG

CTGTTGATTrCACTATGAATGTGCCTG

ACACCATCCCACACFAGCATCATAG

ACAcYIGGGGGACTGGTGATACACTA

TGATGCCTGACACCATCCCACACTTIA

ACATGATG

CTATCGCGAGGGTGAGGGCAGTTCTA

TGCCAAGGTF[CTCATCACAGAGATAC

AGAGGAAGCTGGGCCTGTCT[AGGGT

TGGCTGTCTGGAGATCCTGGAGCCCT

GGAGGTGGGTAGCAAGAACAAAGGA

AGTACTTCACCTGATAAAAACAGTrC

CCAGAGAAACACATATACGCTTCATA

TAGAGGAGTGCGAGTGTGTGTGTGCG

CGCAGAGAGGCAGAGGCCTGGAAG'r CAAAAGTTCAGGGCCAGTTTGTGTGC Fgl3/Fgf IM000380 ATG 714 K 4

GGGGTTGACTAGAAGAAGGAGGCGATTAGGG

TGTATCATATGAGAGAAGAATAA'k&AGGA AAAAATAAATIT'ACAAGGjAUAAAAAGTAAT

TACATFACATACATACATACATACATFCCATACA

TACATACATACAAGTTAAACTGTrATGGTAGC IM000381 ATO 715 D AGGATGATATIMCTAGTTCCATCCA'FrGCCT AAGAATrCrrGAAFrCATTGCTTfTAATAGCT GAGTAGTACTCCA1TFGTAAGTATACCA'FAT TGTCTGTATCCA'TrCCTCTGTTGAAGGACATCT GGGTTCI=CCAGCI'CTGGCTA't'ATAAATIG IM000382 AAG'TrGCTATGAACATAGTGAAGCATG 716 R CATGCCTGCAGGTCACAGCC-FlGCGCGCCT'CC AGITGCCCAGCGTfCAfiAGTGACACAGACTCTG

TCAGGATGGTTCAAATGCAAATCTCTGCAACT

GCGTTrAGCCGCTTCTAACCAAGACAGAAAGCT

GCCGTCCTGTCCTITCGTGTCTFGTCCCCATACCC

CATATCGGGTAGCTrrC1TTCAGCATTGTCCA GACACCATCATATGCCTACAITCGCACAAGTF7C TCTGAGGCCAGATAATTrGGCAGCACTCCTGrT

GTGTGCCGAGAGTGCAGAAAAGGGCTATCCC

GAAAAGGTGTGATCTGGAAAGAAGGAJAAA

IM000383 c 717 D

ATCFI=GGCCAGAGCAAGCAGGGACTGAGT

GAGCAGAGGTGACAGGAGCGAGCAAGGCTGA

CAAAGTCTT'CCATA'ITCCTACTAGGATGACCC

ATTAAGCCCCATTTAAAGCATrCCATTGCM1

CCAAATACAAAGTCCCAAAATCCACATTCMT

IM000384 CAAATAAAAGCATG 718 C I M000385__1TAACATATGGT1ITAAAAATCCATAATGAG 1719 1 D

CATATGATAGAGAAGTCATCAGAGCTCTTCAG

CTCCACATCATCTGTCCCCAGAAGTAT*TACTA

CTCCTAACTTGCTGAGCCAAGGCACAGATATr CTrFGTGTAAGCATCTCTG=ATCCTGTGI'T

GCCACGCAGGAGCACGCACACTGCTTCCTGTC

TGAGG'ITGT7CCATATCAGCATG

CATGCCAGGGCTTGAATTAACACAAGTGCCCC

IM000386 AGAT 720 D IM000387 CCTGTCTGTATATGCAGATG 721 D

CATGGAAAATGAGAAACATCCACTTGACGAC

ITGAAGAATGACGAAATCACTGGAAATCGTG

AAAAATGAGAAATGCACACTGTAGGACCTGG

AATATGGCGAGAAAAGTGAAAATCACGGAAA

ATGAGAAATACACACTAGTACGTGAAATAT

IM000388 GGCGAGGAAAACTGAAAAAGGTGG 722 R

CATGAAGGTAAATTATGACCATCAGGGTTCAG

ACCTCAGCTCGACCGGAGACCAGCCTGCAAN

TCCCCACAGCCCTCCCTAAAGTGG'TAAAAG

IM000389 ACAGAAAAGAATTAAATATCTGA 723 R GATGCACTAGCAAGA=rIGCTGAAAGGACCC IM000390 AGAT 724 R IM000391 GACACATACAGACACATG 725 D GTAAATGTATTAGGT-rCAGAACTGGCACTGCT ICACTTATGTTCACAGTTG1TTGGGTAAAACTA

GAACCAAACACAAAAGCAAAAGAGCCAAGCA

GCAGAGCAGGGAGCAAGGGGCTTGGGGAAAA

CACTCACCTCTGTrGTGTCTTCTrCTAGCTGTC

AGGGCAT'TGAGTGGCAAGGAGTGGAAAGGAA

C=TGGGCA1TCCGAGTCAGGAAAAGTGTAGC AAAATAACACTATGGAGQTrAGCAAGTGTTCT IM000392 AGACGGGCAGAATAAATACATG 726 D

GTITAGGTCATGGTGGTACACTCTCCAAGGA

CAGTATAAATrGATTTICTGTATCCTTCTT TGTTC'rGGCCATAAGGCACTrGGAGTGCATT

AATATGTACTTATT-ATACTATGTC=TTG

TCMIGGCTrAAAAGAAACAGGGTCAAGTGAC IM000393 CATG 727 C AG1T~rC1TAAAAAAATAAAGTAGGAATGAA

ACTGGAACAAAAATGCAATAAATI=AAAGC

IM000394 ATCACCGCTAAAACATG 728 D IM000395 CATGA'r=CAGTn7T'GCCATATTCCAG 729 R

GAGAGGAGCCTGGGGAAATGAAGGT

CCAGCAACAGGCCCAAAGTGGGATC

CAGCTLTAAGGGGAGGCCCCAAGGCC

TGACACTATACTGAGGCTATGGAGC

1M000396. ACTCATAAAAATGGACCCAGCATG 730 R IM0003 97 1CATGGCAGCCTTGGAGTATCAGGCTG r731 1 D

CTG'ITCCCAATGTGGGATGCAGAGGG.

CACTGCCAGCCTGGTTATCACGCACC

ACTGTCACACAGGGAAGCGCCCCY[

ccc

GGAG'J-TCTTCT'CAATFAACAGAGTAAAMTC

TCCCTCAGCAGTTCTCCCAGGAAACCCATAj\G IM000398 CTAGCCATG 732 D

CCTTAGATGTTGTCTAATCGACAAAATACTI'

IM000399 TATATGTGAAAAGGAAAGCATG 733 D

AATAATCAGATITCCAGAGCTCCCAG

GAACTAAACCAACAACCAACGAATA

IM000400 CACATG 734 R ATCCAGTAATCATTCATCTrATrGTrCCACAC

AGGAAAACCTGTAATAGATGGUTCATCAGCIT

TATT'rATAACTICTATCT-rGAAAGCAACTGG AATGCCCTTCAGTrAGGTFAAGCAGATACACITAG

GCTCACCTCAACTATAGGCACAATGAAAGGA

ATGAAATGTCAACTCACGAAAGGTAAGTACA

IM000401 CATG 735 D

CCTGGCCATATTTCACGTCCTAAAGTGTGTAT

TACTCA3TTCCGiTGAY=FCAG1YFFrC'CGCC

ATATTCCAGGTCCTI'CAG'GITCATTTCTCATT

1T-rCAAGFTTAGTGATFCGTCGTTITCA IM000402 AGITCGTICAAGTGGATGTITicTrCA=h1CCATG 736 R

CATGCAAGAACAGGACAAATGTCTGTGAAGA

AAATGAGTGAGCGTIGAACAGGAGGTCAAGGA

TCCGGTCCCAGGCAGCTCTCAGTCTrGGGCAAG CATTTCTAAAC1TGCCTTCCT-rCCTGTTFGGGG fgJ3/Fg/ IM000403 GTGAAGGTCTG 737 K 4

AATAGGAGTAGATGAGAATGAAGAT-ITCA

A1TI'AAAGGACCAGCAAATAGCTFFCAGCAAA A'rATAGAAGAAAACTTCCCATACCTAAAGA IM000404 AAGATGCCCATG 738 R CATGCAGCCCCA'TAGTGATTGATCCTGTfrCC IM000405 ATATAA 739 D

CATGGGCTCTCTGCTGATAATGCTGA

GGCTG7TI'FGTGCTGTAGTCTGCGCTTr

TTGCGCCCTCTCAGAAAAACTGTATG

TCATAGG3AGTITGCTGGCTATTGGGTA

CATAAGCAAAGCCACCCTA'ITGTGCC

AGTGCCTITAGACAGTGAGAGAAGAA

AGGCCCCTGGTTAGAAATCTTA'rCAG

GACTGGGAATGTAACTCAGTITGATAA

GAGTGC'ITGCTFAGCGTGCACACAGC

CCTGGG'ITCAAGCGCCTAGTAGTACA

GAAACTGAGTGTGGCTTCACACACCT

GTAATCCCAGCACIYFGGAGAGATAGA

TGGAGGAGGATTAGAAGTTCAAGG'TT

I M000406 IATC1TTAGTCACATAGTATTGGTAGG 740 1 R I

CAGCCAGCCTGGAATACTTGAGATAC

TTACAGGAAGGAAGGAAGGAAGGAA

AGAAGGAG*3GAGAGAGGACAGGAG

GAAGGAGATAGATATACACAGAAAG

AGACAGAGAAACAGAGATTCAGGAG

ACAGAAAGACATACGGAGACACAGT

GAGA

CATGTGGTTGCTGGGGATTGAACTCAGGAGCT

CTGGAAGAGCAGTCAATGCTCTTAACCGCTGA

GCCATCTCTCCAGCTCCC'I=AGACTrCTTAG TAGCAGCATAATrCTTGCTrGGM~CAGTTCT

GACAACCACAGCAGTCAGGAGTGAGTAAG

IM000407 AGG 741 R CCTCATAATGT1TGTITGAGCATITU

TITAAAACCTAACTTGTCTT=GCTTAT

CTATTGTGGTITICTTAGTGTGTGTGTG

TGTGTGTGTGTATGCGCGCGTGTGCT

IM000408 CTGGTCTTCGTGCACATG 742 D ATrGTGACATCTTAGGAGCTTAGGTTGGTCT

TCGAGACACAGGGCTGTCCCTGTAAAGCAGG

TTCGATCAGTGACTCCAGGGTI=AGCAGTrC AGTGGCGTAGTI=CAGACTGCT'rAAGATJTTC

TCAAGGGCTAGGCGTGGGGCAGAGACGCTGC

AGACCTGGCTAGAACAGANGCCCTGGc3AGA FgJ3/Fg IM000409 CAGTTGAGGGTGCTCAACTGTGGAGGACATG 743 K 4

CATGTATGCACAACCAAAACT-TATAAATATGA

GAATrCACTrATAGTCCTAGTCC1TAATACA GAATrrAGCArTCCGATATAAAACAACAGATr IM000410 AAACCCCAACAG'ErAGAATAGAGCAG 744 D AATAGGAGTAGATGAGAATGAAGAT17TCAA CTTrAAAGGGCCAGCAAATATCTrCAACAAAAT AATAGAAGAAAACT-rCCCCAACCTAAAGAAA IM000411I GAGATGCCCATG 745 R

CATGCACAGCCTACTCCTGGGTGATGGTACCA

GCTCCAGCCTCTGTTCTGCACGCTrGTGCCTTC 1M000412 AACCTGGCAACCTCC 746 K WntJ

CATGAAAACCTGTCTCAGAAAACAAAAACAC

G'ITGAGAGCCAGCATAGAAGGCATAGGAGGT

AATGTGTGTGTGTCTGTATATATGACAAGAGC

IM00041 3 AGACCTGTGCTGAACCAGTTAACTAC=r1G 747 D CATGCTACTAACCAG11TGAGGCAGTACCAGT GTTrGAAGATGCTGTCMI7ATCCAATGGATGG

TI=AGCTCCTTGTCAAAGATCAGGTGATCA

TAGGGTGTGAGTTMTrrCTGGGTCTFCAGTT ATATTrCCAT'rGATCTACTGGCCTGTAATTGTA TM000414 CCAATAC 748 R GGTrAGGAATTCTGGACAGTTGGTACT'rGGTT TGAATATAGTAGGTGACAAGCTGTGCCTrGAG IM000415 ITGGGGTGGCAAGCAGGGrrCTCTGCAGCAGG 74 C 220

ATGCAGTGTACATG

CATGAAAATGYFAAGTCCTGACAGACAGGGT

GCCATCTGCCAAoAA'YrrGAGTAATCTAGKA IM000416 CAGAAAT 750 D IM000417 CATGGGGTFTGTGGATCTG 751 D

CAGAACAAATAAGCTGGAAAGGATGAAGCAG

CCACAACATAACTGCTGT-rGGC'TCTTTGTGT ACATT-1TAAACC1W[CUCTGAAAGiAGTGACCA ATGCTI=AACTGCTGAGT'rATCTCACCCGAC ITACTIYTCTCTCTCTCTCTCTCTfT-CC1TCTFrC CTAAAATrAATGT3TGTGTATGTGTGTGTGT GTGTATGAirCAGAAACC7hrATGTGGTGjGT IM0004 18 AGAAGACCATCTGCAGc3ATTCATG 752 D

CATGGTCCCACAAGCCTAGAATGATF

1M000419 CGTGGAT 753 D

GGGGTCCAGGAGAGAAACTTGAGTC

IM000420 ATG 754 D GGAAAGAGATIAC'TCAAGACCAACTT-rACCAC C1TCA1TrAGCCAGGACTGCTCTATrC1TCCT ATI'ACTGCTAAGAAACAAGATrCC1TGT1TCT

TGAGATAAGAAACGGGCATAACATCCTATCT

IM000421 GGTGCCATACTCACCAGACCATG 755 D GTCCTCCCAAAGAATAGTGTrAACTGAGCTC T'rTGGGTGGCAATAAATGAATTGCTCTGGTGG

GACAGGCAGTGCACATATGGGGAGGGGGAGA

IM000422 CACATG 756 D 1M000423 CATGTTC'JTACTTCTTGTrG 757 D GiGGTAITATGAATTATATATATATGTGTGTATA IM000424 TATGTATACAGGCATG 758 D

CATGCGCCCTAAGACTCATCTCCACGAATGAC

GTGACGACCTAATTGCATCCT-FCTAACCCAC

TGATTAGGCAAACCACCCTCCAAAGGGCTCGC

TGAGTI'CcCTC1TCGGGAAGAGGTGTGTTGAGT IM000425 ACGCTGGAATGGATAT-rCGAGGGCTGAGG 759 R CATCTCTCGAGCCCTTGCCCAGCCTTVIC~r AAAATTGTA'WTAAA1ATTICTGITACA IM000426 CAGGTGTGTGAGTGTrGAACATG 760 D

CATGTGGACCTGGGGGCTAAGTCAGGGTGAA

GCT-rCCACAGCTAAGTGGCTGGAGGCTGCCCT

AAAAGCTCAGGAGGCACCGCAAGCAAGCCTT

GAAAAAGCTTrACCCACCAGCTTGACCTTAGAC rrCTGGCCTCAGGCTGTGACAATACATTGCT GCTGITAAAGAACCATATGGI1'GGTGAITG'1IT TTGTTTGTTTCTGGTTC'r=GTGTTGGTG1TI- T'rGCGGGGTGTGTGTGTGTGTGTGTGTG TGTGTGTGTGTGTGTGTGTrGCAGTGCTAGAG Fg/3/Fgf IM000427 ATAAGATCTGA 761 K 4 GTCTAAAG1T=CAAATGATGGATAAGrrTGTrT

AAACCTCCTIAAGATCTCAAGCACAAAAAG

AAAGACATGAAATACGAATAGTAGAAAGGAA

AGGAGA1TfCGAACTAGAGGGCCCCAAGAGTC ATAAAGAGAAGAA1TAAACAACTGTACCCA CAAATTCAITAGCATAGATCAAGTAGTCCA1T IM000428 TCT7CATG 762 C

CATGTATGTTCTCGATGCCTTGGCCT

IM000429 G 763 D

AAAGACATTAACTCTTGAGAACCAAGGGGTA

GGACAGTATAGACTGAA=IIGCCTCCCCTCT

TCATAAGTrrGTCACTGCTAACCTCATCAGA IM000430 ACTTAAGCATATAACC1TCATG 764 D-

CATGGAGAACTAGCAAGAGCAGGATGGCGTT

1M00043 1 TCTCTAGAATGCCGTATAG 765 D

CATGGTGAC'ITCCATCMTAGAACCATAATC

IM000432 ANGTTAAT 766 D

CATGCTTATATCCCTCAAAAAT]TACAGTTA

AACTGAAAATGCTrACrACTTTITCTTAC YTATATCTAGTATCGATAAGAACfrGTCCCAAA IM000433 GGACAC 767 D

CTGGGTCITAGTCCTCTGAGGTCCCTAGCACA

TCAGAGGTTCATCAGTTCCAAGAGATGACACA Fgf3/Fgf IM000434 GCCGCAGTCATG 768 K 4 CATGGAGAATGCACAGTCAAAACGC1TGCAT IM000435 CCT 769 D

CACCCCCTCCGCCTTACATCAATCC

TGGGTGCACAATGGGACTGTGGATGA

CTGATGTCTGCGCAAACAACTfGCGG Fgf3/Fg/ IM000436 GGAAGTCTAGCTGACAAACGCTCATG 770 K 4

ATGTATCCAATGGCAAAGCACGGGGOAGGCT

TCATC=GAAGAGAAGAGTGCTCTTGGTAGGC

TATCCTITITrGAGACAACTAGAAATAGGAG CAIT17CAACAATCTGGACATATGTCCTCCCAC AAGAACTrG17GAGAATGGGTCTGAATTAACT GGAAATAAAAGTGAACACATrCTCCTATACAC IM000437 ATG 771 D

TCACTCCATTYAGTTCAAATGCTAC

AACTCCTTTGAGCACCACTGTCA'Tr 1M000438 CAAGACC'FrATTCTGTGAATACCATG 772 C CATGCTTAGCCCAGGGAATGACACTATrCGAG GTGTGGCCTrArJ7GGAGCAGGTGTGGCCTrGT

TGGAAGAAGTGTGTCACTCACTGTTGGGGTGG

GAMrGAGAGCTrCCTCCTAGCTGCTTGAGGA IM000439 TGCCGGTCTT 773 R CATGAGCTGGGTGAACGACAGCAAAGGMTG Mm.202 IM000440 M~CTCITIAAGGAAGACAATGGTGTGAAAT 74 B TGGTTrGATCCTITGGGGGAAATG7ITGGCCCCT

T

CATGATCTCACTGTGAGGGCTGGCTACCTTGG

AGCTICACTGTACTIGAAA'I'AT[IC'GGCCGAYFG

CCTC3TCGCTGGTr7ATGGGCACACACAGTIA CTrGTCTATGAGTCTITGTrAGGCTGAGCCTA

GTGGTGCAGGCCTGTCATCTCCCCTACTIAC

1M000441 TITAGGCTCTGAGGCAGGAGGAT 775 D

TCTGGTAACTL'GGGGGTCTGATAAAA

CAGTTGGGGGATITCTI=CflCGC

GTCTGAAGCCAATGTTATI'ACAGGTG

TGTGCTTGTCTCTCCCACACCCTGCCC

CTGTTGCCTAACACACGCGGCACACA

IM000442 CATG 776 D CATGACTCTlCCTCCAGAGTTAGAGGTGGAGC

CAGGACAAAGTCTAAAGAAAAGAAACCCCAA

TrcAAAAAGGGAAGCTGGTATCATCCAACCTTI 1M000443 AAATTACTCCACATCCGTCCAGAG 777 D

CATGTCTGTCCCAAAAGGAAGTTCCFICCTCT

GTCCTCCACATCTGACCAGCACCATCA3TCAA TCTGCAACCCAAACCAGACATTrACATCATCT ATGCCTCC1ICCTGCTTGTCTCCCCTCAACCA

GCACCCAGCAAGCTYCAGGTATCCCCTTAGT

GT7GTCAGGATCTCTCCAGT7CTCCAGACCCC 1M000444 AATTCTGTrCTCACTCTACACTGCTAGC 778 D AAAGCTAACTTrCTCATCACCTACCTAATAGCC TGAGAGCCCTGTGTAGAAAAAT-7AAGGAGTTI' IM000445 AGTTCCY[-CATG 779 C

CATGCAGACAAAGTAAATAAGAAAACAAATTI

IM000446 AAATGTAOGCTGGACGOATAGATGGT 780 D

CTCAGCTCCTAGGCAACAC'TGTAGACCCACA

GCCCCTTCACACACACACACACACACACACAC

ACACACACACACACGGCTGGGGATGCAACCC

ATCTCGTCC'11I'ACACGTGCTCTACCATCACAC CACACATTTCCAGCAC1TTATCTGAAGT'GMh IM000447 CC1TIA'rGTGCATG 781 K Wnt]

CATAACCACTATAACCAGCCTGCTTACYTGGC

'TfGTTTCGAGGGC=h~GTIAGAGCTCM~ CTI=rACCCTTCTCCGTGTGTGTGTGTGTGTG

TGTGTGTGTGTGTGTGTGTGTGTCTGTCTGTCT

IM000448 GTCTGTCITGjTCTGTCTTAGTrGYIG'L'ACATIG 782 C CATGTGGTCCACGGTI1ACTTfACTAGGGAG

CAACCTGTACCACAGGGAGAGAGGCCTAAGG

AGAGGAAAGGAGCTGACCCAGAACTFGAAAAG

IM000449 GCACACACCATTCTGCCAGCACTTCCC 783 C CATGTCCTACAGTGGACATI-IrfCTAAATrCCC FFCTf1TCAG=1CCTCGCCATATTTCACGT IM000450 ,CCrAAAGTGTGTATCTCTCAFI=CCGTTAMh 784 R TCAGGTATCTCGCCATATTCCAG'FrCCTACAG TGTGCATCTCATTCTrCACG1TI1CAGTGA TTTCGTCATITTATCAAGTCGTCAAGTGAA1Tr 1TrCAT1TTCTCTGA1TICAG=TICTCGCC CATGTrGCCTCAAGACAGATCTCCACTITTAAA GACATAGCTAAAGGCCTGGAAGCTrAGTCAAT TAAGC17CCTGCCCAGACACTCCTCCCTGAA

AAAGGTA'ITTAACCTCAGGCCCACCCTGAGAA

IM00045 1 GTGGGOTATGATI=ACTCATCCAcTrrc 785 R CATGGTrrCTA1TACTGTG1TGAAGCACCCTG ACCAAAGCCAA'rrGGGGGACGAAAGGGTITA TrGGCTrAAAC117CCAAATCAGTGTrrATCAT IM000452 TAAAGGAAGTCAGGGTAG 786 R

GGAAGTGTCAGACGGCTCTCAGGGAGATACA

CATAGC1TJAY[GGATAACTGCAGCTTGAAGA IM000453 CATG 787 D CATGTACCTATGTGTGTGTAAGATITFGCCTAT'r T-rCACACAG1rAAGAAAGCATCGT'rATGAAAA TCATTACAACT1rCCAGATAAACAGATCCACT ilI000454 CAGCCACAGAT 788 D GCCC1TCTCTCTGAACTI=CAGTTrCCTGGATA AAGTCAGTGTrCCACCTCTATACCTGACTAGT IM000455 TTrrcCTAAAT-CTGAGTCAAGCATATT-rCATG 789 D

GACCTCGTGGGCGGGCCTGAGGAGACAGTGC

AGATGAGGTGTCAGTAAGGAGGATGGAAGCA

AGAAAGATGGAGGAGATGATGGAGAAGCTGA

AGAAGGCACTGAAGAAGGCACAGGGAAGAA

IM000456 GAGTGCATG 790 D CrGCCGTrGAGAGCGTCCAGATCCCCTGACT TGAGTGGGTCCACCTrGTITTGG1TrGGTrCGC IM000457 AGTGTCGGCTGTGGAGCCCCAGGCCITGCATG 791 C

TTCTTAT)CCACTGAGCCACACTGCTAATACTG

IM000458 TGATGTC1TITIAAGACTCACCATG 792 D GGGTTCAACACATTMIGGAGA1TGATCAAAA 1M000459 TTAAAACATG 793 D

CATGAAGGAGAGTCTGAGGCTACATCCACCA

GGCTCTATGATCTCCCTCTGCTGCATCCAGGA

CA1TCTCCT'rCTGGATGAAGATGATGCTGGCG

CTGGCGCTGGCGCTGACGCTGATGCTGCTCGC

IM000460 TrrCTGCGTCCT 794 C

CCYJIGTCCTCAAATTACAAAACTCCC

TAGGGTCTMF-CTCTGGGCTACAAAA

TTCTGCAAATGGACTCAGGAGGAATC

AATGTGGAAATrCACTTrGCITrCC

CAATCAGCAAAATAATG'IMGCCAAA

ATCGT'TAGATTCTFrCCCCTAAGTAGA129 GCTACTGCCGACTTGAAAGCAGTGGTA429 IM000461 ITCCAGAACCCGAGCCCAGGGGCTGCC 795 B 8

ACTFCCTAITGCATG

CCCTTGTCCTCAAAYITACAAACTTCCT

TAGGGITLYTLT1TGGCTNCAAAATT

TTNCAAAGGGCTTCAGGAGGAATAAT

GGTGGGAAA'11ACTHGCTIrTCCA

ATCAACAAAAAAATGGTTGGCCAAA

TCGGTAGAAflCTITfCCCTAAATAAG

CTACTGCCGACTTFGAAAGCAGTGGGT

TCAGAACCCGACCCAAGGGCTGCCCT

IM000462 1ITCTATGCATG 796 D

CATGTATCITAAGAACAGAGCCAGTGCTCTCC

IM000463 CTCTCCCAC~rGAT 797 D

CATGCAGANTAAAGTACATATATGTAAAPAAA

IM000464 TAAAAATfAAATGTFFF 798 D

GTGCTCTCCCTTGCCTCTCCTCTCCTG

AGTITTCTCTGTAGGTGTAAGGGCTGG

AGGTGGGCCCAAGAACCAGAGATCA

GAGGAGGGAACTTCCGGAGCAGAGG

CCCTGGGAGCAGTGYFAAGCAGGCTrr

TGGCCAGGI'CTGGAGG'I'GTCCAGGCA

GGGAGGTGGAGCTGGAAGAGACCAA

TTAGTCAAACGGCTGCAATTGGCCAT

TTGGAAGCAATTAACAGGGTCTCCAT

TACCATATI'ATGCCCCTCCACCCCCTC

CACACTCTACTAGGCTCTGCTCTGTA

TGGAAGGGGGAAGGTGGAGGCTCAN

CTCAAGCCAGGGAGACTACAATGGA

GGCCCAGTGCTCGCCAGGATGCACAC

ACTCAGGCACCCTCCGTGTGAGGAGG

GGAGGGCAGGGCAGCATCTGAAGCA

ACCTGTCATTCACAGCCTGANAGANG

GTGGGAACAANGGCTTNCAAAGCCA

AGAANGCANGTGGNTAGAAATGCAN

GAAAACCTCTCTGGTAAGAAAGGC'I'G

AANGAAGCAGCTAGGGTTrGTAAAAC Fgf3/Fgf IM000465 AAGANCAT 799 K 4

CTCCCTCTCCCTCTAGCTGCICCTAGCAGGGGC

CAATACAACTGCAGGGAATCAAGGAAGAGCC

rL=CCTGAACTGTCCTGGATGCCCCAGTCCA ACAGCAACTCCCAC'FrGCCCTGGCTTGG1TG

CTCCACTGT'CCTGAAGGCACAGTGTGATATCC

CAGACCTCCAGCGAGACAGCCCAACCTGCAA

GCCTGATGGGAGGGGTGGCCTGAGACAACA A15 5005 IM000466 GTACCTACATG 800 B 7

CATGGACTCCAGGGTCAGGGTGTAAGAAAAA

GGTGGAGCCTGCTAGGTGTGGTGACACACAC

CTIfTAACCCCAGAACTCAGAAAGCTGAGGCA GGTGACTIAGCCAGGAGTTrCAAGGTCATCTAGT TCATCAGATCTATAGAGTGAAACACGCCAGGCT F]/g IM000467 ACAITGAGATC 801 K4

GCTCAACACTJTAAAAGCGCCTGCAGAGGGGT

GGGGGTTrAATCCCAGCACACACATAGTGGG TCAGGGAATCTGAAGCCCTCTrCTGGCCACTG IM000468 CGTGAACTGCATG 802 D

GTGGGAAGCTATACGAAAGTAAAACACACTC

TAAGAAAGAGAACAGGCTGCCTGGGAGAGGG

AGGTGCCAGGGGCTTAGACAGGAAGGTAGTT

TTCAAAAAGTGAAAAC'ITAAGCTATCTGAATG

AATGATACAAAATAAAAGAAGACACAAGAAT

TrCCAGTCACCTGAGATATCTCACACTCCTGT

TCTTTCAACCTTCTAGCTGAAAGGAGAAAGAG

IM000469 CCATG 803 D CATGGAAGGAGTrACAGAGACAATGMTGGA

GCTGAGACGAAAGGATGGACCATCTAGAGAC

TGCCATATCCAGGGATCCATC1TATAATCAGC

CTCCAAACCCTGACACCATTGCATACACCAGC

AAGATI=GCTGAAAGGACCCTGATATAGCTG

TCTCTTGTGAGGCTATGCTGGGGCCTAGCAAA

IM000470 CACAGT 804 R CATGCTTrAGATGACCGCAATATGTGTGGTAC TCTrCAGAC1T[AAAGATTTGCTGAATATCCT ATI'CCCCTrAAATTGTGATCACCCTAGCTAGA TCTAATCTrAGATCTCGAAAGTTCTACAATTT GCCTCAAMTGArrAGTGTI=CCTCCTTGAAG IM000471 AC 805 D

CTTGCCTTGGGAAGTGAGGGGTTCTAATGAAG

GTTFGCAAGCCTGTCCACCCAGGGCCCTGCTAA

AGAAGGAATGGTCCCCAGCCTGTITGTCCCC

TCTGTGGCTTCTrAGTTCTGGACACTGAGCCA GTCTGGGCAGCAGGCAATrCACACTGTGAATT

TCTGTGGAAAGCA=IIGGGGGTTCTGAAAGC

CCTGTACATrCTGTGFAAGGACAGAGGGCCT FgI3/Fgf IM000472 CCTGCATG 806 K 4

CATGGGGGCTATGTCCTAGGGTAGACACCCCC

m7ATCCCTCACCTCCTrCCCTGTCTrAGCAGT

GGTGTCCCCCACTGTGACTCTACTGCATCTGG

GAGCTGTCTCCCGGGGGACTTCCTCCTGCTGG

AGTGAGTAGGTGGCTAGGGCGAAGCCTGTGT

AAGAGGCAGGAGGTGTM~GCACAACTCCAA

AGGGTGCAGATCCTGCTGGCTCCAGCTrCCCA FgJ3/Fgf IM000473 GGGCCAGACCCCCAAATACcc1TCACCCAGC 807 K 4 GTGTATGTrCTCTGGTGAAAGTGTrAACCAGC TCACTCCGTGAAGAGCACGCTGCTrCAGATC AGTGTITCAGAGTCTTGAATAATI'GGTI1TAG

AATCATAAAATTGCAGTCCTITACAAAGGACT

IM000474 GGAAGTGAGTCATG 808 D CATGTGAATTCTCTATTrGCAATGTGCTTGGT-r GATACTrCCATACTCTACCCAGAGCCTGTTAG IM00475AAAAATCACTC'TCCCCACCCTATrCTTCACC 1M00475AGTCAATATGTATCTAGTATTCTAAACITCCT CCCTCGTAAGGjCAGjTGGGGAAG

CATGTGTACTCTCACCATCAGAATFATGAGGA

ACCCACAATTTCTrCACATTTATAACTGAGC AGI'cTIGAGGTIArFrGCC'I-1-AGCAACAGAAA IM000476 CTGAACTCAAAACAATCGGCACAC 810 C

CCATIATCAGACCAACC'ICCCACACAACAGTA

GGCCACCAGGTGGGGGCAAAGTCCTGGGTAA

GG1TIC'TTGGCACTGTAAT1TGAATCCCAATA IM000477 ATAATGACTGTG'I1ATTTGCTCATG 811 D TAAAACC1TAGGGAGCTGATAAAAATCTATC AAAACAACACTcTrGTCTCTCGTATCCAGCCAT 1M000478 CCATG 812 C TCTGCCCAGCC'FflTGCTrCCTFCCCTGGTAACA AA 1177 IM00 0479 GGATGCTAA'FrAGAATTCATG 813 B 84

CATGTAAAAAAAAACTTCAT-TAACAA

CTACAACAAAGCAGAGACC'GGCCC

TTGGATTGGGGCCCCTCTGAGAGCTA

IM000480 TAGGCTGGGATACTGG 814 D

GTGCGTGATAACCAGGCTGGCAGTGCCCTCTIG

CATCCCACATrGGGAACAGCAGCCTGATACTFC 1M000481 CAAGGCTGCCATG 815 D

ATGTCAACATTGAGTCCAGTAAGGACATCGTA

TATGCTGGTCA7FrATrATAGCTCrfAAGGGTrC

ATACATGAGACAGACCACCCCCTI'ACCCCCTC

CCCCGTCTGGGCTAAAAGCAGACACACTGGG

IM000482 TFGGTGAGAGAGCAGCAG 816 K WntI

CATGAGACAGACCACCCCCITACCCCCTCCCC

CGTCTGGGCTAAAAGCAGACACACTGGGITG

IM0 00483 GTGAGAGAGCAGCAG 817 K Wntl CATGAGAAAAATrGTCTCTAATTCTCT'TGYI GAATFMrGTGTGG'I1TIYGA'I'ATICAGGTGA'' IM000484 GTGGCCTCATACAATGAATGTGG 818 R CCAGTGAAGTAAACCCAGCAGGACCC1TPrAC 1M000485 AAAGCCAGGACATG 819 D TCGGGGGAAAGITIAn'TITATACCYFCCCGCT CTGGATrAAG(GGAGGGTAGGAAAGGATrGGA

TGAAGCTAGAGACAGAGTGGCAGGAAGGTGG

TAGACCTGAAATTrGTCAGACAACCACTTATCG YI7000AAGGGTATAAGGTGACCACAGCACTA GCAGACTGTrc~iGGACGTAGTAAGGAG'FI'CCT GCAGGGGAGGAGTGGGTCAGCCTrGAATCC IM000486 CATATGGTGG'I1TCACAAGTCAGCCTACATG 820 D CATGTG1TTTAGCAACTGTGCTCATThITCTGC

TGCTGCI'AGGAATAAAATCAAATCTAGTANA

A'ITGCT'1TAATACAAAGTTrATTGTCATCCATCT

CTGAAGATCTGAAGTATTGCTOGGGGGGTCTCC

1M000487 AACTCACCGACC 821 D

CAAGGGCCTCTCCTCCCACTGATGGTCGACCA

GGCCATGCTCTGCTACATATGCAGCTAGAGAC

ACAGGTCTGGGGGGGGGTACTGGTTAGTTCA

TATTGTTGTCCCTCCTATAGGGITGCAGACCA

CTTTAGGTCCCTGGGTACT-rCTCTAGCTCCTT CA'TAGGGGCCCTGTGTrCCATCCAATAGATG ACTGTGAGCTTCT-FATAAGCATAAAC1TCAC IM000488 TTACCACATG 822 R CATGGTGTrAGCCTCCAGGCAGGAAGCATACC AGAGGAGAACTCCACAGGAAGCC'rrGrr GTGCTGTTrAAAAACAAAGTATGATGGGGCTA

GAAGAGGCTTTAAGAGGTCCTCTGGAGAAAA

IM000489 GAATCTATTTTCCAT7 823 D

CATGAGAGGTTTAAGTCCTGAAAGACCATC

ATACCTAGAGTCTATACAACAAATAAACTTGG

AATACAGTGAAGCTAGTAAAAATAACrCCTG 1M000490 AGCTTATGG 824 D

CACAGTCAGGAAGCAGAAAGATGAACG'ITGA

CTCTCAGCTCTCCTrCTCCCTAGT-rCTATGG Fg/3/Fgfr IM000491 AGGTCTCCAGCCCATG 825 K 4 CATGATAAAAGTCTTGGAAAGATCAAGAA~r

CAAGGCCCATAAATAAACATAOTACAAGCAA

TATACAGCAAACACAGTAGCCAACATCAAAC

TAAATAGAGAGAAACT-rGAAACAATCCCACT

AAAATCAGGGACTAGACAAAGTTGCCCACTC

TCTCITAACTGTTCAATAGAGTACTCAAAAT

IM000492 CCTAGC 826 R CATGGTAGCTrrTCTAGTGAGGTCTCT IM000493 TCC 827 D

AGTACCCTTAGCCAATAAACCATCCCTCTAGT

CCCTGTTT G II II TAAAGACAGG Fg/3/Fgf IM000494 GTCTCACCATG 828 K 4

CATGAGCTAGGCCATCTGCAAGCTGGTCTCGT

CrrGACCAGGAGTACACAGAAGCCTGGCTCA IM000495 GGACTTGGTAAC 829 D GTrGMTATGCAGATCTCTCAGCGUTAGC(AT CTATGGGA1Tl IGGAAGACCyf-CAGTl ATCTTCCA1TTCTGAGGCTGMTCTAGGCAAC GGAGTGGTACCCTFIAATCTnCCCCTGAC C1TICTGCCTATGAAGATG'rrGACTAGTGAG CCCGTGGGGATGTGTA~rATCTGnACAMA MIATGGC1TGGTAGCGACTCCTG~fGTGT'G 1M000496 TCAGCTrCATG 830 D

CATGCCTCCCTCAGCCTCCTCCCACC

CCTI'CCTGTCCTGCCTCCTCATCACTG

TGTAAATAATrGCACCGAAATGTGG

CCGCAGAGCCACGCGTTGGGTTATGT

AAATAAAACTAMrATTGTGCTGGGT IM000497 TC 831 K WntJ TCTAAGTCCAGTC=rCACACACACTGACrlTF IM000498 GGTCATCTGTAATCACAACArIG 832 D GATGCACACAAACTGGCCCTGAACmprGAC-r TCCAGGCCTC'rGCCTCTCTGCGCGCACACACA CACTCGCAC'ICCTIGTATATGAAGCGTATATGT Fgf3/Fgf rM000499 GTYI7CTCTGGGAACTGrITIATCAGGTGAAG 833 K 4

GGGCTGAAGGAAAATG'TGTGTCATC

IM000500 YT7GTGGCATG 834 D

CATGTACCACTT[GCTAATCCCCTA

AGCGCCCCTTGGTAAGCATCTAAAGT

GATATATCTCYJIGGTCTACTGAAGTT

CTGCCCTGTCTCCATCGGGGATTCTC

GGGAGGCTAAAA'ITATAGACTAYTTG

IM000501 TGAAAG 835 D 1M000502 CATGTCCTTATGATATGGAAAAA 836 D

CATGTGCGAAGAGCCATTACAGGCTC

AGACTAACATCTGCCTGTAAACAACG

GTTGCTAAGTTCCAGGGAAGCGTAA

IM000503 G 837 D CCAGATGACCTTGAACTCAGAGATCTCCfl-TGC C'ITAGCCTCCTGGGA~rCATAGCCGCTATIGCC 1M000504 TCAAGATCTCCATG 838 R

CATGTAGITGCAAACAAGACATCCCTIGGTAT

IM000505 ATCCAGAACC'rGAGCTATGC 839 D GGATATAGTGTCAAACAGTCTGATGTAT-fCA'I' AGGTMGTATCCATAGTTATCAAATrCTC''CAT 1M000506 G 840 D CATGTACCACACACAGACTrGGTA.AI'AGTTA GATGATAA1TACAAAAGCAACAAAITAAAACC 1M000507 AACAAAACAAAACAAAGCTTGGTAATA 841 D GT'rAGGAGCACGAACI'GCTC1TCAGAGGACC 1M000508 TGGGMTAATTFCCCAACACTCACATG 842 R CATcGICAA'rGATAAACA'FrCCAAAACACCA AAACCATCCrCTCTGTACAGGCTATGATGATr CAACTGCTGCCC7ZrCCTCAfflTCTTGTTCCCAA IMOO0509 CTCCTACTGAATATTTCCTGCAT 843 D

CATGATAGAAGACCACGTCTGGGATGGGGTA

AGGGM~CTCAGAGTACCTfGCCCTGGGGCCA IM0005 10 CATCCTAAATCTACAACAAAGCTGACCCTA 844 D CAAGT1TIGTAAGGGAGCTAAGAAAGGCATT OTTGGTFAGG'TrGGAAAGAGGGGGCAGGACC

TGGCTCTCGCTTCAGCCCACTCCCCTCTGCCCC

CCAGCCTCAAACACT1TACCCTAGCATAGCA IM000511 GAAACATG 845 D W00012)CATGAACTCAGTGGGCAGATGAAGAGfyI=G 84K 1M005 12TGTGAACTGGGGCTIrrGCCCTTATCATCCTGT 86 K FJ/g GTGTTCTCCTGGTGACCCTCAAGCTTGGCTGC 4 AATGATCCCCAC1TACAGAT

GTTTAITACTCCAATGATTCGCACAGCCGGGT

TGCAAGTCTAAGGCAGGCTGTCTGCCTrCCTG GAGGTACrACCCCACCTCCCCCTCTGGGGGA IM000513 GCTCCACTTGGCCATG 847 R CATGAFICrAG1TTGCCATAT-FCCACGT TCTACAGTAGACAflCTAATCCAJLCTp' TTCAG1TrCCTCGCCATA1TTCACGTCCTAAA GTGTGAAT17CTCATTCCGTGATITCAGTF- IM000514 TTCTCGCCATATTCCAGGTC 848 R GTAACCACTCA1TACCTGCCCCAATGATGTC TGGGCCAAGGCACTrAAATrCATATCTACT IM000515 GTGACTATAGGTGCCCATG 849 D CATGACACTGCTCACTGTrGCTCTCTAACCn IM000516 GGTCCAG 850 D GNGCTrGGCAGAGTAGAGAAACTC1TrGGGA IM0005 17 AACTrGGTTCAGATCCAGACATG 851 C CACCTCTGCCTCAGTirTCCCTGATTAT IM0 005 18 CAACAAGTGCTCATG 852 D

CATGTAACTCAAGAAAGTGTAGTAGGCGTAGT

GGTAAATGCCTrTGATCCCAGCACTTGGGAGG TAGAGGCAGGTGGGATCTCTACA~FlC&G

ACTGGTCTGGTCTATATAGTGAGFTCCAGGCC

AACCTCACATrGAATrCATCTCA4ACAAT IM000519 AAAAATAGAGGAAGATATAGTCAGGCAC 853 R GAAGACATTCATTITI=CTrGGGAGGGGATA 1M000520 GAATCCAAGGCTCCAAAGCAGAGUTCATG 854 D

GACCACGCTGGCCTCGAACTCAGAAATCTGCC

TGCCTCTGCCTCCCAAGTGCTGGGAIh&AGG CTGTGCCACCACTGTGCTrACTGATCTCMIGA TGTCCCAGTTATAGCTCTTGGGflCCCCACCC A MTGTAGGGGGACCCAGGACACCTCAGAGC TCTCCCAAGTCTAAAAAGGGCAGGyrCTOG CTCCCTTAATGCCT'rATCAAGCACAACAGAAC TCAGGGGCAGAAATGrrFCCCAGGAAGAACT IM000521 TAGCTGTGGGGAGAGTCATG 855 R CAT=RCTIT7ATAGCTGAGTGUTATCCACTG CAAAAAMTGAATATrCCACTATUCTGU7GAT GAATGTTAGGCTGGTCACGTTCTTC~p.'

GTGAATGGAGCAGCAATAAACATAAGTGGGC

IM000522 ATG 856 D

CTCCATTGGGCCGAGTGAAGCTGTGGTTCAGA

GAAACTCTATGGACAAGCTGACnCCAGAAC ATrGACCTGTCTTGAGATCAACAGCGTAG IM000523 GAAAGCCATG 857 D 1M000524 CATGGGAAAGTAATCCGTGGCTAACACAAAG 1858 D

GGGAAATAAAGTAATATT

CATGTAGGACCCTGAATGCCAGCAATGAACA

ATAGCAGCTFGGTMCGGACTCTTGC'v-FrCTC CTCCCTCCACTACTAACTfACiCCTCACCG1TrGC ATCTFIGTGACTCAGAGGTCTG'rrrCCAGGC 'FrCCTTCCT-rCCAGTGTTCT'rCTAATGCATCTA IM000525 AAGTGAAGGGGTGG 859 D

CATGCAAAGCCTCTGCAGGGCCGACAGCAAG

GAAGGCCCT'rCTAGATCTCCAGCACTCIc3TcA

AAAGCCATCACTCGGGAGGCAGGCAACCACA

ATGTAGGGAAGACCTGTAAAGCCT'rCAGAGA

GGAACAGCTIGGCAGCCCCTGGGTCACTCAGA

GTGGCCAACAGCTACTC'rGTGGAGACAGCA

GGAGGAGGCCTAGACTATAGAAGGATGGAGG

1M000526 AC 860 D CATGCACACAAACTGGCCCTGAACTrrGACT

TCCAGGCCTCTGCCTCTCTGCGCTCACACACA

CACTCGCACTCCTrGTIATATrGAAGCGTATATGT Fgf3/Fgf IM000527 GMITCTGGG 861 K 4 CATGAAACATTATTfN=1fGGAAGI' IM000528 CTGCAGGTAAACTrAAATAGG'rTAJ\ 862 R AGCAAGAACAAAGGAAGTAC7FrCACCTGATA

AAAACAGTTCCCAGAGAAACACATATACOCT

TCATAI'ACAGGAGTFGCGAGTGTGTGTGTGAGC

GCAGAGAGGCAGAGGCCTGGAAGTCAAAGT Fgf3Fgf IM000529 TCAGGGCCAG'ITGTGTGCATG 863 K 4 GAT-FYTrA1TCCTFAGCATCCTGATTGGAGA FgJ3Fgf IM000530 TGCCTGGGTGCACATG 864 K 4

CATGTAGAGACTGCCATATCGAGGGATCCACC

CCATAATCAGCATCCAAACACTGACACCATTG

CATACACTAGCAAGAThI'TAT'TGAAAGGACGC IM000531I AGATCJ'rAG 865 R GACCTGTACCCTACCCTCTGATGGAGGCCA'[c TA'1TGCCTGTCCCCAGGAGTCCCCAAACTGC

TCAAAGAACAGACTGTGGGCTCTGGAAAGCT

AGCAGGITGACCCCGGGGGATGTTCTGAGCAG

TGCCTrACTGAAGFITATCCAGGCCCTAGGGjT

CCCCTCAACTGCTCACACAGCCTAGGGTGGGT

CTCTTGAGGAGTCACT'rGTCACT-TCTG1'I'GCYF

CCCAAGAGACCCAGGGAAAAAAGGAAGGAA

IM000532 GGCCATG 866 D ATCTCACTCGTrAAAATGAACAAAGGGACTGC AGAGATGGCTCTGAGCT1TfAAGACCAT'AGCC

TGCPVITCCAGAGAGCCCAGGCTTCATI-CCC

AGCCCACATATGGCAGI-rCACAACCA'rCTACA ACTCTAGTTCCTGGGGATCTCACACT1-~JGTCT TCTGTGGGCACTGCGCAAATGTGCACAGAAAT Fg(3/Fgf IM000533 ACACGCAAGGAAAACACCCATG 867 K 4

AAGAAACACTCTTAGCTGGGCCTGGAAGTGC

1M000534 ACATG 868 D CTAAAGCAGATTATrATACrrTUCTACTGAC

CATAATGCAACCACTATATATAAA&CAGAACA

TACTATAAGTGAATAACArTAGGATACAAA&J ATGTATAAAAGGGGAGAGAGGATAACCAT'rG TGAAGTATGTIAAATAAAATGTIT7GGGATn-T GAGGAAArrAATAAATrAGTACCCTnTGC 1M000535 'I1TGGGGAAAGAAAGGCAGCATG 869 D

CAGCCCCAAACCCATCAGCCTGAGACTGATGC

ACAGGAGGCAGGCCAGTI'AGT-rATTCTCTGGG CCCCTCTA I I IIGCCTrCTGTAGGTTAATCCCA CCGCTCCCAGTGCTGGAAAGTGCAAGCATrGT 1M000536 GGGAAGTTAAAAACGTGCCACCATG 870 D

CATGGACAATGCACCCCTCAAGCAGTGTCTTC

CATACAGACAAGCATATrATICTATACAG Fg/3Fgf IM000537 ACAGCAAC'FIGCTGAGGTGTAAGG 871 K 4 GGATGAAGAAGCCCkAAGGTATAGGTCAGTC TTGCTCTGACTrCTCACAGTAAAAATACAACT

CCCAGGGACTAAAATGACACAGAACAGCUTA

GCCTCTGGACA7ITGCTTFrGGATrGCAAAGTG ATAAGTGAAAAAGTAATAAGTCTATCTAGAfT GGAAAACATrTGGTAACnTCAMIAAACACAC 1M000538 TGCCCATG 872 D CATGTCCTACATTGGACATyfCTA =r~CCATCTTITCAGTT1CCTCAC

CATATTCACGTCCTAAAGTGTGTAT

TTCTTCACGTGTArrCGTrGGTTGUTGG

TTTAGTTCCTGGGAGCTCTGGAAATC

IM000539 TGAFI'ATT 873 R TGGAAAATGAGAAACATCCACTrGACGACTT

GAAAAATGAGGAAATCACTAAAAAACGTGAA

AAATGAGAAATGCACACTGAGGGACCTGGAA

TATGGCGAGAAAACTGAAAATCACGGAAAAJT

GAGAAATACACAG1TAGGACGTGTAATATGT CGAGGAAAACTGAAAAGGGTGGAGAAmIAG

AAATGTCCACTGTAGGACGTGGAATATGGCA

IN4000540 Ac3AAAACTGAAAATCATG 874 R

TGACATACAGAAAGAACACAAATACCTGTAG

CTGCTGTGACAGGACCAACCA'rrCTAAATATC

AAAGCAGCTGTTGACACCTAAGGACTGGTCTG

ACTGCTAGATCTAGGAGTrCAACUrGCAAA IM000541 GCTGGCTITGATGCTCATG 875 C TTATATATATATATCG1TrTCrnACTCCTGA 1M000542 ATCAGTGACATG 876 D

CATGTCAGCCCTCAGCMTACACAGGTGTCAA

AAAAAAACCOCGGTTC

GTCTGCCA1'rAGCTGTTATTGTGTACAT-rAAG IM000543 TAATCCGTrACCGCAT~G 877 D

TCACCCCAGTATTCAAGGAGGTGCCACAGGA

CTCAAAGGATACAGAAGTFACATA'1-'AAAXC

CCAATCTCGTAGAGGATTCAGAGGAACTAAG

TT~GGAGGGGCACAGATTGTAGTACCATTFAA

GCCCCTCTGTrCCTCGTGGAGAACCACTACTG

TCCAGCAAGGCGGGAAGGACCCAAATCAAGC

AAATGAGACTrGTTcTrGG

CATGATANATCCCITFGTGAGCAT

TCCATAGCCTCAGTAATAGTGTCTGA

CCTTGGGACCACGCTGTATCCCACTN

TGGGACCTITCYI=CNTCAGGCTACTC

TCCATF1rCCATrfNCTGTAAII'CTTTCA

ACAGAAACA'TATGGGTCANAGGTG

TGACTGTGGGAGGACAACCCCATCCC

TCAC'ITGATGTCCTGTCTTCCTGCTGG

AGGTGGGCTFATAAGTCCCTNCCC

CTACTGNCCAGCAYITCATCAAAGAT

CCCTCCCTAGGAATCCT'GGGAACCTC

IM000544 TC 878 D GATAAGCT-fATCTTGAACTrGAATGTATATGG

AGAAGCAGAAACCTGAAACAGCCCACAGA

ACTGAAGAAGGATGAAGGGAC'r*C'rCAOC IM000545 T'GGAATA'FCAITG 879 D CATGTTCCCAGCTGcJGCAAGGCCTCGGG'ITICC

TCGGTGAAGAGTGTGGACCAGCCGATFGAGCC

CTCCGACG'IOCTGGATGAAACGGCTGGC'FFrTG MTAGTITGTrTAACCTCCCCAACGAGACTr TGATCAGCTCCACcTrcGAAAATGTUCGCGAAA

GATGCGGAGAGCCTGAGGGACTGCGGGGCAG

CAACGGGCTCCGGCCTAGCCGGGCCCGCCGG A14 1328 IM000546 CCCCCAGA 880 B3 8 ACCAAGTGT[AATAATGTACTGArG'(GCyToIC IM000 547 CCTGTGGCAGTACAC1TrGTCCTCTrACACATG 881 C CC~rACTGCAGAGATGACTCGGCCAACGGC'1 CGAGCCCCTGACCAC'TCCTCAGGTIrGGT'FI TGTTrAGiTflTCTCACAGCAAITGGGAAGCAT

AATCAATACAACTT-CCCAGAATGCGACCTGTG

ACAAGGCGAATGAGCAGACTCAAGGCT(JGUC

ACATAAAAGCACCA A AA AA AAAACTCCCI7 IM000548 GCAGTTA117G'FCATG 882 D

GACTGAGCCTGCCTGGGGCCGTAGGG

AAGGGGGGGTTGGACCCTCTGGTATT

TGCAGTTACCACTOACAGGEITTT=C

CGAGATGCCAGTGTCAGGGTGTITCGG

TGCTGACCCCCCAGGGACCGTGCAGC

CCCGATGGCTGTCI'CGGTCCTCTCM4 CM-fICCGCCACCCCTGGGATATI'CA

GGACTCANTCCCCGCAACAGCTCTGA

CTGAGGTCAGCTCTGTGACCAGGGNC

CCTGTCCCCGGTGTGNNGTGTATFIG

IM000549 CATG 883 K Wnl] CATGTAGAAGGCAGAGGACAACC1TCAGGGA IM000550 TTAnTICTGCCCGAC 884 C GT-rCCTCGAT'rCFGCTGC'ITCTCCGTGATACAT TGAGT'rACAGCAGCCCACGCGTACACACTCTC 1M000551 GCACATG 885 K W,tl

CATGCCACCAACAAATAAGTAAGTA&AAG

AAGGAAGGAAGGAAGGAAGGAAAGAAAGAA

I1M000552 AACA1TrAAATCTGTAAT 886 D CGGAGC~rAGGTCTATCAMTAAAGATACAAC CAAATAGGCAGAATCATrCCTGAGGAOCCC

ATF=CMTATCTCAGGTCCTGCAGATTTCTCC

CTGGTA'TrATCAGGGAGGAGCAc3CAGCTGAG CTATCCTATCTCCrTTACTAATAGAAAAAACG

CCMIAGGGCTTGAGCACAGGACCTGTAMJIC

AGGGGAATGTTGACAATCCATAACTCCAGGG

TGGACTACTAAGCCCTGCAAGGTGAGTGIAC

IM000553 CCCGGCCGAGAATAAGGCCCATG 887 R CATGGCCTGAGAGTGGAAGAGTAUrGTA GCAGGGGTrGT[CCAGAAAGM~AGAATATAC AGACACTATACTCTATCCAGACT7C-FGGCAC AGGGAGTTrCAAATGTAGACTCTGAGCCCCGTC CTGGGGCAGCTrC'TCCACCTGC I IGGGTAG AAGCAGGCAX3ACTCTGGGTAGACTCTGA1TCC

AAGGCTAAGTAACCCCTGAACCCAGAACAGT

IM000554 G=T~C 888 D CCAGATATCATACTGAGTTCGTAGGTGGyT]- IM000555 AATTAATCACGGGCCCCTGGCATGj 889 D

TTGGTGATCCAAACCCAAAGAGACAAATGCT

GAATGTCACTCTCAT=CTFGUrCTAGCTCC AATCTrCAGATATGAGTAAGCAACACATA

ATTFATGAAGGGACCATACTGGGATGTAGGGG

IM000556 GCTTGCATG 890 D

CATGAGCACTGCTCTAGGGACACCTC

CCATCCCT'TCCTAGCACCCCAAATGC

CCCT'rCCCATCTCTCCTTrCCAGAAGnT 1M000557 GGA 891 K Wnt-3

ATATAGCTGTCTCCTGAGGGCCTATGCCAGTG

CCTGGCAAATACAGAAGTGGATGCTCACJ&AT

CATCCAT-rGGACAGAGCACAGAGTCCCCAAT

GAAGGAGCTAGAGAAAGTACCCAAG(JAGCTG

AAGGGGTCTGAAGCCCCATAGGAGGJ&ACATC

AATATGAACTAACCAGTGCCCCCAAGpCCT TAGAAC7AAACCACCAATCAAAGAAAACACA IM000558 TG 892 R CATGATAAGGTTAGAG=1GTGAGCTCCP.

AACCTITGCTCAGCAAGCGTrooGTTy'rGCA GCCGAGCTGCCATC17CTCATCCCCGATAGA GCCAGCCGCCCfGTCGTGTCGTAGH I14000559 AGAGGAGGCATTATAGAGCGGACC-1A&ACAT .893 D TrOCCTTGGAGCCTGAGGGATGGGGA'FrGGCT

GAATGTGAAT

CAGAAcTrGTGCTCTIAGGAAGCCAGACGC'I'A TGCCTTAGGCCCTG'rrCGCTGCAGACCI'1GCTC IM000560 TGiTGCTIACAGTGTAAAAGCGAAGATCATG 894 D

GAGAATTAGAAAAGAGAI'AACAAAGGCGAGA

IM000561 AAGAGAGGCGTGTGAGAGCATG 895 D

GTTITCCAGAYIG(TCCTAGTAGCGTGGGCTGCAG

IM000562 GAACAGCCAGCATG 896 C

GGGGGTGGGGGTGGTAAGAGAAGATTAAITA

GCCTAGCATATATAAGGTITGGATTrCAATCT'

TCAACTCCACCCCTTAAAGAATAAATAAACAA

GTAGATAGATTATAGACAGACAGcTrAGATGG

ATAGACAGATAGCTACATAGATACATAGATA

GATGATAGATAATrAGACAGACAGACAGATAA

ATGATAGATAGATGATAGGAAGTCCCAGUTA

ACAAATGGAAATAAAAAGACAAAAGTCCCCTr IM000563 TTGTCCATG 897 D GTATATGGAATATGGCAAGAAAACTGAAAATr IM000564 CATG 898 R

CATGGTAAAGGTCAGGAGTACACCTGTGCTTC

TGTGTTCT-rCTGTGTTGGCTGACAGCTGGGCA

GAAGTGAGTTCAGGAGGNCAACCCATACGAT

GAGACAAGCCGGGGCAAAGTGGGATATGTGG

ACCGCAGCACATCAGAAGGGTGTGCCCGACA AAI 1113 IM000565 TAC899 B 54 CATGAAGTATA'T7A'IAGAGGGGAACTAGTCT TACTGCTGAGCAGCGTGTTG'rCI'ICTIACAGAG GATrGTTT"IGTGTrTCTGGAAThFTAAAATTACTTlA

AAGTIAATAGTGTCAATGAAACGTTGTCCGGTG

ACTrGCTTCYTTAAATGATCACTrGTTrAGACA IM000566 GGGA 900 R

AATAATCAGATTTCCAGAGCTCCCAG

GAACTAAACCAACAACCAACGAATA

IM000567 CACATG 901 R CATGAT'ITGATAGGGTT1TGGTTCTCTGGA ATCTAACTrC1TGAGTr=GTGTATIA'rTGGA IM000568 TA11'AGCCC1'Cr 902 R GCAAAT'AGTCG-'fTGTACCGAACT'TCCACACA GTAATGTAGTGAAYVIA1TAAAA'flTATF7CCTrT AATCTITrTAAAGTCCAGACTCTATCCCCCT CC~rGTCCACCCTCTGATTGTTCCACATCCCAT IM000569 ACCTCCTTGCCTCATG 903 R TTCCATCTCT'GTA7ITCTGT-rGCTGATGCTCAC ATCTATGTTTCCAGA'IIC'I-rrCCTAGITG1TF'C TATICTICCACTGTTIGCCTCACTFGGG'TMI1 TA~rGTGTCCACT17CC1TVIAGGTCrrGGAT IM000570 ,GGT1T'rGAATTCCATCACCTrnTrGG-TGT 904 C GTTrCCTGCAATrCITrAAGGGA1TTGTGT TTCCTCF=AATGTCT7CTACCTGT1GGT1-AT G1TICCTGTAATTC1rAAGGGATI=IGTGT T'rCCTcTIAATGTCTrCTACTGTITAGCAGT G1TCTCCTGCATrTCMIAAGTGAGTrATTTAA GTCCTTCrGATTCCTCTACCATCATCATG CATGAG=r~CTACTTrATAAAATTATATA AAGTCAT1AGTAGAACCTAGCMTAT7AAT T1TACCAATTAATATAAGGCCACTGATATrAT TGACTrTrGTCACTACAAAATACAGCAATGAA ATAAT=flCTTCTAGGCTCCTCCTCACAA CTAGTTCITCAGCTCACATrAATAC'Ir=CA AGTrGTAAGGGACCTCAGGGACAGGGGGC IM00057 1 905 CATGAGCTrATAG1CAGTAAGAGAGCATAG ATAGAATATAGGTGCCTGTGCGCTGCTCrT TGGTrGTAT1TTAAATCCTrrATCTCTGAGAAGT CGGAACTGTrrGGCAACAGACAATATGGTAGC IM000572 c 906 D

CTGACACAGGTATGCCCAGTCCATAGTGTGCA

GAGCACAGATGGCCAAGGATAACTAGGAATG

AGACCTACTAACCCAAACTCCAAACAT-rATG AAACTIAAAAAAATGAC1TCAGTTGAAc=r 1M000573 GCAGGTAACCACATCATG 907 D ATGTGTCC'TrrAACA1TCTTGCTTI'AGTAGA ACATCCTCTGACCCGTATCTGATTrCAGTGAAA AATFCCTrCACGAGTCTGCCTrAGCAAAACAT CCIrGACCTGTGTCTGCTrCAGGAAAACACC IM000574 CCTTCACATG 908 R

CATGTTGGTAACAGATACAACAAGCAGACTT

AAACTAATAAGAAAACAGCTATGATTAATAT

GTTrTATAACTTAGCTGAAGAGAATGTATGGAG C1T-rGAAG-rAATCT=rCATATACACAGGAA

TGCCTTCAAAAAGCATTGCAGCAGATF[CA&A

IM000575 GGATTAAACTCAT 909 D CATGTGGCGAACCAGCATCACTTGCTTTr CCTACTAACCCAGGACATCCATCAnrATII

AATAGCATCCACCCTAGTAGATATAAGGTGAT

ACCTTATTrGTGAMrCA1TTGCCTrCTCTGAA GATCACTAACAATCAAAATCTGGTrCATM-yI TTTATGAATrCTCATTTGTCTJ-I

IIGCTAAATAT

ATGTCACAATC11CAAMAAAAGCAA TTGTI=G1TAATAATGAGCTAACTI=CATAC 1M000576 AT-rGAAG 910 D

TTGCTGTGGGCCTAATTCAAGGCTGA

TAGATCACCACAGAAGGACACTG1T

TCCTCCGGGCAGCAGGAAGTACAGG

GTAGGGACTCTAGAATCACTGCCCTA A166396 IM000577 GGGCATG 911 B 9 GTACTrGAAGTTITrAGCTAGAGCAAAAAGAC IM000578 tAATGGAAGGAGATCAAGGGAATACAAAGTGG 912 R GAAAGAAGTCAcJAGTATCA'fl7ATc3TCCAGG'I'

GATATGATAGITATACATAAATGACCCTAITAGA

Y[FACACCTAAGACCTCTACAGTGGATAAATAC

TAAAATATrrACTACACAGAAATCACCCCATG CATGCAAGGTATGAAcTrCACTAATAA IM000579 GGGGATA 913 D CATGGTrICACACTCCATAATATCTTGTTFCTCAC

TAATTCCTCTAATCCCATAATATACACCAATA

A1i-i-AACAAGGGAATTTCTIACATTGA3TrGTA ATAAGGGAGATACTGTGTGAACfACCCAC

AAAAGTCTCCAATAGAAGTGTGGATACCACA

GGAAGTC1GTGACAACCA117AAAATJTGGGT

CTGATAAGAAGATAACCCITAAATATATAGA

IM000580 ITATGTAAAG 914 D

GATGGGCTGGGGAAAGGCAGAGAGAAGAACA

TCTGGATTGTTCCTAACMhGCC1TrAAAATGA GACTTCAATAATACTTAGACGTACCAGCTfCT CACAGTCAGT'rAAAATGTrGACACACAGACCTC IM000581 TCAGCAGACTGAATGGGTGAG 915 D AGAGATGGTTGGGA3TTAAGT-FlACCA

GGGTAGGGTCACCACAATCAACCCTT

IM000582 GATGCCTTTrATAGGAAGAAACATG 916 D CATGGAAGTCTAAAAGACATrAGGTTCTGGAT GGAAGAAGAGAAAA11'ATC'T7AAGFI=AGA

AAAGGGATGATAAAACAAGTCTTAAATCTTCT

CAATT-frGCCATAATTCA11GAATrAATA~rG

GTAAATGCTTGTGTGGTCCCATAAAGTTCA

TGTGTTATATCACTAAGTAGTrATTTGTAAAA 1M000583 TTATAAATAGCCTCTAT 917 C CTTGTGAATTG1TTAACTGThFTGAAAAAGTA

GATGTTTCTCTATTFATTIT-FGGGACAATTAT

CAGAATrTGAAACAAACTGTGTATCTCTrATr IM0005 84 I'ACJ-TCTGCTTAACCCCCATG 918 D CATGG'IrGCTATA'FrCATrAACACAAATCATr TAAAATCCTTrAATGTAAAATGGGCACATrTTC AAAATrAAAATAT'ATIGAAAACCAA'rAAAGAT

AGAAAATTI'AGGAAAAAAAATAATCCAAGCA

AGATGTrAAGATCCAACCACAGCAGCAT'ATII'A

GCAGCAGGACAAAAATAAGGACAACAACCAA

GAAAGGGATrGTGGTTAATGTATGCCTCATTG GAAGGGATAATAGGATGTAAAAGTG'rGAGAA

TAAAGAGAAAAAAATCTCTMIAAAATGTAA

GTTAAAATAATAAAAATAAT-hrAAAAATTFGGTr G1TCTCAGGGCTGGATAATA'fl'ACTAACAAAA CCAGGGAATTATrAATAAAAAATCTCTTATCA IM000585 GTTAT 919 D AACAAGITI'AAATrGGGGCATAGTGGATGAC A1TIGTGATCCCAGCAGTTGGAAGGTAGAAAT AGGTAAATAAGAGTTCAAGGTCATrCTCAG 1M000586 n-ATIGTAGTTGTACArICTAGCGATGTAGTTr 920 D

GAGTTCAAGGCCATG

GTCCTCCAATGTGCATCTCA1T1TCACGTT IM000587 TITCAGGT-fCTCGCCATAFIcCATG 921 R AAITGCAFrGAATCTGTGGA1TrCTA1TAACA AGATGOCCATFIr=CCTATGTTAATCGTACT

GATCCATCAGGATGGCAGTCMJCCATCTTCT

GATATCGGCCTCAA'ITrCTTCAGGGGCITT IM000588 GAAGTTATCGCCATG 922 R GGCTAGGTACTCCTAAACG1TCCTCTGCTATC IM000589 CTAGGCCCAATAGAAAAAAAGTGGCCCATG 923 D AATAATACTrCACTGTACTrAAAATATTAT

CTCCTATCTCACTCTAATAC'CTGTGAAAGA

AGCAATATCGTCTCTITGTAGATAAAAATGGC

TGAGAAGGGCACCTTrCAAGACACTAAGTGAC IM000590 TAACTCAGACTCAGAAGTTCAGAGACCATG 924 D CATGCTCTACTATGTrCACAGCAGTCT-A-TrrA TAAC3TCCAGATACTGGAAGCAACTCAGATGT

TCCTCAATGTAAGAATGGATACAGAAAAT

ATGGTACAMTACACAATGGGGTACAACTCAG

IM000591 CrTTAAGiAACAATGAC 925 R

AAAACCCAAGAACAATTAAGCTGTA

GTJ'CCCAAGTGTAATTATATTATGGT

TGMrCTGCTTGCTTrATATCCCTATA TACAAMTATGATFCAAGTAHrAGTG IM000592 GGAATAGACTAATGGCATG 926 C IM000593 CATGCCAAGCCTI'CTGGTATCACCCTAAAGGC 927 C- CATGCTCTTCTCTGCTGrrCTrACTGAAy-Tfl AATAAGAACAATrCCACACAGTGAAGCA CTGCTCAATrAAGAGATATTCCTACCAGGCAT CTTrGGAATCCTGCAA.GCACCTCTTCTCTGTr CCrGATGACCCTCAAM~GGTrGTGTCCAGAG

GTGGTGOGGAGGAGGGGAGGGGAAACGAA

GCrrATTTrrAATGCAAGTCAATMAJ~' IM000594 CAATGTTCTCGAT 928 D CATGCTAGGCAAATGCTCCACTGAATGAATrA CATITCCAATCTIAGATGCA=r-AAAGAG AAAAGATrGAGTACTGAAG-II-GAATAGAAT

ACAGGAATAAGGGACTAAACATATATATAGC

CTTATATAGAGAAATArAAGTAAGTAGTAAC 1M000595 Ti-rGCrGTGTGTGTGTGTGTG~rGCACAC 929 D CATGCCA'TrAGTCTATTCCCACTAATACTUGA ATCATAAATrGTATATAGGGATATAJ&AGCAA GCAGAAACAACCATAATATAATrACACTTGG 1M000596 GAACTACAGCTAArrGTC1-GGGT= 930 C

CATGCACAGCTGGTGAGTGAGTTGTCTTCTGG

TACAAAAATCTCCTCACAGGCACATrACAAG

TGCCTATATCTTGCTAGCITCAAGAACACA

I M000597 JAGAAGGGACACACAAAAGCTCrCTGAGTT 931 _A D

CCITCTCCTGCTGI'I'AFUTG

ATCGTCAAAGTTIAGCAAAATTATAAATGI'GAA

1M000598 ArrCATG 932 D

CATGAAKFATGTTTGTTITATITCTTT

TGTACATCATTCAATGCAGTAATCTA

AAGT1TGGGGTC'I1IGGTCTTATATCTT GGAACTTCAGTGACYT'ATrIGGTTrCTA 1M000599 ACG 933 D AGAGACAGTCACAAAAGGGGCCCATFFCTTG'11

AAGAATGGGGCAGTGGAGAAGTTCGGGTTAG

TGGAGTAGCCTGCCTCAcYITCCTCCTGTCTTC F-gf3/Fgf IM000600 TGTAG'ITAAATGTGjTTAATGGITFAACATG 934 K 4 1M000601 CATGTAGCATITFATCTI'AGCCAGCAC 935 D CATGTACAGACTATGAACAGiGAAATGTTTTTG

CAAATAACTCTGTGCATTAGAATMTTCAG

AAATATAACCA1TITGACAG1TGTAGG1TIACA C11TIAAAATTACAAAATCAATAAAATTGATC TACAAACCGAGGCCIFACAAAACCCIrGCTGG IM000602 ATATrGAAGACGGGATAATATTAAAG 4-56 936 D AAYPCCCACCACCCACAGGGTGGCTCCATrAAC

CATCTIGTAACTCCAGTCTCAGGGAGTCCAAGG

CCCTCMTTGGCTTGCAAGGGCTrGCACACAC Fg/3Fg/ IM000603 ACAGCGCACACATG 937 K 4

CATGGTGAATGAT-FG=I~GATGTG'ITCTTGG

AMTGGTU'I'CGAGAAYI=ATTGACTATI1TrGG CA'rrAATACTCATAAGGGAAA'FrGGTCTGAAG TTC1TCCTTGTTGAGTC'1ATGAGGGTATCA

ATATAA'GTGGATTCATAGAGCAAGTTAGAT

TGTGTTCCTTrCTGTrTATIT'1GTGGAA'rAIT TrGAAGAGTATTGGTrAIrAGA'r(YTrCCTTGAA GGTATGATAGAAfFrGAACTAAACCCATATG GTTFCTGGATfTTGGFGGAAGACCAATG ACTGCTITCTATTTC1TrAGGTGT7ATGGGACTG TATAGATGGTTTATCTGAACCAGiAThr-AAcT-r

TGGTATTFTGT-I'ATGTG'LT[AGAAAATTGCCCAT

TTCATCCATAMhCCCAGTTGTGTTGAGTATAG GCTM~GTAGTAGGATATAATGMTI1GAAT 'TTGCTCAGTATG'TCATATCTCCC=rCC AT17CTGAT1TGTTAATGTGGATACTATCTCT GTGTCCTCTGTTTAGTCTGGCTAAGGGTTF-c 1M000604 TATCTGTTGA'FITrCTG 938 R CATGGG'I'T'AACAGTGGGCCCTAAAC'JTIGAAC'r' AGAAAACrrAAAGATGCTCATAGGGAAGAAG AAAAGAGCAGAAAGCTrAGCT-rCTAGACAGG GGTAAGGC'FrAGAGCTCAATAAAAAAGGAAC IM000605 Iccc 939 K Wntl

CATGGCCTGTCTCAGTTTACTTCACAGCTGAA

IM000606 I CAAGAGGCAGAGAGTGACAGGTAG 940 K Wntl

U-

CATGCTCGCCAGTCCCAGAACCTGGA

AGGCTGAGGCAGGAGGATTAAA.JAG

CCTFTGGGGACACCAGGCTTGGTGGCA

CCGGTCGTAAATCCAGCACTGGGGAG

TITAAGAAGCAAGTGAGTCACATCTGT

GAGTCTGAGGGTATGTTGGTCTACGT

AACGAGCTCTAGTATAGCGAGCCTGG

GATACATAGTAAGCAGT[CTAGTATA

GCCAGCCTGOGATACACAGTAACGA

GTITCTAGTATAGCCAGCCTGGGATAC

I1M000607 ACC 941 D

CATATGCGTATTCACATTTGTGTGGGAACGTC

GTTGGAGAAAGCAGGAGCAGGAGTrACAGAC

AGTATAAGCTGCCTGACCTGGGTGCTGGGA

ACACCTCAGGTCCTCTGGAAGAGCAGTAAGTC

CCCTTAACCAATGAACCATCTATCCGTCCAGC

CTACATTAATrGnrC'ATT-rACTTGTCT IM000608 GCATG 942 R

CACACACACACACACACGGGTGGGGATCCAA

CCCATCTCGTCCTTACACGTGCTCTACCATCA

CGCCACACA'TrTCCAGCACN'TrATCTGAAGT IM000609 GTrCC I I rAITTGTGCATG 943 K Wntl

CATGCCTGGTGCCTGCAGAGGTCAGAAAGTGT

TGGATGCCCTGGAATTAGAGTAACACATAGn~ ATAAGATGCTGCGTGGGTGCTGGGATmfGAAJC

CCUTGTCCTCTGCAAGAGCAGCCAGTGCCT

AACCACCGAGCCATCCCTCCAGCCCCTGATA

CTCACTCTTCACGGCTCAATCGTAGG

TAflGAGGCTGCCAAGTGACGCAAGAGCACC

TAGGAAGGCAGCCACATCGGTGGCACTCTGG

AAGCACTGCGAGGATGACTGCACACAI-JGCC

IM000610 GGTTGTC 944 K Notch] CATGCTGGCCATTATTGATmAAGTTATAC

TCTAGACCTTTGTAAATATTAGCCATTGCATA

TTACAGAAATrrCTTAGCAGAGATAGTCTCTC

ACTCTTAGTGATGAGCAAGCTGGAGTCAGCA

TTATTCTCCCAGCTAAGATACAGAAJ-rACAGA

CGMIATGACGGACACATCTGGATGTAGTTJA

IM000611 CTTAGTCCAC 945 D

CCCCCCCCGCCCCTGCCAGACCGCAGCCCGA

IM000612 GCACAGCATG 946 D CATGCCTCCCTCAGCCTCCTCCACCCCTrCCTG TCCTGCCTCCTCATCACTGTGTAATAAM1GC ACCGAAATGTGGCCGCAGAGCCACGCGTrCG GTTATGTAAATAAAACTATrATGTGCTGGG Fg/3/Fgf 1M000613 TFCCAGCCTGGGTTGCAGAGACCACCGT 947 K 4

CATGAATTCAATGGTGTGCTGCTATA.AATGC

AAATAAACCATATATATCATATTACACTC&AT

TlTAAATATT1CCTAATATrAATAAAGGTG IM000614 IATGGGGAACTr 948 D

CATGTCTAC'TTIATL'GCATATFAGGAT

GTCAGGTCCTGCTCGTTTCCTGGGAC

CAMhGCCTGGAAGACATFFCCATT CITIACTCTGAGATAGTTCCTGTCrT TGTTGYITGAGGTGTG7TFC'rrGTATTC U AGCAAAATGCTGGATCTTGTTITGCGA ATCCAGTCTIGT-rAGCTTATGTCTFF-If ACAGGTGAA'FrGAGTCCAT[AATATT GAGAGATATTAAAGAGAAATGAC[Tl TGGTlCCTGATATALTG1TITCTAG TFAG3TTGTGTGC'TTGGGACTCTCTC CCT1TGACTGTGJTGTGAGATGCTTA Cl ATATCTfTGTCCTATCTTTGGTGCAGGT GTCTTCCTTGTGI'TAGAGTI=CATTfC CAGGTTTCTCTGTAGTG-rATG'ITAG AAGACATATACTGCTrGAATrAGrI' CI ~T-TGCCTGGAATA=FTGrI=CTCCAT

CTATGTTIGATTGAGAGTTFCTGGGT

AAAATAGCCTANCCTGGCATTTGTGT

TcTrc'iTAAAAGTCTGTATGACC'FCTG 1N4000615 ACTANGC=1TCTGGCC 949 D CATGGTGAATGATTG'TflGATGTIGT TCTTGGATITTGGTTTCGAGAATTTrTAT TGACTA3TIGGCATFAATACTCATA AGGGAAATfl'GGTGTGAAGTTCTTcCC

T-G'TTGAGTCTTTATGAGGGTATCAA

TATAATTGTGGATTCATAGAGCAAGT

TGGATflGTGTTCC'TGCTGTTTATAIfT TGTGGAATATTrrTGAAGAGTA1TGG'T ATTAGATTTTC7ETGAAGG'rATGATA GAATrCTGAACTAAACCCATATGGrT

CTGGA=II-ITGGTTGGAAGACCA

ATGACTGCTCTATCTITAGGTGT[

ATGGGACTGTATAGATGGMIIATCTG

AACCAGATTTlAACTTTGGTAMIGTT ATCTGM~AGAAAA'ITrGCCCAT[CA

TCCATATICCCAGTTGTGTTGAGTAT

AGGC=TGTAGTAGGATATAATGAT

TFITGAATLTCCTCAGTATG1TPCT TATATCTCCCTTGATTrCTGATM

GTFTAATGTGGATAGTATCTCCGTGTG

IM000616 CCC 950 R CCATGTCAGGTGGTrAACCTGTGAGTCTAACT

TCCAGGAATGCAATGCCTCTGGCATCTACAGG

CATAAACATACrGTGGCTrACACCAACTG

ACACACCAACACATATGTGCAGGCGCACACA

CACACACACCAAATTAAAAATAAAATAACCC

TFrrAAfiAATATAGAATCTATAGATAATT 1M0006 17 GCTTTACTGCACTCACAAACI1TrAGGATC 951 D IM000618 ACACTAACACAAAGAAGGGGATC 952 D

Claims (18)

1. 2. The method according to claim 1, wherein the expression product is a mRNA having a sequence of SEQ ID NO: 1587.
2. 3. A method of diagnosing carcinoma, lymphoma, prostate cancer, colon cancer, stomach cancer or breast cancer comprising: a) determining the level of an expression product comprising a nucleotide sequence at least 98% identical to SEQ ID NO: 1587, or a full complement thereof, in a patient sample; and b) comparing the level of the expression product in to a level of the expression product in a second sample, the second sample comprising a normal tissue, wherein a difference between the level of the expression products in (a) and the level of the expression products in the second sample indicates that the patient has carcinoma, lymphoma, prostate cancer, colon cancer, stomach cancer or breast cancer. 242
3. 4. A method of diagnosing prostate, colon, stomach or breast cancer in a patient Ucomprising: contacting a polynucleotide that hybridizes under highly stringent conditions to a nucleotide sequence which encodes a polypeptide encoded for by a nucleotide sequence at least 98% identical to SEQ ID NO: 1587 with nucleic acids of a patient prostate, colon, stomach or breast sample under binding conditions suitable to form a duplex, wherein the polypeptide has protein phosphatase activity; and S(b) comparing the amount of the duplex formed to the amount of duplex formed when the polynucleotide is contacted with nucleic acids of a normal, non-cancerous control, wherein increased levels of the amount of duplex formed upon contacting the polynucleotide with the nucleic acids of the patient sample compared to the amount of duplex formed upon contacting the polynucleotide and the nucleic acids of the non-cancerous control indicates that the patient has prostate, colon, stomach or breast cancer. The method according to claim 4, wherein hybridization is performed at 50 'C to 'C in 5 X SSC (9mM saline/0.9 mM sodium citrate).
4. 6. A method of screening drug candidates comprising: a) providing a cell that expresses a carcinoma associated (CA) gene comprising or encoding a nucleotide sequence at least 98% identical to SEQ ID NO: 1587; b) adding a drug candidate to the cell; and c) determining the effect of the drug candidate on the expression of the CA gene.
5. 7. The method according to claim 6, wherein the determining in step comprises comparing the level of expression in the absence of the drug candidate to the level of expression in the presence of the drug candidate.
6. 8. A method for screening for a bioactive agent capable of binding to a CA protein (CAP), wherein the CAP is encoded by a gene comprising or encoding a nucleotide sequence at least 98% identical to SEQ ID NO: 1587, the method comprising: a) combining the CAP and a candidate bioactive agent; and b) determining the binding of the candidate agent to the CAP.
7. 9. A method for screening for a bioactive agent capable of modulating the activity of a CA protein (CAP), wherein the CAP is encoded by a gene comprising or encoding a nucleotide sequence at least 98% identical to SEQ ID NO: 1587, the method comprising: a) combining the CAP and a candidate bioactive agent; and b) determining the effect of the candidate agent on the bioactivity of the CAP. A method of evaluating the effect of a candidate anti-cancer drug comprising: a) administering the drug to a patient; b) removing a sample from the patient; and c) determining alterations in the sample in the expression or activation of a gene comprising or encoding a nucleotide sequence at least 98% identical to SEQ ID NO: 1587.
8. 11. A method for inhibiting the activity of a CA protein (CAP), wherein the CAP is encoded by a gene comprising or encoding a nucleotide sequence at least 98% identical to SEQ ID NO: 1587, the method comprising binding an inhibitor to the CAP.
9. 12. A method of treating carcinoma, lymphoma, prostate cancer, colon cancer, stomach cancer or breast cancer, comprising administering to a patient an inhibitor of a CA protein (CAP) wherein the CAP is encoded by a gene comprising or encoding a nucleotide sequence at least 98% identical to SEQ ID NO: 1587.
10. 13. A method of neutralizing the effect of a CA protein (CAP), wherein the CAP is encoded by a gene comprising or encoding a nucleotide sequence at least 98% identical to SEQ ID NO: 1587, comprising contacting an agent specific for the CAP protein with the CAP protein in an amount sufficient to effect neutralization.
11. 14. A method of diagnosing carcinoma, lymphoma, prostate cancer, colon cancer, stomach cancer or breast cancer or a propensity to carcinoma, lymphoma, prostate cancer, colon cancer, stomach cancer or breast cancer by sequencing at N least one CA gene of an individual, the gene comprising or encoding a ri nucleotide sequence at least 98% identical to SEQ ID NO: 1587.
12. 15. A method of determining CA gene copy number comprising adding a CA gene probe to a sample genomic DNA from an individual under conditions suitable (N for hybridization, the CA gene probe comprising a nucleotide sequence at least 98% identical to SEQ ID NO: 1587.
13. 16. The method according to any one of claims 1, 3, 12 and 14 wherein the cancer is lymphoma, colon cancer, stomach cancer or breast cancer.
14. 17. The method according to any one of claims 1, 3, 12 and 14 wherein the cancer is colon cancer.
15. 18. The method according to any one of claims 1-3, wherein the level of the expression product in the sample is increased at least 100% relative to the control.
16. 19. The method of any of claims 1-3, wherein the level of the expression product in the sample is increased at least 150% relative to the control. A polypeptide which specifically binds to a protein encoded by a gene comprising a nucleotide sequence at least 98% identical to SEQ ID NO: 1587.
17. 21. A polypeptide according to claim 15, comprising an antibody which specifically binds to a protein encoded by a gene comprising or encoding a nucleotide sequence of SEQ ID NO: 1587.
18. 22. A biochip comprising one or more nucleic acid segments of SEQ ID NO: 1587 or fragments thereof.